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Summary 
The Cryptococcus gattii species complex is a group of pathogenic basidiomycetous yeasts, 
closely related to the C. neoformans species complex. Together they comprise the aetiological 
agents of cryptococcosis. Members of the C. gattii species complex have a strong 
environmental association with decaying wood, and eucalypt tree hollows in Australia 
present an ideal environment for C. gattii VGI. Host mucosal colonisation and infection by the 
C. gattii species complex occurs subsequent to environmental exposure, most likely after the 
inhalation of reproductive basidiospores. In Australia, koalas (Phascolarctos cinereus) are 
known to exhibit a comparatively high prevalence of clinical and subclinical disease and nasal 
colonisation caused by C. gattii VGI, and occasionally C. gattii VGII. This, combined with their 
close and regular contact with eucalypts, makes them an ideal naturally-occurring model and 
sentinel for this disease, as well as a biological sampler for environmental members of the C. 
gattii species complex. Despite this potential, very little is known about cryptococcosis in free-
ranging koala populations. This thesis will study aspects of cryptococcosis in koalas and other 
Australian animals, including: the environmental associations of Cryptococcus spp., diagnosis 
and treatment, prevalence of disease and colonisation in free-ranging populations, host-
pathogen-environment interactions, and molecular epidemiology.  
Section 1, the introduction and literature review, contextualises this thesis in the 
current body of knowledge and outlines the aims and overarching hypothesis, that ‘disease is 
a random outcome of heavy environmental exposure’. 
 In section 2, the ecological associations of Cryptococcus spp. in Australia are explored 
at a microbiome level using a robust amplicon-based next generation sequencing technique. 
The fungal community, or mycobiome, of Australian tree hollows was characterised and 
results were compared to culture-dependent methods for the detection of Cryptococcus spp. 
in environmental samples. Statistical analyses were also performed to determine if 
relationships between Cryptococcus and other fungal taxa exist in these tree hollows. The 
mycobiome was found to be comprised predominantly of fungi associated with ligneous 
breakdown. This was supportive of the assumption that the fungal community in tree hollows 
would be skewed towards wood degradation. The findings from culture-dependent and 
culture-independent methods were reasonably consistent, but discrepancies emphasised the 
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complementarity of these techniques. Culture remains advantageous in many scenarios due 
to the ability to perform downstream high-resolution genotyping of isolates, and the 
confirmation that an infectious yeast or spore was present in the sample. No associations 
between Cryptococcus and other fungal taxa were identified amongst the tree hollows 
studied, although some patterns of difference in relative abundance indicate that other 
relationships could be at play and further studies are warranted. This section also expanded 
the known environmental niches of the C. gattii species complex in Australia, with a further 
five tree species associations described.  
 Section 3 presents three publications that address clinical aspects of cryptococcosis in 
koalas, including its diagnosis and treatment, and the prevalence of subclinical disease and 
nasal colonisation in a free-ranging population. Firstly, section 3.1 describes and characterises 
two unusual cases of cryptococcosis in related free-ranging koalas (a mother and joey) and 
discusses the pathogenesis, diagnosis and treatment of the disease in this context. 
Importantly, these were also sentinel cases for the case cluster investigated in section 4.1. 
The likely underlying cause of these cases was common exposure to a heavy environmental 
source of infection, and the successful treatment of the subclinical case is the first ever 
reported. The treatment of cryptococcosis in koalas is also discussed in detail, and 
recommendations are made for therapeutic protocols and monitoring.  
Section 3.2 compares two serological tests for cryptococcal antigen detection, the 
latex cryptococcal antigen agglutination test (LCAT) and a lateral flow immunoassay (LFA), in 
order to validate the latter for use in koalas, along with cats and dogs. The LFA was confirmed 
as a highly useful screening test for cryptococcosis in all three species, but its variable 
specificity and positive predictive values indicate that positive results should be followed up 
by other confirmatory testing, such as an LCAT or mycological culture. It is likely that the LFA 
is more sensitive to cryptococcal antigen in these species and is thus detecting very low levels 
of antigenaemia (possibly indicative of heavy nasal colonisation or early exposure) that are 
generally not clinically relevant to the animal. This is particularly problematic in the koala, and 
indeed the specificity was poorest in this species. Despite this, its newly confirmed utility as a 
screening test is an important finding for the diagnosis of this disease, as the LFA is 
advantageous over the LCAT in its shelf-stability, ease of use and low cost per test strip. This 
makes it desirable for use ‘cage-side’ in veterinary hospitals and in remote field locations. 
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Section 3.3 then applies the LFA to a group of free-ranging koalas, while also screening 
for nasal colonisation. This sub-population was investigated due to the recent finding of a 
koala mortality attributable to cryptococcal pneumonia. The LFA proved ideal in this scenario, 
as it could be used rapidly in the field and provided evidence for early exposure to 
environmental Cryptococcus spp. This study was the first to systematically characterise 
cryptococcosis in any free-ranging population of koalas and identified a relatively low 
prevalence of both antigenaemia and nasal colonisation. This suggests that the higher 
prevalence of these phenomena seen in some captive populations is a consequence of the 
artificial conditions in captivity, namely the amplification of environmental Cryptococcus spp. 
from the high-density of koalas. The systematic exploration of this population also allowed 
for statistical analyses into individual koala and environmental factors that could increase the 
likelihood of colonisation or antigenaemia. No significant relationships could be identified, 
suggesting that these are random outcomes of host-pathogen-environment interactions in 
this population. An obvious trend was observed, however, between the abundance of 
Eucalyptus camaldulensis in the proximate environment and antigenaemia, and this requires 
further study. A significant relationship was noted between nasal colonisation and 
antigenaemia, which is intuitive considering that mucosal colonisation is a likely prerequisite 
to tissue invasion. 
In section 4, one publication and three manuscripts are presented to explore the 
molecular epidemiology of cryptococcosis in Australian animals. Section 4.1 describes a 
spatial and temporal case cluster of cryptococcosis, caused by C. gattii VGI, in a group of free-
ranging koalas. This was investigated through the collection of disease isolates and the culture 
of nasal swabs (collected from koalas in both the hotspot area for cases of disease and the 
broader region) and environmental samples (from trees in the hotspot area). This revealed 
that koalas in this localised area were significantly more likely to be colonised than koalas 
from the broader region, and that C. gattii VGI was easy to isolate from trees within the same 
area (although likely not at an unusually high environmental prevalence). Multi-locus 
sequence typing and phylogenetic analysis of the resulting disease, colonising and 
environmental isolates indicated that no single, emergent outbreak strain was implicated in 
this cluster. It did, however, offer great insights into host-pathogen-environment interactions 
through its suggestion that a distinct genetic difference between most disease and 
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environmental isolates exists in this scenario. Whether this difference is due to rarer 
environmental isolates (potentially of higher virulence) being more likely to cause disease, 
microevolution occurring after contact with the host (during nasal colonisation), or by chance 
remains undetermined. Whole genome sequencing would be needed to address this further. 
Another pertinent finding of this study was the large number of sequence types, and broad 
distribution across the phylogenetic tree, of nasal colonising isolates. This indicates that 
koalas are in fact excellent biological samplers for environmental C. gatti VGI in a naturally-
occurring, free-ranging context. 
In sections 4.2 and 4.3, cases of cryptococcosis caused by C. gattii VGI in a captive bird 
and a domestic ferret were investigated. Environmental point sources of infection are usually 
very difficult to determine in cases of cryptococcosis, but the highly limited and known range 
of domicile of the hosts in both scenarios permitted a thorough investigation. This involved 
the collection of disease isolates, nasal swabs (section 4.3 only) and environmental samples. 
In both scenarios, only one site cultured positive, and multi-locus sequence typing provided 
further support for these as point sources of infection (and nasal colonisation, in section 4.3). 
These sections emphasise that any host species can offer pertinent insights into the 
pathogenesis of cryptococcosis. 
In section 4.4, another case cluster of cryptococcosis in koalas is investigated. In this 
instance, the cluster involved a group of captive animals (spread across several co-owned 
facilities within the same region) and C. gattii VGII as the main culprit. Similar methods were 
used, including culture of nasal swabs and environmental samples and multi-locus sequence 
typing of the resulting isolates. In this case, whole genome sequencing was also performed 
on a representative sample of isolates to provide higher-resolution genotyping, as most 
isolates proved to be of an identical multi-locus sequence type. Through this, it was 
determined that C. gattii VGII was introduced to these facilities in eastern Australia through 
the transfer of a koala from Western Australia, where VGII is endemic. The results also 
indicated that the transfer of koalas between the related facilities in eastern Australia had 
spread C. gattii VGII into new environments, and that this molecular type may even be able 
to outcompete the local population of C. gattii VGI in the environment. This study proved 
definitively that colonised koalas can transfer members of the C. gattii species complex into 
new environments. This finding, and confirmation that this ability extends to C. gattii VGII, 
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has implications for the management and prevention of cryptococcosis in koalas and of 
possible future outbreaks in Australia. This study also provided the first evidence that 
environmental decontamination may be valuable to the management of cryptococcosis in 
captive animal environments.  
Section 5 then discusses the major findings of this thesis in the context of the aims 
and hypothesis and suggests future directions for research. 
This thesis has provided a body of evidence largely in support of the central 
hypothesis, that ‘disease is a random outcome of heavy environmental exposure’, while also 
indicating that this relationship is highly complex and needs to be explored further, 
particularly in natural environments. Risk factors involved in the exposure to environmental 
members of the C. gattii species complex and the development of disease have been 
elucidated, while important clinical methodologies in diagnosis and treatment have been 
validated and discussed. The importance of animals in studying this environmentally-acquired 
disease has been emphasised through the confirmation that the koala acts as both a biological 
sampler and dispersal mechanism for environmental Cryptococcus spp. in Australia. Koalas 
and the other animal species discussed in this thesis have great potential as sentinels and 
naturally-occurring models for improving our understanding of the pathogenesis of 
cryptococcosis.  
  
vii 
 
Acknowledgements 
I am indebted to my primary supervisor, Professor Mark Krockenberger, for being not only an 
excellent mentor, but for also becoming a great friend. Mark: thank you for encouraging me 
to make the most of the whole PhD experience, for sending so many fantastic opportunities 
my way and for always somehow finding the time for a coffee and a chat. I am also grateful 
to my secondary supervisors, Dr Richard Malik and Professor Wieland Meyer, for their 
guidance. Richard: thank you for the enormous amount of support and mentorship you have 
offered me over the past few years, and for always being so quick to give constructive 
feedback. Your input was invaluable, and your honesty was always much appreciated. 
Wieland: thank you for the amazing opportunity to work with your team at The Westmead 
Institute for Medical Research, and for all the time and resources you put in to bringing this 
together. I also thank Dr Alison Stuart for introducing me to Richard and thus paving the way 
for this thesis. 
I am grateful for the financial support that I received: a Research Training Program 
scholarship, The Westmead Institute for Medical Research’s Top-up Scholarship, the Eric 
Horatio Maclean Scholarship and assistance from the Postgraduate Research Support Scheme 
at The University of Sydney. 
Thank you to the veterinarians who assisted by providing samples and records: Drs 
Kate Bodley, Patrizia Danesi, Donald Hudson, Patricia Martin, Laura Setyo, Kathryn Stalder, 
Alison Wardman and the Marlin Coast Veterinary Hospital. Port Stephens Koalas and Wildlife 
Tropical North Queensland were integral to the investigations of the koala case clusters, and 
I thank all involved for their support. I am grateful to Juan Monroy-Nieto and Drs Laszlo Irinyi, 
Jeff Powell, David Engelthaler and Jolene Bowers for their collaboration in sequencing and 
data analysis. Christine Black, Aziza Khan, Caroline Marschner, Krystyna Maszewska and Dr 
Kennio Ferreira-Paim taught me various laboratory techniques, while Veronica Ventura made 
the many bird seed agar plates used in this thesis. The Liverpool Plains field work was 
facilitated by the hard work of Dr Valentina Mella, Associate Professor Mathew Crowther, 
George Madani, and the many others who assisted in sample collection. Thank you to the 
farmers who gave us access to their properties (particularly Robert Frend, Kate Wilson and 
Sam Clift) – this work would not have been possible without their hospitality and generosity.  
viii 
 
Thank you to all the students from the JD Stewart postgraduate room and level 4 at 
The Westmead Institute for Medical Research for the conversations, snacks and support over 
the past few years. I am also very lucky to have made two close (and hopefully lifelong) friends 
through this experience, Lana and Valentina. Thank you both for always listening, keeping me 
fed and caffeinated, improving my fashion sense and sometimes even helping with my 
research. Your support made this so much easier and a lot more fun. To my ‘non-PhD friends’: 
you were my constant reminder of life outside of my thesis. Thank you for keeping me sane.  
Finally, thank you to my family. I am very lucky to have a whole team of trailblazing 
grandparents, parents and other relatives to motivate me through their own achievements. 
To my parents, Gary, Susan, Ron and Marcia: you made this possible through the many years 
of emotional and financial support, and I can’t thank you enough. Paul, thank you for the 
coffee breaks and the inspiring conversations. Frida, thanks for your constant (albeit mostly 
silent) companionship. Lastly, to Noni: this thesis started partly as a ticket back to Sydney to 
be closer to you. Now that it has ended, I’m lucky enough to get to call you my wife. You are 
my cheerleader, my project manager and my rock. I simply couldn’t have done this without 
you. Thank you.  
 
As a wise friend once told me, ‘everyone runs their own marathon.’ This was mine. 
 
 
 
 
 
 
 
 
ix 
 
Table of contents 
Statement of authentication ...................................................................................................... i 
Summary .................................................................................................................................... ii 
Acknowledgements .................................................................................................................. vii 
Publications .............................................................................................................................. xii 
Presentations .......................................................................................................................... xiii 
Abbreviations ...........................................................................................................................xiv 
 
1. Introduction and literature review ................................................................................ 1 
1.1 The pathogen ................................................................................................................... 2 
1.1.1 Taxonomy .............................................................................................................. 2 
1.1.2 Geographical distribution ..................................................................................... 3 
1.1.3 Virulence ............................................................................................................... 5 
1.1.4 Reproduction ........................................................................................................ 8 
1.1.5 Genotyping ............................................................................................................ 8 
1.2 The environment ............................................................................................................ 11 
1.2.1 Role and dispersal ............................................................................................... 11 
1.2.2 Tree associations ................................................................................................. 12 
1.2.3 Methods of detection and isolation ................................................................... 14 
  1.2.3.1 Culture-dependent .............................................................................. 14 
  1.2.3.2 Culture-independent ........................................................................... 15 
1.3 Cryptococcosis - the disease .......................................................................................... 16 
1.3.1 Host-pathogen-environment interactions .......................................................... 16 
  1.3.1.1 Incubation period ................................................................................. 18 
1.3.2 Colonisation ........................................................................................................ 18 
1.3.3 Subclinical disease .............................................................................................. 19 
1.3.4 Range of host species ......................................................................................... 20 
  1.3.4.1 Koalas and other Australian native mammals ..................................... 21 
  1.3.4.2 Birds ..................................................................................................... 25 
  1.3.4.3 Ferrets .................................................................................................. 26 
1.3.5 Diagnosis ............................................................................................................. 27 
1.3.5.1 Serological testing  ............................................................................... 28 
1.3.5.2 Adjunct diagnostic tools ...................................................................... 30 
 
x 
 
1.3.6 Treatment ........................................................................................................... 32 
1.3.6.1 Azoles  .................................................................................................. 33 
1.3.6.2 Amphotericin B  ................................................................................... 35 
1.3.6.3 Other treatments ................................................................................. 36 
1.3.6.4 Koalas, birds and ferrets ...................................................................... 37 
1.3.6.5 Antifungal resistance ........................................................................... 41 
1.3.7 Management and prognosis ............................................................................... 42 
1.3.7.1 Management ........................................................................................ 42 
1.3.7.2 Prognosis .............................................................................................. 43 
1.3.8 Outbreaks and case clusters ............................................................................... 44 
1.3.8.1 Animals as sentinels ............................................................................. 45 
1.4 Aims and hypothesis ...................................................................................................... 46 
1.4.1 Aims..................................................................................................................... 46 
 
2. Environmental associations ........................................................................................ 48 
2.1 The mycobiome of Australian tree hollows in relation to the Cryptococcus gattii and C. 
neoformans species complexes............................................................................................ 49 
 
3. Koala cryptococcosis ................................................................................................... 78 
3.1 Cryptococcosis in the koala (Phascolarctos cinereus): pathogenesis and treatment in the 
context of two atypical cases ............................................................................................... 80 
 
3.2 Comparing immunochromatography with latex antigen agglutination testing for the 
diagnosis of cryptococcosis in cats, dogs and koalas ........................................................... 92 
 
3.3 Prevalence of cryptococcal antigenemia and nasal colonization in a free-ranging koala 
population .......................................................................................................................... 101 
 
4. Fine-scale molecular epidemiology ........................................................................... 112 
4.1 Molecular epidemiology of cryptococcosis in koalas offers insights into host-pathogen-
environment interactions ................................................................................................... 115 
 
4.2 Multi-locus sequence typing as a tool to investigate environmental sources of infection 
for cryptococcosis in captive birds ..................................................................................... 137 
 
4.3 Identification of the environmental source of infection for a domestic ferret with 
cryptococcosis .................................................................................................................... 144 
xi 
 
4.4 Jet-setting koalas spread Cryptococcus gattii VGII in Australia ................................... 161 
 
5. General discussion and future directions ................................................................... 180 
5.1 General discussion........................................................................................................ 180 
5.2 Future directions .......................................................................................................... 189 
5.3 Final comments ............................................................................................................ 191 
 
6. References ................................................................................................................ 192 
 
Appendices .................................................................................................................. 224 
Appendix 1: Supplementary methods................................................................................ 224 
Appendix 2: Isolates and sequencing data ......................................................................... 231 
Appendix 3: Other publications ......................................................................................... 239 
 
 
 
  
 
 
 
 
 
 
 
xii 
 
Publications 
 
Schmertmann, L.J., Danesi, P., Monroy-Nieto, J., Bowers, J., Engelthaler, D.M., Malik, R., 
Meyer, W. & Krockenberger, M.B. 2019. Jet-setting koalas spread Cryptococcus gattii VGII in 
Australia. mSphere, 4, e00216-19. 
 
Schmertmann, L.J., Kan, A., Mella, V.S.A., Fernandez, C.M., Crowther, M. S., Madani, G., Malik, 
R., Meyer, W. & Krockenberger, M.B. 2019. Prevalence of cryptococcal antigenemia and nasal 
colonization in a free-ranging koala population. Medical Mycology. 
doi:10.1093/mmy/myy144 
 
Krockenberger, M.B., Marschner, C., Martin, P., Reppas, G., Halliday, C., Schmertmann, L.J., 
Harvey, A.M. & Malik, R. 2019. Comparing immunochromatography with latex antigen 
agglutination testing for the diagnosis of cryptococcosis in cats, dogs and koalas. Medical 
Mycology. doi:10.1093/mmy/myz010 
 
Schmertmann, L.J., Bodley, K., Meyer, W., Malik, R. & Krockenberger, M.B. 2018. Multi-locus 
sequence typing as a tool to investigate environmental sources of infection for cryptococcosis 
in captive birds. Medical Mycology. doi:10.1093/mmy/myy098 
 
Schmertmann, L.J., Stalder, K., Hudson, D., Martin, P., Makara, M., Meyer, W., Malik, R. & 
Krockenberger, M.B. 2018. Cryptococcosis in the koala (Phascolarctos cinereus): pathogenesis 
and treatment in the context of two atypical cases. Medical Mycology, 56, 926-936. 
doi:10.1093/mmy/myx146 
 
 
xiii 
 
Presentations 
 
Schmertmann, L.J., Malik, R., Meyer, W. & Krockenberger, M.B. Molecular epidemiology of 
cryptococcosis. Australian and New Zealand College of Veterinary Scientists: Science Week 
(Pathobiology chapter), 5th-7th July 2018. Gold Coast, Queensland, Australia. 
 
Schmertmann, L.J., Malik, R., Meyer, W. & Krockenberger, M.B. Cryptococcosis in koalas: 
host-pathogen-environment interactions and molecular epidemiology. Fundação Oswaldo 
Cruz Mycology Student Symposium, 7th April 2017. Rio de Janeiro, Brazil. 
 
Schmertmann, L.J., Bodley, K., Krockenberger, M., Malik, R. & Meyer, W. Identification of the 
likely point source of infection in a case of avian cryptococcosis. 10th International Conference 
on Cryptococcus and Cryptococcosis, 26th-30th March 2017. Foz do Iguaçu, Brazil. 
 
Schmertmann, L.J., Krockenberger, M., Malik, R. & Meyer, W. Investigating a localised case 
cluster of cryptococcosis in koalas (Phascolarctos cinereus) in New South Wales, Australia. 
10th International Conference on Cryptococcus and Cryptococcosis, 26th-30th March 2017. Foz 
do Iguaçu, Brazil. 
 
Schmertmann, L.J., Malik, R., Meyer, W. & Krockenberger, M.B. Unusual presentation of 
cryptococcosis in koalas: a case cluster in Port Stephens, New South Wales. Australian and 
New Zealand Mycology Interest Group meeting, 22nd February 2017. Adelaide, South 
Australia, Australia. 
 
 
 
xiv 
 
Abbreviations 
 
 
Abbreviation Meaning 
AFLP Amplified fragment length polymorphism 
AIDS Acquired immunodeficiency syndrome 
AMB Amphotericin B 
AT Allele type 
CFU Colony-forming unit 
CGB L-canavanine glycine bromythymol blue 
CNS Central nervous system 
CSF Cerebrospinal fluid 
CT Computed tomography 
CYP Cytochrome P450 monooxygenase 
DNA Deoxyribonucleic acid 
EDTA Ethylenediaminetetraacetic acid 
FeLV Feline leukaemia virus 
FFPE Formalin-fixed paraffin-embedded 
FIV Feline immunodeficiency virus 
GA General anaesthesia 
GXM Glucuronoxylomannan 
HIV Human immunodeficiency virus 
ITS Internal transcribed spacer 
KoRV Koala retrovirus 
LCAT Latex cryptococcal antigen agglutination test 
LFA Lateral flow cryptococcal antigen immunoassay 
MALDI-TOF Matrix-assisted laser desorption ionisation time-of-flight  
MHC Major histocompatibility complex 
MIC Minimum inhibitory concentration 
MLST Multi-locus sequence typing 
MRI Magnetic resonance imaging 
NGS Next generation sequencing 
NSW New South Wales 
NT Northern Territory 
OTU Operational taxonomic unit 
PCR Polymerase chain reaction 
QLD Queensland 
RAPD Random amplification of polymorphic DNA 
RFLP Restriction fragment length polymorphism 
SDA Sabouraud dextrose agar 
SDS Sodium dodecyl sulphate 
ST Sequence type 
VIC Victoria 
WA Western Australia 
WGS Whole genome sequencing 
ZOTU Zero-radius operational taxonomic unit 
1. Introduction and literature review
The Cryptococcus gattii species complex comprises a group of saprophytic, environmental 
yeasts of the phylum Basidiomycota that occupy an environmental niche of decaying organic 
matter, most commonly in trees. The closely related C. neoformans species complex also 
comprises environmental basidiomycetous yeasts and occupies a similar ecological niche. 
Members of both species complexes can cause the severe mycotic disease cryptococcosis 
across a wide range of host species.  The epidemiology of cryptococcosis caused by the C. 
gattii species complex began to be differentiated from the C. neoformans species complex 
following the HIV/AIDS outbreak, as it became apparent that disease caused by the C. gattii 
species complex was not strongly associated with severe immunosuppression in people, in 
contrast to disease caused by the C. neoformans species complex (Chen et al., 2014, Maziarz 
& Perfect, 2016). Both species complexes are primarily considered environmental organisms 
that opportunistically cause disease, possibly after exposure to a large inoculum and/or a 
particularly virulent strain. 
Animals are assumed to be at the front line of exposure to Cryptococcus spp. in the 
environment, thus the role that domestic, captive and free-ranging animals can play as both 
sentinels and naturally-occurring models for disease caused by the C. gattii species complex 
should not be underestimated (Craig et al., 2002, Malik et al., 2011). In Australia, a wide 
variety of domestic animals and free-ranging or captive native species are known to be 
susceptible to cryptococcosis (Krockenberger et al., 2005, Malik et al., 2011). In particular, the 
koala (Phascolarctos cinereus) presents an interesting case study, as it exhibits a seemingly 
higher prevalence of disease than any other species and is readily exposed to one of the 
predominant environmental niches of the C. gattii molecular type VGI in Australia – eucalypt 
trees (Krockenberger et al., 2003). Therefore, this thesis focuses largely on koalas as a 
naturally-occurring model for cryptococcosis. This introduction will outline and review the C. 
gattii species complex and cryptococcosis, with emphasis on Australia and animal disease, by 
following the basic format of pathogen, environment and disease in the host. 
1
1.1 The pathogen 
1.1.1 Taxonomy 
Prior to 1970, all members of the C. gattii species complex were considered to be of a single 
species, C. neoformans. The early taxonomy of C. neoformans is convoluted and begins with 
the naming of the Cryptococcus genus by Kϋtzing (1833), followed by the discovery of several 
similar yeast species classified under numerous genera in the following years, including one 
designated as C. neoformans (Vuillemin, 1901). Benham (1935) later determined that all 
belonged to the genus Cryptococcus. This eventually led to  the proposal that all these species 
should fall under the name C. neoformans and that the disease they cause should be referred 
to as cryptococcosis (Benham, 1950).  
Vanbreuseghem & Takashio (1970) created the first separation between the C. gattii 
and C. neoformans species complexes, introducing the term C. neoformans var. gattii, and the 
taxonomical history from this point onwards is presented in Table 1.1. Numerous taxonomical 
shifts occurred in the following decades, with C. gattii first appearing as a distinct species in 
2002 (Kwon-Chung et al., 2002). The addition of the sexual teleomorph species, Filobasidiella 
bacillispora (Kwon-Chung, 1976b), persisted until January 2013, when the use of separate 
names for teleomorphs and anamorphs in fungal taxonomy was discontinued (Hawksworth, 
2011). The taxonomy remained stable until the publication of a new proposal to divide C. 
gattii into five species (Hagen et al., 2015). This division was based on their separation into 
distinct genetic clades according to molecular typing techniques, namely amplified fragment 
length polymorphism (AFLP) and restriction fragment length polymorphism (RFLP) analysis 
(both methods are discussed further in section 1.1.5).  The proposal by Hagen et al. (2015) 
was not universally accepted amongst the cryptococcal research community during 
discussion at the 10th International Conference on Cryptococcus and Cryptococcosis at Foz do 
Iguaçu, Brazil in March 2017. Due to concerns regarding ongoing taxonomic instability, the 
adoption of the term ‘species complex’ to encompass the C. gattii molecular types VGI, VGII, 
VGIII and VGIV was proposed as an interim solution (Kwon-Chung et al., 2017), and this 
nomenclature will therefore be used throughout this thesis. 
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TABLE 1.1 History of the taxonomy of the C. gattii species complex in chronological order, 
beginning from its first separation from C. neoformans in 1970. 
 
Reference Nomenclature 
Vanbreuseghem & Takashio (1970) C. neoformans var. gattii 
Kwon-Chung (1976b) C. neoformans var. gattii / F. bacillispora 
Kwon-Chung et al. (1978) C. bacillisporus / F. bacillispora 
Kwon-Chung et al. (1982a) C. neoformans var. gattii / F. bacillispora 
Boekhout et al. (2001) C. bacillisporus / F. bacillispora 
Kwon-Chung et al. (2002) C. gattii / F. bacillispora 
Hagen et al. (2015) 
C. gattii (VGI, AFLP4) 
C. deuterogattii (VGII, AFLP6) 
C. bacillisporus (VGIII, AFLP5) 
C. tetragattii (VGIV, AFLP7) 
C. decagattii (VGIV/VGIIIc, AFLP10) 
Kwon-Chung et al. (2017) C. gattii species complex (VGI-IV) 
 
1.1.2 Geographical distribution 
Members of the C. gattii species complex were classically considered tropical or sub-tropical 
pathogens, with some temperate distribution, including parts of Australasia (Kwon-Chung & 
Bennett, 1984). In the past 20 years, particularly following the ongoing North American 
Vancouver Island and Pacific Northwest C. gattii VGII outbreak (Craig et al., 2002, Hoang et 
al., 2004, Kidd et al., 2004), its association with temperate zones is unequivocal, and it is now 
considered to be widely distributed globally, albeit reasonably uncommon in some areas such 
as Europe (Baró et al., 1998, Chowdhary et al., 2012a, Hagen et al., 2012). Chen et al. (2014) 
performed a meta-analysis of C. gattii species complex strains from a multitude of studies 
worldwide to highlight the striking differences between the global distribution of certain C. 
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gattii molecular types, including a tendency for isolates from African studies to be 
predominantly C. gattii VGIV (a genotype very uncommon elsewhere in the world). In the 
Americas, VGII tends to dominate, while VGI is predominant in Asia, Australasia and Europe 
(Chen et al., 2014). These findings are outlined in Table 1.2. 
 
TABLE 1.2 Geographical distribution of all isolations of the molecular types of the C. gattii 
species complex by continent, with molecular types ordered by their frequency of detection, 
based on meta-analysis data presented in two publications (Chen et al., 2014, Engelthaler & 
Meyer, 2017).  
 
Continent C. gattii molecular types 
Africa VGIV, VGIII, VGII, VGI 
Americas South and Central VGII, VGIII, VGI, VGIV 
North VGII, VGIII, VGI, VGIV 
Asia VGI, VGII, VGIII, VGIV 
Australasia VGI, VGII, VGIII 
Europe VGI, VGII 
 
Early speculation that the Vancouver Island outbreak may have arisen from Australia 
via the importation of eucalypts (particularly Eucalyptus camaldulensis) in the early 1900s was 
based on the genetic similarity between the comparatively low virulence Vancouver Island 
outbreak isolates and Australian isolates, with presumed in situ development of the 
hypervirulent outbreak strain (Fraser et al., 2005, Byrnes III et al., 2010). On the other hand, 
Ngamskulrungroj et al. (2009) noted that the greatest diversity of C. gattii species complex 
isolates globally was found in South America, and thus concluded that this was the most likely 
origin of the outbreak strains. This was further supported by phylogenetic and recombination 
analyses (Chowdhary et al., 2012b, Hagen et al., 2013). A theory of radiation from South 
America has progressively gained support, with slight shifts in the exact proposed area of 
origin (Souto et al., 2016) and observations that the patterns of global distribution could also 
be traced back to the supercontinent, Pangea, and continental drift (Casadevall et al., 2017, 
Engelthaler & Meyer, 2017).  
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In Australia, C. gattii VGI and VGII are the major molecular types (Sorrell et al., 1996a), 
with VGIII considered very rare (Firacative et al., 2016) and VGIV undetected. C. gattii VGI and 
VGII exhibit striking variation in their geographical distribution within Australia, with VGI 
predominant in eastern Australia, while VGII is comparatively more abundant in western and 
northern central Australia (Sorrell et al., 1996a, Chen et al., 1997a, Campbell et al., 2005, 
McGill et al., 2009). The Australian C. gattii VGII population exhibits relative clonality, with 
most strains found to be identical in one study using multi-locus sequence typing (MLST), 
grouping as type VGIIb (Carriconde et al., 2011). This same type was identified as one of the 
strains involved in the Vancouver Island outbreak (Kidd et al., 2004). 
 
1.1.3 Virulence 
The C. gattii and C. neoformans species complexes have many recognised and shared 
virulence traits which could also be considered advantageous for their environmental survival 
(Casadevall et al., 2003). The major traits are: thermotolerance, the polysaccharide capsule, 
intracellular survival, along with melanin, phospholipase and urease production. 
There has been speculation that endothermy in mammals provided an evolutionary 
advantage over other non-mammalian species through natural resistance to most fungal 
diseases, with cryptococcosis providing one of relatively few exceptions (Casadevall, 2005). 
Most fungi are unable to grow at mammalian or avian physiological temperature, making the 
C. gattii and C. neoformans species complexes comparatively unusual in their ability to grow 
at up to 40°C, and thus capable of causing disease in these hosts (Casadevall, 2005, Perfect, 
2006, Robert & Casadevall, 2009). This is an important quality for a mammalian pathogen to 
cause disease at central anatomic sites and would also allow the organism to survive and grow 
in the environment at high ambient temperatures. 
The size of the polysaccharide capsule in vitro is considered the dominant virulence 
trait in the C. neoformans species complex (McClelland et al., 2006). In the C. gattii and C. 
neoformans species complexes, the capsule is comprised predominantly of 
glucuronoxylomannan (GXM) (Cherniak & Sundstrom, 1994) and contains antigenic 
structures that allow the designation of four serotypes and hybrids within the C. neoformans 
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(A and D) and C. gattii (B and C) species complexes (Wilson et al., 1968, Bennett et al., 1977), 
providing a historically useful means of differentiating between groups within the species 
complexes prior to the development of molecular typing techniques. The polysaccharide 
capsule likely provides protection from desiccation (Casadevall et al., 2018) and predation, 
e.g. by amoebae and paramecia, in the environment (Steenbergen et al., 2001, Frager et al., 
2010, Casadevall et al., 2019). In the host, this also provides protection from phagocytosis by 
immune cells such as macrophages and components of the capsular antigen have been 
associated with immunomodulation (Vecchiarelli, 2000). If phagocytosed, the cryptococcal 
capsule can increase in size and provide further protection against oxidative stress and 
lysosomal breakdown, allowing for improved intracellular survival (Dykstra et al., 1977, 
Zaragoza et al., 2008). Vomocytosis, where live yeasts are expelled by macrophages, has been 
observed after intracellular survival likely due to protection from the capsule, and this is 
proposed as a ‘Trojan horse’ mechanism to facilitate penetration through the blood-brain 
barrier (Alvarez & Casadevall, 2006, Ma et al., 2006, Voelz et al., 2009). Exposure to 
mammalian or amoebae polar lipids, along with extracts from macrophages and mammalian 
serum, can also trigger capsule enlargement (Chrisman et al., 2011). Casadevall et al. (2018) 
reviewed the literature on the C. neoformans species complex capsule and noted that its size 
shows substantial variation both between strains and within the same strain, the latter in 
response to differences in culture media, in vitro versus in vivo isolates, or in disparate tissues 
during disease (lung versus brain).  
The dark cell wall pigment present in the C. gattii and C. neoformans species 
complexes was first noted by Staib (1962) and later identified as melanin (Wang et al., 1995). 
Staib’s differential media, Guizotia abyssinica seed extract agar (also known as niger seed agar 
or bird seed agar), remains a staple for the detection of Cryptococcus spp. from the 
environment (discussed further in section 1.2.3.1). Laccase is the enzyme responsible for 
melanin production in the C. gattii and C. neoformans species complexes (Williamson, 1994). 
Melanin has been shown to be a critical virulence factor in cryptococcal disease (Kwon-Chung 
et al., 1982b, Williamson, 1997). Its presence in cell walls is thought to protect cells from 
oxidative stress and harsh environmental conditions, such as ultraviolet radiation (Wang & 
Casadevall, 1994, Williamson, 1997, Casadevall et al., 2003). 
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Phospholipase is considered a critical virulence factor due to its ability to breakdown 
host cell membranes and therefore facilitate the penetration of yeasts through tissues, such 
as from an alveolus into the bloodstream (Chen et al., 1997b). Mutations to the phospholipase 
B (PLB1) gene lead to decreased virulence (Cox et al., 2001). Speculations regarding the 
benefits of phospholipase for the environmental survival of Cryptococcus spp. centre around 
its potential as a protectant against phagocytosis by amoebae and its use for nutritional 
purposes (Casadevall et al., 2003). 
Urease production is an important virulence trait of the C. gattii and C. neoformans 
species complexes and provides a useful means to distinguish them from other fungal species 
(Cox et al., 2000, de Hoog et al., 2000). Urease causes alkalinisation, which could aid 
intracellular survival after phagocytosis, and may also play a role in the pathogenesis of 
central nervous system (CNS) invasion by permitting dissemination in macrophages 
(Olszewski et al., 2004, Fu et al., 2018).  
Cryptococcal cell body gigantism, also referred to as giant or ‘titan’ cells, has been 
observed for some time in pulmonary cryptococcosis (Okagaki et al., 2010, Zaragoza et al., 
2010). This adaptive change with polyploidy can impair phagocytosis and enhance 
dissemination (Crabtree et al., 2012, Okagaki & Nielsen, 2012). Most studies have centred 
around this phenomenon in the C. neoformans species complex, but there is some evidence 
that gigantism occurs also in the C. gattii species complex (Firacative et al., 2014). 
Within the C. gattii species complex, variations in virulence have been observed 
between different molecular types. C. gattii VGII generally exhibits greater virulence than VGI; 
within VGII, VGIIa is considered more virulent than VGIIb (Fraser et al., 2005, D'Souza et al., 
2011). However, this pattern may not extend to disease outcomes observed in patients 
(Galanis & MacDougall, 2010). A similar phenomenon was observed within VGIII (Byrnes III et 
al., 2011). Fernandes et al. (2016) also observed differences in thermotolerance and capsule 
size between different C. gattii molecular types. Other studies, however, have suggested that 
all C. gattii molecular types can exhibit a range of virulence (Firacative et al., 2014). A review 
by Chen et al. (2014) noted numerous inconsistencies in the published data, suggesting that 
such broad conclusions regarding virulence in relation to certain molecular types may be 
premature.  
1. Introduction and literature review
7
1.1.4 Reproduction 
Broadly speaking, members of the C. gattii species complex reproduce by either asexual 
budding, haploid fruiting or sexual reproduction. Haploid fruiting involves a switch from 
asexual budding to the production of hyphae and basidiospores (the likely infectious 
propagule) and has been observed in mating type α and a isolates (designated by the mating 
type [MAT] locus) (Wickes et al., 1996, Tscharke et al., 2003, Hsueh et al., 2011). Sexual 
reproduction requires the fusion of cells, also leading to the production of hyphae and 
basidiospores, and was originally thought to occur as part of a bipolar mating system between 
α and a mating types (Kwon-Chung, 1976a, Hull & Heitman, 2002, Lengeler et al., 2002, Hsueh 
et al., 2011). Sexual reproduction has been induced under laboratory conditions but is yet to 
be observed in the environment (Kwon-Chung, 1975, Kwon-Chung & Bennett, 1978), although 
circumstantial evidence of environmental recombination indicates that it does occur (Saul et 
al., 2008). There is some evidence that fertility can also vary within molecular types of the C. 
gattii species complex (Ngamskulrungroj et al., 2008). 
Most clinical and environmental isolates globally were classically found to be mating 
type α (Kwon-Chung & Bennett, 1978), although mating type a is found at greater frequency 
in South America (Escandón et al., 2006) and appears to be more common amongst 
environmental isolates than clinical isolates (Hsueh et al., 2011). In Australia, while most 
isolates are also mating type α, significant environmental populations of mating type a have 
also been found (Halliday et al., 1999, Saul et al., 2008). The preponderance of mating type α 
isolates globally led to the discovery of same-sex mating as a means of reproduction and 
recombination and the proposal that this mechanism played a role in the Vancouver Island 
outbreak (Fraser et al., 2005, Lin et al., 2005). 
 
1.1.5 Genotyping 
A wide variety of methods have been used over the past few decades to make genotypic 
distinctions between strains of the C. gattii species complex, allowing for separation into 
molecular types. Genotyping also allows for molecular epidemiological analyses of isolates in 
a global or local context. The genomes of the C. gattii and C. neoformans species complexes 
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separate into largely stable groups, which have remained consistent even with the 
introduction of increasingly discriminatory genotyping techniques. 
Genotyping of the C. gattii and C. neoformans species complexes began with PCR 
fingerprinting, a relatively simple method involving the use of primers, such as M13 (derived 
from the wild-type phage M13) and simple repetitive oligonucleotides, such as (GACA)4 and 
(GTG)5, to generate amplifications of highly mutable and repetitive DNA sequences (Sidrim et 
al., 2010). The products of this amplification then undergo separation and visualisation by gel 
electrophoresis, and the patterns generated are distinct between the major molecular types 
of the C. gattii and C. neoformans species complexes (Meyer et al., 1993, Meyer & Mitchell, 
1995, Meyer et al., 1999). Random amplification of polymorphic DNA (RAPD) analysis 
provided another early method of distinguishing between molecular types of the C. gattii 
species complex (Haynes et al., 1995, Sorrell et al., 1996b, Meyer et al., 1999). The 
disadvantages of both PCR fingerprinting and RAPD analysis primarily centre on their poor 
reproducibility between different laboratories (Sidrim et al., 2010). 
AFLP analysis provides a higher resolution and increased specificity in detecting 
molecular types, separating the C. gattii and C. neoformans species complexes into 11 distinct 
clades (AFLP1 - AFLP11). These clades correspond with the eight molecular types (VGI – VGIV, 
VNI – VNIV) and allow for the identification of several inter-variety and interspecies hybrids 
(Boekhout et al., 2001, Hagen et al., 2010). AFLP provides a reliable and reproducible method 
of differentiating between molecular types and hybrids but involves numerous steps and 
reagents, thus increasing its complexity and cost (Sidrim et al., 2010). 
RFLP analysis involves the double enzyme digestion of a PCR product. In the case of 
the C. gattii and C. neoformans species complexes, the URA5 (orotidine monophosphate 
pyrophosphorylase) gene is most commonly used. Visualisation by gel electrophoresis against 
known standard strains then allows for the determination of the molecular type (Meyer et 
al., 2003). This method is again highly reproducible and reliable but is less sensitive than AFLP 
in the event of isolated mutations and can struggle to differentiate between some hybrids 
(Sidrim et al., 2010). Nevertheless, its simplicity, affordability and high reproducibility make it 
desirable as a reasonably fast and accessible method of determining molecular type. 
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A consensus MLST scheme for the C. gattii and C. neoformans species complexes was 
created by Meyer et al. (2009) involving the use of seven loci: six housekeeping genes CAP59 
(capsular-associated protein), GPD1 (glyceraldehyde-3-phosphate dehydrogenase), LAC1 
(laccase), PLB1, SOD1 (Cu, Zn superoxide dismutase) and URA5, three of which (CAP59, LAC1 
and PLB1) also code for virulence traits, along with the IGS1 region (ribosomal RNA intergenic 
spacer). A PCR amplification of each of these seven loci then undergoes sequencing of forward 
and reverse reads, which are then aligned and the contig sequence is assigned an allele type 
(AT) number using a consensus database, namely the Fungal MLST Database 
(http://mlst.mycologylab.org) (Meyer et al., 2009). The unique combination of AT numbers 
then allows for the designation of a sequence type (ST) number. Concatenated sequences can 
then be used for downstream phylogenetic analysis. MLST reliably distinguishes between the 
molecular types and allows for more fine-scale distinctions to be made between strains. MLST 
is widely used amongst the C. gattii species complex research community to characterise 
isolates, as it allows for direct comparisons at both a local and global level. Its major limitation 
is the potential for the highly conserved housekeeping genes to offer inadequate 
discriminatory power to distinguish between closely related strains (Sidrim et al., 2010). 
The development of next generation sequencing (NGS) has made whole genome 
sequencing (WGS) increasingly available to researchers (Mardis, 2008). This has extended to 
the C. gattii species complex, with the first published study involving a comparison between 
the C. gattii VGI and VGII genomes (D'Souza et al., 2011). Gillece et al. (2011) expanded upon 
this, showing that WGS allowed for a higher discriminatory power between isolates than 
MLST, but also proving that the two methods were comparable in grouping isolates 
phylogenetically. WGS later provided both further evidence in support of the South American 
origins of the major Vancouver Island VGII outbreak strain, evidence of microevolution and 
further proof of the distinct molecular type lineages of the C. gattii species complex (Billmyre 
et al., 2014, Engelthaler et al., 2014, Farrer et al., 2015, Farrer et al., 2016). Another study 
showed that WGS could also be used for MLST analysis within the C. neoformans species 
complex (Chen et al., 2015). WGS is now a relatively standard tool in the cryptococcal research 
community, but its use remains somewhat hampered by the requirement for complex 
bioinformatics analyses and concerns regarding the standardisation of methods and 
appropriate storage and accessibility of large data sets (Farrer & Fisher, 2017). 
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1.2 The environment 
1.2.1 Role and dispersal 
As an environmentally-acquired pathogen and saprobe, understanding the role that members 
of the C. gattii species complex may play in the environment, along with the niche that they 
occupy, is critical to also understanding host exposure and eventual tissue invasion. Relatively 
little is known about the function of Cryptococcus spp. in the environment, but the strong 
association between members of the C. gattii species complex and decaying wood, including 
eucalypt tree hollows in Australia (Ellis & Pfeiffer, 1990), suggests that these yeasts may both 
contribute to this process while also using it as a source of nutrition and a growth substrate 
(Lazéra et al., 1998, Halliday & Carter, 2003). The detection of C. gattii VGI and VGII in air, soil, 
sea water and fresh water samples collected to investigate the Vancouver Island outbreak 
suggest that their environmental presence may be more complex than purely an association 
with trees and decaying wood (Kidd et al., 2007b). 
 A specific fungal microenvironment, or mycobiome, could play a role in allowing for 
the survival, growth and reproduction of environmental Cryptococcus spp., but there is no 
conclusive evidence yet in support of this theory. The isolation of the C. gattii species complex 
in insect frass (Kidd et al., 2003) could suggest that a relationship exists with mycoparasitic 
fungi of the same order as Cryptococcus spp. (Tremellales), such as Tremella spp. These fungi 
are also associated with wood detritus and insect frass and are capable of parasitising other 
wood-decaying fungi (Zugmaier et al., 1994, Findley et al., 2009). It appears likely that 
Cryptococcus spp. have diverged from a common ancestor with mycoparasitic fungi, but no 
longer exhibit this trait (Guého et al., 1993, Fell et al., 2000, Findley et al., 2009). In a 
mycobiome study of African trees, Vanhove et al. (2017) could not find any evidence of a 
relationship between the presence of Cryptococcus spp. and other fungi. 
 The environmental dispersal mechanisms of the C. gattii species complex, although 
presumably intended to allow the colonisation of new environments, are likely also critical in 
host exposure to these pathogens. Probably the most important dispersal mechanism is 
haploid fruiting, which allows for the production and dissemination of basidiospores in the 
absence of mating (Wickes et al., 1996, Tscharke et al., 2003). The C. gattii species complex 
1. Introduction and literature review
11
has also been detected in air samples collected under flowering E. camaldulensis trees, 
suggesting that flowering plants may present a method of dispersal (Ellis & Pfeiffer, 1990). 
Free-living birds could also play a role in the dispersal of members of the C. neoformans 
species complex, given their isolation from the cloacae of some birds of prey (Cafarchia et al., 
2006b). Preliminary evidence of a similar phenomenon has been observed in the C. gattii 
species complex, with captive koalas exhibiting cryptococcal nasal or skin colonisation 
seemingly able to seed previously uncontaminated environments (Krockenberger et al., 
2002b). One study offered strong evidence of anthropogenic environmental disturbances as 
a dispersal mechanism for C. gattii VGI and VGII, while also suggesting that domestic and wild 
animals could play a role (Kidd et al., 2007a). Water may also play a role in dispersal, with C. 
gattii VGII able to survive in sea water (at 4°C and room temperature) and distilled water (at 
room temperature) for a year (Kidd et al., 2007b). The polysaccharide capsule could provide 
critical buoyancy for this mode of dissemination (Vij et al., 2018). 
 
1.2.2 Tree associations 
Australia has long been central to our understanding of the environmental niche of the C. 
gattii species complex. Ellis & Pfeiffer (1990) described the first environmental isolation of 
the C. gattii species complex from E. camaldulensis trees in South Australia, and shortly 
thereafter also provided the first isolation from the same tree species in North America  
(Pfeiffer & Ellis, 1991). The same phenomenon was later observed in E. camaldulensis trees 
in a wide variety of locations worldwide, including India (Chakrabarti et al., 1997), Mexico 
(Argüero Licea et al., 1999),  Egypt (Mahmoud, 1999), Brazil (Montenegro & Paula, 2000) and 
Colombia (Granados & Castañeda, 2005). These studies solidified the early opinion that the 
C. gattii species complex had a strong association with E. camaldulensis, and that its global 
presence is related to the exportation of eucalypts (later deemed unlikely, as discussed in 
section 1.1.2). 
In Australia, the list of trees from which C. gattii VGI has been isolated now includes: 
E. camaldulensis (Ellis & Pfeiffer, 1990); E. tereticornis (Pfeiffer & Ellis, 1992); E. bella (Sorrell 
et al., 1996a); E. blakelyi, E. gomphocephala and E. rudis (Pfeiffer & Ellis, 1997); Angophora 
costata and E. grandis (Halliday et al., 1999); and E. microcorys and Syncarpia glomulifera 
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(Krockenberger et al., 2002b, Vilcins et al., 2002). This is further summarised in Table 2.1.1. It 
is now apparent that the C. gattii species complex, particularly VGI, can be associated with an 
expanding range of Australian tree species, although the strong association with E. 
camaldulensis and E. tereticornis (with mature trees frequently heavily colonised) appears to 
remain. It can be speculated that this occurs due to the propensity for these two species to 
drop branches and thus generate large hollows (Brooker & Kleinig, 2006) in which C. gattii 
VGI can thrive, due to the abundance of decaying wood substrate and protection from 
environmental conditions (Lazéra et al., 2000, Saul, 2009). 
The Australian environmental niche of VGII remains largely cryptic (Chen et al., 1997a), 
with its first published environmental isolation in Australia from plant material in a sheep 
paddock in Western Australia (WA) (although it is unclear if this isolate was due to direct 
contamination from diseased sheep) (Sorrell et al., 1996a). Kidd et al. (2003) later detected C. 
gattii VGII in insect frass attached to an E. tereticornis tree in New South Wales (NSW) and 
referenced unpublished findings of prior VGII detections in E. camaldulensis, E. miniata and 
E. tetrodonta. This was later expanded to include isolations from heavily colonised E. miniata, 
E. tetrodonta, Erythrophleum chlorostachys and Corymbia bella trees in the Northern 
Territory (NT), but overall recovery rates from these tree species were low (Saul, 2009).  
 Globally, environmental isolates of the C. gattii species complex have been detected 
in a wide variety of trees including (but not limited to) Australian eucalypts. Examples of non-
eucalypt tree associations outside of Australia include (with the molecular type noted, if 
reported): Acacia spp. in Argentina (VGI) (Refojo et al., 2009), Colombia (Granados & 
Castañeda, 2005) and India (VGI) (Randhawa et al., 2008); Cassia grandis in Brazil (Lazéra et 
al., 2000); Ceratonia siliqua in Spain (VGI) (Colom et al., 2012); Ficus spp. in Brazil (Lazéra et 
al., 2000); Moquilea tomentosa in Brazil (Lazéra et al., 1998); Pinus spp. in Colombia 
(Granados & Castañeda, 2005) and North America (VGII, VGIII) (Kidd et al., 2007b, Springer et 
al., 2014) Pseudotsuga spp. in Canada (VGII) (Kidd et al., 2004); Syzygium cumini in India 
(Randhawa et al., 2003) and Terminalia catappa in Colombia (Callejas et al., 1998). Soil 
associated with the base of trees (in the root zone) has also proven to be an environmental 
source of the C. gattii species complex, for example with Pseudotsuga menziesii var. menziesii 
(VGII) (Kidd et al., 2007b), Liquidambar styraciflua and Pinus canariensis trees (VGIII) (Springer 
et al., 2014) in parts of North America and S. cumini in India (VGI) (Randhawa et al., 2008). 
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1.2.3 Methods of detection and isolation 
1.2.3.1 Culture-dependent 
The primary method of the detection and isolation of members of the C. gattii species 
complex from environmental samples is by culture using differential and/or selective media. 
The classic media for this is Staib’s bird seed agar (as mentioned in section 1.1.3), which 
incorporates a G. abyssinica seed extract that provides substrate for the production of 
melanin (Staib, 1962). Consequently, yeast colonies of the C. gattii and C. neoformans species 
complexes (along with some other Cryptococcus spp.) can be identified by the brown-colour-
effect (Staib et al., 1987). Antibiotics were later introduced to bird seed agar to restrict 
bacterial growth (Shields & Ajello, 1966). Hopfer & Blank (1975) later confirmed that the need 
for the time-consuming extraction process from G. abyssinica seeds could be bypassed 
through the use of pure caffeic acid in the media. The presence of fast-growing filamentous 
fungi in environmental samples remains an ongoing problem for the isolation of Cryptococcus 
spp., as these fungi often overgrow the culture plates and likely out-compete the slower-
growing yeasts. The addition of other compounds to bird seed agar may aid in inhibiting the 
growth of filamentous fungi (Pham et al., 2014, de Matos Castro e Silva et al., 2015). 
Nonetheless, bird seed agar remains the staple for environmental isolations of Cryptococcus 
spp. (Alvarez et al., 2013). 
 Once suspect cryptococcal growth is identified on a primary isolation plate, individual 
colonies then typically undergo further isolation on standard mycological media, such as 
Sabouraud’s dextrose agar (SDA). At this stage, utilising the thermotolerance trait of the C. 
gattii species complex (by incubating plates at 37°C) can help to further rule out the accidental 
isolation of some other yeast species. Once a pure single colony isolate is obtained, DNA can 
be extracted, and genotyping techniques (as discussed in section 1.1.5) or barcoding (Schoch 
et al., 2012) (see 1.2.3.2) can subsequently be used to confirm the species and/or molecular 
type of the isolate. Classic biochemical and physiological methods of differentiation can also 
still be used to confirm that an isolate is a member of the C. gattii and C. neoformans species 
complexes, such as positive hydrolysis of urea, negative sugar fermentation, positive 
assimilation of most sugars and negative assimilation of nitrate (Ellis et al., 2007a). L-
canavanine glycine bromothymol blue (CGB) agar can be used to differentiate between the C. 
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gattii and C. neoformans species complexes, with growth of the C. gattii species complex 
producing a blue colour change (indicating the assimilation of glycine). The C. neoformans 
species complex does not grow on CGB agar, and thus fails to cause a colour change (Kwon-
Chung et al., 1982a). Serotyping can also distinguish between the two species complexes, and 
somewhat within them (Wilson et al., 1968, Meyer et al., 1999, Meyer et al., 2003), although 
the commercial kit for this test was discontinued and PCR is now widely used to determine 
the serotype when needed (Ito‐Kuwa et al., 2007). 
 
1.2.3.2 Culture-independent 
Barcoding of fungi typically involves sequencing a PCR product of the internal transcribed 
spacer (ITS) region to distinguish between different species (Schoch et al., 2012). Amplicon-
based metagenomics combines NGS technology with fungal barcoding of DNA directly 
extracted from samples, and thus allows for the culture-independent identification of fungi 
in environmental or clinical samples (Riesenfeld et al., 2004, Lindahl et al., 2013). This method 
does not rely on the visual identification of cryptococcal growth, is not affected by the 
presence of fast-growing filamentous fungi and allows for species to be considered within the 
context of the entire mycobiome (Lindahl et al., 2013). Its limitations include its need for high 
quality reference databases and complex bioinformatics analyses, questionable biological 
relevance (the presence of DNA does not necessarily equate to a live, infectious pathogen), 
unknown potential for PCR bias, and limited size of the amplicon (which can prevent more in-
depth characterisation) (Santamaria et al., 2012, Kõljalg et al., 2013, Lindahl et al., 2013, 
Tedersoo et al., 2014, Nguyen et al., 2015a). This method has not yet been compared to 
culture-based methods as a means of detecting environmental Cryptococcus spp., but it has 
been known to provide discrepant, though perhaps complementary, results when compared 
to culture in other studies of environmental fungi (Romao et al., 2017). 
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1.3  Cryptococcosis - the disease 
1.3.1 Host-pathogen-environment interactions 
Exposure to members of the C. gattii species complex usually occurs due to their inhalation 
from the environment. The infectious propagule is not yet clearly defined but considered 
most likely to be basidiospores or poorly-encapsulated yeasts (Velagapudi et al., 2009, 
Maziarz & Perfect, 2016). Inhalation then results in the deposition of the propagules into the 
upper and/or lower respiratory tract (likely dependent on the host species) at which point 
they may be cleared by the host or go on to colonise the respiratory mucosa and/or invade 
tissue to cause subclinical or clinical disease. The outcome likely depends on the size of the 
inoculum, the individual strain/s, and the anatomy and susceptibility of the host 
(Krockenberger et al., 2010, Malik et al., 2011, Maziarz & Perfect, 2016). Prolonged exposure 
to an environment with a high environmental burden of Cryptococcus spp. is likely a risk factor 
in the development of colonisation and subclinical disease, as demonstrated in koalas 
(Krockenberger et al., 2002a), and will be discussed in more detail in section 1.3.4.1. In a rat 
model of cryptococcosis caused by the C. gattii species complex (using an intratracheal 
inoculation route), the infective dose was found to be a critical factor in pathogenesis, with 
doses below a certain threshold not initiating disease (Krockenberger et al., 2010).  
After initial tissue invasion, eventual penetration into the bloodstream or lymphatics 
can lead to widespread haematogenous dissemination or spread to regional lymph nodes, 
respectively. At this stage, CNS disease often occurs, as the fungus appears to have a 
propensity to disseminate to this anatomical site (Chen et al., 2014, Maziarz & Perfect, 2016). 
Disseminated lesions are observed in a wide variety of other anatomical sites, but these are 
often smaller and are usually detected incidentally (Krockenberger et al., 2003). In animals, 
direct penetration of an invasive upper respiratory tract lesion through the cribriform plate 
of the ethmoid bone  is also suspected as a means of initiating CNS cryptococcosis (Malik et 
al., 2011).  
Consequently, the classic presenting signs of cryptococcosis tend to be indicative of 
respiratory or CNS disease, although this varies between different host species and possibly 
different genotypes or routes of infection. Although most cases of cryptococcosis due to the 
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C. gattii species complex in humans manifest as meningitis (Chen et al., 2014, Maziarz & 
Perfect, 2016), lung disease was the predominant manifestation of human disease in the 
Vancouver Island C. gattii VGII outbreak (Harris et al., 2011). A similar phenomenon was 
observed in humans with VGII disease in the NT, Australia (Jenney et al., 2004). Disease 
presentation and the primary site of lesions also varies between host species, for example, 
with domestic cats primarily presenting with upper respiratory tract disease and koalas 
exhibiting both upper and lower respiratory disease in relatively equal proportions 
(Krockenberger et al., 2003, Malik et al., 2011, Pennisi et al., 2013). This suggests that other 
factors, likely including host anatomy, local and systemic immunity and strain differences, are 
at play in the development of disease. 
Direct inoculation has also been suggested as a route of infection in cases of primary 
cutaneous cryptococcosis where no other lesions can be detected (Christianson et al., 2003). 
Leão et al. (2011) offered a pertinent example of a patient with cutaneous cryptococcosis 
caused by C. gattii VGII, likely subsequent to traumatic injuries from barbed wire. Primary 
cutaneous disease is observed in some animal cases of cryptococcosis, including cats (Pennisi 
et al., 2013), birds (Malik et al., 2003) and koalas (Krockenberger et al., 2003). An increasing 
number of case reports of primary abdominal cryptococcosis in dogs (Tangeman et al., 2015) 
has led to the consideration of ingestion as another possible route of infection, while 
inoculation via the teat canal is the likely cause of cryptococcal mastitis seen in dairies (Pal & 
Mehrotra, 1983). 
Zoonotic transmission of both the C. gattii and C. neoformans species complexes has 
been reported, but the supportive evidence for this phenomenon is weak. Two cases of 
cryptococcosis due to the C. neoformans species complex were purported zoonotic 
transmission events, with the human patients presumptively infected through exposure to 
the droppings of apparently healthy pet birds (Nosanchuk et al., 2000, Lagrou et al., 2005). 
Tsunemi et al. (2001) speculated that a human patient became infected with the C. gattii 
species complex after contact with koalas in Australia. None of these reports are supported 
by in-depth genotyping, and it appears more likely that both the humans and animals were in 
contact with a common environmental source of Cryptococcus spp. 
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1.3.1.1 Incubation period 
The incubation period of cryptococcosis caused by the C. gattii species complex, or the time 
between first contact with a host and expression of clinical signs, is usually very difficult to 
determine, as the exact time of exposure to an environmental source is often impossible to 
determine. Travellers returning from areas associated with the Vancouver Island outbreak in 
North America that later developed disease caused by an outbreak strain (C. gattii VGIIa) 
provided a unique opportunity to study this, and an incubation period ranging from 2 to 11 
months (with a median of 6 to 7 months) was established (MacDougall & Fyfe, 2006). Cases 
of cryptococcosis attributed to the C. gattii species complex were identified in Europe that 
likely exhibited several year incubation periods, or a state of dormancy, before clinical disease 
developed (Hagen et al., 2012). Other considerations of the incubation period are typically 
confined to individual case reports and are usually speculative, but nonetheless it is likely that 
it can vary greatly beyond the findings of MacDougall & Fyfe (2006). Some reports of 
cryptococcosis caused by the C. gattii species complex have speculated that incubation 
periods of less than one month (Tsunemi et al., 2001) or greater than seven years (Maccolini 
et al., 2017) are possible. An estimated three-year incubation period was recorded in one 
captive koala, based on its infection with a C. gattii VGII isolate and travel history from a VGII 
endemic area (WA to eastern Australia) (Saul, 2009).  
 The tendency for some hosts to exhibit sustained mucosal colonisation by members 
of the C. gattii species complex presents another difficulty, as the exact time of tissue invasion 
is problematic to determine. The koala is a pertinent example of this phenomenon (Connolly 
et al., 1999, Krockenberger et al., 2002a, Krockenberger et al., 2002b). This will be discussed 
further in sections 1.3.2 and 1.3.4.1. 
 
1.3.2 Colonisation 
Members of both the C. gattii and C. neoformans species complexes can colonise hosts, i.e. 
survive and/or proliferate on or in a host without causing clinical or subclinical disease. This 
typically occurs at the nasal mucosa (Malik et al., 1997b), but skin colonisation of koalas has 
also been documented (Krockenberger et al., 2002b) and lower airway colonisation is known 
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in humans (Maziarz & Perfect, 2016). The C. neoformans species complex may also be able to 
colonise the gastrointestinal tract of some species, with findings in birds of prey in Europe 
suggestive of this (Cafarchia et al., 2006b). 
Numerous studies have documented cryptococcal nasal colonisation in cats, dogs, 
ferrets, humans, koalas and squirrels (Malik et al., 1997b, Connolly et al., 1999, Krockenberger 
et al., 2002b, Duncan et al., 2005b, Duncan et al., 2006, Morera et al., 2011, Kido et al., 2012, 
Danesi et al., 2014a). Attempts to resolve koala nasal colonisation by various forms of 
systemic and topical treatment have yielded inconclusive results (Kido et al., 2012). One study 
showed that groups of captive koalas living in heavily contaminated environments and 
exhibiting cryptococcal nasal colonisation were more likely to develop subclinical disease, but 
that progression to clinical disease was relatively rare (Krockenberger et al., 2002a). The point 
at which nasal colonisation can progress to subclinical, and perhaps clinical, disease remains 
unclear (Malik et al., 2011). 
 
1.3.3 Subclinical disease 
Subclinical cryptococcosis is primarily diagnosed by the detection of cryptococcal 
antigenaemia in asymptomatic patients. Human patients with HIV/AIDS and low CD4 T cell 
counts represent a cohort notoriously susceptible to C. neoformans species complex 
cryptococcal meningitis (Fries & Cox, 2011). Early screening can lead to the detection of 
circulating cryptococcal capsular antigen in asymptomatic human patients (Yuen et al., 1994, 
Feldmesser et al., 1996), with one study identifying this phenomenon three weeks prior to 
the onset of symptoms (French et al., 2002). The methods for such detection will be discussed 
later, in section 1.3.5.1. Cryptococcal antigen screening is now recommended for all at-risk 
HIV-positive patients (with low CD4 T cell counts) (World Health Organization, 2018). This is 
particularly important in areas with a high burden of cryptococcal meningitis, such as Sub-
Saharan Africa (Rajasingham et al., 2012). 
 In animals, the primary example of subclinical cryptococcosis is the koala. Amongst 
some groups of captive koalas, over 50% of individuals can test positive for cryptococcal 
antigenaemia in the absence of clinical signs. Some of these koalas go on to develop clinical 
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disease while others can either remain persistently positive or the antigenaemia can resolve 
completely (Krockenberger et al., 2002a). This typically occurs in concert with a high 
prevalence of cryptococcal nasal colonisation and a heavy environmental presence of 
Cryptococcus spp. Although Krockenberger et al. (2002a) thoroughly explored this concept in 
captive koalas, only 14 free-ranging koalas were tested, and all were negative. A later study 
identified subclinical cryptococcosis in koalas at postmortem through the detection of small 
respiratory lesions (Krockenberger et al., 2003), while another koala with cryptococcosis was 
diagnosed incidentally while undergoing pre-shipment testing (Wynne et al., 2012). 
Cryptococcosis in koalas will be discussed further in section 1.3.4.1. Duncan et al. (2005b) 
identified that subclinical cryptococcosis can also affect cats and dogs. A follow-up study by 
the same authors found that, as in koalas, the antigenaemia either progressed to clinical 
disease, persisted or resolved spontaneously (Duncan et al., 2005a). 
 
1.3.4 Range of host species 
A broad range of host species, from protozoa and nematodes (Mylonakis et al., 2002, Malliaris 
et al., 2004) to humans and a wide variety of domestic and free-ranging animals, are 
susceptible to cryptococcosis (Malik et al., 2011, Chen et al., 2014). Some species of protozoa, 
invertebrates and rodents have also proven susceptible through their use in disease models, 
as reviewed by Sabiiti et al. (2012). More recently, zebra fish have also been used (Tenor et 
al., 2015). Rodents are also susceptible to naturally-occurring infection (Bauwens et al., 2004, 
Krockenberger et al., 2005, Payne et al., 2005, Singh et al., 2007).  Cryptococcosis has also 
been documented in amphibians (Seixas et al., 2008), reptiles (McNamara et al., 1994, Hough, 
1998) and birds (Malik et al., 2003). A huge number of eutherian mammalian species are 
susceptible to cryptococcosis, as reviewed thoroughly by Malik et al. (2011) and Singh et al. 
(2018). Reports of the disease in Australian marsupial species (particularly the koala) are also 
prevalent (Krockenberger et al., 2003, Krockenberger et al., 2005), and will be discussed 
further in section 1.3.4.1. In summary, this suggests that any host species could develop 
cryptococcosis, although some, such as domestic cats and koalas, appear comparatively more 
susceptible for reasons that are not well understood (Malik et al., 2011). Unlike in humans, 
where a link between C. neoformans species complex disease and immunocompromise is 
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well-described (Maziarz & Perfect, 2016), there is limited evidence that immunosuppression 
plays a role in animal cryptococcosis caused by the C. gattii or C. neoformans species 
complexes. Most studies have explored this issue indirectly looking for co-infection with feline 
immunodeficiency virus (FIV) or feline leukaemia virus (FeLV) in cats. A number of large 
studies have noted cryptococcosis in feline patients with FIV or FeLV co-infection but the 
prevalence has not been considered unusual and case outcomes were generally similar across 
all cats (Malik et al., 1992, O'Brien et al., 2004, O'Brien et al., 2006, Trivedi et al., 2011). A 
higher likelihood of treatment failure has been documented in FIV or FeLV-positive cats with 
cryptococcosis (Jacobs et al., 1997), however, and thus the relationship between 
cryptococcosis and immunosuppression in cats remains somewhat unclear. Therefore, the 
distinction between the C. neoformans species complex causing disease in the 
immunocompromised and the C. gattii species complex in the immunocompetent does not 
appear to apply to cats, as both species complexes are implicated across a range of patients 
(Malik et al., 1992, Malik et al., 2011, Trivedi et al., 2011). Indeed, this assumption is 
increasingly problematic in human patients (Lui et al., 2006, Maziarz & Perfect, 2016). 
This thesis focuses on the koala, with two components encompassing avian and ferret 
cases. Thus, the literature regarding koala, avian and ferret cryptococcosis will be prioritised 
for further review.  
 
1.3.4.1 Koalas and other Australian native mammals 
Cryptococcosis in koalas was first reported by Backhouse & Bolliger (1960) and was quickly 
identified as an important infectious disease for this species (Backhouse & Bolliger, 1961, 
Bolliger & Finckh, 1962). Numerous case reports appeared in the literature over the following 
four decades (Gardiner & Nairn, 1964, Canfield et al., 1986, Canfield, 1987, Spencer et al., 
1993, Malik et al., 1997a, Woods & Blyde, 1997, Makimura et al., 2002). Krockenberger et al. 
(2003) offered the first systematic insight into koala cryptococcosis, reviewing all 11 
previously published cases and adding a further 32 to the literature. The major findings of this 
study were that the C. gattii species complex was responsible for all cases (in which a species 
identification could be obtained), respiratory disease (particularly pneumonia but often 
sinonasal disease, occasionally both) was present in over 70% of cases and CNS disease in 
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37%, while 30% of koalas exhibited lesions of widespread dissemination to various other 
anatomical sites. The authors also documented cases of localised disease, including two with 
only cutaneous lesions and one with only an inguinal lymph node apparently affected. Overall, 
Krockenberger et al. (2003) confirmed cryptococcosis as a significant but still uncommon 
infectious disease of koalas, but its prevalence, particularly amongst free-ranging koalas, 
remained undetermined. This was later explored in a mortality survey conducted as part of a 
BSc (vet) thesis by Stalder (2003). Overall, this indicated that approximately 3-4% of free-
ranging koalas exhibited cryptococcal lesions at postmortem (Stalder, 2003, Krockenberger 
et al., 2005, Malik et al., 2011). Cases of cryptococcosis in captive koalas are periodically 
reported in the literature, particularly in animals in overseas zoological parks (Bercier et al., 
2012, Wynne et al., 2012, Martínez-Nevado et al., 2017, Hanaki et al., 2018), and are often 
managed but not reported in Australia (M.B. Krockenberger, pers. comm.). C. neoformans var. 
grubii was implicated as the aetiological agent in one case (involving a captive koala in Spain) 
(Martínez-Nevado et al., 2017). All other reported cases in koalas have been attributed to the 
C. gattii species complex. 
 As previously mentioned, captive koalas frequently exhibit cryptococcal nasal and skin 
colonisation (Connolly et al., 1999, Krockenberger et al., 2002b, Kido et al., 2012). Critically, 
Krockenberger et al. (2002b) also noted that colonised captive koalas were able to both 
amplify the amount of environmental Cryptococcus spp. and seed it into previously 
uncontaminated environments, although this observation was not underpinned by in-depth 
molecular analysis. In the same study, it was hypothesised that the koala sinonasal cavity 
could act as an ideal biological sampler and offer insights into environmental members of the 
C. gattii species complex in Australia. Cryptococcal nasal colonisation was also found to 
extend to koalas held in captivity overseas (Kido et al., 2012). Contrary to the findings of 
Krockenberger et al. (2002b), where the majority of colonising isolates were members of the 
C. gattii species complex, Kido et al. (2012) detected mostly C. neoformans species complex 
isolates. Another Australian study also found a high proportion of C. neoformans species 
complex isolates (Connolly et al., 1999). Subclinical disease in captive koalas was defined by 
Krockenberger et al. (2002a) using latex cryptococcal antigen agglutination testing (LCAT), a 
serological diagnostic test that was successfully trialled by Malik et al. (1996b) in a few koalas 
and will be further described in section 1.3.5.1. A case of subclinical disease was hinted at in 
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a report by Makimura et al. (2002), where a koala exported to Japan later died of 
cryptococcosis that was presumably acquired in Australia, and another case was successfully 
identified through pre-shipment testing of a captive individual (Wynne et al., 2012). Despite 
attempts to detect cryptococcal colonisation (Krockenberger et al., 2002b) and asymptomatic 
antigenaemia (Krockenberger et al., 2002a) in small numbers of free-ranging koalas, this has 
not been reported to date and there have been no systematic studies of this issue. It therefore 
remains possible that both occur because of the artificial amplification of the C. gattii species 
complex in captivity, rather than occurring in nature. 
The host-pathogen-environment interactions involved in the comparatively higher 
prevalence of cryptococcosis in koalas and the propensity for them to be infected or colonised 
by members of the C. gattii species complex remains unclear, but their close and frequent 
contact with eucalypts has long been speculated to play an important role (Krockenberger et 
al., 2003). E. camaldulensis and E. tereticornis are commonly used feed trees for koalas (Lee 
et al., 1988), and have strong associations with C. gattii VGI (Ellis & Pfeiffer, 1990, Pfeiffer & 
Ellis, 1992).  Koalas are not generally considered to enter or use eucalypt hollows but there 
are occasional anecdotal reports, including two recent observations of this behaviour (both 
occurring in summer in the Liverpool Plains region of NSW) (J. Lemon, pers. comm.; A. Rus & 
A. Kan, pers. comm.). There are, however, no systematic studies on this behaviour and how 
often it occurs. The Liverpool Plains region suffered a notorious heatwave in which an 
estimated 25% of the koala population was killed (Lunney et al., 2012). With eucalypt tree 
hollows exhibiting relatively stable internal temperatures (Saul, 2009), it is reasonable to 
assume that koalas in this area could use tree hollows for shelter on extremely hot days.  
Krockenberger et al. (2005) summarised cryptococcosis in other native Australian 
animals and suggested that it is much more sporadic than in the koala. Many other native 
Australian animals regularly use eucalypts and their hollows for nesting and shelter 
(Goldingay, 2009), and so it remains unclear as to why a similarly high prevalence of disease 
is not seen in these species. Brushtail possums (Trichosurus vulpecula) in the Sydney region 
were opportunistically tested for cryptococcal nasal colonisation and antigenaemia, and all 
were negative (M.B. Krockenberger, unpublished data). Many reports of cryptococcosis in 
Australian native wildlife remain unpublished (thus difficult to access), are not peer reviewed, 
have minimal case details and/or do not definitively identify the causative organism, making 
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systematic review difficult. Published reports encompass monotremes (Ladds, 2009), 
numbats (Gaynor et al., 1990), dasyurids (Holz, 2008), bandicoots and bilbies (Lynch, 2008), 
wombats (Reece & Hartley, 1994) possums and gliders (Booth, 1994, Reece & Hartley, 1994), 
macropods (Canfield & Hartley, 1992, Vaughan et al., 2007, Vogelnest & Portas, 2008) and 
rodents (Payne et al., 2005). Most of these reports concern captive animals, meaning that our 
understanding of the prevalence of cryptococcosis in free-ranging Australian wildlife is 
extremely limited. 
There is no evidence that immunocompromise or co-infection plays a role in 
cryptococcosis in koalas (Krockenberger et al., 2003). Koala retrovirus (KoRV) co-infection 
could potentially predispose koalas to develop symptomatic cryptococcosis. There are many 
known variants of KoRV, with some (KoRV-A) considered endogenous and having no known 
immune impacts, while exogenous variants (such as KoRV-B) have been associated with 
alterations to the immune system, chlamydiosis and lymphoma/leukaemia (Xu et al., 2013, 
Maher & Higgins, 2016, Waugh et al., 2017). KoRV-A has been found in the genome of 100% 
of koalas in some areas of eastern Australia (Simmons et al., 2012), but KoRV-B is presumed 
to be at a lower prevalence (Waugh et al., 2017). The relationship between KoRV infection 
and cryptococcosis is unknown. Cryptococcosis and KoRV co-infection has been reported in 
one captive koala in Japan, but it is unclear which variant/s the authors tested for (Hanaki et 
al., 2018). There have been some studies into the major histocompatibility complex (MHC) in 
the koala, and a reasonable diversity of MHC II has been shown in many populations (Jobbins 
et al., 2012, Lau et al., 2014b). Some MHC II variants and other immune genes have been 
associated with the development of chlamydiosis (Lau et al., 2014a, Johnson et al., 2018). It 
is possible that similar factors could be involved in cryptococcosis in koalas, but this remains 
untested. Anatomy could also play a role in the propensity of koalas to develop colonisation 
and upper respiratory tract cryptococcosis. Hemsley et al. (2013) noted the presence of a 
large ventral conchal sinus that was deemed likely to greatly slow airflow through the nasal 
passages, potentially allowing more time for inhaled particles, such as cryptococcal 
basidiospores, to adhere to the mucosa. The same study also found that the complexity of 
the nasal turbinates was greatly reduced in koalas compared to most mammals, which could 
explain why koalas have an equal, if not greater, tendency to develop lower respiratory tract 
disease (Krockenberger et al., 2003), as less filtering of inspired gases might facilitate 
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deposition of infectious propagules in the lower airways. As an aside, the same phenomenon 
might explain how cetaceans develop cryptococcosis (Gales et al., 1985), potentially from low 
concentrations of Cryptococcus spp. in seawater (Kidd et al., 2007b) . 
 
1.3.4.2 Birds 
Avian cryptococcosis was first reported by Griner & Walch (1978) and sporadic case reports 
followed until all 11 published cases, and 15 new cases, were presented and thoroughly 
reviewed by Malik et al. (2003). Parrots accounted for most of the reports, with a few cases 
in Columbiformes, kiwis (Apteryx mantelli) and domestic poultry also noted. Most cases 
presented with upper respiratory tract disease, including lesions of the nasal cavity and 
sinuses. Invasive lesions that had extended from the respiratory tract into neighbouring 
tissues, such as the beak and subcutis of the infraorbital region, were also observed (Malik et 
al., 2003). Localised cutaneous lesions, pneumonia, air sac disease and lesions of 
dissemination in the brain, kidney, bone, along with other visceral organs were occasionally 
observed. Malik et al. (2003) also noted that most cases in Australia were attributable to the 
C. gattii species complex and speculated that cases caused by the C. neoformans species 
complex (mostly in North America and Europe) may have involved immunocompromised 
individuals. This was based on the observation that widespread dissemination to central 
anatomical sites mostly occurred in cases involving the C. neoformans species complex. The 
core body temperature of birds has generally been considered too high to allow for the 
growth of Cryptococcus spp., and this was also proposed as a reason for upper respiratory 
lesions at more peripheral sites being the primary presentation (Malik et al., 2003). A study 
of the C. neoformans species complex, however,  found that it was able to proliferate at avian 
core body temperature, but that avian macrophages were capable of suppressing its growth, 
and this may explain the rarity of disseminated disease in birds (Johnston et al., 2016). 
 A handful of reports of avian cryptococcosis have followed since the 2003 review. 
Notably, an outbreak in psittacine birds at a Brazilian aviary caused by the C. gattii species 
complex was reported (Raso et al., 2004). Many of the birds had upper and lower respiratory 
tract disease, and dissemination to the viscera was common. The cause of the outbreak could 
not be identified. One case in a parrot (with a fluctuant cutaneous mass) was described as 
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part of the Vancouver Island outbreak investigation (Lester et al., 2004), while Krockenberger 
et al. (2005) mention a further five cases in Australian psittacine birds (with no case details 
provided). An unusual case of C. gattii species complex cryptococcosis occurred in a parrot 
where the primary and presenting lesion was a cryptococcal osteomyelitis of the humerus 
(Molter et al., 2014). The authors speculated that, as a pneumatic bone, infection could occur 
here directly via an aerosol, or haematogenously (cryptococcal lesions were also reported in 
the trachea). C. gattii VGIIa was the culprit in another case with classic upper respiratory tract 
disease and widespread disseminated lesions (Maccolini et al., 2017). These cases further 
reinforce the observations that cases are mostly seen in psittacine birds, upper respiratory 
tract lesions account for the majority of cases and that both the C. gattii and C. neoformans 
species complexes can be associated with disseminated disease (Malik et al., 2003, Raso et 
al., 2004, Maccolini et al., 2017). 
 Many species of native Australian parrots use eucalypt tree hollows for shelter and 
nesting (Goldingay, 2009), and this could present an exposure risk to C. gattii VGI (and possibly 
VGII, but its niche remains largely cryptic) for some avian species. Little is known about the 
prevalence of cryptococcosis in free-ranging birds in Australia, or indeed anywhere 
worldwide. Therefore, it can only be speculated that the hollow-dwelling tendencies of some 
parrots could play a role in infection. 
 
1.3.4.3 Ferrets 
Cryptococcosis in domestic ferrets (Mustela putorius furo) is reasonably well-documented but 
uncommon, with the first published report in 1954 (Skulski & Symmers, 1954) and with Malik 
et al. (2002), Morera et al. (2011) then Wyre et al. (2013) later collectively reviewing the 16  
published cases. Two cases in WA were reported that were not included in these reviews 
(McGill et al. 2009), and Morera et al. (2014) later added another two cases to the literature. 
Ferrets are susceptible to members of both the C. gattii and C. neoformans species 
complexes, with the aetiological agent in the reported cases divided roughly equally between 
the two (Morera et al., 2011, Wyre et al., 2013). Sex differences have been noted amongst 
the reported cases, with more male ferrets (13) than females (3) affected (based on the 
publications where sex is reported) (Wyre et al., 2013). Nearly half of the published cases 
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have been reported in Australian ferrets (Lewington, 1982, Malik et al., 2000, Malik et al., 
2002, McGill et al., 2009), with the rest divided amongst North America and Europe (Wyre et 
al., 2013), although this may simply reflect global patterns of ferret ownership and/or 
research groups with an interest in the disease in this host species. 
 Respiratory disease is the most common manifestation of cryptococcosis in ferrets, 
with both the upper and lower respiratory tracts affected. Nasal discharge, mass lesions or 
facial asymmetry, sneezing, coughing and dyspnoea are all common clinical signs of ferret 
cryptococcosis (Malik et al., 2002, Morera et al., 2011, Wyre et al., 2013). Neurological disease 
(Greenlee & Stephens, 1984) and lymphadenopathies (Malik et al., 2002, Hanley et al., 2006) 
have also been reported. Cases presenting with cutaneous (Malik et al., 2002), ocular (Morera 
et al., 2011, Ropstad et al., 2011), gastrointestinal (Hanley et al., 2006, Eshar et al., 2010) and 
musculoskeletal disease (Malik et al., 2002) also occur. 
 Immunosuppression and co-morbidities could play a role in some cases of ferret 
cryptococcosis, with one case having both a history of recent treatment with systemic 
corticosteroids and suffering from congestive heart failure (Greenlee & Stephens, 1984), one 
with lymphoma (Erdman et al., 1992) and another that tested positive for Aleutian virus 
(Morera et al., 2014). There is speculation that ferrets may be more susceptible to 
cryptococcosis than some other species based on their behavioural tendencies [often sniffing, 
digging and exploring in dirt and confined spaces (Boyce et al., 2001)] and propensity to 
develop various upper respiratory tract ailments, collectively known as ‘snuffles’, (Lewington, 
2007, Johnson-Delaney & Orosz, 2011) which present co-morbidities that could affect their 
local and systemic immune responses. 
 
1.3.5 Diagnosis 
An early presumptive diagnosis of cryptococcosis is often obtained through the direct 
visualisation of suspect organisms (e.g. in cytological smears from needle aspirates, 
cerebrospinal fluid (CSF), nasal washings or bronchoalveolar lavage fluid specimens) in  
patients with consistent clinical signs, such as respiratory or neurological disease (Chen et al., 
2014, Sykes & Malik, 2014, Maziarz & Perfect, 2016). Confirmation of the diagnosis can then 
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be achieved, and the possibility of invasive disease caused by other pathogenic yeasts ruled 
out, by specific serological antigen testing and/or mycological culture (Sykes & Malik, 2014, 
Maziarz & Perfect, 2016). In a veterinary context, the initial visualisation of organisms is 
typically achieved through the cytopathological evaluation of aspirates or smears taken from 
masses and/or exudates (using a rapid Romanowsky-type stain). Histopathology (with 
standard haematoxylin and eosin [H & E] staining, or variably fungal specific stains such as 
mucicarmine or periodic acid Schiff) is also often used, but has a longer turnaround time 
(Malik et al., 1992, Blanshard & Bodley, 2008, Pennisi et al., 2013, Sykes & Malik, 2014).  
Culture of cryptococcal organisms directly from lesions, blood or CSF remains the gold 
standard for diagnosis as it allows for the definitive phenotypic and genotypic identification 
of the causative organism and permits downstream antifungal susceptibility testing (Chen et 
al., 2014, Sykes & Malik, 2014). Culture of Cryptococcus spp. can involve the use of differential 
and/or selective media such as bird seed agar (useful when sampling normally contaminated 
sites such as the nasal cavity) or CGB agar, but standard mycological media such as SDA are 
primarily used (as mentioned in section 1.2.3.1) (Kwon-Chung et al., 1982a, Staib et al., 1987). 
Culture also allows for other identification procedures to be performed, such as MALDI-TOF 
mass spectrometry (Firacative et al., 2012). Culture results must be interpreted in the context 
of the clinical signs and be supported by other diagnostic tests, as a positive culture could 
simply indicate mucosal colonisation in some samples (e.g. nasal swabs) (Malik et al., 1997b, 
Connolly et al., 1999, Maziarz & Perfect, 2016). 
 
1.3.5.1 Serological testing 
In animals, the LCAT remains one of the most frequently employed serological tests for 
cryptococcal antigen detection. This test uses latex particles coated with a monoclonal 
antibody that targets the capsular polysaccharide (GXM), resulting in a visible agglutination 
reaction in the presence of cryptococcal antigen (Merdian Bioscience, 2016). It is well-
validated (particularly in humans, cats, dogs and koalas) and considered highly sensitive and 
specific for cryptococcosis (Temstet et al., 1992, Malik et al., 1996b). False results are largely 
avoided if pronase pre-treatment and heat inactivation steps are adhered to (Gray & Roberts, 
1988, Malik et al., 1996b). The LCAT can also be used to determine the antigen titre, which 
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has proven to be a useful tool to monitor response to treatment in cats and dogs (Malik et al., 
1996b), and can be used to detect subclinical disease in cats, dogs and koalas (Krockenberger 
et al., 2002a, Duncan et al., 2005b). The major limitations of this test include its requirement 
for an experienced technician and laboratory equipment, prolonged turnaround time, and 
the risk of false results due to cross-reactivity, contaminants or uncommon varieties of the C. 
gattii and C. neoformans species complexes (such as hybrids) (Heelan et al., 1991, Blevins et 
al., 1995, Wilson et al., 2011, Rickerts et al., 2015, Tone et al., 2016). 
A lateral flow immunoassay (LFA) for cryptococcal capsular antigen, developed in 2010 
(CrAg® LFA, IMMY, Norman, Oklahoma, USA), revolutionised the diagnosis of cryptococcosis 
in humans (particularly in the developing world) through its use as a simple, inexpensive 
point-of-care diagnostic test (Jarvis et al., 2011, Lindsley et al., 2011, Kozel & Bauman, 2012). 
This test incorporates two monoclonal antibodies (to cover all serotypes of the C. gattii and 
C. neoformans species complexes) that bind to cryptococcal GXM and are then wicked along 
the test strip to interact with immobilised antibodies on the test line. Here, the antibody-
antigen complexes form a sandwich to produce a visible positive result (Kozel & Bauman, 
2012, IMMY, 2016). Originally intended for use with serum, plasma and CSF samples, it has 
since also proven useful for whole blood and urine (Jarvis et al., 2011, Huang et al., 2015, 
Williams et al., 2015, Vidal et al., 2016, Brito-Santos et al., 2017). The test is shelf-stable, has 
a rapid turnaround time, requires minimal equipment and is simple to interpret (Kozel & 
Bauman, 2012). The LFA is proven to be more sensitive than the LCAT to lower levels of 
antigen both in clinical specimens and GXM-spiked saline (McMullan et al., 2012, Gates-
Hollingsworth & Kozel, 2013, Boulware et al., 2014), which has led to its use as a screening 
test for asymptomatic cryptococcal antigenaemia in high-risk human patients (Rajasingham 
et al., 2012). It can detect all molecular types and hybrids of the C. gattii and C. neoformans 
species complexes (Kozel & Bauman, 2012, Gates-Hollingsworth & Kozel, 2013, Rickerts et al., 
2015), and has relatively few false-positive (Rivet-Dañon et al., 2015, Dubbels et al., 2017) and 
false-negative results reported (all hypothesised to have been caused by the prozone, or 
‘high-dose hook’ effect) (Lourens et al., 2014, Lee et al., 2018). The LFA has been validated by 
many clinical diagnostic laboratories around the world for use in humans (Jarvis et al., 2011, 
Lindsley et al., 2011, McMullan et al., 2012, Boulware et al., 2014, Huang et al., 2015). The 
requirement for using multiple test strips to determine a semi-quantitative antigen titre may 
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prove problematic in a veterinary context, where there are typically more cost constraints. 
Nevertheless, it shows great potential (particularly as a screening test) for use in veterinary 
hospitals, field research and diagnostic laboratories, but remains unvalidated in animals. 
Several similar immunochromatography methods have been developed more recently by 
other manufacturers, most notably the CryptoPS (BioSynex®, Illkirch-Graffenstaden, France) 
and the StrongStep® (Liming Bio, Nanjing, China). The CryptoPS showed excellent specificity 
in all sample types but variable sensitivity (particularly in serum), although it shows promise 
as a useful test for the screening of urine (Temfack et al., 2018). The StrongStep® exhibited 
good results in CSF samples, but its performance in plasma samples proved less than desirable 
(Mpoza et al., 2018). Further studies are required to determine the reliability and utility of 
these and other newly developed cryptococcal antigen assays (Rajasingham et al., 2019), 
particularly in animals. 
 
1.3.5.2 Adjunct diagnostic tools 
Diagnostic imaging can be an adjunct diagnostic tool, as although it cannot definitively 
confirm cryptococcosis, many techniques can help to identify and characterise the disease in 
the context of the patient’s clinical signs (particularly in the event of mass lesions). 
Ultrasonography, radiography and endoscopy are often used in animals and although these 
methods can identify some mass lesions and accumulations of abnormal fluid, they do not 
provide a tissue for cytology, histology and/or culture, which is ultimately required to make a 
definitive diagnosis of cryptococcosis. Ultrasonography and endoscopy, however, also 
provide opportunities to accurately collect samples for further diagnostic testing, such as 
aspirates or punch biopsies (Sykes & Malik, 2014, Martínez-Nevado et al., 2017). Advanced 
cross-sectional imaging techniques, including computed tomography (CT) and magnetic 
resonance imaging (MRI), are frequently used in human patients thought to have 
cryptococcosis, and are often especially helpful for evaluating the nasal cavity, middle ear (CT) 
and CNS (MRI) (Chen et al., 2014, Maziarz & Perfect, 2016). There are many examples of the 
successful use of advanced imaging in referral veterinary settings (Woods & Blyde, 1997, 
Sykes et al., 2010, Kwiatkowska et al., 2011, Bercier et al., 2012, Siak et al., 2015, Martínez-
Nevado et al., 2017), and although they are considered highly useful tools in the diagnosis of 
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cryptococcosis (Sykes & Malik, 2014), these technologies are not accessible to many general 
practice veterinarians and patients due to their high cost. General anaesthesia (GA) is usually 
required to perform CT scans or MRI studies in animals, which can introduce an added 
element of cost and risk to the investigation, for example GA may have exacerbated CNS 
disease in one koala (Martínez-Nevado et al., 2017). 
CSF collection and analysis, although routinely performed in humans for antigen 
testing, culture and/or India ink visualisation of cryptococcal organisms (Chen et al., 2014, 
Maziarz & Perfect, 2016), is generally not recommended in animals unless other diagnostic 
tests have proven inconclusive, due to the risk of cerebellar tonsil herniation (Pennisi et al., 
2013, Sykes & Malik, 2014). Nevertheless, there are many reports of its collection during the 
work-up of animal cases of cryptococcosis (Sykes et al., 2010, Kwiatkowska et al., 2011), but 
in two cases (both localised sinonasal disease in koalas) it yielded no evidence of cryptococcal 
disease (Woods & Blyde, 1997, Wynne et al., 2012). Sometimes CSF is collected from animals 
in which cryptococcosis was not initially considered as a differential diagnosis, and yet its 
proper analysis yields a definitive diagnosis of cryptococcosis; this happens most often in 
regions where the disease is uncommon (R. Malik, pers. comm.). CSF collection in companion 
animals is typically performed in a referral hospital setting under GA, and ideally MRI or CT is 
undertaken first to assess the risk for cerebellar tonsil herniation. Because of the high cost 
and risks associated with GA, advanced imaging and CSF collection, it is prudent to perform 
serological testing for cryptococcal antigen before embarking on these procedures (Sykes & 
Malik, 2014). Should the patient be antigen positive, the animal’s owner and attending 
veterinarian can then determine whether the risk and expense of further investigation is 
justified. 
In free-ranging animals, diagnoses are often made at postmortem examination, thus 
appropriate samples for antigen testing and mycological culture may not have been collected 
(especially when the ante-mortem diagnosis of cryptococcosis had not been suspected). In 
these cases, immunohistochemistry can be used to confirm which species complex is 
implicated in a suspect cryptococcal lesion observed during histopathological examination of 
tissues (Krockenberger et al., 2001, Krockenberger et al., 2003). The extraction of DNA from 
formalin-fixed paraffin-embedded (FFPE) tissues can also often allow for PCR amplification of 
the ITS region and barcoding analysis (Meason‐Smith et al., 2017). 
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1.3.6 Treatment 
In humans, the antifungal treatment guidelines for cryptococcosis are well-described and 
follow the steps of induction, consolidation and maintenance (or suppression) (Perfect et al., 
2010, World Health Organization, 2018). For the induction phase, the recommended 
treatment is generally intravenous amphotericin B (AMB) and oral (or intravenous) 
flucytosine for a period of 2-6 weeks, with the exact time depending on the clinical status of 
the patient, the type of disease present and sometimes also the causative organism (Perfect 
et al., 2010, Chen et al., 2013). A two-week induction protocol is the current recommendation 
for HIV-infected patients, and this ideally involves a week of AMB and flucytosine combination 
therapy followed by a week of high-dose fluconazole (World Health Organization, 2018). The 
consolidation phase then typically involves a high dose of fluconazole given as a monotherapy 
for approximately eight weeks, ideally using therapeutic monitoring to ensure optimal blood 
levels are obtained (Perfect et al., 2010, World Health Organization, 2018). Fluconazole is 
continued in the maintenance phase, but the dose is roughly halved. This phase continues 
typically for 6-12 months (but can be much longer). Itraconazole (or another triazole) can be 
substituted for fluconazole if there is resistance or it is not well tolerated by the patient 
(Perfect et al., 2010, Mourad & Perfect, 2018, World Health Organization, 2018). 
The treatment of cryptococcosis in animals should ideally approach these guidelines, 
but often this is not possible. For example, flucytosine can be difficult to source, cost-
prohibitive, problematic to administer (due to 6-8 hourly dosing) and associated with drug 
reactions in some species (particularly dogs), making it uncommonly used (Sykes & Papich, 
2014). The administration of intravenous AMB can also be difficult due to the requirement 
for prolonged hospitalisation, which can make the process cost-prohibitive and logistically 
difficult for some animals, such as koalas (and other wildlife species) or fractious cats and 
dogs (Malik et al., 1996a). The ideal protocol in all animal species involves the initial use of 
AMB, to a cumulative dose of approximately 20-40 mg/kg, and the addition of an oral triazole 
antifungal (most commonly fluconazole, but itraconazole is also often used).  
After AMB treatment is ceased, triazole monotherapy should be continued until the 
animal shows full resolution of all clinical signs and until cryptococcal antigenaemia is no 
longer detectable. It is generally recommended that treatment continues at least one month 
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beyond a negative result on a serological cryptococcal antigen test, and that follow-up 
serological testing is performed to confirm that the animal remains antigen-negative. This can 
take months to years, and sometimes results in life-long treatment (Malik et al., 1996b, 
Blanshard & Bodley, 2008, Pennisi et al., 2013, Sykes & Malik, 2014). Decreases in sequential 
antigen titres tend to indicate a favourable response to treatment, although they do not 
always reflect the clinical status of the patient (with the fall in the LCAT typically lagging 
behind a favourable clinical response) (Malik et al., 1996b). In the event of a failure to respond 
to treatment (i.e. a lack of clinical response and/or persistence or increase from the baseline 
antigen titre), antifungal susceptibility testing and therapeutic drug concentration monitoring 
are recommended to determine if resistance or an ineffective dosing regimen are the 
underlying cause (Sykes & Malik, 2014). 
In animals, the dose of the oral triazole is often not adjusted [as it is in humans from 
the consolidation to maintenance phase (Perfect et al., 2010, World Health Organization, 
2018)] unless evidence from therapeutic drug level monitoring, antifungal susceptibility 
testing or the condition of the patient suggest that this is required (Sykes & Malik, 2014, Sykes 
& Papich, 2014). Antifungal drugs, adjunct therapies and the peculiarities of treatment in 
different animal species (focusing on koalas, birds and ferrets) will be discussed further in this 
section. 
 
1.3.6.1 Azoles 
Azole antifungals are fungistatic inhibitors of fungal membrane synthesis that remain a 
cornerstone of the treatment of cryptococcosis. Fluconazole and itraconazole are triazoles 
widely used in a variety of animal species, likely due to their affordability, ease of oral 
administration and larger scale reports of their successful use, particularly in cats and dogs 
(Malik et al., 1992, Medleau et al., 1995, O'Brien et al., 2006, Sykes & Malik, 2014, Sykes & 
Papich, 2014). Fluconazole exhibits greater CNS penetration than itraconazole (Felton et al., 
2014) and is generally cheaper. The lower cost is attributable to reliable generic formulations 
being readily available, and the ability of compounding pharmacists to offer a consistent 
product formulated to the exact size of the patient and/or presented in a formulation that is 
palatable to animals. Fluconazole is generally exceptionally well tolerated and has few 
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reported adverse effects, resulting in it often being the first choice for treatment in all animal 
species, including birds (Sykes & Malik, 2014). Itraconazole has become increasingly popular 
due to more stable plasma levels at once daily dosing (Sykes & Malik, 2014), which is 
logistically preferable in many animal patients. Problems with the absorption of compounded 
formulations (Molter et al., 2014, Renschler et al., 2018) and fewer generic options 
(particularly in liquid form), however, often make this drug much more expensive than 
fluconazole. Although both fluconazole and itraconazole are usually well tolerated in animals, 
inappetence, anorexia and vomiting can occur with either, and it is recommended that liver 
function is monitored regularly during treatment due to the potential for hepatotoxicity 
(particularly during itraconazole therapy) (Sykes & Papich, 2014).  
As mentioned previously, either drug may be selected initially and given in conjunction 
with AMB, particularly in cases of severe cryptococcosis (which could be defined as disease 
that is extensively invasive, disseminated and/or in which the CNS is involved), for an 
induction period (Sykes & Malik, 2014). Although not ideal, triazole monotherapy (with no 
AMB induction period) can also be suitable to treat some milder cases in humans and animals, 
particularly if subclinical or localised, minimally-invasive cryptococcosis is present (Sykes & 
Malik, 2014, Mourad & Perfect, 2018). For example, mild to moderate pulmonary disease 
(with no CNS disease) in humans can be treated with fluconazole monotherapy (Perfect et al., 
2010). Likewise, uncomplicated cryptococcal rhinosinusitis in cats and koalas can often be 
successfully treated by long courses of high dose fluconazole, with therapeutic monitoring to 
ensure the serum fluconazole concentration is at least twice or even four-times the minimum 
inhibitory concentration (MIC) of the isolate (R. Malik, pers. comm.). Evidence in cats suggests 
that if presented in a timely manner for veterinary attention, many respond well to 
fluconazole or itraconazole alone (particularly if there is no dissemination or CNS 
involvement) (O'Brien et al., 2006).  
Several other azole antifungals are occasionally used to treat cryptococcosis. 
Ketoconazole tends to be avoided due to an increased risk of side effects, such as 
hepatotoxicity (Sykes & Papich, 2014), but examples of its successful use have been reported, 
including one in a koala (Woods & Blyde, 1997). It was favoured by many Canadian 
veterinarians treating C gattii VGII cases seen as part of the Vancouver Island outbreak (Lester 
et al., 2004). Ketoconazole is no longer commercially available in oral formulations in 
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Australia, but it can be sourced by compounding pharmacists and it continues to be reported 
as a treatment option in cats (Pennisi et al., 2013). Other triazole antifungals, such as 
voriconazole and posaconazole, are expensive and have not been thoroughly validated in 
animals. Voriconazole has potential as a useful treatment option in dogs but has been 
associated with neurological abnormalities in cats (including ataxia and visual deficits), 
probably due to excessive blood concentrations as a result of not using therapeutic 
monitoring (Quimby et al., 2010, Sykes & Papich, 2014). Voriconazole might have a place in 
managing fluconazole and/or itraconazole resistance, as it has good penetration of the CNS 
(Felton et al., 2014). Posaconazole exhibits a broad spectrum of antifungal activity, is generally 
very well tolerated and is available in a palatable liquid formulation (suitable for cats and small 
dogs) (Sykes & Papich, 2014) or as a sustained release tablet (relatively cost effective for 
medium and large dogs) (R. Malik, pers. comm.). It remains much more expensive than 
fluconazole, however, and has found no special utility for treating human cryptococcosis 
(Mourad & Perfect, 2018). It shows some potential as a treatment for cryptococcosis in 
animals, but there is very limited data regarding its use (Sykes & Papich, 2014, Kendall & 
Papich, 2015, Gharibi et al., 2017). 
 
1.3.6.2 Amphotericin B 
AMB is a polyene antifungal, thought to be fungicidal at high doses, that binds irreversibly to 
sterols in the fungal cell membrane (thus creating channels and allowing for leakage of ions). 
It is the second pillar of treatment for cryptococcosis in animals (Malik et al., 1996a, Sykes & 
Papich, 2014). Although only detectable at low concentrations in the brain and CSF after 
intravenous administration, AMB still achieves clinical resolution in humans and animals with 
cryptococcal meningitis (O'Brien et al., 2006, Felton et al., 2014, Sykes & Malik, 2014, Sykes 
& Papich, 2014, Stott et al., 2018). It is available in several preparations, most notably as AMB 
deoxycholate or in lipid formulations (including liposomal and lipid complex). AMB 
deoxycholate is associated with higher risks of nephrotoxicity and other adverse effects 
compared to lipid formulations, and thus is usually not considered the gold standard for 
human patients but remains an important option in animals due to its utility in a 
subcutaneous administration protocol (discussed further in the following paragraph). AMB 
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deoxycholate is also typically more cost effective, which makes it an ideal choice in many 
veterinary settings and in the developing world (Sykes & Papich, 2014, Mourad & Perfect, 
2018, World Health Organization, 2018). AMB deoxycholate is likely the most commonly used 
form in Australian veterinary hospitals (R. Malik, pers. comm.). Liposomal AMB is 
recommended for use in humans wherever possible due to a decreased risk of nephrotoxicity 
and other adverse effects (Mourad & Perfect, 2018), but it is rarely used in animals due to its 
cost. The most common lipid formulation used intravenously in animals is AMB lipid complex, 
largely because it is more cost effective that the liposomal form. The risk of adverse effects 
for AMB lipid complex typically falls between the deoxycholate and liposomal formulations 
(Sykes & Papich, 2014). 
Addition of AMB to an azole treatment protocol is recommended in most cases of 
animal cryptococcosis where there is severe invasive disease, disseminated disease or CNS 
involvement (Sykes & Malik, 2014), but it also can be used for subclinical disease in koalas 
(Govendir et al., 2016), particularly if the antigen titre fails to change in response to protracted 
azole monotherapy (M.B. Krockenberger, pers. comm.). The cumulative dose requirement is 
not well characterised but is thought to range from approximately 20-40 mg/kg (Malik et al., 
1996a, Pennisi et al., 2013), given over many months. Short breaks can be taken during 
therapy if there is any evidence of impaired kidney function, as any AMB-related 
nephrotoxicity is transient if detected promptly (Sykes & Papich, 2014). The risk of 
nephrotoxicity and its expense (primarily due to the need for slow intravenous administration 
using a fluid pump, and/or the higher cost of lipid formulations) present limitations to the use 
of AMB in animals. Malik et al. (1996a) circumvented some of these concerns by instead 
administering AMB deoxycholate subcutaneously (lipid formulations cannot be used this 
way). This involved the AMB being administered two to three times weekly (to cats and dogs 
with cryptococcosis) as a subcutaneous bolus in a 0.45% saline and 2.5% dextrose solution. 
The same technique has been adapted for koalas (Govendir et al., 2016). 
 
1.3.6.3 Other treatments 
Flucytosine presents a useful treatment alternative to azoles in cats but is generally not used 
in dogs due to an association with toxic epidermal necrolysis (Panciera & Bevier, 1987, Malik 
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et al., 1996c, Sykes & Malik, 2014). Monotherapy with flucytosine is not recommended 
because of the rapid emergence of mutational resistance during a course of therapy, but 
when given in concert with AMB there is synergy (Beggs, 1986, Schwarz et al., 2003). This 
combination is considered a highly effective treatment protocol and is the gold standard for 
human patients (Mourad & Perfect, 2018, World Health Organization, 2018). The various 
downsides of flucytosine therapy in animals (high cost, limited access, requirement for dosing 
3-4 times a day and minor risks of bone marrow dyscrasias) mean that it is rarely used, mainly 
in cats with CNS cryptococcosis (Sykes & Papich, 2014). Terbinafine presents another 
treatment option for cryptococcosis and can lead to good outcomes in some animals, but its 
use is generally reserved for cases of azole resistance, or where other antifungal drugs have 
failed to resolve clinical signs (Pennisi et al., 2013, Sykes & Malik, 2014). 
 Symptomatic and supportive care is an important aspect of treatment, potentially 
including fluid therapy, nutritional support (e.g. assisted feeding), seizure management and 
oxygen supplementation (Sykes & Malik, 2014). Short term anti-inflammatory corticosteroid 
use has also been reported to improve outcomes for cats and dogs with CNS cryptococcosis 
during preliminary therapy (when the sudden release of fungal antigens can cause transient 
deterioration in neurological function) (Sykes et al., 2010). Surgical removal of accessible 
lesions or debulking (in conjunction with antifungal therapy) is also recommended in some 
patients (Malik et al., 2002, Malik et al., 2003, Bercier et al., 2012, Pennisi et al., 2013), but 
medical treatment alone is considered capable of resolving even large cryptococcal lesions 
(Sykes & Malik, 2014). 
 
1.3.6.4 Koalas, birds and ferrets 
Koalas with cryptococcosis present unique problems in relation to implementing practical 
therapy. Studies have shown that koalas require large doses of xenobiotics, including 
antifungal agents. For example, roughly double the dose of oral fluconazole (on a mg/kg basis, 
when compared to cats and dogs) is required for koalas to reach adequate plasma 
concentrations (Black et al., 2014, Govendir et al., 2016). Thus, extrapolating dose rates from 
companion animal species will lead to ineffective therapy (Govendir, 2018). This pattern of 
low bioavailability and/or high hepatic biotransformation for orally administered agents is not 
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unique to antifungals and is reflected amongst other drugs (xenobiotics) administered orally 
to koalas, including non-steroidal anti-inflammatories and antibiotics (Griffith et al., 2010, 
Kimble et al., 2013). The exact mechanism for this impaired bioavailability is unknown but 
may reflect poor absorption due to the huge amounts of particulate material in the koala 
gastrointestinal tract, which could potentially act as a ‘lipid sink’ (Blanshard & Bodley, 2008). 
This does not, however, explain the koala’s higher requirement for many drugs administered 
parenterally (Griffith et al., 2010, Kimble et al., 2013, Black et al., 2014, Govendir et al., 2016). 
Enhanced hepatic metabolism in koalas (hypothesised to be related to their diet of eucalypt 
leaves, which contain high concentrations of plant secondary metabolites) is also considered 
likely to be involved, with oral bioavailability especially impacted by an accentuated first-pass 
effect (Pass & Brown, 1990). Several studies have found that cytochrome P450 
monooxygenase (CYP) activity is enhanced in koalas, as reviewed by Govendir (2018). A recent 
study of the koala genome characterised an expansion of the CYP pathways when compared 
to other species and revealed that these had high hepatic expression (suggestive of their role 
in detoxifying eucalypts and likely also other xenobiotics) (Johnson et al., 2018). Other factors 
that can hamper the treatment of koalas include difficulties in their hospitalisation and the 
maintenance of intravenous access, along with their tendency to present late in the course of 
disease, as will be discussed further in section 1.3.7.2. 
 Nevertheless, some protocols have been suggested for koalas. Originally, these were 
based largely on empirical observations during attempted therapy and a few published 
reports. These reports led to the recommendation of either itraconazole orally at 100 mg per 
koala once daily (approximately 10-20 mg/kg, depending on the individual koala’s body 
weight) or fluconazole orally at 50-100 mg (approximately 10-20 mg/kg) twice daily, 
combined with AMB administered subcutaneously [according to the protocol devised by 
Malik et al. (1996a)] at 0.5 mg/kg twice weekly in 350 mL 0.45% NaCl and 2.5% dextrose 
(Blanshard & Bodley, 2008). This recommendation was later adjusted to oral fluconazole 20-
25 mg/kg twice daily and subcutaneous AMB 0.7-0.8 mg/kg twice weekly (Govendir et al., 
2016), although the clinical utility of this regimen and the pharmacokinetics of this dose of 
fluconazole when given in concert with AMB have not been documented. Further studies into 
the bioavailability of other antifungals (particularly itraconazole) and systematic reviews to 
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assess the optimal treatment for koala cryptococcosis are still needed, including a 
retrospective study into the large number of unpublished cases. 
 One study also reported the treatment of subclinical cryptococcosis in three koalas 
using a protocol of oral fluconazole 10 mg/kg twice daily, but the outcome for these 
individuals was unclear (Govendir et al., 2016). As mentioned in section 1.3.6.2, AMB is 
sometimes added to the treatment protocol for subclinical disease in koalas, but this is usually 
reserved for cases where the antigen titre does not decline as expected during azole 
monotherapy. Subclinical cryptococcosis in koalas has been successfully managed, although 
results of retrospective case series are yet to be collated and presented as a peer-reviewed 
publication (M.B. Krockenberger, pers. comm.). 
 Although the antifungal therapy of cryptococcosis in koalas is largely restricted to the 
use of fluconazole or itraconazole (often with subcutaneous AMB), one case was successfully 
treated with ketoconazole (Woods & Blyde, 1997), posaconazole shows some promise as a 
possible treatment (Gharibi et al., 2017), and alternative methods of AMB administration 
have also been reported with mixed success. An AMB protocol that alternated between the 
use of subcutaneous, intravenous and intra-lesional AMB (along with fluconazole or 
itraconazole orally) contributed to the successful treatment of one koala with a sinonasal 
mass lesion (Wynne et al., 2012). There have also been two reports of the use of AMB in a 
nebulised form for presumptive nasal cryptococcosis, but both were unsuccessful (Kido et al., 
2012, Hanaki et al., 2018). Surgical excision or debulking of lesions is generally uncommon in 
koalas but has been reported (Bercier et al., 2012). 
 The treatment of avian cryptococcosis has not been systematically reported, with 
dose ranges and protocols largely extrapolated from a handful of case reports (where 
protocols were developed empirically) and anecdotal information. Fluconazole monotherapy 
is often used as a first-line treatment at a dose of 10-15 mg/kg twice daily (or potentially 20-
25 mg/kg once daily, as twice daily administration can be difficult to achieve in some birds 
given husbandry constraints), and this is the current recommendation of some experts with 
experience in treating this disease (R. Malik, pers. comm.). Itraconazole (approximately 10 
mg/kg once daily) or potentially compounded ketoconazole (approximately 5-20 mg/kg per 
day) can be substituted if these drugs prove easier to access, are better tolerated or there is 
proven resistance to fluconazole. Terbinafine, flucytosine and compounded voriconazole eye 
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drops (for ocular cryptococcosis) have also been used as part of combination protocols, with 
mixed success (Malik et al., 2003, Molter et al., 2014, Schunk et al., 2017). Intra-lesional and 
nebulised AMB likely represent useful adjunct treatments for avian cryptococcosis (Malik et 
al., 2003, Molter et al., 2014). Intravenous AMB administration has also been reported 
(Schunk et al., 2017) but is not well-characterised, although all methods of AMB 
administration are likely difficult in most avian patients (probably requiring GA). Nevertheless, 
AMB should be considered for cases of severe disease, or where there is a failure of response 
to other treatments. Surgical excision or debulking of lesions can also present an important 
treatment option for avian cryptococcosis, particularly considering the propensity for lesions 
to often be located superficially and the paucity of information regarding the use of antifungal 
drugs in avian species (Malik et al., 2003).  
 Richardson & Perpiñán (2017) reported that oral itraconazole monotherapy (25-33 
mg/kg once daily) is the treatment of choice for cryptococcosis in ferrets. This is generally 
supported by an early case series (Malik et al., 2002) and a later review (Wyre et al., 2013). 
Itraconazole doses of 10-15 mg/kg once daily can also lead to good outcomes and are often 
better tolerated by ferrets (with less anorexia and inappetence observed) (R. Malik, pers. 
comm.). Itraconazole is likely preferred over fluconazole in ferrets due to a greater ease of 
accurately dosing these small patients, as liquid formulations or capsules (which can be 
opened and easily divided into small doses) are readily available. Fluconazole can also be used 
as a monotherapy with a reported recommended dose of 10 mg/kg once daily (Richardson & 
Perpiñán, 2017), but twice daily administration at a dose of 10-15 mg/kg is likely to be more 
successful (R. Malik, pers. comm.). AMB is rarely used, most likely because of the difficulty of 
administration in this species (due to issues of size and temperament) and the paucity of 
published reports. Both subcutaneous and intravenous administration of AMB would likely 
require GA and prolonged hospitalisation in this species, which could quickly become cost-
prohibitive in many cases. AMB was administered intravenously to one ferret that later 
succumbed to disease (Eshar et al., 2010), and a dose rate of 0.4-0.8 mg/kg once daily for a 
week has been recommended (Richardson & Perpiñán, 2017). Further research into effective 
dose ranges for antifungal drugs and protocols for the treatment of cryptococcosis are 
required in all species discussed in this section. 
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1.3.6.5 Antifungal resistance 
Given the relatively limited antifungal arsenal, resistance presents a potential problem for the 
treatment of cryptococcosis (Mourad & Perfect, 2018). Luckily, most isolates from the C. gattii 
and C. neoformans species complexes in Australia are susceptible to AMB, flucytosine, 
itraconazole and fluconazole (Ellis et al., 2007b, Chen et al., 2014). The lack of breakpoints for 
the C. gattii and C. neoformans species complexes presents a problem in classifying 
susceptibility and resistance, with epidemiological cut-off values the current alternative 
(Lockhart et al., 2017). In the C. gattii species complex, intrinsic resistance is usually 
considered the main mechanism (Varma & Kwon-Chung, 2010, Cheong & McCormack, 2013) 
but acquired resistance (during a course of therapy) has also been reported (Sykes et al., 
2017). This can be duplicated in the laboratory by gradually increasing fluconazole 
concentration in growth media (Varma & Kwon-Chung, 2010). Most reports of resistance 
involve triazole antifungals (mainly fluconazole), but resistance to AMB and flucytosine 
(particularly if used as a monotherapy) are also occasionally reported (Vermes et al., 2000, 
Thompson III et al., 2009, Chen et al., 2014, Smith et al., 2015). 
 There is evidence that members of the C. gattii species complex exhibit more 
antifungal resistance, especially to fluconazole, than those of the C. neoformans species 
complex (Varma & Kwon-Chung, 2010). Differences in antifungal susceptibility may also exist 
within each species complex, with VGII found to have higher MICs for flucytosine and triazoles 
(especially fluconazole) than other C. gattii molecular types (Chong et al., 2010). In the same 
study, a similar difference was noted in the C. neoformans species complex, with VNII isolates 
exhibiting lower MICs for fluconazole than VNI isolates. When Chen et al. (2014) reviewed the 
literature on antifungal susceptibilities and resistance between the two species complexes 
and within the C. gattii species complex, inconsistencies were noted between the findings of 
many studies worldwide (some of which were likely skewed by the inclusion of large numbers 
of environmental isolates). These observations have also led to the conclusion that antifungal 
susceptibility testing is often unnecessary unless there is evidence of a failure to respond to 
treatment (Chen et al., 2014, Sykes & Malik, 2014). 
 The major recognised mechanisms for acquired azole resistance in Cryptococcus spp. 
are mutations or over-expressions of the ERG11 gene (which encodes a target for azoles) or 
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over-expression of plasma membrane proteins that ‘pump’ azoles out of fungal cells (Chen et 
al., 2014). Hetero-resistance, an intrinsic mechanism where a sub-population of a strain 
typically considered susceptible to an antifungal can transiently express resistance (Ferreira 
& Santos, 2017), has also been reported in both the C. gattii and C. neoformans species 
complexes, particularly to fluconazole (Mondon et al., 1999, Varma & Kwon-Chung, 2010). 
This was noted as the likely cause treatment failure in a feline case of cryptococcosis caused 
by C. gattii VGIII (Sykes et al., 2017). Intrinsic resistance is considered to be a more common 
mechanism than acquired resistance in cryptococcosis (Cheong & McCormack, 2013). 
 
1.3.7 Management and prognosis 
1.3.7.1 Management 
The management and prevention of cryptococcosis in animals has not been systematically 
explored, and at present is largely based on anecdotal evidence. In captive or domestic 
settings, decontamination of the environment using disinfectants could theoretically be 
beneficial if there is a known reservoir of environmental Cryptococcus spp. and/or at-risk 
animals (Tell et al., 1997). Krangvichain et al. (2016) found bleach and a quaternary 
ammonium compound used at standard dilutions to be effective fungicides, when used on a 
mixture of sterilised pigeon droppings and C. neoformans var. grubii in a laboratory setting. 
The decontamination and disinfection of enclosure ‘furniture’ in captive scenarios is often 
recommended for koalas (M.B. Krockenberger, pers. comm.), but there is no systematic or 
published evidence to indicate if this is effective. 
 Another common management strategy for cryptococcosis in captive koalas is regular 
screening for antigenaemia, and this approach is used in Australia, especially  prior to the 
shipping and export of koalas overseas (Australian Government, 2009). One published case 
of early sinonasal disease was successfully picked up on a pre-shipment screening test in the 
USA (Wynne et al., 2012), while another reported case may have been prevented by testing 
prior to export (Makimura et al., 2002). Hence there is evidence that this is an effective 
strategy, and it can potentially allow for the treatment of subclinical cryptococcosis before 
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progression of disease (Govendir et al., 2016), especially considering that transport and new 
surroundings can cause stress and thus potentially some amount of immunosuppression. 
 
1.3.7.2 Prognosis 
In animals, the prognosis is generally considered good to guarded, regardless of the exact 
causative species complex or molecular type. In one study that followed case outcomes in 
cats and dogs with cryptococcosis, 76% of cats and 55% of dogs were treated successfully 
(O’Brien et al., 2006). Given that some strains of C. gattii VGII appear to exhibit comparatively 
higher MICs for some antifungals and greater virulence, cases involving this molecular type 
are often considered more cautiously and poorer outcomes are sometimes reported (for 
example, in animals in WA, where VGII is endemic) (Lester et al., 2004, McGill et al., 2009, 
Malik et al., 2011). Within the C. neoformans species complex, there is evidence that genotype 
can predict clinical outcome in humans in Africa (Wiesner et al., 2012). Despite this, resource-
limited settings and delayed diagnosis are generally considered more important prognostic 
indicators than genotype in human patients (Maziarz & Perfect, 2016). Overall, early diagnosis 
is also considered the most important prognostic factor in animals, along with prompt and 
aggressive antifungal therapy (Krockenberger et al., 2003, Blanshard & Bodley, 2008, Sykes & 
Malik, 2014). In cats with early diagnosis and sustained assiduous treatment, including good 
compliance with drug therapy, the prognosis is often favourable (Pennisi et al., 2013). 
Localised disease is also associated with better clinical outcomes in birds and ferrets (Malik et 
al., 2003, Wyre et al., 2013), while CNS involvement is generally associated with a poorer 
prognosis in cats, dogs and koalas (Blanshard & Bodley, 2008, Sykes et al., 2010). A similar 
phenomenon has been observed in immunocompetent humans with CNS disease, where 
delayed diagnosis (typically due to cryptococcosis not being considered as an early differential 
diagnosis) can lead to poorer case outcomes (Ecevit et al., 2006). 
 In koalas, a diagnosis is often obtained late in the course of disease, particularly in 
free-ranging animals but sometimes also in captivity (Krockenberger et al., 2003), and 
treatment can be difficult due to the factors mentioned in section 1.3.6.4. Thus overall, the 
prognosis is anecdotally poorer in koalas. Despite this, cryptococcosis can be successfully 
treated in captive koalas, but full resolution of cryptococcal antigenaemia and long-term 
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outcomes are often not reported (Woods & Blyde, 1997, Bercier et al., 2012, Wynne et al., 
2012, Govendir et al., 2016). 
 
1.3.8 Outbreaks and case clusters 
Spatial and/or temporal case clusters and outbreaks of cryptococcosis can occur, presumably 
due to exposure of a group of animals to a common, high-level, environmental source of 
infection and/or a highly virulent strain. In recent times this is predominantly associated with 
C. gattii VGII, but clusters of C. neoformans species complex cryptococcosis have been 
reported in captive animals (Tell et al., 1997, Bauwens et al., 2004), and outbreaks in goats 
caused by the C. gattii VGI have been reported on several occasions across a relatively limited 
area in one province of western Spain (Baró et al., 1998, Torres-Rodríguez et al., 2006). 
Several case clusters of C. gattii species complex cryptococcosis where the causative organism 
was not identified to molecular type level have also been reported, including a group of 
psittacine birds housed in a Brazilian aviary (Raso et al., 2004). 
 In Australia, C. gattii VGII case clusters are occasionally documented. A flock of 
domestic sheep in WA exhibited numerous deaths attributed to cryptococcosis, although case 
details are scant and isolates could be obtained from only three sheep (all were C. gattii VGII) 
(Sorrell et al., 1996a, Malik et al., 2011). In the NT, C. gattii VGII case clustering has been 
observed amongst Aboriginal people in Arnhem Land (Fisher et al., 1993, Chen et al., 1997a). 
There is also some evidence suggestive of spatial and temporal case clustering in captive 
koalas with cryptococcosis (Krockenberger et al., 2003, Malik et al., 2011), particularly that 
caused by C. gattii VGII (Saul, 2009), but this has not been established definitively. Several 
cases of cryptococcosis caused by the C. gattii species complex were observed across multiple 
host species (including a parrot, macropod and rodent) at a zoological park in WA, but the 
molecular type was not reported (Payne et al., 2005). 
The Vancouver Island C. gattii VGII cryptococcosis outbreak offers the prime example 
of the ability of this pathogen to cause spatial and temporal clustering, with cases reported in 
humans and across a wide range of animal species (Craig et al., 2002, Kidd et al., 2004, Lester 
et al., 2004). The outbreak then expanded to other areas of British Columbia in Canada and 
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the Pacific Northwest region of the USA (MacDougall et al., 2007, Byrnes III et al., 2009). This 
outbreak was caused predominantly by an emergent highly virulent strain, C. gattii VGIIa, and 
a secondary strain, VGIIb (Kidd et al., 2004). A third strain, VGIIc, was identified in the Pacific 
Northwest, and this may have emerged subsequent to evolutionary pressure (Byrnes III et al., 
2010). Numerous contributing factors to this outbreak have already been discussed, including 
same-sex mating (Fraser et al., 2005) and dispersal events from South America (potentially 
anthropogenic) as the likely underlying origin (Hagen et al., 2013, Roe et al., 2018). 
 
1.3.8.1  Animals as sentinels 
Given that cryptococcosis is acquired from the environment, animals could reasonably be 
considered at the front line of exposure to this disease and thus can be used to examine the 
interface with the environment (Malik et al., 2011). One advantage of using animals as 
sentinels is that, generally-speaking and depending on the species, they have a more finite 
and easily defined geographical range compared to humans. The Vancouver Island outbreak 
provided evidence that animals could act as critical sentinels for cryptococcosis in humans, 
with an increase in the prevalence of animal cases noted before the disease was 
systematically reported in humans (Craig et al., 2002, Hoang et al., 2004, Lester et al., 2004). 
Domestic animal cases also provided an early indication that the outbreak was spreading 
beyond Vancouver Island (Lester et al., 2004, MacDougall et al., 2007). The domestic animals 
(Duncan et al., 2005b) and wildlife (Duncan et al., 2006) of Vancouver Island were later 
surveyed for cryptococcal nasal colonisation and subclinical disease to provide further insights 
into the distribution of C. gattii VGII in the area and the risks of exposure for humans. Other 
animals, including rodents (Singh et al., 2007) and ferrets (Morera et al., 2014), have also been 
proposed as useful sentinel species.  Given that forested and/or rural areas are considered by 
some as the highest risk for exposure to members of the C. gattii species complex (Springer 
& Chaturvedi, 2010), it seems reasonable that free-ranging animals in contact with these 
areas offer great potential as useful sentinel species. 
 It is extremely difficult to identify the precise environmental source of infection in 
many cases of human cryptococcosis, but animals (particularly domestic and captive) provide 
a unique opportunity to explore this, given their known and often highly restricted range of 
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domicile (Malik et al., 2011). Despite this, it remains rare for definitive sources of infection to 
be detected. Some studies in animals have tried and failed to achieve this end (Raso et al., 
2004, Torres-Rodríguez et al., 2006), while others have found some indication of a source of 
infection but did not support this with in-depth genotyping of isolates (Sorrell et al., 1996a, 
Bauwens et al., 2004, Singh et al., 2007, Morera et al., 2014). 
 
1.4 Aims and hypothesis 
Cryptococcosis is clearly a consequence of environmental exposure to members of the C. 
gattii (or C. neoformans) species complex, but the exact mechanism for the acquisition of 
naturally-occurring colonisation or disease is poorly understood. It remains unclear if this is 
simply a random event, or if a heavy inoculum, specific strain/s, exposure to a particular 
environment, and/or concurrent insults to host defence mechanisms are required to establish 
colonisation and disease. This thesis will therefore aim to address the following overarching 
hypothesis: 
 ‘Cryptococcosis is a random outcome of heavy environmental exposure’ 
This hypothesis will be tested by using koalas as naturally-occurring models for exposure to, 
and infection by, C. gattii VGI and VGII in Australia, with other animals (parrots and ferrets) 
also included. 
 
1.4.1 Aims 
This thesis will address the hypothesis through the following aims: 
1. Explore the ecological associations of C. gattii VGI in the mycobiome of Australian tree 
hollows, using amplicon-based metagenomics (section 2.1). 
2. Systematically document the successful diagnosis and therapy of subclinical 
cryptococcosis in free-ranging koalas (section 3.1 and 3.2). 
3. Assess the relationship between environmental presence, nasal colonisation and 
disease in some free-ranging koala populations (sections 3.3 and 4.1). 
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4. Explore the interface between environment and disease in naturally-occurring cases 
of cryptococcosis in Australian animals through molecular epidemiology and 
phylogenetic analyses (sections 4.1 to 4.4). 
5. Determine the point source of infection or exposure in naturally-occurring disease or 
colonisation, caused by C. gattii VGI, in representative cases in captive animals using 
molecular epidemiology (sections 4.2 and 4.3). 
6. Assess clusters of cryptococcosis in koalas for their outbreak potential (sections 4.1 
and 4.4). 
7. Examine the ability of koalas to translocate C. gattii VGII into new environments 
(section 4.4). 
Aim 1 addresses the hypothesis by determining if the microenvironment can play a 
role in the presence or abundance of Cryptococcus spp. in tree hollows, which could thus 
affect the likelihood of host exposure. Aims 2 to 4 further examine the potential randomness 
of disease through exploring the relationship between colonisation, subclinical disease, 
clinical disease and the environment (using captive and free-ranging koalas with naturally-
occurring disease or colonisation). Aims 5 and 6 both look more specifically at interactions 
between animals and their environment in naturally-occurring cryptococcosis, which provides 
models for assessing when and how the disease is acquired. Aim 7 explores how the organism 
is spread by koalas in Australia, and the implications that this may have for both koalas and 
other host species. 
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2. Environmental associations
Background: 
Tree hollows are an important ecological niche for Cryptococcus spp. (particularly C. gattii 
VGI in Australia), and therefore also present a source of infection. Little is known about the 
tree hollow microbiome and the role that other fungi could play in the survival, growth and 
proliferation of this pathogen in the environment. The ability to detect Cryptococcus spp. in 
environmental samples is a critical step in identifying potential sources of infection, yet 
traditional culture-based methods can be problematic. Culture-independent methods have 
not been explored as a method of detection for environmental C. gattii VGI in Australia.  
This section uses amplicon-based NGS of DNA extracted directly from tree hollow 
debris in Australia to: characterise the mycobiome, assess the utility of this method for 
identifying environmental Cryptococcus spp., and expand the environmental associations of 
C. gattii VGI. This approach included statistical analyses to assess if Cryptococcus spp. was
linked to other fungal taxa, thus testing for important associations within the mycobiome. 
The comparison between culture and NGS highlighted the limitations of both methods and 
provided an opportunity to discuss these in detail. 
Aims: 
- Aim 1: explore the ecological associations of C. gattii VGI in the mycobiome of
Australian tree hollows, using amplicon-based metagenomics.
Sections: 
- 2.1: The mycobiome of Australian tree hollows in relation to the Cryptococcus gattii
and C. neoformans species complexes.
Impact: 
An enhanced understanding of the environmental niche of C. gattii VGI may help to identify 
risk factors for exposure to this pathogen, while improved methods for its detection could 
aid in the identification of sources of infection. This is applicable to the management and 
prevention of cryptococcosis in many species, particularly captive or domestic animals. 
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2.1  The mycobiome of Australian tree hollows in relation 
to the Cryptococcus gattii and C. neoformans species 
complexes 
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ABSTRACT 
Cryptococcosis is a fungal infection caused by members of the Cryptococcus gattii and C. 
neoformans species complexes. The C. gattii species complex has a strong environmental 
association with eucalypt hollows (particularly Eucalyptus camaldulensis), which may 
present a source of infection. It remains unclear whether a specific mycobiome is required 
to support its environmental survival and growth. Conventional detection of environmental 
Cryptococcus spp. involves culture on differential media, such as Guizotia abyssinica seed 
agar. Next-generation sequencing (NGS)-based culture-independent identification aids in 
contextualising these species in the environmental mycobiome. Samples from 23 Australian 
tree hollows were subjected to both culture- and amplicon-based metagenomic analysis to 
characterise the mycobiome and assess relationships between Cryptococcus spp. and other 
fungal taxa. The most abundant genera detected were Coniochaeta, Aspergillus and 
Penicillium, all being commonly isolated from decaying wood. There was no correlation 
between the presence of Cryptococcus spp. in a tree hollow and the presence of any other 
fungal genus. Some differences in the abundance of numerous taxa were noted in a 
differential heat tree comparing samples with or without Cryptococcus-NGS reads. The 
study expanded the known environmental niche of the C. gattii and C. neoformans species 
complexes in Australia with detections from a further five tree species. Discrepancies 
between the detection of Cryptococcus spp. using culture or NGS suggest that neither is 
superior per se and that, rather, these methodologies are complementary. The inherent 
biases of amplicon-based metagenomics require cautious interpretation of data through 
consideration of its biological relevance. 
INTRODUCTION 
Cryptococcosis is a potentially lethal mycosis affecting both humans and animals, caused by 
basidiomycetous yeasts in the C. gattii and Cryptococcus neoformans species complexes 
(Kwon-Chung et al., 2017). The infection is acquired from the environment by the inhalation 
of basidiospores or desiccated yeast cells (Kwon-Chung et al., 2014). The C. gattii and C. 
neoformans species complexes inhabit various ecological niches and are associated with 
decaying organic material, such as tree hollow debris and accumulations of avian excreta (K. 
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Nielsen et al., 2007, Springer et al., 2014). The ecological role of Cryptococcus spp. is not 
well understood but their presence in decaying organic matter suggests that they contribute 
to the process of decomposition (Voříšková & Baldrian, 2013). 
The C. gattii species complex has traditionally been regarded as tropical or 
subtropical, whereas the C. neoformans species complex is globally distributed. There is 
increasing evidence, however, that the C. gattii species complex is also prevalent in 
temperate climates (Kidd et al., 2004, Chowdhary et al., 2012, Colom et al., 2012). Ellis & 
Pfeiffer (1990) described a specific ecological association between the C. gattii species 
complex and eucalypt trees in Australia, most notably the river red gum (Eucalyptus 
camaldulensis), in a wide variety of temperate and subtropical locations. Since then, the C. 
gattii species complex has been found globally in decaying wood, particularly inside trunk 
hollows and in various living tree species, suggesting that trees could be its primary natural 
habitat (Lazera et al., 2000, Randhawa et al., 2008, Cogliati et al., 2016). 
In Australia, eucalypts appear to be a key environmental niche for the C. gattii 
species complex (particularly C. gattii VGI), and the range of tree species from which it has 
been isolated continues to expand (Table 2.1.1). Koalas (Phascolarctos cinereus) exhibit 
comparatively high rates of both clinical and subclinical cryptococcosis, likely preceded by 
nasal colonisation by Cryptococcus spp., with this association presumably related to their 
close association with eucalypts (Krockenberger et al., 2003). In recent years, several cases 
of cryptococcosis have been observed in free-ranging koalas (Phascolarctos cinereus) 
inhabiting the Port Stephens (Schmertmann et al., 2018b) and Liverpool Plains 
(Schmertmann et al., 2019) regions of New South Wales (NSW), Australia. As the Vancouver 
Island C. gattii VGII outbreak highlighted the potential for animals to represent key sentinels 
for human disease (Craig et al., 2002), we were prompted to conduct environmental 
investigations in both areas. 
The presence of a specific fungal community or critical species could support the 
growth of Cryptococcus spp. in the environment, but this remains undetermined. A study 
conducted in Africa attempted to characterise this notion but did not find any associations 
between the presence of any specific fungal taxa and Cryptococcus spp. (Vanhove et al., 
2017). The fungal community residing in eucalypt tree hollows in association with the C. 
gattii species complex in Australia remains unexplored. 
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TABLE 2.1.1 Tree species from which the Cryptococcus gattii species complex has been 
isolated in Australia. 
 
Scientific name Common name 
Cryptococcus spp. 
association 
Method of 
first detection 
Source of 
first detection 
Angophora costata Smooth-barked apple C. gattii VGI Culture (Halliday et al., 1999) 
Eucalyptus albens White box C. gattii VGI Culture (Schmertmann et al., 
2019) 
E. bella Ghost gum C. gattii VGII  Culture (Sorrell et al., 1996a) 
E. blakelyi Blakely’s red gum C. gattii VGI Culture  (Pfeiffer & Ellis, 1997) 
E. camaldulensis River red gum  C. gattii VGI Culture (Ellis & Pfeiffer, 1990) 
E. gomphocephala Tuart C. gattii VGI Culture (Pfeiffer & Ellis, 1997) 
E. grandis Flooded gum  C. gattii VGI Culture (Halliday et al., 1999) 
E. microcorys Tallowwood C. gattii VGI Culture (Krockenberger et al., 
2002b) 
E. rudis Flooded gum  C. gattii VGI Culture (Pfeiffer & Ellis, 1997) 
E. tereticornis Forest red gum  C. gattii VGI Culture (Pfeiffer & Ellis, 1992) 
Syncarpia 
glomulifera 
Turpentine gum  C. gattii VGI Culture (Krockenberger et al., 
2002b) 
 
NGS = next-generation sequencing. 
 
The detection of Cryptococcus spp. from the environment is important in the context 
of cryptococcosis in order to pinpoint potential infection sources, with culture being the 
primary means of achieving this. Staib’s Guizotia abyssinica seed extract agar (bird seed 
agar) containing antibiotics underpins the conventional detection of Cryptococcus spp. from 
environmental samples through mycological culture (Shields & Ajello, 1966, Paliwal & 
Randhawa, 1978). The method is based on Cryptococcus spp. colonies exhibiting the brown-
colour-effect, due to the production of melanin by cryptococcal laccase (a phenoloxidase 
enzyme) (Staib, 1962). It is therefore dependent on the visual recognition of suspect 
cryptococcal colonies, which can be challenging when multiple fast-growing filamentous 
fungi are present concurrently. 
New culture-independent methods, such as next-generation sequencing (NGS), have 
the potential to detect any organism, including Cryptococcus spp., in the environment 
without relying on growth in vitro, therefore aiding in the identification of sources of 
infection. In addition, they can also define the microbial communities present in 
environmental samples (Taberlet, et al., 2012, Hamad et al., 2017, Tong et al., 2017). There 
has been a fundamental shift away from conventional DNA sequencing introduced by 
Sanger et al. (1977), considered as first-generation sequencing technology, to newer 
methods, such as NGS. High-throughput sequencing technologies have revolutionised 
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biological research and allowed for the in-depth characterisation of microbial diversity, 
without the need for morpho-taxonomy (Creer et al., 2016). 
Fungi might represent the largest genetic diversity amongst the eukaryotes, with an 
estimated 5.1 million species, including taxa ranging from unicellular yeasts and microscopic 
moulds to large mushrooms (Blackwell, 2011). Of this enormous number of species, only a 
small number are known to be potential mammalian pathogens. To overcome inherent 
limitations of culture-based methods of characterising microbial communities, indirect 
molecular methods have been developed based on the total DNA content of the sample. 
Amplicon-based metagenomics analyses (metabarcoding) have become a widely used 
technology in various fields, ranging from microbial ecology studies to infectious disease 
surveillance (Tedersoo et al., 2014, Tonge et al., 2014, L.D.N. Nguyen et al., 2015). Currently, 
this is the standard tool and the most efficient method for culture-independent assessment 
of microbiomes, even if its broad application is still hampered by relatively high cost and the 
need for advanced bioinformatic analyses (Tang et al., 2015). The approach combines the 
methodologies of DNA barcoding (Hebert et al., 2003) with high-throughput sequencing 
technology. It is based on the concept that each operational taxonomic unit (OTU) can be 
unequivocally identified using DNA barcodes. The general strategy involves: (i) extraction of 
DNA from an environmental sample or organism, (ii) amplification of the species-specific 
DNA barcodes, (iii) sequencing of the DNA amplicons, (iv) analyses of the generated 
sequences using appropriate pipelines and (v) taxonomic assignment of the detected 
sequences. PCR-based metabarcoding has become a rapid and accurate method for species 
level identification from complex environmental and clinical samples without the 
requirement for culture, thereby providing unprecedented insights into the underlying 
biological diversity (Bik et al., 2012). 
In this study, used amplicon-based NGS was used as a tool to assess the co-existence 
of Cryptococcus spp. with other fungi in eucalypt and other Australian native tree hollows, 
while simultaneously characterising the fungal community (mycobiome) of tree hollows 
from two areas of NSW, Australia that have recently been associated with cryptococcosis in 
koalas. We also compared conventional culture-based methods to NGS, to assess which was 
more sensitive at detecting pathogenic Cryptococcus spp. in environmental samples. 
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MATERIALS AND METHODS 
Sample collection 
Debris and related material from hollows were collected from 23 trees at multiple locations 
within the Port Stephens (9) and Liverpool Plains (14) regions of New South Wales, Australia 
(Table 2.1.2). Samples were collected as part of a disease investigation into cases of koala 
cryptococcosis. The areas for sample collection were selected based both on proximity to 
these cases and reported koala habitat (according to our observations and/or the 
recommendation of local rescue groups). Trees in these areas were then selected randomly 
for sampling based on the presence of one or more tree hollows that were accessible from 
the ground. A generous amount of material was collected from the interior of each tree 
hollow and placed into a clean plastic bag, which was sealed and labelled. Tree species from 
which samples were collected included E. camaldulensis (12), E. pilularis (2), E. tereticornis 
(2), Eucalyptus spp. (2), Angophora floribunda (1), E. albens (1), E. populnea (1), E. robusta 
(1) and Melaleuca spp. (1). 
 A mock fungal community was created (as a positive control) by obtaining a mixture 
of yeast and filamentous fungi isolates from the Medical Mycology Culture Collection at The 
Westmead Institute for Medical Research in Westmead,  NSW, Australia. This comprised a 
total of 12 isolates and included the genera Aspergillus, Candida, Fusarium, Kodamaea, 
Pichia and Scedosporium, along with one C. gattii VGI and one C. neoformans VNI isolate. 
 
Culture 
Samples were inoculated onto bird seed agar (containing penicillin and gentamicin) as soon 
as possible after collection by introducing a sterile swab, pre-moistened with sterile saline, 
into the sample and then gently rolling the swab across the plate. Plates were incubated at 
27°C for a minimum of seven days and monitored daily. Cryptococcus spp. colonies were 
identified by the brown-colour-effect and their yeast-like growth on bird seed agar. Once 
suspected cryptococcal colonies were observed, the agar plate was removed from the 
incubator and one or more colonies were subcultured onto Sabouraud’s dextrose agar for 
isolation of a pure culture, which was followed by DNA extraction (see below). Samples 
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E2657, E2666 and E2704 had five, four and three isolates collected, respectively, from each 
primary isolation plate. In all other positive samples, only one isolate was collected. DNA 
extraction from cryptococcal isolates was performed using an established fungal DNA 
extraction method (Ferrer et al., 2001). Restriction fragment length polymorphism (RFLP) 
analysis of a URA5 PCR product was used as described previously (Meyer et al., 2003) to 
determine the cryptococcal species and molecular type of each isolate. 
 
DNA Extraction for NGS 
DNA was extracted directly from the mock fungal community and approximately 20 g of 
each sample of tree hollow material by first grinding them with liquid nitrogen and a mortar 
and pestle. This homogenised the samples and aided in breaking down both the 
cryptococcal capsule and fungal cell walls. DNA was then extracted using the DNeasy 
PowerSoil kit (Qiagen GmbH, Hilden, Germany) following the manufacturer’s instructions.  
 
PCR amplification of the ITS1 region 
Fragments were amplified with ITS1F (CTTGGTCATTTAGAGGAAGTAA) and ITS2 
(GCTGCGTTCTTCATCGATGC) (White et al., 1990) targeting the ITS1 region of the rRNA gene 
complex. PCR amplicons were generated using AmpliTaq Gold 360 Master Mix 
(ThermoFisher Scientific, North Ryde, NSW, Australia) for the primary PCR with the following 
amplification protocol: 7 min initial denaturing at 95°C, followed by 35 cycles of 30 s at 94°C, 
45 s annealing at 55°C, 60 s at 72°C and 7 min final extension at 72°C. A secondary PCR to 
index the amplicons was performed with TaKaRa Taq DNA Polymerase (Clontech 
Laboratories, Mountain View, California, USA). All PCRs included negative controls. 
 
Sequencing 
Sequencing of PCR amplicons was conducted with MiSeq® System of Illumina (Illumina, San 
Diego, California, USA) by the Australian Genome Research Facility. The Illumina bcl2fastq 
2.18.0.12 pipeline was used to generate the sequence data. Pair-end reads 2 × 300bp were 
generated up to 0.15 GB per sample. 
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Bioinformatics pipeline and analysis 
Reads were processed according to the protocol described in the USEARCH package (Edgar, 
2010) version 10.0. The sets of OTUs were generated, then ‘zero-radius OTUs’ (ZOTUs) (i.e. 
error-corrected [denoised] sequences) were produced using the UNOISE algorithm including 
chimera filtering (Edgar, 2016b) to identify all correct biological sequences. The ZOTU table 
was normalised to the same number of reads per sample (5,000) prior to downstream 
analysis. Singletons were kept for downstream analysis. The taxonomy was predicted for 
ZOTU sequences using the SINTAX classifier (Edgar, 2016a) against both the UNITE full 
dataset (Kõljalg et al., 2013) (accessed on 04.03.2017) and ISHAM-ITS (Irinyi et al., 2015) 
database (containing all relevant ITS sequences of Cryptococcus spp.). All identified OTUs 
were retained for downstream analysis, including singletons.  
Fungal OTUs from each sample were used to determine Shannon and Evenness 
indices as indicators of soil microbial diversity and structure, respectively. α-diversity 
metrics were calculated using USEARCH package (Edgar, 2010) version 10.0 (Table 2.1.3). To 
estimate the potential correlation between Cryptococcus spp. and other genera, Pearson 
and Spearman co-occurrence coefficients were then calculated with SparCC (Friedman & 
Alm, 2012) for each sample, separately. Taxon pairs with SparCC values > 0.6 were 
considered as exhibiting a co-occurrence relationship with a positive correlation.  
MetacodeR was used to visualise the mycobiome diversity of tree hollows in heat 
tree format (RCore, 2013, Foster et al., 2017). A differential heat tree was created to 
indicate which taxa are more abundant in the presence of Cryptococcus spp. reads. For 
statistical support, one-sample Wilcoxon signed rank test was used in R (RCore, 2013) to test 
the hypothesis that certain taxa may be enriched for lower p value ranks than other taxa. 
Benjamini-Hochberg (FDR) correction (Benjamini & Hochberg, 1995) was used to adjust p 
values for multiple comparisons to limit the probability of even one false discovery. 
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RESULTS 
Detection of Cryptococcus spp. by culture 
Cryptococcal colonies were observed after culture on bird seed agar in 14/23 (61%) tree 
hollow samples studied (Table 2.1.2). URA5-RFLP analysis identified all isolates as C. gattii 
VGI. The C. neoformans species complex and other members of the C. gattii species complex 
were not identified in any samples. Tree species in which C. gattii VGI was identified include: 
A. floribunda, E. albens, E. camaldulensis, E. pilularis, E. robusta, E. tereticornis and 
Melaleuca spp. (Table 2.1.2). 
 
TABLE 2.1.2 Detection of Cryptococcus spp. from 23 tree hollow samples in New South 
Wales, Australia using conventional culturing and next generation sequencing. Samples are 
ordered by positive or negative culture results and degree of growth. Bold text indicates 
samples with a discordance between the results of sequencing and culture.  
 
Sample Tree species Region 
Culture / URA5-
RFLP results 
Number of reads detected with 
amplicon based (ITS1) NGS 
Total 
reads 
C. gattii 
VGI 
C. neoformans 
VNI/VNII 
E2699 Melaleuca spp. PS + / C. gattii VGI 152490 – – 
E2771 Eucalyptus 
camaldulensis 
LP + / C. gattii VGI 149970 2 – 
E2666 Angophora 
floribunda 
PS ++ / C. gattii VGI 125784 3 1 
E2697 E. robusta PS ++ / C. gattii VGI 89683 – – 
E2704 E. tereticornis PS ++ / C. gattii VGI 226974 1 1 
E2768 E. camaldulensis LP ++ / C. gattii VGI 70250 1 1 
E2772 E. camaldulensis LP ++ / C. gattii VGI 206302 11 10 
E2773 E. camaldulensis LP ++ / C. gattii VGI 152861 3 7 
E2774 E. camaldulensis LP ++ / C. gattii VGI 129923 2 2 
E2657 E. pilularis PS +++ / C. gattii VGI 131034 – – 
E2760 E. albens LP +++ / C. gattii VGI 104095 6 2 
E2761 E. camaldulensis LP +++ / C. gattii VGI 104725 52 1 
E2764 E. camaldulensis LP +++ / C. gattii VGI 142580 4 4 
E2770 E. camaldulensis LP +++ / C. gattii VGI 145686 11 5 
E2668 E. tereticornis PS – 158773 – – 
E2677 Eucalyptus spp. PS – 114688 – – 
E2698 Eucalyptus spp. PS – 126651 – – 
E2711 E. pilularis PS – 71419 – – 
E2757 E. populnea LP – 105099 3 – 
E2762 E. camaldulensis LP – 133183 5 – 
E2765 E. camaldulensis LP – 118666 1 – 
E2766 E. camaldulensis LP – 163204 1 1 
E2769 E. camaldulensis LP – 108789 6 7 
 
LP = Liverpool Plains; PS = Port Stephens; RFLP = restriction fragment length polymorphism analysis; + = low (1-
10 cryptococcal colonies), ++ = moderate (11-100 colonies), +++ = heavy (>100 colonies); – = negative. 
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Detection of Cryptococcus spp. using NGS technology 
C. gattii or C. neoformans species complex sequence reads were identified in 16/23 (70%) 
samples. C. gattii species complex reads were detected in all these 16 samples, with C. 
neoformans species complex reads concurrently detected in 12. C. neoformans species 
complex reads were not recorded in the absence of C. gattii species complex reads in any 
sample. No Cryptococcus spp. reads were identified in seven samples (Figure 2.1.1 A). All C. 
gattii species complex reads were VGI, while C. neoformans species complex reads were 
VNI/VNII. C. gattii VGI and C. neoformans VNI reads were also successfully identified in the 
mock community. 
 
FIGURE 2.1.1 (A) Number of unique Cryptococcus gattii/C. neoformans species complex ITS1 
sequence reads detected from 23 tree hollows in New South Wales, Australia. (B) Alignment 
of the C. gattii/C. neoformans species complex ITS1 region identified in next-generation 
sequencing (Zotu_5 and Zotu_6) and reference sequences (Katsu et al., 2004).  
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Concordance between NGS and culture results was observed in 15/23 (65%) 
samples: 11 samples were NGS- and culture-positive for the C. gattii species complex while 
four samples were NGS- and culture-negative for all Cryptococcus spp. In three samples, C. 
gattii VGI was identified by culture but not NGS. In another five samples, Cryptococcus spp. 
reads were identified by NGS, but culture yielded negative results (Table 2.1.2). 
 
Mycobiome of eucalypt tree hollows 
The number of generated sequence reads per sample was highly variable (mean 126,381; 
standard deviation 44,207) and thus the OTU table was normalised to the same number of 
reads (5,000) per sample. We identified a total of 2,638 OTUs which were assigned at 
different taxonomic levels: 199 to species (7.5%), 565 to genus (21.4%), 741 to family 
(28.1%), 1,185 to order (44.9%), 1,557 to class (59.0%), 1,982 to phylum (75.1%) and 2,638 
to kingdom level (100%) (Figure 2.1.2). The number of OTUs differed in each sample, with a 
mean of 550 and standard deviation of 273. 
 
FIGURE 2.1.2 Operational taxonomic unit assignment rates at different taxonomical levels 
using ITS1 amplicon-based metagenomics analysis of samples from 23 tree hollows in New 
South Wales, Australia. 
 
OTUs classified in the Ascomycota were observed most frequently (1,660 OTUs; 
62.9% sequences), followed by the Basidiomycota (226 OTUs; 8.6% sequences) 
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(Supplementary figure S2.1.1). The distributions of taxa at lower taxonomical levels, such as 
class, order, family and genus, per sample, are shown in Supplementary figures S2.1.2 to 
S2.1.5. Much less abundant fungi included Mortierellomycota (38 OTUs; 1.4% sequences), 
Chytridiomycota (22 OTUs; 0.8% sequences), Rozellomycota (18 OTUs; 0.7% sequences) and 
Mucormycota (12 OTUs; 0.5% sequences). Some 25% of the sequences (662 OTUs) 
remained unassigned at phylum level (Figure 2.1.2).  
Amongst the Ascomycota, Sordariomycetes (28.1%), Eurotiomycetes (25.9%), 
Dothideomycetes (12.5%) Leotiomycetes (4.4%) and Saccharomycetes (2.7%) were the most 
abundant classes. Amongst the Basidiomycota, Agaricomycetes (51.3% sequences), 
Tremellomycetes (22.6%) and Microbotryomycetes (4.9%) were most abundant. 
At genus level, amongst Ascomycota, Penicillium (2.3%), Aspergillus (1.6%) and 
Scytalidium (1.5%) were the most abundant genera. In the Basidiomycota, Trechispora (4%), 
Jaapia (2.7%) and Cryptococcus (2.5%) were the most dominant. In Mortierellomycota, the 
most common genera were Mortierella (55.3%) and Gamsiella (2.6%). The overall ten most 
abundant genera in each sample are shown in Supplementary figure S2.1.6. 
At species level, 901 OTUs (34.2%) were singletons, 371 (14.1%) and 205 (7.8%) 
OTUs were represented by only two and three reads, respectively. A total of 1,719/2,638 
OTUs (65.2%) were represented by less than five reads. The most abundant genus across all 
samples was Coniochaeta (anamorph: Lecythophora), followed by Aspergillus and 
Penicillium. The mycobiome structure of the 23 tree hollows are displayed in Figure 2.1.3. In 
analysis of the mock community, all the known fungal species were successfully identified. 
Co-occurrence analysis did not show any significant correlation between the 
occurrence of Cryptococcus spp. and other taxa or genera (Figure 2.1.4). The correlation 
analysis likewise did not show any statistical significance (p < 0.05) or correlation between 
Cryptococcus spp. and other genera (Figure 2.1.4). 
The differential heat tree analysis (Figure 2.1.5) highlighted numerous taxa that 
differed in abundance between samples with no Cryptococcus spp. reads compared to those 
with one or more reads. In samples with no Cryptococcus spp. reads, Ascomycota, 
Eurotiomycetes, Eurotiales and Aspergillus were comparatively more abundant at phylum, 
class, order and genus level, respectively. In those with Cryptococcus spp. reads, numerous 
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taxa were identified as comparatively more abundant at phylum, class, order and family 
levels. At the genus level, four genera were highlighted as being of greater abundance – 
Coniochaeta, Cryptococcus, Penicillium and Scytalidium (Supplementary figures S2.1.5 and 
Figure S2.1.6) 
 
FIGURE 2.1.3 Heat tree of the mycobiome structure of the 23 tree hollows in New South 
Wales, Australia. The size and colour of nodes and edges are correlated with the abundance 
of taxa in each community. 
 
 
2. Environmental associations
62
Diversity indices did not at all highlight any specific predictors likely to explain the 
occurrence of Cryptococcus spp. in certain tree hollows. Fungal communities varied, based 
on OTU numbers and Shannon and Evenness indices (Table 2.1.3). The number of detected 
OTUs in each sample varied between 125 and 1,062, with a mean of 570. The Simpson 
index, which indicates whether a single large OTU dominates the sample, was also highly 
variable (0.022-0.952). The values closer to 1 indicated that a few OTUs dominated the 
sample contrary to a value closer to 0 indicating that the samples were composed of 
multiple OTUs, none of which dominated the sample. The Berger-Parker and Robbins 
frequency indexes showed that the samples with more OTUs detected had many singletons. 
One sample (E2697) had Simpson and Berger-Parker values indicative of a single large OTU 
dominating the sample. Supplementary figures S2.1.1 to S2.1.6 confirm this pattern and 
indicate that the single dominant OTU in this sample can be attributed to Aspergillus. 
 
FIGURE 2.1.4 Correlation analysis using SparCC, Pearson and Spearman correlations 
between Cryptococcus spp. and other fungal genera detected in the 23 tree hollows in New 
South Wales, Australia. Red text denotes the 10 most common genera. 
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FIGURE 2.1.5 Differential heat tree showing the relative abundance of different fungal taxa 
in the presence of Cryptococcus gattii/C. neoformans species complex reads in 23 Australian 
tree hollows, as detected by next generation sequencing. The colour of each taxon 
represents the log-2 ratio of median proportions of reads observed in C. gattii/C. 
neoformans species complex negative and positive samples. Taxa coloured brown are more 
abundant in negative while those coloured blue are more abundant in positive samples. 
Only significant differences are coloured, as determined using a Wilcox rank-sum test 
followed by a Benjamini-Hochberg (FDR) correction for multiple comparisons. 
 
 
DISCUSSION 
In this study, the mycobiome of Australian native tree hollows was characterised and no 
definitive correlations were found between the presence of Cryptococcus spp. and other 
genera. Discrepancies were established between culture-dependent and culture-
independent methods used for the detection of the C. gattii and C. neoformans species 
complexes in environmental samples. Although these methodologies were often in 
agreement, discordant results were observed in 8/23 samples. These findings can likely be 
explained by biases in both methods, which will be explored throughout the discussion. This 
study has also expanded the known environmental niche of C. gattii VGI through its 
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detection in the hollows of another five tree species: three eucalypts (E. pilularis, E. 
populnea and E. robusta), a Melaleuca spp. and an Angophora spp. 
 
TABLE 2.1.3 Estimations of fungal species richness of 23 tree hollows in New South Wales, 
Australia obtained with different models. 
 
Sample 
Number 
of reads 
Diversity metrics Evenness metrics 
Richness Shannon_2 Jost1 Simpson Dominance Berger_Parker Robbins 
E2657 131034 245 3.41 10.6 0.195 0.805 0.378 0.187 
E2666 125784 535 4.1 17.1 0.158 0.842 0.342 0.185 
E2668 158773 482 3.65 12.5 0.284 0.716 0.522 0.197 
E2677 114688 323 3.44 10.8 0.192 0.808 0.312 0.29 
E2697 89683 125 0.265 1.2 0.952 0.0478 0.976 0.413 
E2698 126651 143 2.96 7.79 0.222 0.778 0.342 0.319 
E2699 152490 524 4.1 17.2 0.188 0.812 0.367 0.145 
E2704 226974 520 5.84 57.4 0.0381 0.962 0.0938 0.0768 
E2711 71419 216 3 7.99 0.213 0.787 0.376 0.313 
E2757 105099 940 6.89 118.5 0.0222 0.978 0.0726 0.119 
E2760 104095 803 6.2 73.6 0.051 0.949 0.192 0.149 
E2761 104725 780 5.17 36 0.0853 0.915 0.244 0.25 
E2762 133183 537 3.37 10.3 0.217 0.783 0.405 0.229 
E2764 142580 461 4.06 16.7 0.194 0.806 0.416 0.24 
E2765 118666 560 3.7 13 0.214 0.786 0.427 0.271 
E2766 163204 1062 6.41 85.1 0.0343 0.966 0.113 0.148 
E2768 70250 780 5.61 48.7 0.102 0.898 0.304 0.213 
E2769 108789 776 4.46 22 0.212 0.788 0.45 0.227 
E2770 145686 701 5.78 55.1 0.051 0.949 0.175 0.172 
E2771 149970 894 5.73 52.9 0.0665 0.933 0.163 0.169 
E2772 206302 228 4.63 24.7 0.0811 0.919 0.177 0.17 
E2773 152861 683 4.82 28.2 0.0997 0.9 0.246 0.161 
E2774 129923 808 4.36 20.5 0.237 0.763 0.477 0.193 
 
Richness: number of operational taxonomic units (OTUs) with at least one read for the sample. 
Shannon_2: Shannon index logs to base 2. Accounts for abundance and evenness of species in the sample. 
Jost1: Jost index of order 1, the effective number of species given by the Shannon index. 
Simpson: probability that two randomly selected reads will belong to the same OTU. Values close to 1 indicate 
that a single large OTU dominates the sample; small values indicate distribution of reads over many OTUs. 
Dominance: probability that two randomly selected reads will belong to different OTUs. 
Berger_Parker: frequency of the most abundant OTU. Values close to 1 indicate that a single large OTU 
dominates the sample, small values indicate distribution of reads over many OTUs.  
Robbins: Robbins index, calculated as S/(N + 1) where S is the number of singleton OTUs and N is the total 
number of OTUs. 
 
 
Culture-based identification remains challenging due to the rapid growth of 
filamentous fungi which may impair the detection of Cryptococcus spp. in some samples. All 
conventional culture-based methods have limitations, including their unknown and 
potentially low sensitivity, cost (due to the need to frequently use multiple media) and 
turnaround time (often up to a week, potentially longer when the time required for 
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subculturing and molecular confirmation of the phenotypic identification is considered). 
Given the unknown sensitivity of this method, perhaps repeated cultures of each sample in 
this study could have yielded different results. It may also have been of use to add an 
inhibitor of mould growth to the bird seed agar (Pham et al., 2014, de Matos Castro e Silva 
et al., 2015). 
It is also possible that cryptococcal DNA was detected using NGS but insufficient 
viable organisms were present in these samples for culture-based detection to be 
successful. Viable but non-culturable organisms could also be present (Hommel et al., 2019). 
This observation may have clinical relevance and should be considered carefully if NGS 
results are used as part of a disease investigation, as viable live yeast cells or basidiospores 
are required to initiate infection. The potential for environmental DNA to complicate NGS 
results is further explained later in the discussion. The culture-positive but NGS-negative 
results for Cryptococcus spp. are likely related to the multitude of biases encountered in 
amplicon-based metagenomics, which will be explored later in the discussion. It is also of 
note that the number of Cryptococcus spp. reads based on NGS did not appear to be 
consistent with the culture-based grading of low, moderate or heavy. These findings again 
suggest that abundance-based results are generally considered unreliable in amplicon-based 
metagenomics studies (N.H. Nguyen et al., 2015, Tessler et al., 2017). 
Many samples were found to contain C. neoformans VNI/VNII sequences using NGS, 
as this method is unable to distinguish between VNI and VNII since their ITS1 regions are 
identical (Figure 2.1.1 B) (Katsu et al., 2004). These findings were not supported by the 
culture results, as none of the isolates collected were identified as members of the C. 
neoformans species complex. This could have occurred by chance, since only a few isolates 
were obtained from each positive sample for downstream molecular typing. Members of 
the C. neoformans species complex may also have been in a quiescent state (Hommel et al., 
2019) or were outcompeted on the culture plates by C. gattii VGI and other fungi. However, 
this discrepancy could also be due to the potential high error rate of NGS and a very high 
similarity between the ITS1 regions of the C. gattii and C. neoformans species complexes. 
Differentiating between them relies on only three polymorphic sites in the ITS1 region 
(Figure 2.1.1 B) (Katsu et al., 2004), which may also explain that C. neoformans VNI/VNII 
reads were only obtained in samples that also had C. gattii VGI reads. All Cryptococcus raw 
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reads were extracted, visually checked and their taxonomic assignments were confirmed 
using BLAST. The choice of another target, more discriminatory between the C. gattii and C. 
neoformans species complexes, such as the entire ITS region or the URA5 gene (Meyer et 
al., 2003) may have circumvented this, but the size of both regions precluded their 
compatibility with the technology (MiSeq® System of Illumina) used in this study. The use of 
long read sequencing technologies, such as MinION™ from Oxford Nanopore Technologies 
(Eisenstein, 2012), may improve discriminatory power by allowing for the sequencing of the 
entire ITS region or other targets, such as the URA5 gene. 
Although we identified 2,638 OTUs amongst the samples, only 7.5% were classified 
to species and 25.6% to genus level. Moreover, 34.2% of the OTUs were singletons which 
are largely due to the choice of the algorithm in the downstream analysis. Below order level, 
most OTUs remained unclassified without any taxonomic predictions. Our findings regarding 
the assignment success rate of OTUs agree with previous metagenomics studies carried out 
in a different environment (Schmidt et al., 2013, Sun et al., 2015, Soliman et al, 2017, Yuan 
et al., 2017). 
The mycobiome of Australian tree hollows characterised in this study appears to be 
reasonably consistent with our expectations of a decaying, hardwood micro-environment. 
Three genera: Coniochaeta, Aspergillus and Penicillium; dominated the mycobiome. Species 
in the Coniochaeta genus (pleomorphic yeasts) are known pathogens of trees and are often 
isolated from necrotic wood samples but can also cause opportunistic human infections 
after traumatic implantation, such as keratitis, subcutaneous abscesses, peritonitis and 
endocarditis (de Hoog et al., 2000, Taniguchi et al., 2009, Damm et al., 2010, Khan et al., 
2013). There is some speculation that yeasts may be overrepresented in NGS analyses due 
to their higher nucleus to cytoplasm ratio when compared to filamentous fungal species 
with longer cells (Lindahl et al., 2013). Aspergillus and Penicillium spp. are well-known fungal 
genera associated with wood degradation (soft rot fungi) in nature, since they tolerate wide 
ranges of temperature, humidity and pH, and attack a variety of wood substrates. Soft rot 
fungi are more common in hardwood, such as Eucalyptus spp., than in softwood which 
might be due to differences in the quality of the lignin (Hamed, 2013). Other genera, such as 
Scytalidium, Blastobotrys, Jaapia or Mortierella, are also commonly found in decaying 
organic matter and produce enzymes which enhance the degradation of proteins in the 
2. Environmental associations
67
wood of dead trees (Middelhoven & Kurtzman, 2007, Takahashi & Oda, 2008, Wagner et al., 
2013, Telleria et al., 2015). Statistical comparisons between tree hollow mycobiomes were 
not considered relevant in this study, because the primary focus of the sampling was to 
investigate the connection between cryptococcosis cases of koalas and the environmental 
source of these infections, with the mycobiome analysis performed opportunistically. Since 
a power analysis was not performed (regarding the number of samples for mycobiome and 
correlation analyses) and relatively few samples were used overall, this can be considered a 
pilot study. A more in-depth statistical analysis, requiring additional information about trees 
and tree hollow characteristics and a greater sample size (justified by a power analysis), will 
be subject of future studies. Further work of interest to the authors will be directed towards 
characterising the mycobiome of the koala nasal cavity to determine how closely this 
reflects that of nearby tree hollows. 
The lack of a relationship between the presence of Cryptococcus and any other 
fungal genera based on the correlation analysis is consistent with a prior study (Vanhove et 
al., 2017). The differential heat tree analysis, however, suggested some differences in the 
relative abundance of numerous taxa in samples with versus without Cryptococcus reads. At 
genus level, Aspergillus was more abundant in Cryptococcus NGS-negative samples and 
Coniochaeta, Penicillium and Sctyalidium were more abundant in Cryptococcus NGS-positive 
samples. However, both the correlation and heat tree analysis rely on NGS data, and as we 
have already demonstrated, NGS results may not always reflect the biological reality of the 
mycobiome. Of particular note in this study is one tree in which a heavy growth of C. gattii 
VGI was observed on culture, yet no Cryptococcus reads could be identified using NGS 
(Table 2.1.2; E2657). As previously mentioned, abundance-based results are also often 
considered unreliable in NGS studies (N.H. Nguyen et al., 2015, Tessler et al., 2017). 
Therefore, it is difficult to draw definitive conclusions from these findings, and further work, 
such as more systematic sampling and numerous technical replicates, would be required to 
determine how reliable these potential associations are. We also did not attempt to find 
correlations between Cryptococcus and bacteria or parasites in Australian tree hollows, 
which most likely will also influence the composition of the mycobiome but are beyond the 
scope of the current work. 
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NGS metabarcoding results should be interpreted with care, as a number of 
technical issues and biases inherent in amplicon-based metabarcoding have been reported, 
including: PCR primer selection (Pinto & Raskin, 2012, Elbrecht & Leese, 2015), tag switching 
(Esling, Lejzerowicz & Pawlowski, 2015, Schnell, Bohmann & Gilbert, 2015), template 
concentration, amplification conditions (Kennedu et al., 2014), and PCR and sequencing 
errors (Turnbaugh et al., 2010, Nakamura et al., 2011, Tremblay et al., 2015). Such errors are 
difficult to distinguish from true biological variation (Edgar, 2016b, Leray & Knowlton, 2017). 
The denoising algorithm used in this study aims to remove sequencing noise and preserve 
all biological reads in the sample, an important step in NGS data analysis. We used the 
UNOISE improved error correction algorithm (Edgar, 2016b). However, denoising algorithms 
present a challenge and another potential bias of NGS data interpretation, as defining an 
abundance threshold that differentiates correct sequences from random errors is difficult 
(Schirmer et al., 2015). The high number of singletons observed in the data set might have 
been attributable to the UNOISE algorithm used in the analysis. It is also well recognised 
that inferences from metagenomics studies are greatly influenced and varied by the fields, 
laboratories and analytic techniques utilised (Majaneva et al., 2015). Besides technical 
biases in sample preparation, DNA extraction and sequencing, there is also another level of 
complexity and biases in downstream analyses and databases. 
Another major limitation of NGS metabarcoding is the requirement for reference 
databases in order to determine the phylogenetic affiliation of sequence reads. Taxonomical 
assignments can only be as reliable as these reference databases (Santamaria et al., 2012). 
This study used the UNITE full dataset (Kõljalg et al., 2013) which also includes the ISHAM-
ITS (Irinyi et al., 2015) dataset containing all relevant ITS sequences of Cryptococcus spp. The 
SINTAX taxonomy classifier (Edgar, 2016a) was chosen to predict the taxonomy of the 
identified sequences, as it achieved comparable or better accuracy than the popular RDP 
Naive Bayesian Classifier (Wang et al., 2007). The SINTAX algorithm predicts taxonomy by 
using k-mer similarity to identify the top hit in a reference database, supported by bootstrap 
values for all ranks in the prediction (Edgar, 2016a). 
Another bias of amplicon-based metagenomics is the uncertainty as to whether the 
detected DNA belongs to a live or a dead microbe. DNA is ubiquitous and stable in the 
environment and can account for roughly 10% of extractable phosphorus in soil (Turner & 
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Newman, 2005). Extracellular DNA fragments can persist over time in many environments, 
allowing for their detection with high-throughput sequencing technology (K.M. Nielsen, et 
al., 2007). Tree hollows could protect environmental DNA from some forms of degradation, 
including extreme heat and UV-radiation. 
This study presents the first published detection of the C. gattii species complex in 
Australia from A. floribunda, E. pilularis, E. populnea, E. robusta and Melaleuca spp. to the 
best of our knowledge. The detection from E. populnea, however, was only based on NGS 
and could not be confirmed by culture. It is possible that this represents a sampling error 
when plated on culture media for the detection of fungal growth, non-viable organisms or 
erroneous sequence reads. Nevertheless, it is becoming increasingly clear that the 
ecological niche of C. gattii VGI in Australia extends far beyond the classic association with E. 
camaldulensis and E. tereticornis. 
Based on our findings of discrepancies between culture and NGS-based identification 
of Cryptococcus spp. from environmental samples, neither approach can be considered 
definitive, and they are likely complementary. NGS may have proven unable to differentiate 
between the C. gattii and C. neoformans species complexes in these samples, no significant 
correlation between the presence of Cryptococcus spp. and other fungal genera or taxa 
could be identified, and abundance-based analyses were inconclusive. As expected, the 
mycobiome of Australian tree hollows reflected the microenvironment of decaying wood. 
Given the discrepancies between culture and NGS results and the multitude of potential 
biases in amplicon-based metagenomics, meaningful inferences are difficult to establish, 
and results must be interpreted with caution. Further improvements in NGS, such as whole 
genome shotgun and long-read sequencing, together with appropriate data analysis 
pipelines and the extension of reference databases, should significantly contribute to better 
characterisation and understanding of such complex microbial community structures. 
Further work in this area should include assessing possible correlations between 
Cryptococcus spp. and bacteria, free living amoebae and nematodes. 
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 SUPPLEMENTARY FIGURE S2.1.1 The inferred taxonomic composition of fungal communities at phylum level for environmental samples 
collected from 23 tree hollows in New South Wales, Australia   
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SUPPLEMENTARY FIGURE S2.1.2 The inferred taxonomic composition of fungal communities at class level for environmental samples collected 
from 23 tree hollows in New South Wales, Australia.   
2. Environmental associations
73
 
 
 
SUPPLEMENTARY FIGURE S2.1.3 The inferred taxonomic composition of fungal communities at order level for environmental samples 
collected from 23 tree hollows in New South Wales, Australia.   
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SUPPLEMENTARY FIGURE S2.1.4 The inferred taxonomic composition of fungal communities at family level for environmental samples 
collected from 23 tree hollows in New South Wales, Australia.   
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SUPPLEMENTARY FIGURE S2.1.5 The inferred taxonomic composition of fungal communities at genus level for environmental samples 
collected from 23 tree hollows New South Wales, Australia.   
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SUPPLEMENTARY FIGURE S2.1.6 The 10 most abundant genera within the mycobiome of the 23 tree hollows in New South Wales, Australia, 
without the unassigned operational taxonomic unit for each sample. 
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3. Koala cryptococcosis
Background: 
Cryptococcosis has been well-characterised in captive koalas, but free-ranging populations 
remain largely unstudied. In particular, the acquisition and prevalence of disease (both clinical 
and subclinical) and nasal colonisation in these animals is unknown. The diagnosis and 
treatment of cryptococcosis in both captive and free-ranging animals also remain 
problematic: there have been no systematic studies into treatment protocols, and the most 
widely used serological test in this species, the LCAT, is expensive, time-consuming and 
inaccessible to field researchers. This has likely impeded large-scale studies in free-ranging 
populations. Individual and environmental risk factors for the development of colonisation or 
disease in free-ranging koalas remain unexplored, and it is difficult to survey animals for 
evidence of early exposure. In this section, three publications are presented together based 
on their relevance to clinical disease, diagnostics and treatment, while also providing insights 
into host-pathogen-environment interactions and thus addressing the central hypothesis.  
Section 3.1 reports unusual cases of cryptococcosis in an adult free-ranging koala and 
concurrent subclinical disease in its joey (index cases for the cluster discussed in section 4.1). 
These cases provided an opportunity to explore the acquisition, diagnosis and treatment of 
clinical and subclinical cryptococcosis in the context of previously published reports. Section 
3.2 compares two methodologies for serological testing in koalas (along with cats and dogs) 
– the LFA and the LCAT, to validate the LFA in these species. Inter-species differences in the
sensitivity and specificity of this test are also discussed. Section 3.3 used a surveillance finding 
of cryptococcal pneumonia in an individual to prompt an investigation into the prevalence of 
subclinical disease and nasal colonisation in a sub-population of free-ranging koalas. The 
validation of the LFA in the previous section was vital to this. This explored the utility of koalas 
as a sentinel species while also assessing risk factors for developing cryptococcosis, an 
important consideration in addressing the central hypothesis. 
Aims: 
- Aim 2: systematically document the successful diagnosis and therapy of subclinical
cryptococcosis in free-ranging koalas; and
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- Aim 3: assess the relationship between environmental presence, nasal colonisation
and disease in some free-ranging koala populations.
Sections: 
- 3.1: Cryptococcosis in the koala (Phascolarctos cinereus): pathogenesis and treatment
in the context of two atypical cases;
- 3.2: Comparing immunochromatography with latex antigen agglutination testing for
the diagnosis of cryptococcosis in cats, dogs and koalas; and
- 3.3: Prevalence of cryptococcal antigenemia and nasal colonization in a free-ranging
koala population.
Impact: 
An improved understanding of factors involved in the acquisition of this disease by the host, 
along with its effective and prompt diagnosis and treatment, will aid in the prevention and 
management of cryptococcosis in all species. Reports of successful treatment, and reviews of 
previously attempted protocols, will aid in the future treatment and management of 
cryptococcosis in koalas. Serological testing for cryptococcal antigen could be improved and 
simplified in koalas (and other animal species) through the validation of the LFA, which may 
allow for reliable screening, the detection of both low-grade exposure to environmental 
Cryptococcus spp. and the determination of the full resolution of disease during treatment. 
Critically, the LFA could also provide a means for rapid, cost-effective point-of-care serological 
testing, including during remote field work with free-ranging animals. Broad-scale testing of 
a sub-population of free-ranging koalas could also allow for risk factors involved in the 
acquisition of subclinical disease and/or nasal colonisation to be identified. This addresses the 
central hypothesis of the thesis and tests the utility of free-ranging koalas as sentinels for 
cryptococcosis in humans and other species in Australia. 
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3.1  Cryptococcosis in the koala (Phascolarctos cinereus): 
pathogenesis and treatment in the context of two atypical 
cases 
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Abstract 
Disseminated cryptococcosis caused by Cryptococcus gattii (molecular type VGI) was 
diagnosed in an adult free-ranging female koala (Phascolarctos cinereus). Subclinical 
cryptococcosis was later diagnosed in this koala's joey. In the adult koala, a pathologi­
cal fracture of the tibia was associated with the bone lysis of marked focal cryptococcal 
osteomyelitis. Limb-sparing orthopedic intervention, in the setting of disseminated cryp­
tococcosis, was judged to have a poor prognosis, and the adult koala was euthanized. 
The joey was removed and hand-reared. Serological testing revealed persistent and in­
creasing cryptococcal capsular antigenemia in the absence of clinical signs of disease 
and it was subsequently treated with oral fluconazole for approximately 16 months, reha­
bilitated and released into the wild. It was sighted 3 months post-release in a good state 
of health and again at 18 months post-release but was not recaptured on either occasion. 
This is the first published report of cryptococcal appendicular osteomyelitis in a koala. It 
is also the first report of concurrent disease in a dependent juvenile and the successful 
treatment of subclinical cryptococcosis to full resolution of the cryptococcal antigenemia 
in a free-ranging koala. This paper provides a discussion of cryptococcal osteomyeli­
tis in animals, host-pathogen-environment interactions and treatment and monitoring 
926 © The Author(s) 2017. Published by Oxford University Press on behalf of The International Society for Human and Animal 
Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 
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protocols for cryptococcosis in koalas. Published reports describing the treatment of 
cryptococcosis in koalas are also collated and summarised. 
Key words: cryptococcosis, Cryptococcus gattii, koala, osteomyelitis, treatment. 
Introduction 
Cryptococcosis, an invasive fungal disease affecting a wide 
variety of animals worldwide, is caused by members of 
the Cryptococcus neoformans and C. gattii species com­
plexes, 1 with recent proposed division of these complexes 
into seven species and several hybrids remaining controver­
sial.2 The koala (Phascolarctos cinereus) exhibits a compar­
atively high prevalence of both clinical and subclinical cryp­
tococcosis and of asymptomatic colonisation of the nasal 
mucosa by members of the C. gattii species complex, pre­
sumably due to its close association with eucalypts. 3-6 Up
to 4% of koala mortalities have been estimated to be at­
tributable to this disease.7 
Inhalation is considered the primary route of infection, 
with koalas being no exception; thus the respiratory tract 
is the most common site of initial cryptococcal lesions. 
Dissemination, especially to the central nervous system, is 
a common sequel to chronic disease.3• 8 Osteomyelitis of
the appendicular skeleton is a rare but well-documented 
manifestation of disseminated cryptococcosis in human 
patients.9 While it has not previously been reported in
the koala, sporadic reports are available in other animal 
species.10-18 
Captive koalas have been treated for clinical and 
subclinical cryptococcosis with varying degrees of suc­
cess using similar protocols to those for domestic small 
animal species, namely, combination therapy using oral tri­
azoles and parenteral amphotericin B, in concert with sur­
gical excision or debulking of mass lesions where possible 
(Table 1) .19-25 Although there are few published reports,
our group frequently manages cases of clinical and subclin­
ical cryptococcosis in captive koalas. However, there are no 
reports of the successful treatment of a free-ranging koala to 
the point of full resolution of the cryptococcal antigenemia 
and subsequent release into the wild. 
This report presents two unique cases of koala cryp­
tococcosis: a free-ranging adult koala with disseminated 
cryptococcosis including appendicular osteomyelitis and 
the successful treatment of subclinical cryptococcosis of the 
adult koala's joey. Cryptococcal osteomyelitis as an unusual 
clinical presentation of disease, host-pathogen-environment 
interactions, and protocols for the diagnosis and treat­
ment of subclinical and clinical cryptococcosis in koalas 
are discussed. Published cases of attempted treatment of 
cryptococcosis in koalas are summarised and reviewed in 
brief. 
Case 1 
An adult female free-ranging koala with a female joey came 
to the attention of the public in Soldiers Point, New South 
Wales (NSW), Australia in September 2013. The pair were 
captured and taken to a local veterinary hospital due to the 
reported presence of a large wound on the right hind limb 
of the adult and its reluctance to move from a single tree 
over several days. On clinical examination, the adult was in 
good body condition and estimated to be approximately 
3 to 4 years of age, based on dentition and microchip 
records indicating a brief capture and release event as a 
subadult approximately 18 months earlier. An ulcerated, 
fleshy, irregularly contoured, multi-lobulated mass (53 x 
40 x 20 mm) protruded from the medial aspect of the dis­
tal tibia and proximal tarsus of the right hind limb (Fig. la) 
with palpable underlying bony instability. The ulcerated 
mass was surrounded by a 10 mm wide zone of alopecia 
and was subject to myiasis. The right inguinal lymph node 
was markedly enlarged. 
Lateral and craniocaudal (Fig. lb) radiographic pro­
jections of the right hind limb demonstrated a large soft 
tissue opacity corresponding to the observed mass with 
underlying severe osteolysis of the distal tibia and prox­
imal tarsus. There was also diffuse soft tissue swelling 
of tissues distal to the right stifle and proximal to the 
metatarsal bones. Three-view thoracic radiographs were 
unremarkable. 
The mass was cleaned, and the koala was treated em­
pirically with subcutaneous enrofloxacin (Enrotril, Ilium) 
at a dose rate of 10 mg/kg once daily to control secondary 
bacterial infection and oral tramadol (Tramal Oral Drops, 
bioCSL Pty Ltd) at 1 mg/kg twice daily for analgesia. 
Hematology revealed a moderate leukocytosis com­
prised of a neutrophilia and monocytosis, (Table 2) con­
sistent with an inflammatory leukogram likely combined 
with a stress response. Serum biochemistries revealed a mild 
hyperglobulinemia, supportive of the inflammatory leuko­
gram, but were otherwise unremarkable (Table 3). Cyto­
logical evaluation of fine needle aspirates of the mass and 
the right inguinal lymph node revealed large numbers of en­
capsulated, narrow-based budding yeast cells suggestive of 
Cryptococcus spp. Latex agglutination cryptococcal anti­
gen testing (LCAT) was positive with a titer of 1:128. The 
positive cryptococcal serology results combined with cy­
tological observations and evidence of spread to a regional 
lymph node were suggestive of disseminated cryptococcosis. 
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Table 1. A summary of published cases of the attempted treatment of cryptococcosis in koalas. 
Source 
19,20 
21 
22 
23 
24 
25 
25 
25 
25 
25 
25 
25 
25 
25 
Captivity 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
C 
This paper FR 
Site of lesion/s 
Nasal 
Nasal 
Nasal 
Unknown 
Nasal 
Unknown 
Unknown 
Unknown 
Unknown 
Nasal; lung* 
Nasal* 
Nasal; lung; 
CNS* 
Mandibular 
abscess* 
Eyelid* 
Unknown 
LCAT titers 
Initial Peak 
1:512 1:2048 
1:1024 1:2048 
1:1024 1:32768 
1:2* 1:4* 
1:2* 1:2* 
1:8* 1:8* 
1:4* 1:128* 
1:256* 1:512* 
Clinical signs Treatment protocol 
Nonspecific 1. FCZ 25 mg/kg BID PO then: 
2. FCZ 25 mg/kg BID PO and AmpB 
0.5 mg/kg SC every 72 hours then: 
3. Surgical debulking and ICZ 10 mg/kg BID 
PO and AmpB 0.25 mg/kg intralesional every 
72 hours (for seven doses) then: 
4. ICZ 10 mg/kg SID PO
Nasal ICZ 10 mg/kg BID PO
Nasal 1. FCZ 20 mg/kg BID PO and AmpB 
0.5 mg/kg SC three times a week then: 
2. KCZ 10 mg/kg BID PO and AmpB 
0.5 mg/kg SC three times a week 
Nasal ICZ 20-40 mg/kg/day PO and AmpB 
1 mg/kg/day vaporised (pulse therapy; three 
pulses of 1 week, 2 weeks and 1.5 months) 
Nasal FCZ 15 mg/kg IV (two doses) and AmpB 
0.5 mg/kg SC (one dose) 
No FCZ 10 mg/kg BID PO 
No FCZ 10 mg/kg BID PO 
No FCZ 10 mg/kg BID PO 
Yes FCZ 10 mg/kg BID PO 
Yes FCZ 10 mg/kg BID PO 
1:32768* 1:32768* Nasal* FCZ 10 mg/kg BID PO and AmpB 
0.7-0.8 mg/kg SC twice weekly 
1:512* 
1:64* 
1:4* 
1:8 
1:2048* Yes 
Yes 
1:8* Yes 
1:64 Nonspecific 
FCZ 15 mg/kg BID PO and AmpB 
0.7-0.8 mg/kg SC twice weekly 
FCZ 15 mg/kg BID PO (and AmpB 
0.7-0.8 mg/kg SC twice weekly*) 
FCZ 15 mg/kg BID PO and AmpB 
0.7-0.8 mg/kg SC twice weekly 
1. FCZ 25 mg/kg BID PO then: 
2.FCZ 50 mg/kg BID PO, gradually reduced 
back to 25 mg/kg BID PO 
Treatment 
duration 
>1 year 
5 days 
6 months 
6 months 
Unknown 
>2 months* 
Outcome 
Survival; 
antigenernia 
unresolved 
Death 
Survival; 
antigenemia 
unresolved 
Death 
Death 
Survival; 
antigenemia 
resolved* 
> 2 months* Survival; 
antigenemia 
resolved* 
> 2 months* Survival; 
>2 months* 
>2 months* 
>18 months* 
:':2 weeks 
>2 months* 
>2 months* 
16 months 
antigenemia 
resolved* 
Survival; 
antigenemia 
resolved* 
Death 
Survival; 
antigenemia 
resolved* 
Death 
Death 
Survival 
Survival; 
antigenemia 
resolved; 
release 
AmpB, amphotericin B; BID, twice daily; C, captive; CNS, central nervous system; FCZ, fluconazole; FR, free-ranging; ICZ, itraconazole; IV, intravenous; KCZ, 
ketoconazole; LCAT, latex cryptococcal antigen agglutination test; PO, by mouth; SC, subcutaneous; SID, once daily. *Unpublished data provided by M.B. 
Krockenberger. 
The koala was euthanized due to an overall poor prognosis 
for full functional recovery. 
Post mortem computed tomography was performed 
at the University Veterinary Teaching Hospital Sydney. 
This confirmed and characterized further the extent of the 
marked destruction of the right distal tibia (Fig. 2). No 
sinonasal lesions were identified. 
Necropsy was performed at the Sydney School of Veteri­
nary Science, The University of Sydney. In addition to the ul­
cerated tibiotarsal lesions and inguinal lymphadenomegaly, 
a round subcutaneous mass (6 mm diameter) containing 
thick yellow to green colored fluid was detected in the 
ventral cervical subcutaneous tissues. Additionally, a focal 
cystic lesion of the dorsal abdominal wall adjacent to the 
aorta at the level of the adrenal glands, a pale focal le­
sion (4 mm diameter) in the right renal cortex, widespread 
multifocal streaky white pulmonary lesions and a well­
circumscribed pulmonary nodule (10 mm diameter) were 
present. Moderate rounding of the hepatic lobar borders 
and widespread, uniform nodularity of the liver were also 
detected. No lesions were detectable grossly in the nasal 
cavity, upon serial sectioning of the head. Cytological eval­
uation of a needle aspirate from the cervical lesion revealed 
encapsulated yeast organisms. Histopathological examina­
tion of tissues revealed further encapsulated yeasts and 
associated granulomatous inflammation in the pulmonary 
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Figure 1. (a) Cryptococcal mass lesion of the distal right hind limb in an adult koala (case 1). (b) Craniocaudal radiographic projection of the distal 
right hind limb in case 1 showing the osteolytic changes consistent with osteomyelitis of the distal tibia and proximal tarsus and surrounding soft 
tissue swelling. This Figure is reproduced in color in the online version of Medical Mycology. 
nodule, scattered throughout the pulmonary parenchyma, 
peri-aortic lesion, right inguinal lymph node, focal renal le­
sion and the mass lesion of the right hind limb. Mycotic 
abscessation of the right inguinal lymph node was also ap­
parent. Small bony fragments were visible in the deeper 
aspects of the hind limb lesion. Mild multifocal meningitis 
and a focal submeningeal granuloma containing encapsu­
lated yeasts were apparent overlying the cerebrum. The liver 
exhibited multifocal moderate fibrosis, occasional small ag­
gregates of a mixed inflammatory infiltrate and increased 
hepatocellular turnover. Samples for culture were collected 
aseptically from the right inguinal lymph node and a mem­
ber of the C. gattii species complex was isolated. Restric­
tion fragment length polymorphism analysis of the URAS 
gene identified the isolate as C. gattii molecular type VGI.26
These results confirmed the diagnosis of disseminated cryp­
tococcosis with appendicular osteomyelitis caused by C. 
gattii molecular type VGI. 
The koala tested positive for koala retrovirus (KoR V) 
variant KoRV-A and negative for variant KoRV-B 
using DNA extracted from formalin-fixed paraffin­
embedded (FFPE) tissues (spleen and lymph node) and a 
minor adaptation of established polymerase chain reac­
tion (PCR) protocols.27 Other KoRV variants were not
tested for. 
Case 2 
The female joey, a dependent backyoung weighing 0.9 kg, 
of case 1 was captured with its dam and presented for 
veterinary assessment. No abnormalities were detected on 
physical examination. The joey was placed in to care with 
Port Stephens Koalas (Port Stephens, NSW, Australia) and 
hand-reared after euthanasia of the adult. Approximately 1 
week after the initial rescue, blood was collected for LCAT 
after the diagnosis of disseminated cryptococcosis in its 
dam was confirmed. A positive result was recorded with 
a titer of 1:8 (Table 4 ). In the absence of clinical signs, 
subclinical cryptococcosis was suspected. Serology was re­
peated one month after the initial test: the LCA T titer had 
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Table 2. Hematology results for case 1 with reference 
intervals. 
Analyte Value Reference interval28 
Hemoglobin(g/1) 94 88-140
Hematocrit 0.31 0.29-0.44
MCH (pg) 29 33.1-35.1
MCHC (g/1) 301 298-330 
MCV (fl) 97 94-117 
Erythrocytes ( x 109 /I) 3.2 2.7-4.2
Leukocytes ( x 109 /I) 24.6 2.8-11.2
Neutrophils ( x 109 /I) 21.2 0.5-6.3
Lymphocytes (x 109 /1) 2.5 0.2-5.8 
Monocytes (x 109 /1) 1.0 0.0-0.6
Eosinophils ( x 109 /I) 0.0 0.0-1.1
Basophils ( x 109 /1) 0.0 
Reticulocytes (%) 4.8 1.5-3.5 
nRBCs (/100 leukocytes) 1 1-20
Platelets (x 109 /1) 392 222-508 
MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin 
concentration; MCV, mean corpuscular volume; nRBCs, nucleated red blood 
cells. 
Table 3. Serum biochemistry results for case 1 with reference 
intervals. 
Analyte Value Reference interval28 
Total protein (g/1) 80 58-83 
Albumin (g/1) 26 34-50
Globulin (g/1) 54 18-39
Alkaline phosphatase (U/1) 58 25-219 
Alanine transaminase (U/1) 20 0-236 
Amylase (U/1) 47 
Bilirubin (µmoll!) 3.42 0-8 
BUN (mmol/1) 2.14 
Creatinine (µmol/1) 62 80-150 
Glucose (mmol/1) 0.2-6.6 2.7-7.2 
Calcium (mmol/1) 2.07 2.28-2.97
Inorganic phosphate (mmol/1) 0.71 0.79-1.96
Potassium (mmol/1) 3.7 3.5-6.8
Sodium (mmol/1) 122 132-145
BUN, blood urea nitrogen. 
changed to 1:64 (Table 4), suggestive of expansion of the 
subclinical focus of infection despite the absence of any 
clinical signs of disease. Antifungal therapy was therefore 
initiated. Oral generic fluconazole (Bova Compounding©) 
was administered at a dose rate of approximately 25 mg/kg 
twice daily. Cryptococcal antigenemia was monitored ev­
ery 1 to 3 months during treatment with the lateral flow 
assay (LFA) (CrAg@ LFA, IMMY) and LCAT (CALAS@, 
Meridian Bioscience, Inc.). Serological testing was per­
formed in the same laboratory in every instance (Vet­
erinary Pathology Diagnostic Services, The University of 
Sydney). 
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During the first month of treatment, the joey became 
acutely unwell, exhibiting a quiet demeanour, diarrhea, 
and inappetence. Supportive care, including subcutaneous 
fluid therapy and nutritional support (Di-Vetelact@, Sharpe 
Laboratories and Nutrigel, Ilium), combined with an in­
creased dose of oral fluconazole (approximately 50 mg/kg 
twice daily) and a single dose (10 mg) of subcutaneous 
dexamethasone (Dexapent, Ilium) was successful in restor­
ing the joey to normal health after several days. The oral 
fluconazole dose was gradually reduced back to approx­
imately 25 mg/kg twice daily. No further such episodes 
occurred, and the joey remained clinically normal until its 
eventual release. 
Treatment continued for a total of 16 months until serol­
ogy was negative for cryptococcal antigen for both the 
LCA T and LF A on consecutive tests at a minimum interval 
of 1 month (Table 4). At the time of the cessation of treat­
ment, the koala was a subadult at over 2 years of age and 
ready for release, pending transfer to the Koala Hospital 
(Port Macquarie, NSW, Australia) for a de-humanization 
period. The koala remained negative for cryptococcal anti­
genemia when tested immediately after transfer and just 
prior to release, the final test being approximately 5 months 
after the cessation of treatment. 
The koala was released approximately 21 months after 
capture. A microchip was implanted, and a yellow num­
bered ear tag was placed in the right ear prior to release 
to aid identification in the event of a sighting or recapture 
event.No other koalas with ear tags are known to be present 
in this region. Three months after release, a sighting of a 
koala with a yellow ear tag in close proximity to the release 
site was reported by a member of the public. Photographic 
evidence of the sighting demonstrates the presence of the tag 
in the right ear, although individual identification cannot be 
definitively confirmed. The koala appeared to be a young 
adult female. Based on the location, sex, and apparent age 
of the koala and presence of the ear tag, it is considered 
extremely likely that this sighting was of the same animal. 
The report and photographs suggest that the koala was be­
having normally. A second sighting of a koala with an ear 
tag was reported in the same area approximately 18 months 
after release, but no photographic evidence is available. 
Discussion 
Cryptococcosis is predominantly acquired from the envi­
ronment by inhalation. Colonization of mucosa! surfaces 
is the initial outcome of infection, potentially followed by 
local disease. This may either be constrained by the nor­
mal innate and acquired immune response of the host or 
progress to clinical disease, depending on factors such as 
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Figure 2. Computed tomographic three-dimensional reconstructions of the distal left and right hind limbs of an adult koala (case 1 ), comparatively 
highlighting the marked destruction of the right distal tibia due to cryptococcal osteomyelitis. This Figure is reproduced in color in the online version 
of Medical Mycology. 
Table 4. Cryptococcal antigen serology results for case 2. 
Date LCAT LCAT titer LFA Comments 
October 2013 Positive 1:8 Initial test 
November 2013 Positive 1:64 Treatment begins 
January 2014 Positive 1:64 
April 2014 Positive 1:8 Positive 
June 2014 Positive 1:2 Positive 
August 2014 Negative Positive 
September 2014 Negative Positive 
October 2014 Negative Positive 
December 2014 Negative Negative 
February 2015 Negative Negative Treatment ceases 
March 2015 Negative Negative After transfer 
June 2015 Negative Before release 
LCAT, Latex cryptococcal antigen agglutination test; LFA, Cryptococcal antigen lateral flow assay. 
the size of the inoculum and the age and overall health of 
the host. Following the development of a primary lesion 
in the upper or lower respiratory tract, the fungus has the 
potential to invade locally into contiguous tissues, or to dis­
seminate hematogenously or via the lymphatics.3, 8 Solitary 
cutaneous lesions have been identified in numerous koalas, 
suggesting that direct inoculation is also a route of infection 
and can give rise to localized variably invasive cutaneous 
and subcutaneous disease.3 The distribution of solitary
cutaneous lesions is generally around the mouth and 
philtrum, the ears, and the base of the claws.4 The au­
thors speculate that cryptococcal colonization of the nails 
and nail beds6 may facilitate inoculation of the skin of 
the head through minor grooming injuries. Appendicular 
osteomyelitis subsequent to disseminated cryptococcosis 
has been reported in canine, equine, feline and avian pa­
tients.11· 12· 14· 15 Several cases involving a solitary cryptococ­
cal lesion of the appendicular skeleton have been identified 
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in dogs and a cat, but in all cases the possibility of dis­
semination from an unidentified primary lesion could not 
be excluded. 10, 13 , 16-1 8 This report presents the first pub­
lished case of cryptococcal appendicular osteomyelitis in 
the koala and indicates that cryptococcosis should be con­
sidered as a differential diagnosis for lameness, mass lesions, 
and destructive bony lesions in this species. Cryptococcal 
osteomyelitis and osteolysis of the axial skeleton have been 
identified as potential sequelae to locally invasive lesions of 
the upper respiratory tract in koalas as well as cats, dogs, 
and birds. 3,29-32 The majority of human cases of cryptococ­
cal appendicular osteomyelitis are attributable to infection 
with the C. neoformans species complex.9 However, in the 
reported animal cases, there is no apparent tendency to­
ward any member of the C. gattii or C. neoformans species 
complexes as the etiological agent, with the notable excep­
tion of koalas, in which all cases have involved the C. gattii 
species complex.3 
The prognosis for cryptococcosis in koalas is generally 
considered guarded to poor, depending on the severity of 
clinical signs and the extent of lesions at the time of diag­
nosis. 33 In this case, due to the degree of destruction of the 
distal tibia in conjunction with disseminated disease and 
the requirement for orthopedic intervention, the prognosis 
was judged to be very poor. Limb-sparing surgery with ef­
fective antifungal therapy and subsequent return to normal 
function for a free-ranging koala was considered unlikely 
to be able to be achieved in this clinical setting. 
While only 77% of koalas with cryptococcosis are found 
to have detectable respiratory tract lesions,3 there is a com­
pelling case for early pathogenesis of cryptococcosis in all 
species to include a primary respiratory focus. Therefore, it 
is likely that the tibiotarsal lesion developed as a result of 
dissemination from the pulmonary lesions. However, it is 
prudent to also consider the possibility of a primary tibio­
tarsal lesion subsequent to direct inoculation. This may be 
supported by the advanced nature of the lesion, marked 
lymphadenopathy of a draining lymph node (in the ab­
sence of a more generalized lymphadenopathy), relatively 
low LCAT titer (1:128) and fairly limited dissemination. 
Co-infection via both inhalation and direct inoculation is 
also possible. 
Host-pathogen-environment interactions involved in 
colonization of koalas by the C. gattii species complex and 
the comparatively high prevalence of subclinical and clin­
ical cryptococcosis in this species remain relatively poorly 
understood. In both cases presented in this report, no ob­
vious causes of increased host susceptibility were apparent. 
Retroviral testing of case 1 was positive for KoRV-A and 
negative for KoRV-B. These findings are consistent with the 
koala originating from a population likely to have 100% 
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prevalence of endemic KoRV-A inserted in the genome.34
KoRV-A is an endogenous variant considered unlikely to 
have any significant immunomodulatory effects on koalas; 
conversely the exogenous variant KoRV-B has been associ­
ated with altered immune function, chlamydiosis and ma­
lignant neoplasia.27·35,36 The relationship between crypto­
coccosis and KoRV infection has not been studied systemat­
ically. No other evidence of concurrent disease or immuno­
suppression could be detected on ante mortem hematology 
or necropsy. Pathogen-related factors, including the pos­
sibility of a highly virulent strain of C. gattii molecular 
type VGI, cannot be excluded, and further epidemiologi­
cal molecular analysis of the strain isolated from this koala 
may be pertinent. 
Most reported cases of clinical cryptococcosis in koalas 
where the causative organism was identified to a species 
level have been attributed to infection with a member of 
the C. gattii species complex,3 •20 with C. neoformans var.
grubii (molecular type VNI) identified as the etiologic agent 
in one case based on PCR and sequencing of DNA extracted 
from FFPE tissue.21 This is in contrast with cats and dogs, 
where the C. neoformans species complex tends to be re­
sponsible for a greater proportion of cases, even in places 
like Australia where the C. gattii species complex is en­
demic. 30,31 ,37 This difference is likely to be attributable to
the close contact between koalas and eucalypts, a common 
environmental niche for C. gattii molecular type VGI, with 
Eucalyptus camaldulensis and E. tereticornis both consis­
tent environmental sources of the C. gattii species com­
plex38,39 and common feed species for koalas.40 E. tereti­
cornis trees are an important part of the bushland at Soldiers 
Point, NSW, Australia from which this koala originated and 
C. gattii molecular type VGI was easily recoverable from
this environment in preliminary investigations, which sug­
gests a substantial cryptococcal environmental load in this
area. High environmental burdens of the C. gattii species
complex have been associated with a higher incidence of
nasal colonization and subclinical disease in koalas.4·5 Fur­
ther sampling is required to expand on this notion and the
role that it may play in the host-pathogen-environment in­
teraction in this specific environment.
The second case presents the first published report of 
the successful treatment of subclinical cryptococcosis in 
a free-ranging koala. Table 1 summarises all published 
cases of attempted treatment of cryptococcosis in koalas. 
With the exception of this publication, all involve only 
captive koalas. Two publications reported successful treat­
ment to the point of survival more than one year af­
ter diagnosis, although both appear to describe the same 
case. 19,20 Another reported treatment success in a captive
koala up to six months after diagnosis but longer term 
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survival is unknown.22 In one publication focusing on the
pharmacokinetics of fluconazole administered orally to 
koalas, treatment was attempted in nine koalas with clini­
cal (n = 6) or subclinical (n = 3) cryptococcosis.25 In the
clinical group, full recovery was reported in two cases,25
although a third case also achieved resolution of antigene­
mia and clinical signs (Krockenberger, M.B., unpublished 
data). Outcomes in the subclinical group were not reported 
but all three koalas survived and the antigenemia fully re­
solved (Krockenberger, M.B., unpublished data). The ex­
act duration of treatment was unclear and cases were lost 
to further follow-up. Among the few published reports, 
common themes for successful treatment appear to include 
early diagnosis and aggressive, persistent antifungal ther­
apy. However, survival and full resolution of antigenemia 
was achieved in one case with a LCAT titer of 1:32768 
and severe clinical signs at the time of diagnosis (Krocken­
berger, M.B., unpublished data). Pulse therapy proved in­
effective in another case.23 In the experience of some of the
current authors, numerous other captive koalas have been 
successfully treated to full resolution for both clinical and 
subclinical cryptococcosis; nevertheless, successful therapy 
is challenging and the majority of these cases remain unpub­
lished. Therapeutic dose monitoring is advisable given the 
known pharmacokinetics of some of the azole agents. This 
paper is the first published report of the full resolution of 
cryptococcosis in a koala to the point of negative serology 
results and subsequent cessation of treatment. 
Subclinical cryptococcosis is considered a relatively com­
mon finding in koalas, particularly in the presence of a high 
cryptococcal load in the environment.5 Depending on in­
dividual circumstances, the authors generally recommend 
treating any koala with an antigen titer greater than 1:8, 
where the titer persists at this level over time, or increases 
further. Treatment at lower antigen titers may be consid­
ered depending on the specific case details. In case 2, the 
initial titer was 1:8 but changed to 1:64 after 1 month, 
and there was concern that the stress of adjusting to han­
dling and captivity was activating a quiescent focus of in­
fection in the joey, particularly knowing that it had been 
exposed to the same environment as its dam which had suc­
cumbed to disseminated cryptococcosis. It is possible that 
this progression to overt clinical cryptococcosis occurred 
when the joey became acutely unwell early in treatment, 
as the LCAT titer of 1:64 at the time is the upper limit of 
what we have seen in subclinical disease in this species.5
It may have been prudent to assess the joey for the pres­
ence of any cryptococcal lesions or concurrent pathologies 
through fecal culture, thoracic imaging, sinonasal computed 
tomography, and/or hematology and serum biochemistry. 
Given that no causative organism was isolated, it is possible 
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that the LCAT and LFA results represented false positives. 
However, this is highly unlikely given the persistence of the 
positive results, the response to treatment exhibited through 
the changing LCAT titer, the joey's exposure to the same 
environment from which its dam contracted cryptococcosis 
and the high prevalence of cryptococcosis in koalas. 
The monitoring protocol used by the authors during 
treatment involved serum antigen testing at approximately 
1-month intervals, with the intention to stop treatment after
three consecutive negative tests. The first negative LCAT re­
sult was obtained approximately nine months after flucona­
zole treatment was initiated, and all LCA T results remained
negative from this point onwards. However, the LFA re­
mained positive for a further three months. At the time of
the third consecutive negative LCA T, the LF A was still pos­
itive, consistent with it being the more sensitive of the two
tests.41-43 Therefore, it was decided to continue treatment
until consecutive negative LFA results were obtained. The
koala was tested again after transfer to a new facility and
just prior to release into the wild, due to concern that the
potential stress of transfer and dehumanization could cause
recrudescence of disease. It remained antigen negative. At
present, the LCA T is still the predominant serological test
for cryptococcosis in animals. The LF A is not yet routinely
used in veterinary diagnostics, primarily due to a lack of
published evidence regarding its use in animals. However,
the LFA's high sensitivity and 'point of care' accessibility
make it an attractive future prospect for veterinary diagnos­
tics.41-44 Preliminary findings suggest that the LFA has an
excellent negative predictive value but is of variable speci­
ficity for serum samples in cats, dogs, and koalas, when
compared to the LCAT (Krockenberger, M.B., unpublished
data). Based on this observation, the authors now com­
monly use the LFA as a screening test for cryptococcosis
in animals in both the laboratory and the field and use the
LCA T to confirm positive results and to determine antigen
titers, due to the high cost of using multiple LFA test strips.
Variations of the treatment protocol for this koala have 
been used relatively successfully by the authors on numer­
ous occasions for the treatment of cryptococcosis in other 
koalas, and are based on treatment protocols for cryptococ­
cosis in dogs, cats and ferrets.31·33·45·46 The dose rate used
for oral fluconazole in small animal patients is typically 
10 mg/kg twice daily.31 The dose rate of 20-25 mg/kg given
orally twice daily for koalas was selected at the time based 
on the prior experience of the authors and has been sup­
ported since by a report of overall low and highly variable 
bioavailability (median 0.53, range 0.20-0.97) in koalas 
when dosed orally at 10 mg/kg.47 Another study showed
that peak plasma fluconazole concentrations failed to reach 
the minimum inhibitory concentration for C. gattii species 
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complex isolates when dosed orally at 10-15 mg/kg twice 
daily.25 Fluconazole levels were not monitored in this case,
though the authors now routinely utilise drug concentra­
tion testing to adjust dosages and treatment protocols in 
koalas. More recently, the authors have begun to use oral 
itraconazole (10-20 mg/kg once daily with Sporanox@ 
Uanssen-Cilag Pty Ltd]; 10 mg/kg using Lozanoc@ [Mayne 
Pharma International Pty Ltd]) with the experience of gen­
erally shorter treatment times and a better tolerance by 
koalas for once daily dosing. However, the pharmacoki­
netic profile of oral itraconazole in the koala remains poorly 
understood. Although there is evidence that posaconazole 
has a reasonable oral bioavailability in koalas,48 there are
limited clinical data regarding its use as a standard treat­
ment for cryptococcosis in any species, and at present it 
is prohibitively expensive for most veterinary applications. 
The use of amphotericin B in conjunction with oral tria­
zole antifungals is recommended for most cases of clinical 
disease and for refractory subclinical disease, if the antigen 
titer remains unresponsive to oral triazole monotherapy.25
The most recent recommendation for amphotericin B dos­
ing in koalas is 0.7-0.8 mg/kg administered subcutaneously 
twice weekly in a 0.45% NaCl and 2.5% dextrose fluid bo­
lus.25,49 A cumulative amphotericin B dose requirement for
the koala is unknown but likely should be a minimum of 
20 mg/kg, based on our experience in adapting protocols 
developed for feline and canine cryptococcosis.46,49 Flu­
conazole monotherapy was preferred in this case, largely 
for logistical reasons. Amphotericin B was not added to the 
treatment protocol based on the response to therapy seen 
through the changing LCA T titer. The use of corticosteroids 
is generally contraindicated in cases of cryptococcosis due 
to the risk of immunosuppression. However, glucocorticoid 
therapy after diagnosis has been associated with improved 
early survival rates in canine and feline patients with central 
nervous system cryptococcosis and may have a role in re­
ducing an overactive inflammatory response. 50 In this case,
dexamethasone was administered on a one-off basis in con­
junction with a high dose of fluconazole due to the rapidly 
declining condition of the koala. 
The release of this koala into the wild had the poten­
tial to cause sufficient stress to allow for a recrudescence 
of latent disease. The first sighting, 3 months after release, 
confirmed its survival, and its apparently normal behavior 
suggested that it was coping adequately with its new en­
vironment. The timing of this sighting was at the start of 
breeding season, the first for this koala as a free-ranging 
adult, and although this stressful period could also have 
resulted in recrudescence of disease, a likely repeat sighting 
approximately 18 months after release suggests the ongoing 
survival of the koala. It would be pertinent to continue to 
Medical Mycology, 2018, Vol. 56, No. 8 
monitor this location for additional sightings to assess the 
health of this individual. 
In conclusion, this report presents the first case of (i) 
disseminated cryptococcosis with appendicular osteomyeli­
tis in a koala and (ii) the successful treatment of subclin­
ical cryptococcosis, to the point of full resolution of the 
cryptococcal antigenemia and subsequent release back into 
the wild, in its dependent juvenile. These cases provided 
an opportunity to broaden the spectrum of clinical pre­
sentations of cryptococcosis and to discuss host-pathogen­
environment interactions, diagnostic testing, and treatment 
protocols for cryptococcosis in koalas. 
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Addendum 
Just prior to publication, the koala was found at the base of a 
tree following a period of extreme hot weather. It was taken into 
care by Port Stephens Koalas, positively identified as the koala (ear 
tag and microchip) and treated for conjunctivitis and heat stress. 
Diagnostics were performed in our laboratory (Veterinary Pathol­
ogy Diagnostic Services). Chlamydia! conjunctivitis was confirmed 
by PCR, cryptococcal serology was negative by both the lateral 
flow assay (LFA) (CrAg® LFA, IMMY) and latex agglutination 
assay (CALAS®, Meridian Bioscience, Inc.) and nasal culture for 
Cryptococcus neoformans and C. gattii species complexes was neg­
ative. It is responding well to therapy for chlamydia! conjunctivitis. 
It remains cryptococcal serology negative without any signs of cryp­
tococcosis almost 3 years following release into the wild. 
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Abstract
Although the point-of-care cryptococcal antigen lateral flow assay (LFA) has revolutionized the diagnosis of
cryptococcosis in human patients, to date there has been no large-scale examination of this test in animals.
We therefore assessed the LFA in cats, dogs and koalas suspected of having cryptococcosis. In sum, 528
serum specimens (129 from cats, 108 from dogs, 291 from koalas) were tested using the LFA and one of
two commercially available latex cryptococcal antigen agglutination test (LCAT) kits. The LCAT is a proven
and well-accepted method in veterinary patients and therefore taken as the “gold standard” against which
the LFA was compared. The LFA achieved a sensitivity of 92%, 100%, and 98% in cats, dogs, and koalas,
respectively, with corresponding negative predictive values of 94%, 100%, and 98%. The specificity of the
LFA was 81%, 84%, and 62% for cats, dogs, and koalas, respectively, with corresponding positive predictive
values of 76%, 48%, and 69%. These findings suggest the most appropriate role for the LFA is as a screening
test to rule out a diagnosis of cryptococcosis in cats, dogs, and koalas. Point-of-care accessibility makes it
equally suited for use in the field and as a cage-side test in veterinary hospitals. The suboptimal specificity
of the LFA makes it less suited to definitive confirmation of cryptococcosis in animals; therefore, all LFA-
positive test results should be confirmed by LCAT testing. The discrepancy between these observations and
the high specificity of the LFA in humans may reflect differences in the host-pathogen interactions amongst
the species.
Key words: lateral flow assay, cryptococcal antigen, immunochromatography, Cryptococcus, veterinary.
Introduction
Cryptococcosis is a fungal infection of humans1–3 and ani-
mals4–8 caused by members of the Cryptococcus neoformans
and Cryptococcus gattii species complexes.9 Rarely, other mini-
mally encapsulated Cryptococcus spp. can cause disease, which
is usually localized and less severe.10 Infection typically occurs by
inhalation of basidiospores, but direct inoculation can occasion-
ally cause localized cutaneous disease.3 In human patients, cryp-
tococcosis classically presents as central nervous system (CNS)
disease and is therefore often diagnosed using a combination
C© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and AnimalMycology.
All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
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of cerebrospinal fluid (CSF) analysis (direct examination, myco-
logical culture, and antigen testing), brain imaging studies (com-
puted tomography [CT] or magnetic resonance imaging [MRI])
and serology.1–3,11,12 In animals, cryptococcosis is more often
associated with respiratory tract disease, classically of the nasal
cavity and sinuses but also the lower respiratory tract in some
species.3–8 The propensity for dissemination to the CNS also
occurs in animals, and therefore neurological changes are still
commonly observed.3–8 A definitive diagnosis in animal cases
is often achieved through a combination of the direct obser-
vation of suspect organisms (using diagnostic cytology and/or
histopathology), mycological culture, or serology. CT and MRI
are often useful in a referral setting but are not yet accessible
to most veterinary general practitioners and can be cost pro-
hibitive.1–8,10-12 Mycological culture remains the gold standard
for diagnosis in all species, as it allows for both a definitive
phenotypic and genotypic identification, and molecular or pro-
teomic (MALDI-tof) typing of the fungal pathogen involved, and
the ability to perform susceptibility testing.3
Measurement of circulating polysaccharide antigen (glu-
curonylmannan) in serum or plasma by latex cryptococcal anti-
gen agglutination testing (LCAT) provides evidence of invasive
cryptococcosis with both high specificity and sensitivity.13 The
monitoring of sequential LCAT titers has proven to be extremely
useful to support therapeutic decisions during the treatment of
birds, cats, dogs, ferrets and koalas with cryptococcosis.4–7,10,14
The accuracy of the procedure is dependent on preincubation of
serumwith pronase (typically included as part of the test kit) and
heat inactivation to remove interfering factors capable of caus-
ing false results, including rheumatoid factor, which can result
in false positive agglutination, and opsonising antibodies, which
can trap cryptococcal antigen.13 The LCAT is well accepted and
validated as a diagnostic test in veterinary laboratories. How-
ever, the procedure requires a skilled technician and access to
laboratory equipment, including a heat block. The test is also
expensive because it is time and labor intensive, which often
necessitates sample batching, further delaying turn-around time.
Rapid confirmation or exclusion of the diagnosis of crypto-
coccosis allows clinicians to adjust diagnostic and therapeutic
strategies and has the potential to hasten the diagnosis and re-
duce costs of investigations for many patients. A cryptococcal
antigen lateral flow assay (LFA) (CrAg R© LFA, IMMY, Nor-
man, OK, USA) was developed in 2010 as a point-of-care (POC)
serological test to diagnose cryptococcosis. The test detects cryp-
tococcal polysaccharide antigen and is currently in widespread
usage in medical diagnostic laboratories worldwide.15–26 This
test platform provides room temperature stability and simplic-
ity of execution with minimal laboratory equipment and no
pronase pretreatment or heat inactivation required.17 It is there-
fore equally suitable as a POC test in a hospital laboratory or in
the field. The test has been validated by several mycology groups
around the world, with consensus from these reports and careful
metanalysis22 indicating that the LFA is highly suitable as a POC
screening test, with comparable specificity and possibly superior
sensitivity to the LCAT.15–26 In Australia, the LFA has tended to
replace LCAT testing in routine medical diagnostic laboratories,
although the LCAT remains available at reference laboratories
and is preferred when an endpoint titer is required for clinical
decision making.17
The LFA has great potential for use in veterinary medicine as
a cage-side or field screening tool to quickly establish whether
cryptococcosis can be excluded as a diagnostic possibility in an-
imal patients presenting with suspicious clinical signs, including
sinonasal disease, CNS disease, or pneumonia. The test, how-
ever, remains unvalidated in animal patients. Cryptococcosis
is seen in a plethora of domestic and free-ranging animals in
Australia, but is most frequently diagnosed in cats, dogs4,5 and
koalas.8 The current study was designed to determine the utility
of a cryptococcal antigen LFA in animals of these three species
in which cryptococcosis was a potential diagnosis.
Methods
Serum specimens included in this study were submitted for cryp-
tococcal antigen testing to two veterinary laboratories (Veteri-
nary Pathology Diagnostic Services, The University of Sydney,
NSW, Australia, and Vetnostics, Macquarie Park, NSW, Aus-
tralia) from 2011 to 2016. A total of 528 serum specimens were
tested, comprising 129 from cats, 108 from dogs, and 291 from
koalas. In some instances, several specimens were submitted
from a single patient, as serial determinations of the cryptococ-
cal antigen titer are typically obtained during therapy. When this
occurred, each sample was considered to be a separate specimen.
Canine and feline serumwas submitted from patients thought
to have cryptococcosis based on signs and cytology, or where
cryptococcosis was a differential diagnosis. Koala samples were
generally submitted as part of routine monitoring of zoos and
wildlife parks for subclinical cryptococcosis, a common condi-
tion in captive koalas. This is defined as a persistent positive
LCAT in the absence of symptoms, typically with a reciprocal
titer no greater than 64.14 Samples were also included from free-
living koalas in the Liverpool Plains region of New South Wales,
Australia, as part of a wider study into the health of this popula-
tion, approved by The University of Sydney Animal Ethics Com-
mittee (project number 2016/955). A small number of koalas
with clinical signs of active (symptomatic) cryptococcosis were
included also. Monitoring of koalas in facilities with high envi-
ronmental levels of the C. gattii species complex and high rates
of cryptococcal nasal colonization, subclinical and clinical cryp-
tococcosis was undertaken with a view to commencing preemp-
tive therapy before the development of clinical signs. This is
analogous to screening high-risk human immunodeficiency virus
(HIV)-positive patients for cryptococcal antigen in places such
as Colombia, Uganda, and other parts of sub-Saharan Africa,
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Figure 1. Latex cryptococcal antigen agglutination test and cryptococcal antigen lateral flow assay results for diagnostic serum specimens from: (A) 129 cats, (B)
108 dogs and (C) 291 koalas. This Figure is reproduced in color in the online version of Medical Mycology.
where early detection and preemptive therapy improves clinical
outcomes and is cost effective.18,24–29
Paired aliquots of serumwere tested with (1) an immunochro-
matography LFA (CrAg R© LFA, IMMY, USA) according to the
manufacturer’s recommendations30 and (2) a LCAT (Crypto-LA
Test, Wampole Cranbury, NJ, USA, from 2011 to 2012 [when
the test became unavailable], and Cryptococcal Antigen La-
tex Agglutination System (CALAS R©), Meridian Bioscience Inc,
Cincinnati, OH, USA from 2012 to 2016), according to man-
ufacturers’ instructions.31 Pronase pretreatment was performed
as a part of the standard operating protocol for all LCATs; it
is incorporated as part of the CALAS R© kit and was added as a
preincubation step before using the Crypto-LA test. The study
design considered LCAT as the gold standard for assigning cryp-
tococcal infection status, with a positive result being defined as
a reciprocal titer ≥2, although in many cases microscopy (cyto-
logical examination of smears and histological examination of
tissue sections) and mycological culture were also performed to
confirm the diagnosis.
Results
Cats
Of the 129 feline serum specimens tested, the findings of the
LCAT and LFA (Fig. 1A) were concordant in 110 instances; 47
were both positive (LCAT reciprocal titers ranging from 2 to
131,072 for the 35 retrievable titers; median titer 128), while 63
were both negative.
Four serum specimens were LCAT-positive and LFA-negative
and were considered false-negatives, as cryptococcosis was con-
firmed via diagnostic imaging, fine needle aspiration, and biopsy.
Two of these samples, both with LCAT reciprocal titers of 16,
were collected from the same cat, 2 years apart; this patient had
a cutaneous lesion on the pad of one distal limb from which
Cryptococcus laurentii was isolated. The other two serum spec-
imens, also from a single cat, had LCAT reciprocal titers of
131,072 and 8132, but were negative with the LFA. The first
specimen was collected at the time of diagnosis, and the sec-
ond after several months of antifungal therapy. Disseminated
intra-abdominal cryptococcosis was confirmed in this cat by ab-
dominal ultrasonography, with C. neoformans var. grubii cul-
tured from aspirates of the intra-abdominal lesions and identified
definitively byMALDI-TOFmass spectrometry. For this patient,
the LFA was repeated on heat and pronase-treated serum and
still tested negative. A semi-quantitative titration was performed
on both specimens using the LFA test and positive results were
recorded after dilutions of 1:8 (Fig. 2) and 1:4, respectively; the
endpoint reciprocal LFA titers were 1,048,576 and 524,288,
respectively.
Fifteen serum specimens were LCAT-negative but LFA-
positive. In these 15 cases, cryptococcosis was excluded as a pos-
sibility by further work-up and diagnostic testing. In the absence
of any other evidence supporting a diagnosis of cryptococcosis,
these were considered false-positives.
Dogs
Of the 108 canine serum specimens tested, the findings of LCAT
and LFA (Fig. 1B) were concordant in 93 instances: 14 results
were both positive (reciprocal LCAT titers ranging from 2 to
16,384 for the 13 retrievable titers; median 64) and 79 results
both negative. Fifteen serum specimens were LFA-positive but
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Figure 2. Prozone (or high-dose hook) effect in the cryptococcal antigen lat-
eral flow assay (CrAgR© LFA, IMMY) in a cat with a positive latex cryptococcal
antigen agglutination test (reciprocal titre of 131,072) and confirmed crypto-
coccosis. The lateral flow assay remained negative in this specimen until a
serial dilution of greater than or equal to 8. This Figure is reproduced in color
in the online version of Medical Mycology.
LCAT-negative and considered false-positives due to a lack of
any further evidence in support of a diagnosis of cryptococ-
cosis. One dog that was LFA-positive but LCAT-negative had
disseminated aspergillosis, suggesting cross-reactivity between
fungal antigens. No specimens were found to be LFA-negative
and LCAT-positive.
The LFA titer was compared to the LCAT titer in eight pos-
itive canine specimens, and in each instance the LFA titer was
substantially higher (160 c.f. 64, 1280 c.f. 64, 80 c.f. 16, 40 c.f.
8, 80 c.f. 32, 640 c.f. 64, >2,560 c.f. 1,024, 40 c.f. 2).
Koalas
Of the 291 koala serum specimens tested, the findings of LCAT
and LFA (Fig. 1C) were concordant in 229 instances; 131 tested
positive with both assays (LCAT titers ranging from 2 to 131,072
for the 115 titers retrievable; median 4), while 98 tested negative
using both methods. Two serum specimens from different koalas
were LCAT-positive (reciprocal titers of 8 and 4) but negative
with LFA, that is, false-negative results; heat and pronase treat-
ment had no effect on these two LFA results. Follow-up sampling
from both koalas 1 month later returned negative results on both
the LCAT and LFA testing.
Sixty serum specimens were LFA-positive (reciprocal titers
of 2 in the four specimens where the titer was determined)
but negative with LCAT and were considered LFA false
positives.
Sensitivity and specificity of the LFA
Using LCAT results as the gold standard, test metrics were calcu-
lated for the three different species independently (Table 1). The
LFA test had excellent sensitivity for all species, 100% in canine
patients, 98% in koalas (due to two specimens presumed to be
LFA false-negatives), and 92% in cats (due to four specimens
from two individuals that were also considered to be LFA false-
negatives). Specificity was reasonable: comparable for feline and
canine specimens (84% and 81%, respectively) but substantially
lower in koalas (62%). The negative predictive value (NPV) was
high in all species (94%, 100%, and 98% for cats, dogs, and
koalas, respectively), whereas the positive predictive value (PPV)
was less impressive (76%, 48% and 69% for cats, dogs and
koalas, respectively) (Table 1).
A representative number of specimens were pretreated with
pronase, as duplicates, to determine if this would affect the re-
sults from the LFA in certain patients, where an unexpected
positive result was obtained. This preincubation step, however,
had no impact on LFA test results.
A rare discordant case
A 6-year-old castrated Siamese cat was presented for progres-
sively worsening stertor. There had been a progressive left-sided
swelling over the nasal bridge associated with a left-sided mu-
copurulent ocular discharge. A needle aspirate was obtained
from the swollen region. Nasal smears stained with Rapid-Diff R©
(Australian Biostain) demonstrated a small number of spher-
ical capsulate narrow-necked budding yeasts. Cytology from
the nasal bridge aspirate demonstrated inflammation featuring
macrophages and lymphocytes but no yeasts. Both specimens
were cultured on Sabouraud’s dextrose agar at 37◦C and bird
seed agar. In each instance there was a light (nasal bridge)
or moderate (nasal swab) heavy growth of weakly-capsulated
narrow-necked budding yeast, producing brown-color-effect on
bird seed agar. Molecular typing established the isolate was
C. neoformans var grubiiVNII. Interestingly, cryptococcal serol-
ogy was negative, using two different Meridian CALAS R© kits
Table 1. Sensitivity, specificity, positive predictive value, and negative predictive value for the IMMY CrAg R© lateral flow assay in cats,
dogs, and koalas when compared to latex cryptococcal antigen agglutination testing.
Species Sensitivity Specificity Positive predictive value Negative predictive value
Cats 92% (47/51) 81% (63/78) 76% (47/62) 94% (63/67)
Dogs 100% (14/14) 84% (79/94) 48% (14/29) 100% (79/79)
Koalas 98% (131/133) 62% (98/158) 69% (131/191) 98% (98/100)
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and the IMMY CrAg R© LFA. The cat was treated with oral flu-
conazole (40 mg twice daily for 6 months) and made an unevent-
ful recovery.
Discussion
The LFA has proven to be highly sensitive and specific in dis-
parate cohorts of human patients.15–26 Consequently, most hu-
man diagnostic laboratories in Australia, and likely globally,
now prefer this assay to the LCAT for routine testing.17 Our
veterinary data demonstrated the LFA to be highly sensitive in
all species examined, concordant with observations from human
patients; however, the specificity and PPV suggest that the test
metrics are less favourable in animals. The NPV derived from
a large and representative number of serum specimens suggests
that the LFA is an effective screening test for cryptococcosis in
cats, dogs, and koalas. Thus, conducting a cage-side LFA in all
animal patients with respiratory or neurological signs potentially
consistent with cryptococcosis will allow veterinary clinicians to
rapidly rule out this disease prior to conducting expensive and
potentially risky diagnostic procedures. However, discrepant re-
sults highlight the necessity of interpreting the LFA with caution
in all animal patients. The findings of this study indicate that
when using the LFA as a screening test, if serum from the pa-
tient tests negative, then cryptococcosis can be excluded with
confidence. If a high degree of suspicion or other compelling
evidence of cryptococcal disease is evident from the diagnostic
findings, the LFA should be repeated on serially diluted serum
specimens and/or an LCAT should be performed to ensure that
a false-negative result is not recorded. A positive LFA result
in cats and dogs provides strong evidence supporting a diag-
nosis of cryptococcosis but requires further confirmation with
the LCAT or other diagnostic tests (e.g., cytology, histology, or
culture).
False-negative LFA results were noted in six specimens (four
cats, two koalas). This study presents the first published reports
of false-negative results using the IMMY CrAg R© LFA on serum
specimens in any species. In one cat from which two sequen-
tial samples were collected, it is presumed that the false-negative
result occurred due to a localized infection with C. laurentii, a
minimally encapsulated cryptococcal species that is not a mem-
ber of either the C. gattii or C. neoformans species complexes.
The LFA presumably failed to detect capsular antigen from this
unusual cryptococcal species.
In another cat (two specimens), the false-negative LFA
results were attributed to the prozone, or high-dose “hook,”
phenomenon. This refers to false-negative or false low-positive
results in immunologic tests due to an excess of either antibodies
or antigen in the diagnostic sample. It is not usually seen with im-
munochromatography methods, but it has been described from
platforms used to measure myoglobin32 and malarial enzyme as-
says.33 A recent human study demonstrated the prozone effect
was considered the probable cause of three false-negative LFA
results obtained on human CSF specimens, as all three speci-
mens tested positive at a dilution of 1:3.34 The prozone effect
has been acknowledged by the manufacturer as a potential lim-
itation of the IMMY CrAg
R©
LFA.30,35 In this scenario, exceed-
ingly high levels of cryptococcal antigen in a specimen are able
to exhaust the binding sites of both the monoclonal gold-labeled
antibodies and the immobilized test line antibodies, resulting
in the absence of a visible test line and a false-negative result.
This likely was observed because widely disseminated disease
(without CNS involvement) is more often a feature of animal
infections than human infections.5 The feline patient in ques-
tion was definitively confirmed to have cryptococcosis, caused
by C. neoformans var. grubii, using culture, imaging, and mass
spectrometry. The two false-negative LFA results in this pa-
tient had resolved by dilutions of 1:8. Therefore, in instances
where there is a high suspicion of disseminated or “bulky” lo-
calized cryptococcosis but where the initial LFA result is nega-
tive, it may be prudent to repeat the LFA test using a dilution of
1:8 to rule out false-negative results, or alternately perform an
LCAT.
In koalas, the two false-negative LFA results were from two
patients with low LCAT titers that resolved to negative at a
subsequent test and were therefore assumed to have a transient
low antigenemia (subclinical cryptococcosis resolving sponta-
neously14) that may have been missed by the LFA. For logistical
reasons, further diagnostic testing could not be performed on
these koalas, and therefore we are unable to definitively deter-
mine the underlying cause of these discrepant results. In one
discordant feline case, false-negatives were obtained from both
the LCAT and LFA, despite the patient being definitively di-
agnosed with a sinonasal C. neoformans var. grubii VNII in-
fection using culture and molecular typing. In this case, we
speculate that the negative results were due to focal lesions re-
sulting in an undetectable level of antigenemia and/or caused
by a poorly encapsulated strain of the C. neoformans species
complex.
False-positive results using the LFA were problematic in all
three species studied. The cause of these potentially erroneous
results could not be determined definitively, although laboratory
error can be excluded, as all tests were performed by a competent
technician and repeated. In all false-positive cases, the LFA test
was also subsequently performed on pronase and heat-treated
serum to ensure that this was not a factor. The inference from
this finding is that the LFA should be regarded as a screening test
when used on samples from cats, dogs, and koalas, with all pos-
itive results requiring confirmation by LCAT testing, and ideally
also by obtaining further evidence for cryptococcal disease in
the patient, such as the visualization of organisms in aspirates or
biopsies and/or culture. The discordant case we present provides
a salutatory lesson that no serological test is likely to be 100%
reliable, and that there continues to be a requirement to further
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investigate suspicious cases that test negative with either LFA or
LCAT.
One false-positive LFA result (LCAT-negative) occurred
in a canine patient with disseminated aspergillosis. Accord-
ing to the manufacturer’s manual, there is some cross-
reactivity between Aspergillus spp. capsular galactomannan
and the IMMY CrAg R© LFA in perhaps 10% of aspergillosis
cases.30,35 A cross-reactive capsular galactomannan from As-
pergillus spp. was also suggested in a study using ELISA.36
Along the same lines, colleagues in the United States have
communicated that the IMMY CrAg R© LFA can be posi-
tive in cats with invasive sporotrichosis (Jane Sykes, personal
communication).
The situation in the koala is somewhat different and com-
plex. Cryptococcosis is a reasonably common infectious disease
in koalas, particularly in captivity, and is detected as a subclin-
ical entity (asymptomatic cryptococcal antigenaemia) with rea-
sonable frequency.8,14 It is therefore recommended that koalas
in Australian zoos and wildlife parks be bled on a regular basis
(typically every 6 to 12 months, dependent on individual circum-
stances) to screen for subclinical cryptococcosis as early detection
may prevent the development of clinical disease with pre-emptive
azole therapy.37 This approach has a higher likelihood of suc-
cess and better welfare outcomes than waiting for clinical disease
to develop, by which time the probability of successful therapy
is low and the prognosis is guarded. The results of this study
show that a LFA result is only straightforward to interpret when
negative, as the NPV of the LFA in koalas is satisfactory (only
2/291 false negative results). A LCAT-negative/LFA-positive re-
sult might represent a false-positive LFA; on the other hand, it
can be argued that the LFA is more sensitive than the LCAT in
humans and capable of detecting exceedingly low concentrations
of polysaccharide antigen. A LFA-positive/LCAT-negative koala
serum could therefore potentially indicate very early subclinical
disease or even heavy nasal colonization by Cryptococcus spp.,
without tissue invasion.14,37–40 In one published case treated by
some of the authors, a koala undergoing treatment for subclin-
ical cryptococcosis began to test LCAT-negative but remained
LFA-positive; to err on the side of caution, treatment was con-
tinued until consecutive LFA-negative results were obtained.40
The clinical relevance of such low levels of circulating antigen
is questionable and may not necessarily be consistent with a di-
agnosis of cryptococcosis. A comparison between the limits of
detection of immunochromatography compared to latex agglu-
tination for different Cryptococcus spp. isolates has shown an 8-
to >200-fold higher analytical sensitivity of the IMMY CrAg R©
LFA compared to LCAT testing.19,21 Supportive of this notion
is the small number of canine cases in which quantitative end-
point titers were compared between LFA and LCAT methods,
with the LFA titer being substantially higher (160 c.f. 64, 1280
c.f. 64, 80 c.f. 16, 40 c.f. 880 c.f. 32, 640 c.f. 64, >2,560 c.f.
1024, 40 c.f. 2). This notion is not, however, consistent with the
two koalas in which the LFA was negative while the LCAT was
transiently positive.
An important limitation of this study is the choice of the
LCAT as the putative gold-standard serological test for cryp-
tococcosis. Factors to consider in support of using the LCAT
as a gold-standard in animals include absence of peer-reviewed
publications of the IMMY test in the context of veterinary cryp-
tococcosis and the LCAT remaining the most commonly used
diagnostic test for cryptococcosis in commercial veterinary labo-
ratories in Australia and abroad. Furthermore, in veterinary pa-
tients it is often difficult for logistical and economic reasons to
obtain definitive confirmation of disease via culture and genotyp-
ing. Therefore, many animals are diagnosed with cryptococcosis
based on LCAT testing combined with consistent clinical signs
and sometimes cytological evaluation of aspirates, biopsies, or
CSF.
Since completion of this work, another lateral flow kit (Cryp-
toPS, Biosynex R©) has come onto the market. This kit has some
advantages over the IMMYCrAg R© LFA in that the immunochro-
matography strip comes within a plastic cassette (and therefore
does not require a tube or rack) (Fig. 3). It can also be purchased
in smaller numbers. However, its requirement for storage at 5◦C
presents a distinct disadvantage when considering a test to use in
the field. The kit must also be brought to room temperature be-
fore use, which would cause a further delay in results. However,
in terms of sensitivity and specificity, our preliminary observa-
tions suggest that this test is comparable to the IMMY CrAg R©
LFA.
Our study highlights the utility of the IMMY LFA as a screen-
ing test to exclude cryptococcosis in diagnostic investigation of
cats, dogs and koalas. A positive LFA result in these species
should be confirmed by LCAT testing (after heat and pronase
pretreatment) and/or by aspirate cytology, histopathology, or
fungal culture. The format of the LFA is suitable for veterinary
practice, especially in large busy hospitals and referral centers,
as a rapid cage-side POC test to exclude cryptococcosis from the
differential diagnosis before embarking on other expensive or
invasive procedures such as cross-sectional imaging. In koalas,
the test is also suitable for excluding clinical or subclinical cryp-
tococcosis, but confirmatory testing of all positive results using
the LCAT is again recommended. The propensity for low level
asymptomatic cryptococcal antigenaemia in this species means
that LFA-positive/LCAT-negative results should be interpreted
with care. Overall, the IMMY LFA’s high sensitivity, near ideal
NPVs, ease of use, and rapid results make it an attractive future
prospect for veterinary diagnostics.
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Abstract
Cryptococcosis, caused by environmental fungi in the Cryptococcus neoformans and Cryptococcus gat-
tii species complexes, affects a variety of hosts, including koalas (Phascolarctos cinereus). Cryptococcal
antigenemia and nasal colonization are well characterized in captive koalas, but free-ranging populations
have not been studied systematically. Free-ranging koalas (181) from the Liverpool Plains region of New
South Wales, Australia, were tested for cryptococcal antigenemia (lateral flow immunoassay) and nasal
colonization (bird seed agar culture). Results were related to environmental and individual koala character-
istics. Eucalypt trees (14) were also randomly tested for the presence of Cryptococcus spp. by bird seed
agar culture. In sum, 5.5% (10/181) and 6.6% (12/181) of koalas were positive for antigenemia and nasal
colonization, respectively, on at least one occasion. And 64.3% (9/14) of eucalypts were culture-positive
for Cryptococcus spp. URA5 restriction fragment length polymorphism analysis identified most isolates as
C. gattii VGI, while C. neoformans VNI was only found in one koala and one tree. Colonized koalas were
significantly more likely to test positive for antigenemia. No associations between antigenemia or coloniza-
tion, and external environmental characteristics (the relative abundance of Eucalyptus camaldulensis and
season), or individual koala characteristics (body condition, sex, and age), could be established, suggest-
ing that antigenemia and colonization are random outcomes of host-pathogen-environment interactions.
The relationship between positive antigenemia status and a relatively high abundance of E. camaldulensis
requires further investigation. This study characterizes cryptococcosis in a free-ranging koala population,
expands the ecological niche of the C. gattii/C. neoformans species complexes and highlights free-ranging
koalas as important sentinels for this disease.
Key words: Cryptococcus, Phascolarctos cinereus, subclinical cryptococcosis, Liverpool Plains, animal sentinel.
C© The Author(s) 2019. Published by Oxford University Press on behalf of The International Society for Human and AnimalMycology.
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Introduction
The Cryptococcus gattii and Cryptococcus neoformans species
complexes comprise the etiological agents of cryptococcosis,
a systemic mycosis affecting humans and a wide variety of
animals that is usually acquired from the environment by
inhalation.1–3 A recent publication proposing their division
into seven species4 remains under deliberation by the cryp-
tococcal research community. In Australia, C. gattii molecu-
lar type VGI has a well-established ecological niche in certain
tree hollows, for example, Eucalyptus camaldulensis (river red
gum) and Eucalyptus tereticornis (forest red gum),5,6 which
presents an important source of infection.7 Our understanding
of the environmental associations of C. gattii VGI has con-
tinued to expand to include numerous other tree species in
Australia.8–11
Animals play an important role as sentinels for this and other
environmentally acquired diseases, with reports of an increased
prevalence of animal cryptococcosis cases aiding in the early
characterization of the C. gattii VGII Vancouver Island out-
break.12 Both captive and free-ranging animals have been consid-
ered as potential sentinels for cryptococcosis.13,14 With forested
or rural areas (particularly those with an abundance of large
trees) considered by some to likely have a higher environmen-
tal abundance of the C. gattii species complex,15 surveillance
of free-ranging animals in particular has the potential to permit
early detection of high risk areas for the acquisition of human
disease.13
The koala (Phascolarctos cinereus) is one of many species
known to be susceptible to cryptococcosis and is unique in
its seemingly higher prevalence of disease than humans and
other animal species, with approximately 3–4% of free-ranging
and captive koalas found to have cryptococcal lesions at
necropsy.3,16–18 Both subclinical cryptococcosis (defined as
asymptomatic cryptococcal antigenemia) and cryptococcal
nasal colonization are common in seemingly healthy captive
koalas.11,19–21 The koala′s tendency to develop cryptococcal
nasal colonization in the presence of a high environmental
burden of Cryptococcus spp. in captivity has led to the koala
nasal cavity being considered an effective ′biological air sampler′
for environmental Cryptococcus spp.11 Although cryptococcal
nasal colonization and antigenemia are well documented in
captive koala populations, the same phenomena in free-ranging
koalas are much less well characterized, and to date, no natural
population has been studied systematically.11,20 In humans,
asymptomatic cryptococcal antigenemia is well described in
patients infected with human immunodeficiency virus (HIV),
especially in sub-Saharan Africa and other similar settings in the
developing world.22–24 It can precede clinical signs by weeks to
months, with early screening tests in high-risk patients allowing
preemptive oral therapy (typically using fluconazole) to prevent
development of overt clinical disease.25 A similar practice
occurs in koalas, with a recent report recording successful
early detection and treatment of subclinical cryptococcosis in a
free-ranging individual.26
In 2015, a deceased adult free-ranging koala found near
Breeza in the Liverpool Plains region of New South Wales, Aus-
tralia, was opportunistically dissected, and multinodular crypto-
coccal pneumonia was identified by the authors as the probable
cause of death, based on gross and histopathologic examination
of tissues. No prior cases of cryptococcosis from free-ranging
koalas in this region were known to the authors or recorded in
the literature. This case therefore prompted an investigation into
the prevalence of cryptococcosis in this population.
This study aimed to investigate exposure to environmental
Cryptococcus spp. in the Liverpool Plains population of free-
ranging koalas by determining the prevalence of both cryptococ-
cal antigenemia and nasal colonization in relation to the presence
of Cryptococcus spp. in the environment. Based on prior stud-
ies that identified some environmental features and individual
koala characteristics as influential factors in nasal colonization
and antigenemia,11,19,20 we attempted to relate our findings to
the relative abundance of E. camaldulensis, season, koala body
condition, sex, and age.
Methods
Koala selection and field trips
A total of 181 free-ranging koalas were captured from five
sites within the Liverpool Plains region of New South Wales,
Australia: 73 from Dimberoy (31◦08′33.4′′S 150◦02′16.1′′E),
two from Gunnedah (31◦01′34.4′′S 150◦15′37.3′′E), seven from
Lake Goran (31◦14′10.2′′S 150◦11′30.1′′E), three from Now-
ley (31◦21′19.5′′S 150◦04′44.6′′E), and 96 from Watermark
(31◦13′49.7′′S 150◦20′17.9′′E). E. camaldulensis trees were fre-
quently observed at the Gunnedah, Lake Goran, Nowley, and
Watermark sites but not encountered at the Dimberoy site, as
identified by experienced ecologists and the use of a eucalypt
identification key.27 In the absence of systematic ecological sur-
vey data, we classified koalas from Dimberoy versus the other
four sites (Gunnedah, Lake Goran, Nowley, and Watermark)
as inhabiting low and high relative abundance E. camaldulensis
areas, respectively.
Six field trips occurred at approximately six-month intervals
(three in spring, two in autumn and one in winter) from Septem-
ber 2015 to July 2018. Some koalas were captured and tested
multiple times at minimum six-monthly intervals, with 51, 17,
four and two koalas captured and tested on two, three, four, or
five occasions, respectively; this resulted in 286 capture events.
After capture, each koala was lightly sedated with alfaxalone
(Alfaxan R©, Jurox; approximately 1.8 mg/kg by intramuscular
injection) to minimize stress and facilitate safe sampling.
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Figure 1.Bird seed (Guizotia abyssinica) extract agar culture of a nasal swab from a free-ranging koala in the Liverpool Plains region of NewSouthWales, Australia,
showing a heavy growth of colony-forming units exhibiting the brown-colour-effect, later identified as Cryptococcus gattii VGI. This Figure is reproduced in color
in the online version of Medical Mycology.
All koalas were examined by a veterinarian for any clinical
signs consistent with cryptococcosis (including nasal discharge,
facial swelling/distortion, or dyspnea); sex, body condition
score (assessed on a scale from 1 to 5),28,29 and tooth wear class
(scored from 1 to 10)30 were recorded.
Koalas were fitted with both a unique numbered ear tag and
a subcutaneous microchip transponder before release for ongo-
ing individual identification in the event of recapture or sight-
ings. All procedures were undertaken with approval from The
University of Sydney Animal Ethics Committee (project number
2016/955) and National Parks and Wildlife Service (scientific
license SL101687).
Culture
Nasal swabs were collected by introducing a sterile swab moist-
ened with saline approximately 2 cm into the nasal vestibule
(one side at a time) and rotating gently, as described in previous
studies.11,19 Environmental samples, collected opportunistically
from hollows in 14 eucalypts (E. albens [1], E camaldulensis
[11], and E. populnea [2]) in the region, were obtained by run-
ning a sterile swab moistened with saline thoroughly over the in-
terior surface of the hollow. All swabs (nasal and environmental)
were inoculated on to Staib′s bird seed (Guizotia abyssinica) ex-
tract agar containing antibiotics (penicillin and gentamicin) and
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incubated at 27◦C for a minimum of 7 days to identify colony-
forming units (cfu) exhibiting the brown-color-effect, consistent
with Cryptococcus spp. (Fig. 1). Positive samples were classi-
fied as having a low (1–10 cfu/plate), moderate (11–100 cfu) or
heavy (>100 cfu) cryptococcal burden.11 A single cfu exhibiting
the brown-color-effect was collected from each positive sample,
sub-cultured on Sabouraud′s dextrose agar (SDA), and incubated
at 37 ◦C for isolation and DNA extraction.
Molecular typing and species determination
Isolates subcultured on SDA underwent DNA extraction using
the same protocol as Ferrer et al. (2001).31 Restriction frag-
ment length polymorphism (RFLP) analysis was performed on
the product of a PCR amplification of theURA5 gene, according
to the protocol developed by Meyer et al. (2003), to determine
cryptococcal species and molecular type.32
Cryptococcal antigen testing
Approximately 3 ml of whole blood was collected into plain
tubes by cephalic venepuncture. Samples were chilled at 4oC,
then centrifuged as soon as possible (on the same day) in a field
laboratory for approximately 5 minutes at 5000 rpm to allow
for separation of the serum. An aliquot of the serum was used
to perform the cryptococcal antigen lateral flow assay (LFA)
(CrAg R© LFA, IMMY, Norman, OK, USA) according to the
manufacturer′s instructions in a field laboratory as a screen-
ing test. All remaining sera were kept frozen in liquid nitrogen
until they could be transferred to a -80˚C freezer. Upon return
from the field, latex cryptococcal antigen agglutination testing
(LCAT) (CALAS R©, Meridian Bioscience, Inc., Cincinatti, OH,
USA) was performed on all LFA-positive samples, according to
the manufacturer′s instructions. Sera from all 51 LFA-negative
koalas captured during the 2016 autumn field trip also under-
went LCAT testing. Reciprocal cryptococcal antigen titres were
determined using the LCAT. For the purposes of this study,
koalas that returned a positive LFA result were considered cryp-
tococcal antigen seropositive, even if the LCAT was negative.
Statistical analysis
We assessed whether antigenemia or nasal colonization status
had a relationship with the relative abundance of E. camaldu-
lensis in a koala′s habitat (low vs high), koala body condition
(score of 1–2 vs score of 3–5), sex (male vs female) and an
approximation of age (tooth wear class 1–5 vs tooth wear class
6–10) using 2 × 2 contingency tables and two-tailed Fisher exact
tests. The same method was used to determine if a relationship
existed between antigenemia and colonization status. A 2 × 3
contingency table and two-tailed Fisher exact test with Freeman-
Halton extension was used to assess for dependent relationships
between antigenemia or colonization status and season (autumn
vs spring vs winter). P values of < .05 were considered statisti-
cally significant.
Results
Culture
Nasal swabs from 12/181 koalas (6.6%) were culture-positive
for cryptococcal cfu on bird seed agar on at least one occasion.
Eight of the 12 positive koalas were tested on more than one
occasion, with 5/8 tested twice and 3/8 tested three times. Of the
koalas tested twice, 2/5 were positive on both occasions, while
the remaining 3/5 progressed from initially testing negative to
positive on the second occasion. The koalas tested three times
were either positive on all three occasions (1/3), positive only
at final test (1/3) or positive twice and then negative on the fi-
nal test (1/3). Among the four koalas that were culture-positive
for nasal colonization on two or more occasions, the extent of
colonization either increased (2/4; moderate to heavy, low to
moderate), reduced (1/4; heavy to moderate) or remained stable
(1/4; heavy) (Table 1). One koala (Table 1, DECC 071) that was
culture-positive for nasal colonization exhibited a small amount
of crusted nasal discharge at the nares and mild hemorrhage
at the nasal philtrum (possibly a mild sign of sinonasal cryp-
tococcosis) (Fig. 2). No clinical signs consistent with sinonasal,
pulmonary, or neurologic cryptococcosis were observed in any
other koalas with nasal colonization
Nine of the 14 (64.3%) tree hollow samples cultured positive
for Cryptococcus spp. (Table 2), consisting of E. albens (1), E.
camaldulensis (7), and E. populnea (1). A total of 4/9 positive
trees exhibited a heavy growth (E. albens [1], E. camaldulensis
[2], and E. populnea [1]), while 4/9 and 1/9 exhibited moderate
and low growths, respectively; all were E. camaldulensis.
Molecular typing and species determination
URA5 RFLP analysis confirmed all isolates to be members of the
C. neoformans/C. gattii species complexes. Most isolates (8/9
environmental; 16/17 koala) were identified as C. gattii VGI.
C. neoformans VNI was isolated from a single koala on one
occasion and from one E. populnea hollow (Table 2).
Serology
Serum samples from 10/181 koalas (5.5%) were positive, on
at least one occasion, for cryptococcal antigen using the LFA.
Five of the 10 LFA-positive koalas also tested positive using the
LCAT, with reciprocal titers of 2 (DECC 092; DECC 104), 8
(DECC 198; USYD 014), and 128 (DECC 071); the remaining
five koalas tested LCAT-negative (Table 1).
Of the 10 koalas that were LFA-positive, eight were tested on
more than one occasion (6/8 tested twice, 2/8 tested three times).
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Figure 2. A free-ranging koala (ID: DECC 071) from the Liverpool Plains population of New South Wales, Australia, that tested positive for both cryptococcal
antigenemia and nasal colonization, while exhibiting possible mild clinical signs of sinonasal cryptococcosis: a small amount of crusted nasal discharge (arrow)
and a mild hemorrhage visible at the nasal philtrum. This Figure is reproduced in color in the online version of Medical Mycology.
Table 2. Culture and molecular typing results for environmental samples (ordered by sample number) collected from tree hollows in the
Liverpool Plains region of New South Wales, Australia.
Sample number Tree species Location Cryptococcal growth∗ Cryptococcus spp. isolated
E2757 Eucalyptus populnea Watermark - NA
E2760 E. albens Watermark +++ C. gattii VGI
E2764 E. camaldulensis Watermark +++ C. gattii VGI
E2765 E. camaldulensis Watermark - NA
E2766 E. camaldulensis Watermark - NA
E2767 E. camaldulensis Watermark - NA
E2768 E. camaldulensis Watermark ++ C. gattii VGI
E2769 E. camaldulensis Watermark - NA
E2770 E. camaldulensis Watermark +++ C. gattii VGI
E2771 E. camaldulensis Watermark + C. gattii VGI
E2772 E. camaldulensis Watermark ++ C. gattii VGI
E2773 E. camaldulensis Watermark ++ C. gattii VGI
E2774 E. camaldulensis Watermark ++ C. gattii VGI
E3049 E. populnea Dimberoy +++ C. neoformans VNI
+, positive; -, negative; NA, not applicable.
∗Number of + represents degree of cryptococcal growth on bird seed agar: + = low (1–10 colony-forming units [cfu] per plate), ++ = moderate (11–100 cfu per plate), +++
= heavy (>100 cfu per plate).
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The six koalas tested twice either progressed from LFA-negative
to positive (4/6), remained consistently positive (1/6), or pro-
gressed from LFA-positive to negative (1/6). One of the koalas
tested on three occasions progressed from LFA-negative to pos-
itive on its final test; the same koala was consistently positive
for nasal colonization across all three testings. The other koala
tested on three occasions was LFA-positive twice but then be-
came negative. Five koalas were positive for both serum antigen
and nasal colonization (Table 1). As mentioned previously, one
LFA-positive and LCAT-positive koala (DECC 071), also pos-
itive for nasal colonization, exhibited symptoms possibly con-
sistent with sinonasal cryptococcosis (Fig. 2). No clinical signs
consistent with sinonasal, pulmonary, or neurologic cryptococ-
cosis were observed in any other koalas with cryptococcal anti-
genemia.
Serum samples from the 51 LFA-negative koalas from the
2016 autumn field trip were all LCAT-negative.
Statistical analysis
Nasal colonization was not significantly associated with the rel-
ative abundance of E. camaldulensis (P = .366), season (P =
.514), koala body condition (P = .764), sex (P = .769), or age
(P = .787). Antigenemia status (LFA result) was not significantly
associated with season (P = .920), koala body condition cate-
gory (P = .305), sex (P = .524), or age (P = .354). There was
a trend for positive serum antigen status being associated with a
relatively high abundance of E. camaldulensis, but this was not
significant due to low power of the analysis (P = .051). Koalas
positive for nasal colonization were significantly more likely to
also test positive for antigenemia (P < .001).
Discussion
This study is the first to our knowledge to systematically es-
tablish the prevalence of cryptococcal antigenemia and nasal
colonization in a population of free-ranging koalas. Our results
of approximately 6% and 7% overall rates of antigenemia and
colonization, respectively, should be viewed in the light of the
observation that 3–4% of all koalas have detectable cryptococ-
cal lesions at post-mortem examination.3,17,18 Our results show
substantially lower rates of nasal colonization and antigenemia
compared to certain sites in studies of captive populations, where
the prevalence of nasal colonization and antigenemia can reach
100% and >50%, respectively.11,20,21 Our findings differ from
preliminary studies of a small number of free-ranging koalas
in Breeza, an area within the Liverpool Plains region and near
the Watermark site, where all koalas were found to be negative
for cryptococcal nasal colonization and antigenemia.11,20 This
discrepancy may be explained simply by the small sample size
utilized in previous studies.
One koala in this study (Table 1; DECC 071) tested positive
for both nasal colonization and antigenemia (LFA-positive and
LCAT-positive) on one occasion, and at this time also exhibited
a small amount of crusted nasal discharge and mild hemorrhage
visible at the nasal philtrum, possibly consistent with sinonasal
cryptococcosis. The reciprocal LCAT titer of 128 also supports
the possibility of clinical disease in this koala, as such a titer falls
within the range where clinical signs are expected.20 However,
the clinical signs in this koala were considered mild, and similar
findings (small amounts of crusted nasal discharge) were seen
occasionally in other koalas in this study that were negative for
both nasal colonization and antigenemia on all occasions tested.
Therefore, at the time of capture this observation was recorded
but was not considered highly suspicious. The development of
more prominent clinical signs in this individual may have been
imminent, or other subtle symptoms may have been present but
undetected due to the limited time of observation. Another koala
(Table 1; DECC 198) exhibited a reciprocal LCAT titer of 8
across two field trips, 6 months apart. A persistent reciprocal
titer of 8 is the point at which treatment for subclinical crypto-
coccosis is considered in captive koalas, depending on individual
circumstances.26 LFA and LCAT results were not available at the
time of capture for any koala; therefore, in the absence of more
definitive symptoms, we did not intervene with these two individ-
uals. Once results were available, capturing these two koalas for
re-assessment and possible treatment on subsequent field trips
was prioritized, but neither could be relocated.
Recent observations by our group suggest that the LFA has a
high sensitivity and excellent negative predictive value for the di-
agnosis of cryptococcosis in koalas when compared to the LCAT,
making it an excellent screening test. Positive results, however,
should be followed up by further testing to assess the likelihood
of subclinical or clinical disease (Krockenberger, in press).33 The
LFA was also used successfully for monitoring response to treat-
ment in a koala with cryptococcosis and remained positive for
four months after the LCAT titer had become negative.26 For
these reasons, we chose to initially screen all koalas for antigen-
emia using the LFA and follow-up positive results with a LCAT.
The internal validation performed in this study, with 51 LFA-
negative samples found to also be LCAT-negative, confirmed the
reliability of the LFA as a screening tool in this setting. Although
10 koalas were antigen-positive using the LFA, only 5/10 were
simultaneously positive using the LCAT. This discrepancy can
likely be explained by the difference in the detection limits of
these two tests, with the LFA proven in vitro and in human
patients to be sensitive to lower antigen levels compared to the
LCAT.34–36 Although such low levels of circulating antigen may
not be clinically relevant in the diagnosis of overt cryptococco-
sis, we considered them to be pertinent to our aim of detecting
evidence of exposure to Cryptococcus spp. We cannot defini-
tively exclude the possibility that the discrepant results represent
3. Koala cryptococcosis
108
Medical Mycology, 2018, Vol. 00, No. 00
false-positives, given that the LFA was associated with false-
positive results due to cross-reactivity in two human patients
diagnosed with Trichosporon spp. fungemia.37 However, given
the propensity of koalas to develop subclinical cryptococcosis20
and the rarity of reports of cross-reactivity using the LFA, we
considered LFA-positive/LCAT-negative results to be true pos-
itives for antigenemia for the purposes of this study. It is not
known whether LFA-positive/LCAT-negative koalas could have
very limited invasive disease, heavy nasal colonization, or both,
and studies using advanced imaging (endoscopy, computerized
tomography, or magnetic resonance imaging) would be required
to address this question. Interestingly, we identified two koalas
with heavy nasal colonization that did not test positive using
either the LFA or LCAT (Table 1: DECC 051 and DECC 135).
Subclinical cryptococcosis often resolves spontaneously in
captive koalas when the reciprocal LCAT titer is less than 64,
particularly if there are no concurrent adverse factors (e.g., stress,
poor nutrition, transport).20 Spontaneous resolution of crypto-
coccal antigenemia has also been observed in cats and dogs stud-
ied on Vancouver Island and its environs.38 Three koalas in this
study (Table 1; DECC 015, DECC 198, and USYD 054) were
captured again after testing seropositive for cryptococcal anti-
gen, and the antigenemia had resolved in 2/3. We also observed
the resolution of nasal colonization in one koala (Table 1; USYD
040), although this is difficult to confirm due to the unknown
sensitivity of nasal swabbing as a means of determining and
quantifying cryptococcal colonization status.
Our findings of a lack of correlation between nasal coloniza-
tion and season or sex differ from a previous study in captive
koalas, which established a potentially weak association with
season and a strong relationship to sex, with more coloniza-
tion apparent in spring and with males being colonized more
frequently than females.19 Seasonal variation was suggested to
occur as a result of increased aerosolization ofCryptococcus spp.
during E. camaldulensis flowering in spring and early summer,
while sex variation was thought to be related to the greater ten-
dency for male koalas to use smell to explore their territory.19
Given that captive koalas appear able to amplify the amount
of the agents of the C. gattii species complex in their proxi-
mate environment,11 it is difficult to directly compare captive
studies to the findings presented here in free-ranging koalas. In
another large study, mostly of captive or hospitalized koalas
but with the opportunistic inclusion of free-ranging koalas from
several regions of coastal New South Wales, also no significant
relationship between season and colonization status could be
established.11 However, it is difficult to assess the accuracy of
any associations detected between nasal colonization and other
variables, due to the previously mentioned unknown sensitivity
of nasal swabbing.
Similar to our findings, sex or season had no effect on antigen-
emia in a study of subclinical cryptococcosis in captive koalas,20
although a tendency toward low or negative antigen titres was
observed in older koalas in one captive group.20 In the present
study, neither antigenemia nor nasal colonization was associ-
ated with tooth wear class (an approximation of age). No prior
studies have compared body condition to subclinical cryptococ-
cosis or nasal colonization status in koalas. We elected to include
this variable in our analyses as we hypothesized that poor body
condition could be associated with antigenemia or colonization
either due to an increased susceptibility in these individuals or
due to subclinical cryptococcosis causing poorer body condi-
tion. We observed, however, that neither antigenemia nor nasal
colonizationwas associated with body condition. Given the well-
established association between E. camaldulensis and C. gattii
VGI,5 we also hypothesized that nasal colonization and/or anti-
genemia may depend on the relative abundance of E. camaldu-
lensis in an individual koala′s habitat. A significant relationship
could not be established, although an obvious trend was ob-
served for antigenemia, with high relative abundance E. camal-
dulensis areas exhibiting a greater prevalence than low abun-
dance areas (8.3% and 1.4%, respectively), suggesting greater
sampling is required. This also suggests that E. camaldulensis is
not the only environmental association of C. gattii VGI in this
area, a point proven by its isolation from other dominant Eu-
calyptus spp. in the region. We were unable to assess for any
correlation with the presence of E. tereticornis, another eucalypt
with a strong association to the C. gattii species complex,6 as
trees of this species were not identified at any of the sampling
sites. The study sites were likely outside of the natural range
of E. tereticornis.27 The relationship between nasal colonization
and antigenemia status, with colonized koalas significantly more
likely to also test positive for antigenemia (P< .001), is intuitive.
Both are indicative of exposure to Cryptococcus spp., and it is
presumed that mucosal colonization precedes tissue invasion,
which in turn leads to antigenemia.20
C. gattii VGI was easily detected in multiple tree hollows in
this study, with the isolation from E. albens being the first from
this tree species, to the best of our knowledge. The isolation
of C. neoformans VNI from E. populnea is also unique. The
detections of C. gattii VGI from both the environment and the
nasal cavities of some koalas further confirms its potential to
cause disease in this region. However, systematic environmental
sampling across all study sites is required to determine the envi-
ronmental prevalence of C. gattii VGI in these areas and better
characterize its habitat in this region. This would also aid in fur-
ther exploring the potential relationship between the abundance
of E. camaldulensis trees and increased risk of exposure to C.
gattiiVGI, and the potential for associations to other Eucalyptus
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spp. The comparison of environmental and nasal colonizing iso-
lates using a more discriminatory genotyping technique, such as
multilocus sequence typing or whole genome sequencing, could
also provide further evidence for environmental exposure to C.
gattiiVGI and offer insights into the virulence of different strains
in this region.
The impact of host immune status and possible coinfections
on cryptococcal antigenemia or nasal colonization status was
not explored in this study. A study of koala major histocom-
patibility complex (MHC) II diversity included a small number
of individuals from the Liverpool Plains region and found that
these koalas belonged to a group exhibiting a comparatively
high MHCII diversity.39 Although there is evidence of the sig-
nificant role of MHCII in the host response to chlamydiosis in
the koala,40 its relationship to cryptococcosis has not been ex-
amined. With the recent availability of the koala genome, there
is now an improved understanding of the changes in regulation
of immune genes in koalas with chlamydiosis.41 This has the
potential to offer insights into the immune response to other in-
tracellular pathogens, such as Cryptococcus spp. Testing koalas
for all forms of the koala retrovirus (KoRV) and Chlamydia
pecorum would also be required to better elucidate the com-
plex host-pathogen-environment interactions at play. KoRV in
particular could play an important role, as infection with the
KoRV-B variant has already been linked to malignant neopla-
sia,42 chlamydiosis,43 and changes to immune cytokine expres-
sion,44 although the relationship with cryptococcosis has not
been studied systematically. Investigating the overall pathogen
burden of this free-ranging koala population and the relation-
ship between KoRV and cryptococcosis will be the subject of
future work by the authors.
Cryptococcal nasal colonization and antigenemia were found
to be at a substantially lower prevalence in the Liverpool Plains
population of free-ranging koalas than in certain well-studied
captive populations.11,19–21 This supports the previous assertion
that captive koalas amplify C. gattii VGI in their immediate en-
vironment. Our findings suggest that although cryptococcosis is
present in this region, and C. gattii VGI is detectable in both
the environment and the nasal cavities of some koalas, this is
unlikely to be an area of increased risk of infection for humans
and other animal species. According to our analyses, cryptococ-
cal antigenemia and nasal colonization are seemingly random
outcomes of the host-pathogen-environment interactions within
this region. However, further work, such as systematic environ-
mental sampling, more discriminatory genotyping of C. gattii
VGI strains, examining host immunity, and testing for pathogen
burden is required to explore this notion. A high relative abun-
dance of E. camaldulensis in a free-ranging koala′s habitat may
be associated with the development of cryptococcal antigene-
mia, but this link could not be established definitively here and
requires further investigation.
Our study expands the current understanding of cryptococco-
sis in free-ranging koalas and the known environmental niches of
theC. gattii/C. neoformans species complexes in Australia, while
also highlighting the koala as an important sentinel species for
this environmentally acquired disease.
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4. Fine-scale molecular epidemiology
Background: 
Some aspects of the host-pathogen-environment interactions of cryptococcosis caused by the 
C. gattii species complex remain poorly understood, particularly the progression from
environmental exposure to mucosal colonisation and finally, in some cases, to disease. The 
identification of environmental sources of infection in some animal cases of cryptococcosis, 
and the ability of koalas to translocate members of the C. gattii species complex, suggest that 
animals play an important role as both sentinels and a dispersal mechanism for environmental 
Cryptococcus spp. Neither phenomenon, however, has been characterised or definitively 
proven using high-resolution genotyping and molecular epidemiology. Captive animals offer 
an ideal opportunity to characterise both sources of infection and the translocation of 
Cryptococcus spp., but the artificial nature of these environments and unusually high density 
of animals could make this problematic for inferring some aspects of host-pathogen-
environment interactions. Therefore, naturally-occurring disease in free-ranging animals 
presents the ideal model to study this, but cases are typically sporadic, unreported and/or 
logistically difficult to investigate. This section utilises in-depth environmental investigations 
and fine-scale molecular epidemiology to infer relationships between disease, colonisation 
and the environment in naturally-occurring animal cryptococcosis in captivity and the wild. 
Section 4.1 investigates an unusual spatial and temporal case cluster of cryptococcosis 
in a sub-population of free-ranging koalas through targeted environmental sampling, and 
MLST and WGS of disease, colonising and environmental C. gattii VGI isolates. The goal was 
to determine if fine-scale molecular epidemiology could yield insights into the underlying 
cause of the cluster, while also using this as a natural model to study host-pathogen-
environment interactions. In sections 4.2 and 4.3, two individual cases of cryptococcosis (one 
in a captive bird and another in a domestic ferret) are similarly characterised, and the possible 
environmental source of infection for both cases is investigated. These two sections highlight 
that all animal species can prove useful as naturally-occurring models and sentinels for 
cryptococcosis. These manuscripts also provide further indication that sources of infection 
can be readily identified with careful sampling in a captive context. In section 4.4, another 
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unusual cluster of cryptococcosis in koalas is studied, but this time its novelty was in the 
implication of C. gattii VGII as the causative agent in a geographic area (eastern Australia), 
where VGII is usually rare. This again provided an opportunity to use high-resolution 
genotyping and fine-scale molecular epidemiology to investigate the origin of this case 
cluster. This study also offered the chance to assess the ability of koalas to translocate 
Cryptococcus spp. and to further characterise the Australian C. gattii VGII population. 
Aims: 
- Aim 3: assess the relationship between environmental presence, nasal colonisation
and disease in some free-ranging koala populations;
- Aim 4: explore the interface between environment and disease in naturally-occurring
cases of cryptococcosis in Australian animals through molecular epidemiology and
phylogenetic analyses;
- Aim 5: determine the point source of infection or exposure in naturally-occurring
disease or colonisation, caused by C. gattii VGI, in representative cases in captive
animals using molecular epidemiology;
- Aim 6: assess two clusters of cryptococcosis in koalas for their outbreak potential; and
- Aim 7: examine the ability of koalas to translocate C. gattii VGII into new
environments.
Sections: 
- 4.1: Molecular epidemiology of cryptococcosis in koalas offers insights into host-
pathogen-environment interactions;
- 4.2: Multi-locus sequence typing as a tool to investigate environmental sources of
infection for cryptococcosis in captive birds;
- 4.3: Identification of the environmental source of infection for a domestic ferret with
cryptococcosis; and
- 4.4: Jet-setting koalas spread Cryptococcus gattii VGII in Australia.
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 Impact: 
The use of high-resolution molecular epidemiology will help to explore the role that animals 
(particularly koalas) could play in determining sources of infection, acting as sentinels and 
biological samplers, and dispersing members of the C. gattii species complex in the 
environment. This section has the potential to compare naturally-occurring disease in koalas 
in the wild and in captivity, and show that fine-scale genotyping in both scenarios could offer 
insights into the underlying pathogenesis of disease (including exploring the rarity of disease 
isolates in the free-ranging environment). The ability of koalas to translocate C. gattii VGII 
could indicate that further strategies are required to mitigate the risk of transferred or 
exported koalas introducing this pathogen into new environments. This could prove vital in 
the management and prevention of potential outbreaks of cryptococcosis in Australia. 
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 4.1  Molecular epidemiology of cryptococcosis in koalas 
offers insights into host-pathogen-environment interactions 
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 ABSTRACT 
The Cryptococcus gattii species complex is a group of environmental basidiomycetous yeasts 
that causes cryptococcosis, a severe and often fatal mycosis, in a wide variety of host species. 
Koalas (Phascolarctos cinereus) exhibit comparatively high rates of symptomatic 
cryptococcosis, subclinical disease and cryptococcal colonisation of the nasal passages. An 
unusual case cluster of cryptococcosis in koalas was investigated, with eight free-ranging 
koalas diagnosed in a focal region of New South Wales, Australia, over an approximately two-
and-a-half-year period. Environmental sampling and molecular epidemiology (URA5 
restriction fragment length polymorphism analysis and multi-locus sequence typing [MLST]) 
were used to investigate this case cluster, confirming the presence of C. gattii VGI in 11/46 
(24%) tree hollows and in the sinonasal cavities of 13/23 (57%) koalas sampled in this area. 
MLST analysis of C. gattii VGI environmental (55), koala-colonising (13) and disease-
associated (8) isolates did not suggest a single emergent outbreak strain, although maximum 
likelihood phylogenetic analysis revealed that disease isolates mostly clustered in a separate 
clade to environmental isolates. Koala colonising isolates were reasonably evenly distributed 
amongst environmental and disease isolates in the phylogenetic tree. The apparent 
difference between disease and environmental isolates suggests that disease isolates could 
either represent a rarer subpopulation in this environment or have undergone 
microevolutionary changes after contact with a host. This offers new insights into host-
pathogen-environment interactions of cryptococcosis and highlights the koala as an 
important sentinel for this disease. Although the underlying cause of this case cluster remains 
unclear, it is possible that co-morbidities and/or anthropogenic threats could have increased 
the susceptibility of this koala population to a normally sporadic disease. 
 
INTRODUCTION 
The potential for pathogenic strains of the Cryptococcus gattii species complex, aetiologic 
agents of the severe systemic mycosis cryptococcosis, to cause case clusters across numerous 
host species has become increasingly apparent over the past few decades (Sorrell et al., 
1996b, Baró et al., 1998, Raso et al., 2004, Chen et al., 2014, Maestrale et al., 2015, Kwon-
Chung et al., 2017). C. gattii VGII has been implicated in many of these case clusters, with the 
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 Vancouver Island and ongoing North American Pacific Northwest outbreaks in humans and 
animals of particular note (Craig et al., 2002, Kidd et al., 2004, Byrnes III et al., 2009). C. gattii 
VGI has also been identified as a culprit, a notable example being clusters of caprine 
cryptococcosis in Spain and Italy (Baró et al., 1998, Maestrale et al., 2015). Animals are 
increasingly considered useful sentinels for this environmentally-acquired disease (Duncan et 
al., 2006, Malik et al., 2011, Morera et al., 2014). The observation of clustered cases of animal 
cryptococcosis was critical in the early identification of the Vancouver Island outbreak (Craig 
et al., 2002).  
 In eastern Australia, the most prevalent member of the C. gattii species complex to 
cause disease is C. gattii VGI (Sorrell et al., 1996a, Chen et al., 2014). This organism has a 
strong environmental association with eucalypt trees, particularly tree hollows of Eucalyptus 
camaldulensis and E. tereticornis (Ellis & Pfeiffer, 1990, Pfeiffer & Ellis, 1992). Its known 
ecological niche continues to expand through ongoing systematic studies, with many other 
trees in Australia also identified as environmental sources and thus representing potential 
sources of infection (Sorrell et al., 1996a, Krockenberger et al., 2002b, Vilcins et al., 2002, Saul, 
2009, Schmertmann et al., 2018a). Disease caused by the C. gattii species complex is acquired 
from the environment, typically by inhalation of basidiospores or desiccated yeast cells. 
Occasionally, direct inoculation has been identified as a likely route of infection 
(Krockenberger et al., 2003, Malik et al., 2003, Chen et al., 2014). The result of host exposure 
is likely influenced by multifaceted interactions between the size of the inoculum, the 
virulence of the strain/s and the host’s immune capacity (Chen et al., 2014). Microevolution 
within the C. gattii species complex is thought to be a factor in the emergence of virulent 
genotypes, anti-fungal resistance and relapse cases of cryptococcosis (Billmyre et al., 2014, 
Farrer et al., 2016, Chen et al., 2017, Cuomo et al., 2018). 
Koalas (Phascolarctos cinereus) are in regular and close contact with eucalypts, with 
E. camaldulnesis and E. tereticornis being favoured feed species (Lee et al., 1988). This may in 
part explain the tendency for cryptococcosis to be an important cause of sporadic morbidity 
and mortality in free-ranging koalas (Krockenberger et al., 2003), with approximately 3-4% 
having detectable cryptococcal lesions at postmortem (Stalder, 2003, Krockenberger et al., 
2005, Malik et al., 2011). Recent findings have also suggested rates of approximately 5-7% for 
both nasal colonisation and subclinical cryptococcosis (asymptomatic antigenaemia) in one 
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 free-ranging koala population (Schmertmann et al., 2019). The situation is different in captive 
koalas, where the animals appear to amplify the amount of the C. gattii species complex in 
their proximate environment, resulting in rates of nasal colonisation and subclinical disease 
that can be as high as 100% and >50%, respectively (Connolly et al., 1999, Krockenberger et 
al., 2002b). Given the propensity for koalas to develop cryptococcal nasal colonisation, the 
sinonasal cavity of the koala could be a useful biological sampler for environmental 
Cryptococcus spp. (Krockenberger et al., 2002b) and could also present a potential site for 
microevolutionary change. 
 The Port Stephens region of New South Wales (NSW), Australia (Figure 4.1.1) supports 
a free-ranging koala population (Lunney et al., 1998) in which cryptococcosis was previously 
diagnosed sporadically (M.B. Krockenberger, pers. comm.). Over an approximately two-and-
a-half-year period (September 2013 to March 2016), eight cases of cryptococcosis (five 
clinical; three subclinical) were identified in free-ranging koalas in this region, with 6/8 
occurring in two adjacent suburbs (Salamander Bay and Soldiers Point) (Table 4.1.1). One of 
these six cases presented with destructive fungal osteomyelitis of the distal hind limb, while 
its joey had subclinical cryptococcosis (based on asymptomatic cryptococcal antigenaemia) 
(Schmertmann et al., 2018b). This was identified as a potential spatial and temporal case 
cluster, raising the possibility that an emergent highly virulent strain and/or an unusually high 
level of environmental infectious cryptococcal propagules were present in this area. Either of 
these have the potential to impact on other animal species and humans in this region.  
URA5 restriction fragment length polymorphism (RFLP) analysis and multi-locus 
sequence (MLST) typing of the C. gattii and C. neoformans species complexes are 
epidemiologic tools that together offer a reasonably high discriminatory power and allow for 
cases to be considered in both a regional and global context (Meyer et al., 2003, Meyer et al., 
2009, Hagen et al., 2010). These techniques also allow comparison of cases within a cluster 
and the potential identification of known highly virulent genotypes. 
 This study aimed to: i) determine the presence of environmental Cryptococcus spp. 
and cryptococcal nasal colonisation in koalas in two adjacent suburbs (Salamander Bay and 
Soldiers Point) and ii) use fine-scale molecular epidemiology and phylogenetic analyses to 
both characterise disease strains and draw comparisons with environmental and nasal 
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 colonising isolates. This will provide insights into the underlying cause of this case cluster and 
the host-pathogen-environment interactions underpinning cryptococcosis in koalas. 
 
FIGURE 4.1.1 Map of the Tomaree and Tilligerry peninsulas within the Port Stephens region 
of New South Wales, Australia with the suburbs of Salamander Bay and Soldiers Point outlined 
in blue and red, respectively. Six koalas were diagnosed with cryptococcosis within these two 
adjacent suburbs from 2013 to 2017. Stars indicate the approximate locations of two other 
koalas diagnosed with cryptococcosis nearby, with the orange and black stars indicating the 
suburbs of Williamtown and Tanilba Bay, respectively. Inset: map of Australia with the 
approximate location of the Port Stephens region identified. 
 
 
TABLE 4.1.1 Clinical details of eight koalas diagnosed with cryptococcosis in the Port Stephens 
region of New South Wales, Australia. 
 
Koala Disease 
Serology Nasal 
colonisation 
KoRV 
(A/B) 
Location Source 
LFA LCAT (titre) 
1* C NR + (1:512) NR +/- Soldiers Point [1] 
2 SC + + (1:64) NR NR Soldiers Point [1] 
3* C NR NR NR NR Tanilba Bay This study 
4 C NR NR NR NR Salamander Bay This study 
5* C NR NR + NR Williamtown This study 
6* C + + (1:131,072) + +/- Salamander Bay This study 
7 SC + + (1:8) + NR Salamander Bay This study 
8 SC + + (1:2) + NR Soldiers Point This study 
 
*Disease isolate available. C = clinical; KoRV = koala retrovirus; LCAT = latex cryptococcal antigen agglutination 
test; LFA = cryptococcal antigen lateral flow assay; NR = not recorded; SC = subclinical; + = positive; - = negative.  
[1] Schmertmann et al., 2018b. 
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 MATERIALS AND METHODS 
Environmental Sampling 
Areas for sampling were identified in the Salamander Bay and Soldiers Point areas of NSW, 
Australia, based on known koala habitats (advised by local koala rescue groups), the capture 
location of diseased koalas, viewing satellite images to identify bushland corridors and 
opportunistically. Trees were examined for the presence of one or more accessible hollows. 
All accessible hollows were sampled, resulting in a total of 46 trees, 19 from 
Salamander Bay and 27 from Soldiers Point (Table 4.1.2), across three sampling trips in April 
2015, September 2015 and November 2017. The interior surface of each tree hollow was 
thoroughly swabbed until the swab tip was discoloured but still intact. Sterile cotton-tipped 
swabs, pre-moistened with sterile saline, were used for this and were then refrigerated as 
soon as possible after collection. If possible, a generous amount (up to several hundred 
grams) of debris inside each hollow was also collected into clean plastic bags. These were 
labelled, sealed and stored at room temperature in the dark. Identification of each tree 
species was performed using a taxonomic key (Brooker & Kleinig, 2006). 
 
Koala nasal swabs 
Nasal swabs (collected by inserting a sterile moistened swab into the nasal vestibule on both 
sides and rotating gently (Connolly et al., 1999, Krockenberger et al., 2002b) from 23 free-
ranging koalas in the Port Stephens region (Table 4.1.3) were submitted to Veterinary 
Pathology Diagnostic Services (VPDS) at The University of Sydney. The swabs were obtained 
from rescued koalas (captured by a local organisation, typically due to suspected injury or 
disease, or being in unsuitable habitat [e.g. adjacent to major roads]) as part of health checks 
performed by a local veterinary hospital prior to release. This hospital began to routinely 
collect nasal swabs for disease surveillance after the first cases of cryptococcosis were 
identified in 2013, and nasal swabbing was considered simpler and less invasive than blood 
collection from conscious free-ranging individuals. Koalas in Salamander Bay and Soldiers 
Point accounted for 9/23 nasal swabs. Koalas with clinical or subclinical cryptococcosis 
accounted for 4/23 nasal swabs. 
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 Disease isolates 
Disease isolates were available from four koalas with clinical cryptococcosis (Table 4.1.1), with 
isolates from three of these koalas provided by VPDS. The fourth koala (Table 4.1.1; Koala 6) 
was diagnosed with severe systemic cryptococcosis and euthanased during the time of this 
study. In this case, disease isolates were collected at postmortem as part of this study. This 
koala had widely disseminated disease and cryptococcal lesions were observed on gross, 
cytological and histopathological examination in the lung, brain, kidney, urine, lymph nodes, 
vertebrae and skin. Swabs and samples of some representative lesions were collected for 
culture. Unfortunately, no isolate was available from the fifth koala, as this diagnosis was 
made based on cytological and histopathological findings from samples collected at 
postmortem by local attending veterinarians. 
 
Culture 
All swabs (environmental, nasal and disease) were inoculated onto Staib’s bird seed agar 
(containing penicillin and gentamicin) as soon as possible, by gently rolling the swabs across 
the entire agar plate. Debris samples were inoculated onto bird seed agar by agitating a small 
amount of debris (approximately 5g) in 100 ml of sterile saline, allowing the debris to settle 
for 5 minutes then spreading 1 ml of the supernatant across the plate. In some cases, a sterile 
moistened swab was also introduced into the bagged samples to mimic the process of 
swabbing the interior of a tree hollow; this swab was then rolled across the agar plate. 
Plates were incubated at 27°C for 7-10 days and monitored a minimum of once daily 
for cryptococcal growth (yeast colonies exhibiting the brown-colour-effect). Samples were 
considered negative if no such colonies were observed after 10 days of observation. If suspect 
cryptococcal colonies were observed, the sample was classified as positive and then 
characterised as having a low (1-10 colonies), moderate (11-100 colonies) or heavy (>100 
colonies) degree of cryptococcal growth. One to eight cryptococcal colonies from each 
positive plate were then sub-cultured on Sabouraud’s agar at 37°C for isolation and DNA 
extraction. 
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 Typing of isolates 
DNA was extracted from all isolates using a pure heavy culture on Sabouraud dextrose agar 
and an established protocol for fungi (Ferrer et al., 2001). The URA5 gene was amplified and 
underwent RFLP analysis as previously described (Meyer et al., 2003). Species and molecular 
types were assigned through comparisons with known C. gattii VGI-IV and C. neoformans VNI-
IV standards (VGI: WM 179; VGII: WM 178; VGIII: WM 175; VGIV: VM 779; VNI: WM 148; VNII: 
WM 626; VNIII: WM 628; VNIV: WM 629) (Meyer et al., 2003).  
The mating type specific genes MFa and MFα were amplified by PCR together with 
known mating type a and α standards (WM 06.38 and WM 179, respectively) using 
established primers (Halliday et al., 1999, Fraser et al., 2003). The mating type was 
determined by visualising the PCR products on a 1.5% agarose gel run at 80V for 20 minutes 
and comparing the results to the known standards. 
PCR amplification of the seven MLST loci (CAP59, GPD1, IGS1, LAC1, PLB1, SOD1 and 
URA5) was performed using the primers and conditions specified by the consensus MLST 
scheme for the C. neoformans and C. gattii species complexes (Meyer et al., 2009). The C. 
gattii MLST database (http://mlst.mycologylab.org) was then used to assign allele and 
sequence type numbers. 
 
Phylogenetic analysis 
MLST sequences were concatenated then aligned by MUSCLE (Edgar, 2004), with subsequent 
alignments undergoing a maximum likelihood phylogenetic analysis to construct a neighbour 
joining tree (using the Jukes-Cantor model with gamma distribution). An Australian C. gattii 
VGIIb ST 7 strain (WM 13.373) was included for outgrouping. This strain was selected as it 
appears to be the most common C. gattii VGII ST in Australia (Carriconde et al., 2011). 
Bootstrap values were obtained from 1,000 replicates using a maximum likelihood algorithm. 
All alignments and analyses were performed using the MEGA7 program (Kumar et al., 2016). 
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 Koala retrovirus testing 
One koala (Table 4.1.1; Koala 6) was tested for koala retrovirus (KoRV) using genomic DNA 
extracted from a blood sample. An established PCR protocol was then used to test DNA for 
variants KoRV-A and KoRV-B (Xu et al., 2013). KoRV results were already available for another 
koala (Table 4.1.1; Koala 1) from a previous publication (Schmertmann et al., 2018b). 
 
Statistical analysis 
The possibility of dependent relationships between environmental sample culture results and 
location (Salamander Bay versus Soldiers Point) or tree species (E. tereticornis versus others) 
and between nasal swab culture results and koala location (Salamander Bay and Soldiers Point 
versus others) were assessed using 2x2 contingency tables and Fisher’s exact test (two-tailed). 
P values < 0.05 were considered significant. 
 
RESULTS 
Culture 
Samples from 14/46 (30%) trees (4 in Salamander Bay; 10 in Soldiers Point) cultured positive 
for Cryptococcus spp. on bird seed agar (Table 4.1.2). A total of 55 environmental isolates 
were successfully subcultured from 11 of these trees: Angophora floribunda (1), E. pilularis 
(1), E. robusta (1), E. tereticornis (5), Melaleuca spp. (1) and Eucalyptus spp. (2). 
Nasal swabs from 13/23 (57%) koalas were positive for Cryptococcus spp., including 
all koalas from Salamander Bay and Soldiers Point (Table 4.1.3). A single strain from each 
positive koala was subcultured, resulting in 13 koala colonising isolates. 
A total of eight disease isolates were available from four clinical cases, with 5/8 
collected from one individual (Table 4.1.1; Koala 6). In this case, Cryptococcus spp. was 
cultured from vertebral and skin lesions, and the bronchi, urine and meninges, with one 
isolate collected from each of these sites. Three other disease isolates (from Koalas 1, 3 and 
5 in Table 4.1.1) were also available. 
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 TABLE 4.1.2 Bird seed agar culture, molecular typing and multi-locus sequence typing results 
for environmental samples from 46 trees in New South Wales, Australia. 
 
Sample Tree species Location Culture Cryptococcus spp. MT ST 
E2650 Eucalyptus haemastoma SP ++ NT NT NT 
E2652 E. tereticornis SP +++ C. gattii VGI α 51 
E2657 E. pilularis SP +++ C. gattii VGI α, a 51, 154 
E2660 E. tereticornis SP ++ C. gattii VGI α 51 
E2661 E. tereticornis SP -    
E2662 E. tereticornis SP -    
E2663 Eucalyptus spp. SP + NT NT NT 
E2666 Angophora floribunda SP +++ C. gattii VGI α 51, 188, 365, 366 
E2667 Melaleuca spp. SP -    
E2669 E. tereticornis SP ++ C. gattii VGI α 366 
E2670 E. tereticornis SP -    
E2672 E. tereticornis SP ++ NT NT NT 
E2675 E. haemastoma SP -    
E2688 E. pilularis SB -    
E2690 Eucalyptus spp. SB -    
E2692 Melaleuca spp. SB -    
E2695 E. robusta SB -    
E2697 E. robusta SB ++ C. gattii VGI α 366 
E2698 Eucalyptus spp. SB -    
E2699 Melaleuca spp. SB + C. gattii VGI α 51 
E2700 E. robusta SB -    
E2701 E. tereticornis SB -    
E2702 A. costata SB -    
E2703 E. tereticornis SB -    
E2704 E. tereticornis SB ++ C. gattii VGI α 51 
E2705 E. tereticornis SB + C. gattii VGI α 51 
E2706 E. pilularis SB -    
E2707 Eucalyptus spp. SB -    
E2708 A. costata SB -    
E2709 E. pilularis SB -    
E2710 Eucalyptus spp. SB -    
E2711 E. pilularis SB -    
E3035 E. longifolia SP -    
E3036 Eucalyptus spp. SP +++ C. gattii VGI α 51 
E3037 E. tereticornis SP -    
E3038 E. tereticornis SP -    
E3039  Eucalyptus spp. SP ++ C. gattii VGI α 51 
E3040 E. longifolia SP -    
E3041 E. longifolia SP -    
E3042 Eucalypt spp. SP -    
E3043 E. resinifera SP -    
E3044 Eucalypt spp. SP -    
E3045 E. longifolia SP -    
E3046 Eucalypt spp. SP -    
E3047 E. tereticornis SP -    
E3048 E. tereticornis SP -    
 
+ = low degree of cryptococcal growth (1-10 colonies), ++ = moderate (11-100 colonies), +++ = heavy (>100 
colonies); - = negative; MT = mating type; NT = not typed; SB = Salamander Bay; SP = Soldiers Point; ST = sequence 
type. 
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 Typing 
In total, 76 Cryptococcus spp. strains underwent molecular typing, with all subsequently being 
identified as C. gattii VGI using URA5 RFLP analysis. Mating type analysis identified 75/76 as 
α; one environmental isolate (from an E. pilularis tree containing two other mating type α 
strains) was mating type a (WM 15.436). 
 
TABLE 4.1.3 Bird seed agar culture, molecular typing and multi-locus sequence typing results 
for nasal swabs from 23 koalas in the Port Stephens region of New South Wales, Australia. 
 
Koala Location Disease Culture Cryptococcus spp. 
(molecular type) 
MT ST 
LS1 Salamander Bay  + C. gattii (VGI) α 154 
LS3 Nelson Bay  -    
LS36 Corlette  -    
LS37 Corlette  -    
LS78 Bobs Farm  +++ C. gattii (VGI) α 188 
LS79 Corlette  + C. gattii (VGI) α 51 
LS81 Soldiers Point  +++ C. gattii (VGI) α 395 
LS82 One Mile  ++ C. gattii (VGI) α 366 
LS83 Williamtown  -    
LS86 Corlette  -    
LS87 Salamander Bay SC ++ C. gattii (VGI) α 396 
LS90 Salamander Bay C +++ C. gattii (VGI) α 57 
LS91 Nelson Bay  -    
LS92 Salamander Bay  +++ C. gattii (VGI) α 188 
LS94 Bobs Farm  -    
LS95 Boat Harbour  -    
LS96 Corlette  -    
LS98 Soldiers Point  ++ C. gattii (VGI) α 51 
LS152 Anna Bay  -    
LS176 Soldiers Point  ++ C. gattii (VGI) α 51 
LS233 Soldiers Point SC +++ C. gattii (VGI) α 57 
14-7190 Salamander Bay  + C. gattii (VGI) α 51 
14-8139 Williamtown C + C. gattii (VGI) α 51 
 
+ = low degree of growth (1-10 colonies), ++ = moderate (11-100 colonies), +++ = heavy (>100 colonies), - = 
negative, C = clinical, MT = mating type, SC = subclinical, ST = sequence type. 
 
All 76 isolates progressed to MLST analysis. Nine unique sequence types (STs) were 
identified: ST 51 (45/76), ST 366 (12/76), ST 57 (8/76), ST 188 (4/76), ST 154 (2/76), ST 365 
(2/76), ST 364 (1/76), ST 395 (1/76) and ST 396 (1/76). Five of these STs were novel to the 
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 MLST database (ST 364, ST 365, ST 366, ST 395 and ST 396). A total of 15 different allele types 
(AT) were identified in this study for the seven MLST loci. Three loci were highly conserved 
across all samples, with only one AT identified (CAP59, GPD1 and PLB1). Two different ATs 
were observed at LAC1 and URA5 loci. The IGS1 and SOD1 loci were the most variable, each 
with four unique ATs. 
Five STs were identified amongst the 55 environmental isolates, with ST 51 and ST 366 
accounting for most of the isolates (39/55 and 11/55, respectively). The remaining five 
isolates were ST 188 (2/55), ST 365 (2/55) and ST 154 (1/55). Of the 11 trees from which 
multiple C. gattii VGI strains were successfully isolated, 9/11 exhibited a clonal population (all 
isolates had the same ST). In one E. pilularis tree, two STs (ST 51 and ST 154) were identified, 
and both mating types (a and α) were also identified in this tree. In a single A. floribunda tree, 
four unique STs were detected (ST 51, ST 188, ST 365 and ST 366).  
Amongst the 13 nasal colonising isolates, seven STs were identified, comprising of ST 
51 (5), ST 57 (2), ST 188 (2), ST 154 (1), ST 366 (1), ST 395 (1) and ST 396 (1). All five disease 
isolates collected from the same koala (Table 4.1.1; Koala 6) were ST 57. The remaining three 
disease isolates were ST 51, ST 57 and ST 364. Four STs identified in this study were found 
only in koalas as colonising or disease isolates (ST 57, ST 364, ST 395 and ST 396) and were 
not detected in the environment.  
Nasal colonising and disease isolates were available from the same individual in two 
cases. In one case, colonising and disease isolates were clonal according to MLST analysis 
(both ST 57). In the other koala, the colonising isolate was disparate to the disease isolate (ST 
51 versus ST 57, respectively). 
 
Phylogenetic analysis 
A total of 72 isolates progressed to maximum likelihood phylogenetic analysis (55 
environmental, 13 colonising and 4 disease isolates). Four disease isolates were excluded as 
all were of an identical ST and originated from the same individual (as mentioned above). The 
isolates separated in to two main clades with high bootstrap support (Figure 4.1.2). Clade 1 
contained 65/72 isolates. The seven isolates in clade 2 were environmental (1), colonising (3) 
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 and disease (3) isolates. Clade 1 was predominantly environmental (54) and colonising (10) 
isolates, with a single disease isolate. 
 
FIGURE 4.1.2 Maximum likelihood phylogenetic tree, using the Jukes-Cantor model with 
gamma distribution, of the nine Cryptococcus gattii VGI sequence types (STs) identified 
amongst koala disease, nasal colonising and environmental isolates from the Port Stephens 
region of New South Wales, Australia. C. gattii VGIIb ST 7 is included as an outgroup. Bootstrap 
values were obtained from 1,000 replicates using a maximum likelihood model, with values 
above 70 shown. Pie charts indicate the distribution of environmental (green), colonising 
(blue) and disease (red) isolates across each ST. Scale bar indicates the number of nucleotide 
substitutions per site. 
 
Koala retrovirus testing 
The two koalas tested were both positive for variant KoRV-A and negative for variant KoRV-B 
(Table 4.1.1; Koalas 1 and 6). 
 
Statistical analysis 
No significant relationships were established between environmental sample culture results 
and location (p = 0.34) or tree species (p = 0.46). Nasal colonisation was dependent on 
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 location (p = < 0.01), with koalas from Salamander Bay and Soldiers Point significantly more 
likely to be colonised than koalas from other areas within the Port Stephens region. 
 
DISCUSSION 
The key finding of this study is the separation of most environmental and disease isolates into 
separate phylogenetic clades. This has significant implications for our understanding of the 
host-pathogen-environment interactions involved in koala cryptococcosis. In addition, we 
identified that colonising isolates were largely representative of the C. gattii VGI population 
in this area. We were unable to definitively ascertain the underlying cause of this case cluster, 
but an unusually high environmental prevalence of C. gattii VGI and/or single emergent 
outbreak strain appear to be unlikely. Increased host susceptibility in this area remains a 
possible contributing factor. 
We identified the phylogenetic separation of most disease and environmental isolates 
(Figure 4.1.2) into two clades, well-supported by bootstrap values, and that four of the nine 
STs characterised in this study were found only in koalas (as colonising or disease isolates). 
These findings support a previous fine-scale epidemiological study into cryptococcosis of 
animals, where minor sequence differences differentiated disease strains from common 
environmental strains to which the animal was exposed (Schmertmann et al., 2018a). We also 
identified that colonising isolates were evenly distributed throughout the phylogenetic tree, 
which suggests that koalas are exposed to a wide range of C. gattii VGI strains in their 
environment. Through this broad exposure, it is possible that koalas ‘select’ for the most 
pathogenic strains from the environment, while these strains exist as rare environmental 
subpopulations. We performed a follow up Fisher’s exact test (two-tailed) to compare the 
distribution of disease and non-disease isolates across the two clades, and we found that 
disease isolates were significantly more likely to be grouped in the lower clade (p = < 0.01). 
Our findings could also be considered supportive of microevolution as a mechanism 
for the observed difference. Multiple isolates collected from relapse cases of central nervous 
system cryptococcosis in one study exhibited phenotypic and genetic changes over time, 
including adaptations to virulence mechanisms and drug resistance, indicative of 
microevolutionary change (Chen et al., 2017). While this phenomenon was not observed in 
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 the single C. gattii VGI isolate included in that study (Chen et al., 2017), these findings still 
suggest that the sustained contact between koala nasal colonising isolates and the host 
mucosa (and likely the mammalian innate immune system) could also result in 
microevolutionary changes. 
The environmental associations of C. gattii VGI continue to expand in Australia beyond 
the historical link with E. camaldulensis and E. tereticornis (Ellis & Pfeiffer, 1990, Pfeiffer & 
Ellis, 1992). Our findings highlight the importance of considering seemingly uncommon 
associations for this pathogen when performing environmental sampling, as the greatest ST 
and mating type diversity found in this study occurred in A. floribunda and E. pilularis tree 
hollows, respectively. Cryptococcus spp. colonies were observed in approximately 30% of the 
tree hollows sampled in this study, but C. gattii VGI could only be isolated and definitively 
identified in approximately 24%. This was typically due to the rapid overgrowth of filamentous 
fungi impeding the isolation of Cryptococcus spp. from the primary plate. In the experience 
of the authors and according to the literature, for a targeted environmental sampling study 
(focusing on the tree hollow as a known ecological niche) in eastern Australia, the herein 
obtained result is not indicative of an unusually heavy environmental burden of C. gattii VGI. 
For example, one study found that in two other coastal areas of NSW supporting large free-
ranging koala populations, 19-28% of environmental samples were positive (Krockenberger 
et al., 2002b). Similar studies have also been conducted in several areas with no koalas, or 
very low population densities: in the northern Sydney and Blue Mountains regions of NSW, 
11% and 9% of samples were positive, respectively (Krockenberger et al., 2002b, Vilcins et al., 
2002), while in the Murray-Darling and Murrumbidgee River basins of NSW, up to 45% and 
64% of samples were positive, respectively (Krockenberger et al., 2002b, Saul, 2009). It must 
be considered that these regions display differences in the tree population, with E. 
camaldulensis common in the inland river basins and Liverpool Plains and E. tereticornis more 
common in coastal areas (Brooker & Kleinig, 2006), as this could also affect the environmental 
prevalence of C. gattii VGI. It is, however, reasonable to conclude that our findings are still 
not supportive of an atypically heavy environmental burden of C. gattii VGI as the cause of 
this case cluster.  
This study found that koala nasal colonising isolates were reasonably evenly 
distributed across the entire phylogenetic tree and exhibited a substantial ST diversity. 
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 Colonising isolates reflected most environmental and disease STs, suggesting that they 
represent an excellent cross-section of the local C. gattii VGI community. This highlights the 
utility of the koala sinonasal cavity as an effective biological air sampler. Indeed, our findings 
suggest that koala nasal swabs may even be superior to environmental sampling to explore 
cryptococcal diversity in any given region. A large systematic study of cryptococcal nasal 
colonisation in the Liverpool Plains population (located in north-western NSW) of free-ranging 
koalas found that approximately 7% of koalas were colonised (Schmertmann et al., 2019). In 
another study, many hospitalised free-ranging koalas from a different region of coastal NSW 
were tested for nasal colonisation, with 35% found to be positive (Krockenberger et al., 
2002b). The rates of nasal colonisation found in the present study, 57% amongst all koalas 
tested and 100% for those from Salamander Bay and Soldiers Point, are considerably higher. 
Indeed, rates of close to 60% and 100% are more representative of koalas residing in captive 
environments with high environmental cryptococcal burdens (Krockenberger et al., 2002b). 
The statistical relationship established between nasal colonisation and location suggests that 
koalas in the two hotspot suburbs are significantly more likely to be colonised than those from 
other areas of the Port Stephens region. The koala population density of these two suburbs 
is unknown, but it is unlikely to vary substantially from other nearby areas with suitable koala 
habitats (Lunney et al., 1998). When interpreting the results of this study, it is important to 
consider both the small sample size of koalas and the fact that some colonised koalas had 
presented to a veterinarian for illness or injury. Four of the colonised koalas (three from 
Soldiers Point and Salamander Bay; one from elsewhere in the Port Stephens region) were 
also considered to have clinical or subclinical cryptococcosis (Table 4.1.1; Koalas 5-8). To 
determine if colonised koalas with confirmed cryptococcosis were biasing the statistical 
analysis, we performed another Fisher’s exact test (two-tailed) excluding these four koalas 
and found that the dependent relationship between colonisation status and location 
persisted (p = < 0.01). 
Of the nine C. gattii VGI STs identified in this study, only four had been previously 
characterised, with ST 51 and ST 154 detected globally in environmental, veterinary and 
human isolates and ST 57 and ST 188 detected in Europe and North America as veterinary and 
human isolates, according to the C. gattii MLST Database. In the present study, ST 57 was 
detected amongst koala colonising and disease isolates, and ST 188 amongst environmental 
4. Fine-scale molecular epidemiology
131
 and colonising isolates. The presence of five previously uncharacterised STs (ST 364, ST 365, 
ST 366, ST 395 and ST 396), one of which accounted in 16% (ST 366) of the isolates, might be 
indicative of a high diversity in this region, although the nucleotide substitution scale of the 
dendrogram (Figure 4.1.2) is not particularly suggestive of this. The finding may simply reflect 
a paucity of molecular epidemiology studies of C. gattii VGI from this area. 
MLST results provided no evidence of an emergent outbreak strain, but the possibility 
of changes to virulence genes outside of the sequenced MLST loci cannot be excluded. If 
highly virulent strains of C. gattii VGI were implicated, a concurrent increase in cases in other 
wildlife species, domestic animals and humans could also reasonably be expected. The same 
could be true if the cause was an extremely high environmental presence. In the opinion of 
an experienced local veterinarian, the case load of cryptococcosis in companion animals in 
this area is not unusual (D. Hudson, pers. comm.). We opportunistically investigated one local 
companion animal case (a cat residing in Soldiers Point with sinonasal cryptococcosis) but 
identified C. neoformans VNII as the aetiological agent, thus it was considered unrelated to 
the koala case cluster. Any increase in the prevalence of human cases could not be 
ascertained. A comprehensive search through the records of the Medical Mycology Culture 
Collection at The Westmead Institute for Medical Research for other C. gattii species complex 
isolates from the Port Stephens region yielded no results. This collection contains thousands 
of environmental, veterinary and human clinical isolates from Australia and worldwide 
spanning several decades. Given the seemingly comparatively high rates of cryptococcosis 
reported in koalas (Krockenberger et al., 2003, Stalder, 2003) and the potential for long 
incubation periods and dormancy in humans and animals with C. gattii species complex 
cryptococcosis (Chen et al., 2014), it is possible that an increased prevalence of cases in other 
species will emerge in time. Therefore, it is pertinent to consider the koala as an important 
sentinel in this region and to monitor for further cases. 
Host immune status and pathogen burden are other important considerations as 
potential contributors to this case cluster. KoRV-B, one of the exogenous KoRV variants, has 
the potential to cause immunomodulatory effects, with links between KoRV-B infection and 
chlamydiosis, malignant neoplasia and variations in immune cytokine expression well-
established (Xu et al., 2013, Maher & Higgins, 2016, Waugh et al., 2017). Both koalas tested 
in this study were KoRV-B negative and KoRV-A positive. KoRV-A is an endogenous variant 
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 considered unlikely to cause significant alterations to host immunity, and the KoRV-A status 
of these two individuals is consistent with prior findings of 100% prevalence in koalas from 
other areas of NSW (Simmons et al., 2012). Therefore, it appears unlikely that KoRV infection 
is implicated in this case cluster. It was not possible to ascertain the KoRV status of other 
koalas in this study, as samples appropriate for this type of testing (sufficiently intact koala 
genomic DNA) were unavailable. The potential relationship between cryptococcosis and KoRV 
has not been systematically studied.  
Numerous other threats to this koala population are prevalent, including habitat 
fragmentation, motor vehicle strikes, dog attacks and bush fires, with the interaction of 
multiple threats known to contribute to a high risk for population decline (Lunney et al., 2007, 
Rhodes et al., 2011). Particularly in Soldiers Point, the koala habitat is highly fragmented by 
private property and roads. It is possible that the increasing number of stressors and threats 
to koalas in this area is contributing to a higher incidence of this normally sporadic, 
environmentally-acquired disease. 
Further work could include environmental sampling throughout other areas of the 
Port Stephens region and the application of whole genome sequencing (WGS) as a higher 
resolution molecular epidemiology tool. WGS could shed further light on the relationship 
between these strains and could highlight if microevolutionary changes are occurring. The 
authors also aim to explore the impact of pathogen burden on koala populations, particularly 
co-infection with C. gattii VGI and exogenous KoRV variants. 
Underlying causes of this case cluster remain elusive in the absence of the 
identification of an emergent outbreak strain or unusually high environmental prevalence of 
C. gattii VGI. Our findings indicate a genotypic distinction between disease and environmental 
isolates, offering further insights into the host-pathogen-environment interactions of 
cryptococcosis. This study cemented the utility of free-ranging koalas as both sentinels for 
this disease and biological samplers to assess the diversity of environmental C. gattii VGI. 
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 SUPPLEMENTARY TABLE S4.1.1 List of cryptococcal isolates from the Port Stephens region of 
New South Wales, Australia included in this study. MLST data, strain information, allele types 
and STs are listed. Strains are ordered by ST number. 
 
 Allele and sequence types 
WM 
number 
Species Date Category Specific source MT 
C
A
P
5
9 
G
P
D
1 
IG
S1
 
LA
C
1 
P
LB
1 
SO
D
1 
U
R
A
5 
ST
 
14.340 C. gattii VGI Nov 2014 Colonising Koala - nasal α 16 5 3 5 5 32 12 51 
14.341 C. gattii VGI Nov 2014 Disease Koala - lung α 16 5 3 5 5 32 12 51 
15.169 C. gattii VGI Dec 2014 Colonising Koala - nasal α 16 5 3 5 5 32 12 51 
15.422 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
15.423 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.424 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.425 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.426 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.427 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.428 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.429 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.430 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.431 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.432 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.433 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.434 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.435 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.437 C. gattii VGI Apr 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
15.438 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
15.439 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
15.440 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
15.441 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
16.01 C. gattii VGI Apr 2015 Enviro Melaleuca spp. α 16 5 3 5 5 32 12 51 
16.02 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
16.04 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
16.27 C. gattii VGI Oct 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
16.28 C. gattii VGI Oct 2015 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
16.29 C. gattii VGI Oct 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
16.30 C. gattii VGI Oct 2015 Enviro E. pilularis α 16 5 3 5 5 32 12 51 
16.53 C. gattii VGI Dec 2015 Colonising Koala - nasal α 16 5 3 5 5 32 12 51 
17.112 C. gattii VGI Apr 2016 Colonising Koala - nasal α 16 5 3 5 5 32 12 51 
17.113 C. gattii VGI Jul 2016 Colonising Koala - nasal α 16 5 3 5 5 32 12 51 
17.114 C. gattii VGI Jul 2016 Enviro E. tereticornis α 16 5 3 5 5 32 12 51 
18.140 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.141 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.142 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.143 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.144 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.145 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.146 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.147 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.148 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.149 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.150 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
18.151 C. gattii VGI Nov 2017 Enviro Eucalyptus spp. α 16 5 3 5 5 32 12 51 
15.170 C. gattii VGI Dec 2014 Disease Koala - hind limb α 16 5 3 5 5 65 12 57 
16.57 C. gattii VGI Feb 2016 Colonising Koala - nasal α 16 5 3 5 5 65 12 57 
16.62 C. gattii VGI Feb 2016 Disease Koala - meninges α 16 5 3 5 5 65 12 57 
18.131 C. gattii VGI Mar 2016 Colonising Koala - nasal α 16 5 3 5 5 65 12 57 
15.436 C. gattii VGI Apr 2015 Enviro E. pilularis a 16 5 3 5 5 45 12 154 
16.32 C. gattii VGI Oct 2015 Colonising Koala - nasal α 16 5 3 5 5 45 12 154 
16.05 C. gattii VGI Apr 2015 Enviro Angophora floribunda α 16 5 12 5 5 32 12 188 
16.08 C. gattii VGI Apr 2015 Enviro A. floribunda α 16 5 12 5 5 32 12 188 
16.52 C. gattii VGI Dec 2015 Colonising Koala - nasal α 16 5 12 5 5 32 12 188 
16.63 C. gattii VGI Mar 2016 Colonising Koala - nasal α 16 5 12 5 5 32 12 188 
13.375 C. gattii VGI Sep 2013 Disease Koala - lymph node α 16 5 3 5 5 45 48 364 
16.03 C. gattii VGI Apr 2015 Enviro A. floribunda α 16 5 20 5 5 111 12 365 
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 16.07 C. gattii VGI Apr 2015 Enviro A. floribunda α 16 5 20 5 5 111 12 365 
16.06 C. gattii VGI Apr 2015 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
16.09 C. gattii VGI Apr 2015 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
16.10 C. gattii VGI Apr 2015 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
16.11 C. gattii VGI Apr 2015 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
16.12 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 20 5 5 32 12 366 
16.13 C. gattii VGI Apr 2015 Enviro E. tereticornis α 16 5 20 5 5 32 12 366 
16.26 C. gattii VGI Oct 2015 Enviro E. robusta α 16 5 20 5 5 32 12 366 
16.55 C. gattii VGI Dec 2015 Colonising Koala - nasal α 16 5 20 5 5 32 12 366 
18.136 C. gattii VGI Sep 2017 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
18.137 C. gattii VGI Sep 2017 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
18.138 C. gattii VGI Sep 2017 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
18.139 C. gattii VGI Sep 2017 Enviro A. floribunda α 16 5 20 5 5 32 12 366 
16.54 C. gattii VGI Dec 2015 Colonising Koala - nasal α 16 5 12 57 5 32 12 395 
16.56 C. gattii VGI Jan 2016 Colonising Koala - nasal α 16 5 97 5 5 32 12 396 
 
 
Apr = April; Dec = December; Enviro = environmental; Feb = February; Jan = January; Jul = July; Mar = March; MT 
= mating type; Nov = November; Oct = October; Sep = September; ST = sequence type; WM = Westmead 
Mycology. 
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Abstract
A systematic investigation into environmental sources of infectionwas conducted at an Australian zoological
park after cryptococcosis, caused by Cryptococcus gattii VGI, was diagnosed in a red-tailed black cockatoo
(Calyptorhynchus banksii) residing in a large aviary with a diverse range of other avian species. A single tree
with an extensive hollow was identified as the likely source of infection based on heavy culture of C. gattii
VGI, multi-locus sequence typing and phylogenetic analysis of environmental and disease-related isolates.
This led to the careful removal of the tree to reduce the risk of future cases of cryptococcosis in this aviary.
Key words: cryptococcosis, Cryptococcus gattii VGI, avian, molecular epidemiology, multi-locus sequence typing.
Brief Report
Cryptococcosis is a severe mycosis of birds, mammals, and
reptiles, which is acquired from the environment (typically by
inhalation) and caused by members of the Cryptococcus neofor-
mans and C. gattii species complexes.1,2 The taxonomy of these
species complexes is under ongoing debate, with the proposed
division into seven species3 not yet universally accepted. In Aus-
tralia, avian cryptococcosis is most commonly caused by mem-
bers of the C. gattii species complex and manifests as localised
invasive upper respiratory disease.4 The prevalence of
avian cryptococcosis in both captive and free-ranging
birds is unknown; while typically considered to be
a sporadic disease, outbreaks caused by the C. gat-
tii species complex can occur, as reported in a Brazil-
ian aviary.5 Avian cryptococcosis is often seemingly
refractory to treatment and mortality is reported in many
cases.4,6,7 Tree hollows of many species provide an environ-
mental niche for the C. gattii species complex, with Eucalyptus
camaldulensis and E. tereticornis in Australia exhibiting particu-
larly strong associations with C. gattii VGI and therefore present
a potential source of infection.8,9 Many native Australian birds,
including red-tailed black cockatoos (Calyptorhynchus banksii),
nest and shelter in eucalypt hollows.10
A red-tailed black cockatoo at a zoological park in Aus-
tralia was diagnosed with cryptococcosis after it was noticed
to be sneezing and have a subcutaneous swelling adjacent to
the eye (Fig. 1, inset), later identified as a cryptococcal lesion
by histopathological examination of a biopsy and subsequent
C© The Author(s) 2018. Published by Oxford University Press on behalf of The International Society for Human and AnimalMycology.
All rights reserved. For permissions, please e-mail: journals.permissions@oup.com
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Figure 1. A dead eucalypt in the free flight aviary at a zoological park in Australia found to be consistently heavily contaminated by Cryptococcus gattii VGI. Inset:
cryptococcal lesion (featherless area indicated by white arrow) in a red-tailed black cockatoo (Calyptorhynchus banksii). This Figure is reproduced in color in the
online version of Medical Mycology.
mycological culture (Gribbles Veterinary Pathology, Clayton,
Victoria, Australia). Serum cryptococcal antigen latex aggluti-
nation testing (CALAS R©, Meridian Bioscience, Inc.) was posi-
tive (titer of 1:2048). The cockatoo was captive bred and raised,
privately in Australia. Three months prior to presentation, the
cockatoo had been transferred to a large free flight aviary with
numerous other avian inhabitants, from a small education aviary
on the same site in which it had been held for 8 years. The diag-
nosis prompted concern that other inhabitants of both aviaries
may be at risk of developing cryptococcosis. An investigation
aimed to identify environmental sources of infection, using cul-
ture, multi-locus sequence typing, and phylogenetic analysis, to
guide management practices and prevent further cases of cryp-
tococcosis.
Environmental samples were collected in May 2015 (Table 1;
samples 1 to 10) from both aviaries. Sampling sites were selected
randomly and through consideration of likely environmental
niches for Cryptococcus spp. and areas favored by the cock-
atoo and other birds. Additional samples were collected from
one site in August 2015 and February 2017 (Table 1; samples
11 to 20).
Samples were inoculated onto birdseed agar as previ-
ously described.11 Two or three mucoid colony forming units
exhibiting the brown-color-effect were isolated from all
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Table 1. Birdseed agar culture and molecular typing results for environmental samples collected from two aviaries at a zoological park in
Victoria, Australia.
Sample Date Aviary Sample site
Culture resulta
(degree of growthb)
Cryptococcus spp.
(sequence types)
Culture collection
accession numbers
1 May 2015 FF Large stag hollow Positive (H) C. gattii VGI (ST57
[n = 2], ST154 [ n = 1])
WM16.14, WM16.15,
WM16.16
2 May 2015 FF Large stag hollow Positive (L) C. gattii VGI (ST57
[n = 2]), C. neoformans
VNI∗
WM16.17, WM16.18,
WM16.19
3 May 2015 FF Large stag hollow Negative
4 May 2015 FF Pooled substrate Negative
5 May 2015 FF Feeding perch Negative
6 May 2015 FF Feeding perch Negative
7 May 2015 Ed Pooled substrate Negative
8 May 2015 Ed Perch surface Negative
9 May 2015 Ed Main perch Negative
10 May 2015 Ed Secondary perch Negative
11 August 2015 FF Large stag hollow Positive (M) C. gattii VGI (ST57
[n = 1], ST154 [n = 1])
WM16.22, WM16.23
12 August 2015 FF Large stag hollow Negative
13 August 2015 FF Large stag hollow Positive (H) C. gattii VGI (ST57
[n = 1], ST51 [n = 1])
WM16.24, WM16.25
14 February 2017 FF Large stag hollow Positive (M)
∧
15 February 2017 FF Large stag hollow Negative
16 February 2017 FF Large stag hollow Positive (H)
∧
17 February 2017 FF Large stag hollow Negative
18 February 2017 FF Large stag hollow Negative
19 February 2017 FF Large stag hollow Negative
20 February 2017 FF Large stag hollow Positive (L)
∧
aPresence (positive) or absence (negative) of mucoid colony forming units (CFUs) exhibiting the brown-colour-effect (BCE) on birdseed agar.
bNumber of CFUs exhibiting the BCE; L = low (1-10 CFUs); M = moderate (11-100 CFUs); H = heavy (>100 CFUs). Ed = Education, FF = Free flight, ST = sequence type.
∗Sequence type not determined.
∧
Molecular type and sequence type not determined.
positive samples collected in 2015. In addition, a disease-related
isolate was provided by Gribbles Veterinary Pathology (Clay-
ton, Victoria, Australia). All isolates are stored in the Medi-
cal Mycology Culture Collection at The Westmead Institute for
Medical Research in Westmead, New South Wales, Australia.
URA5 gene restriction fragment length polymorphism (RFLP)
analysis determined the species and molecular type.12 Multi-
locus sequence typing (MLST) was performed using the consen-
sus scheme for the C. neoformans and C. gattii species com-
plexes,13 with allele types (AT) and sequence types (ST) assigned
using the Fungal MLST Database (http://mlst.mycologylab.org).
Each AT sequence was submitted to Genbank (Supplementary
table 1). Concatenated MLST sequences were aligned and
maximum-likelihood phylogenetic analysis was performed using
the program MEGA7.14 Polymerase chain reaction (PCR) am-
plification of the MFa and MFα genes using published primers
determined the mating type.15,16
The ‘large stag’ (Fig. 1), a dead eucalypt of unknown species
in the free flight aviary, was the only culture-positive site.
Its extensive hollow was heavily culture-positive across multi-
ple samplings (Table 1). The disease-related isolate and nine
environmental isolates were identified as C. gattii VGI. One
environmental isolate was identified as C. neoformans VNI.
MLST analysis of C. gattii VGI isolates revealed four STs: ST57
(n = 6), ST154 (n = 2), ST51 (n = 1), and ST159 (n = 1) (Sup-
plementary table 2). AT differences were observed at the GPD1
and SOD1 loci (two and three unique ATs, respectively). The
disease-related isolate (ST159) differed from two environmental
isolates (ST154) by only a single base pair insertion in theGPD1
allele, which was confirmed by repeated PCR and sequencing.
Phylogenetic analysis revealed a low genetic diversity amongst
the C. gattii VGI isolates, but the identified clades had no boot-
strap support as indicated by low bootstrap values (not shown).
All isolates were mating type α.
This report presents a systematic investigation of environ-
mental sources of avian cryptococcosis and associated molecular
epidemiology. A similar investigation was previously attempted
in a small avian outbreak but the C. gattii species complex could
not be detected in the proximate environment.5 We found a
single tree hollow, used extensively by the aviary’s inhabitants
4. Fine-scale molecular epidemiology
140
Medical Mycology, 2018, Vol. 00, No. 00
(particularly the large parrots), to be consistently heavily con-
taminated by C. gattii VGI. Yeasts of the C. gattii species com-
plex were not detected at any other site. Several trees in the free
flight aviary could not be excluded as infection sources as the
tree heights did not permit sampling, although no hollows were
visible.
Most of isolates in this report were identified as C. gattii
VGI (AFLP417) by RFLP analysis. A 2014 publication describ-
ing a similar environmental investigation, prompted by several
cases of cryptococcosis in ferrets, identified likely sources of in-
fection based on matching disease and environmental isolates
by amplified fragment length polymorphism (AFLP) analysis.18
MLST analysis, a more discriminatory tool than RFLP or AFLP
analysis, was used in the present study and revealed a subtle dif-
ference (single base pair insertion at the GPD1 allele) between
the disease-related strain and one of the identified environmen-
tal STs. If RFLP analysis alone was used, the strains would have
appeared to be identical. The lack of an exact MLST match
could be attributed to the disease-related strain representing a
rare subset of environmental strains at a lower prevalence in
the environment; in this case further sampling may eventually
reveal an exact match. However, the insertion could also re-
flect a micro-evolutionary change.19 The FungalMLSTDatabase
(http://mlst.mycologylab.org) records for the STs identified in
this study suggest that all are well-characterised, with STs 51
and 154 found worldwide in all types of samples (environmen-
tal, veterinary, and human). STs 57 and 159 appear to be pri-
marily disease-associated isolates, with a few detections in hu-
man and veterinary samples from North America, Europe, Asia,
and Africa. This could represent further evidence that ST159
is a rare environmental isolate and could also suggest that our
detection of ST57 in the environment is unusual, but this spec-
ulation requires further investigation. The use of an even more
discriminatory tool, such as whole genome sequencing, may aid
in clarifying the relationship between these strains and could re-
veal a greater genetic diversity than detectable withMLST alone.
The incubation period of C. gattii species complex cryptococco-
sis ranged from 2 to 11 months in a systematic study of C. gattii
VGII disease in humans20 but likely varies beyond this range.
Possible incubation periods as short as 2–4 weeks have been
reported in humans.21 Substantially longer incubation periods
can also occur; for example a presumptive seven year incuba-
tion period was recently reported in another avian patient.6 In
the present study, the cockatoo’s residence at this site for over
8 years suggests that infection was acquired locally, although a
longer incubation period is theoretically possible.
Since upper respiratory disease is considered the most com-
monmanifestation of avian cryptococcosis, the cockatoo’s lesion
likely reflected invasive paranasal sinus disease. Localised cuta-
neous disease can occur, often subsequent to pecking injuries in
heavily contaminated environments.4 Osteomyelitis of the distal
humerus was the presenting lesion in another case.22 The ten-
dency for avian cryptococcosis to manifest as superficial disease
is widely thought to be a consequence of the higher core body
temperatures of birds precluding the growth of Cryptococcus
spp. at more central anatomical sites. However, a recent study
of thermotolerance in the C. neoformans species complex found
that it was able to grow at avian core body temperature but that
avian macrophages may be able to suppress its growth,23 which
could explain why disseminated disease appears to be less com-
mon, but can occur.4,6,7 In the present study, no other cases of
cryptococcosis were identified in either aviary. The cockatoo’s
transfer to the free flight aviary—a large, unfamiliar enclosure
with significantly reduced human contact—may have been a suf-
ficient stressor to increase its susceptibility to disease.
The identification of a single tree as a potential source of infec-
tion has implications for the ongoing management of this aviary.
In captive koala enclosures, the ‘furniture’ is known to become
heavily contaminated byCryptococcus spp.11 Therefore, precau-
tionary regular replacement, decontamination and/or screening
of incoming ‘furniture’ are logical recommendations. In this case,
the size of the hollow and its multiple openings made decontam-
ination or blocking access to it difficult. As such, removing the
tree was considered the best option but proved logistically chal-
lenging, with its size necessitating the use of a chainsaw. The
potential risk to personnel from the aerosolisation of cryptococ-
cal infectious propagules was mitigated by the use of appropriate
personal protective equipment.24 Ideally the aviary’s inhabitants
should be monitored with regular examinations, culture of nares
swabs, and cryptococcal antigen testing.However, this presents a
significant stressor and logistical challenge in such a large aviary
with many birds unaccustomed to handling and is therefore
unfeasible.
Captive animal cryptococcosis offers a unique opportunity
to systematically investigate environmental sources of infection.
MLST has further elucidated the complexities of host-pathogen-
environment interactions involved in avian cryptococcosis,
although additional sampling and finer-scale molecular epidemi-
ology is required to better understand these intricacies. Our find-
ings also reinforce the importance of careful consideration of
enclosure ‘furniture’ and the ongoing monitoring of enclosures
and animals in captivity, particularly when known environmen-
tal niches of the C. gattii species complex are present.
Supplementary material
Supplementary data are available at MMYCOL online.
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SUPPLEMENTARY TABLE 1 Allele sequences deposited to GenBank – allele types and 
corresponding accession numbers for Cryptococcus gattii VGI isolates used in this study. 
 
Locus Allele type number GenBank accession number 
CAP59 16 MH286888 
GPD1 
5 MH286889 
14 MH286890 
IGS1 3 MH286891 
LAC1 5 MH286892 
PLB1 5 MH286893 
SOD1 
32 MH286894 
45 MH286895 
65 MH286896 
URA5 12 MH286897 
 
 
SUPPLEMENTARY TABLE 2 List of Cryptococcus gattii VGI isolates collected for this study, 
including strain information, allele types and sequence types. Strains are ordered by 
sequence type number. Colours indicate allele type differences. 
 Allele and sequence type numbers 
WM 
number 
Other 
number 
Date Country Category 
Specific 
source 
MT 
C
A
P
5
9 
G
P
D
1 
IG
S1
 
LA
C
1 
P
LB
1 
SO
D
1 
U
R
A
5 
ST
 
16.25 E2693-B August 2015 Australia Enviro MZ FFA α 16 5 3 5 5 32 12 51 
16.14 E2678-A May 2015 Australia Enviro MZ FFA α 16 5 3 5 5 65 12 57 
16.15 E2678-B May 2015 Australia Enviro MZ FFA α 16 5 3 5 5 65 12 57 
16.17 E2679-A May 2015 Australia Enviro MZ FFA α 16 5 3 5 5 65 12 57 
16.18 E2679-B May 2015 Australia Enviro MZ FFA α 16 5 3 5 5 65 12 57 
16.22 E2689-A August 2015 Australia Enviro MZ FFA α 16 5 3 5 5 65 12 57 
16.24 E2693-A August 2015 Australia Enviro MZ FFA α 16 5 3 5 5 65 12 57 
16.16 E2678-C May 2015 Australia Enviro MZ FFA α 16 5 3 5 5 45 12 154 
16.23 E2689-B August 2015 Australia Enviro MZ FFA α 16 5 3 5 5 45 12 154 
15.164 - March 2015 Australia Vet RTBC α 16 14 3 5 5 45 12 159 
 
Enviro = environmental; MT = Mating type; MZ FFA = Melbourne Zoo free flight aviary; RTBC = red-tailed black cockatoo; ST = sequence 
type; Vet = veterinary. 
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ABSTRACT 
Cryptococcosis, caused by yeasts of the Cryptococcus gattii/C. neoformans species 
complexes, is an environmentally acquired disease affecting a broad range of host species. 
Amongst nine communally housed ferrets, a 5-year-old castrated ferret domiciled in an 
outdoor enclosure in Sydney, Australia was diagnosed with sinonasal cryptococcosis. All 
clinical signs resolved during 18 months of itraconazole therapy, but it was eventually 
euthanased due to splenic haemangiosarcoma. At postmortem, microscopic foci of persistent 
cryptococcosis were detected in brain and nasal tissues.  The diagnosis raised concerns that 
the owners and other ferrets were exposed to a common environmental source of infection, 
thus prompting an investigation. Soil samples, swabs of a hollow eucalypt log (used for 
behavioural enrichment) and nasal swabs from eight asymptomatic ferrets were collected. 
Nasal exudate (obtained at diagnosis) and tissues (collected at postmortem) were available 
from the clinical case. Bird seed agar culture identified a heavy growth of Cryptococcus spp. 
from one environmental site (the log), one nasal swab and nasal exudate, brain and nasal 
tissues from the clinical case. All other samples were culture-negative. Sub-cultured isolates 
(17; 14 environmental, 1 nasal and 2 disease) were Cryptococcus gattii VGI (11/17, including 
both disease isolates) and C. neoformans VNI (6/17, including the colonising nasal isolate). 
Multi-locus sequence typing revealed both disease and colonising isolates as identical to 
environmental isolates collected from the log, confirming it as the source of clinical disease 
and nasal colonisation. The log was removed to prevent further exposure to a high 
environmental load of Cryptococcus spp. 
 
INTRODUCTION 
Cryptococcosis, an uncommon but important fungal disease of a wide variety of human and 
animal hosts, is caused by yeasts in the Cryptococcus neoformans and C. gattii species 
complexes (Kwon-Chung et al., 2017). Infection typically occurs subsequent to the inhalation 
of either desiccated yeast cells or reproductive basidiospores from the environment, meaning 
that respiratory tract disease is a common manifestation. There are well-established 
environmental niches recorded for these organisms, including accumulations of avian excreta 
(C. neoformans species complex) and tree hollows in a wide range of tree species (both 
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species complexes) (Malik et al., 2011, Chen et al., 2014). In Australia, eucalypt trees exhibit 
a particularly strong association with C. gattii VGI (Ellis & Pfeiffer, 1990, Pfeiffer & Ellis, 1992). 
Ferrets (Mustela putorius furo) are one of many vertebrates in which cryptococcosis 
has been documented. Their behavioural tendencies [digging, soil sniffing, exploring confined 
spaces (Boyce et al., 2001)] and high prevalence of intercurrent nasal cavity disease [snuffles 
(Lewington, 2007)] and nonspecific upper respiratory conditions (Johnson-Delaney & Orosz, 
2011) may predispose them to exposure, colonisation and disease caused by yeasts of the C. 
neoformans and C. gattii species complexes (Malik et al., 2011, Richardson & Perpiñán, 2017). 
This has led to ferrets being considered a sentinel species for human cryptococcosis (Malik et 
al., 2002, Wyre et al., 2013, Morera et al., 2014). In reviews of the ferret cryptococcosis 
literature (Wyre et al., 2013) and subsequent case reports (Morera et al., 2014), ferrets can 
be affected by both the C. neoformans and C. gattii species complexes, with no clear link 
between cryptococcosis and immunosuppression in this host species. They present with a 
range of clinical signs and lesions affecting a variety of body sites, including both the upper 
and lower respiratory tracts (the usual primary site of infection), central nervous system 
(CNS), gastrointestinal tract and cutaneous disease (Malik et al., 2002, Wyre et al., 2013). 
Direct inoculation from penetrating injury may also be a mechanism by which localised 
subcutaneous disease develops (Malik et al., 2002). 
A 5-year-old, albino, castrated male (gib) domestic ferret residing in western Sydney, 
Australia, was diagnosed with sinonasal cryptococcosis. The affected animal was communally 
housed with eight other asymptomatic ferrets. It had been presented with a four-week 
history of violent sneezing, with a bilateral bloody purulent nasal discharge. The ferret had 
access to a confined outdoor area, which included some soil and a large hollow eucalypt log 
provided for environmental enrichment and as a place of refuge. On physical examination, 
marked facial asymmetry was noted with swelling of the nasal bridge on the right-hand side 
(Figure 4.3.1). Cytology was performed on the nasal discharge, revealing numerous 
encapsulated yeasts displaying narrow-necked budding and degenerate inflammatory cells 
(largely macrophages and some neutrophils). In addition, there were some raised circular (0.5 
cm diameter) alopecic skin nodules over the neck, face and body. Cytological examination of 
smears from fine-needle aspirates of the skin lesions also revealed encapsulated yeasts with 
an inflammatory infiltrate dominated by macrophages (Figure 4.3.2). Based on the 
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characteristic cytology, a diagnosis of cryptococcosis was made. The infection presumably 
started in the sinonasal cavity, with subsequent invasion of the adjacent bone and extension 
to subcutaneous tissues of the nasal bridge, and haematogenous dissemination giving rise to 
the multifocal skin nodules. 
The ferret was anaesthetised using isoflurane in 100% oxygen to facilitate the 
collection of blood by jugular venipuncture. After centrifugation to harvest serum, 
cryptococcal antigen testing was performed using both the lateral flow assay (LFA; CrAg® LFA, 
IMMY, Norman, Oklahoma, USA) and latex agglutination test (LCAT, CALAS®, Meridian 
Bioscience, Inc., Cincinnati, Ohio, USA).  Serological testing was positive using both LFA and 
LCAT, the latter recording a reciprocal titre of 1,024. Medical therapy was commenced with 
itraconazole (Sporanox® 100 mg capsules, Janssen, North Ryde, New South Wales, Australia) 
monotherapy at a dose of 10 mg/kg once daily orally mixed in with the ferret’s normal food. 
No possible causes of immunosuppression [e.g. lymphoma (Erdman et al., 1992)] were 
indicated by the history or physical examination, although further investigations were 
precluded due to financial constraints. 
Four weeks after commencing therapy, nasal discharge and sneezing had resolved but 
nasal bridge swelling was still evident. The multifocal skin lesions resolved slowly over the 
next few months. The medication was generally well tolerated, but some intermittent periods 
of anorexia occurred which resolved when itraconazole therapy was interrupted for 2-3 days. 
By 12 months after commencement of therapy, facial asymmetry had disappeared. The ferret 
was maintained on itraconazole therapy, because complete resolution of the cryptococcal 
antigenaemia was considered unlikely at this stage and further serological testing was not 
possible due to financial constraints. 
The ferret had been on itraconazole for 18 months when it developed generalised 
weakness, inappetence, polydipsia, an unkempt coat and became acutely dyspnoeic. On 
physical examination, cutaneous bruising and subcutaneous ecchymoses on the ventrum 
were evident, accompanied by marked dyspnoea and tachypnoea. The ferret was in poor 
body condition, with dull mentation and pale mucous membranes. At the owner’s request, 
the ferret was euthanased with pentobarbitone without further investigations and the body 
was submitted for postmortem examination, during which haemabdomen and a ruptured 
splenic haemangiosarcoma with hepatic metastases were identified. A serum sample was 
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unavailable, but opportunistic cryptococcal antigen testing of serosanguinous peritoneal fluid 
was positive using both the LFA and LCAT (reciprocal titre of 32), and histopathological 
examination of tissues revealed microscopic cryptococcal lesions in the cerebrum (Figure 
4.3.3) and nasal turbinates. Other age-related abnormalities observed incidentally on gross 
and microscopic examination included chronic renal disease and dilated cardiomyopathy. 
This case prompted concerns regarding whether the eight companion ferrets and their 
owners could be at risk of developing cryptococcosis from common exposure to a localised 
identifiable source of heavy environmental contamination. Our aim was therefore to: i) 
determine if exposure of the other ferrets to Cryptococcus spp. had occurred via culture of 
nasal swabs (to assess for colonisation) and serological testing (for subclinical disease) where 
possible; ii) conduct environmental sampling and mycological culture to determine if a source 
of infection was present in the proximate environment and iii) use fine-scale molecular 
genotyping to explore the epidemiology and characterise Cryptococcus spp. isolates.  
 
MATERIALS AND METHODS 
Sample collection 
Three pooled soil samples (from pot plants and garden beds to which ferrets had access) and 
three samples from a log within the enclosure (obtained by running pre-moistened sterile 
cotton swabs over the surfaces of the log) were collected for culture.  
Nasal swabs from the eight asymptomatic ferrets were collected by inserting a sterile, 
pre-moistened, thin-tipped cotton urethral swab into the nares and rotating gently while 
under manual restraint. Samples were obtained over several weeks after the diagnosis of the 
clinical case. A blood sample from one asymptomatic ferret was also opportunistically 
collected by jugular venepuncture while it was under general anaesthesia to investigate an 
intra-abdominal mass (later determined to be intestinal adenocarcinoma).  
A swab of the nasal exudate from the clinical case, collected at the time of diagnosis 
using a similar method to that described above, was available for mycological culture. Several 
tissue samples (nasal turbinate, lung and brain tissue) collected at postmortem examination 
after 18 months of antifungal therapy were also available for culture. 
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Serology 
Serum antigenaemia was determined using the LFA (CrAg® LFA, IMMY) and LCAT (CALAS®, 
Meridian Bioscience, Inc.) kits according to the manufacturers’ instructions on samples from 
one asymptomatic ferret and the ferret with invasive cryptococcosis. Serosanguinous 
abdominal fluid from the clinical case was obtained at postmortem for LFA and LCAT testing. 
 
Culture 
All environmental and nasal swabs were inoculated onto Staib’s bird seed agar (containing 
penicillin and gentamicin) by gently rolling them across the entire surface of an agar plate. 
Soil samples were inoculated by agitating approximately 5-10 g of the sample in 50 mL of 
sterile saline, allowing the mixture to settle for 10 minutes and then spreading 1 mL of 
supernatant across the surface of a bird seed agar plate (Krockenberger et al., 2002b). Tissue 
samples were inoculated directly onto the bird seed agar plates. All plates were incubated at 
27°C and checked daily. Plates were considered positive for Cryptococcus spp. if yeast colonies 
exhibiting the brown-colour-effect were visually identified and were classified as either 
exhibiting a low (1-10 colonies), moderate (11-100 colonies) or heavy (>100 colonies) degree 
of cryptococcal growth. One or more of these colonies were randomly sub-cultured from 
positive plates onto Sabouraud’s dextrose agar for isolation and DNA extraction. If more than 
one colony morphology exhibiting the brown-colour-effect was observed (as in Figure 4.3.4), 
then several colonies of each type were randomly selected for sub-culture. Samples were 
considered negative if no cryptococcal colonies were visible after 10 days of observation. 
 
Molecular and mating type determination 
DNA was extracted from all isolates using a previously established protocol for fungi (Ferrer 
et al., 2001). Restriction fragment length polymorphism (RFLP) analysis of a PCR product of 
the URA5 gene was then performed and compared to known standard strains in the C. gattii 
and C. neoformans species complexes (C. gattii VGI: WM 179; VGII: WM 178; VGIII: WM 175; 
VGIV: WM 779; C. neoformans VNI: WM 148; VNII: WM 626; VNIII: WM 628; VNIV: WM 629) 
to determine species and molecular type (Meyer et al., 2003). 
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PCR amplification of the MFa and MFα genes was performed for all isolates using 
established primers (Halliday et al., 1999, Fraser et al., 2003). PCR products were compared 
to known standards (mating type a: WM 06.38; mating type α: WM 179) using gel 
electrophoresis to determine mating type. 
 
Multi-locus sequence typing and phylogenetic analysis 
All isolates underwent multi-locus sequence typing (MLST) according to the consensus 
scheme for the C. gattii and C. neoformans species complexes (Meyer et al., 2009). This 
involved PCR amplification and sequencing of seven loci (CAP59, GPD1, IGS1, LAC1, PLB1, 
SOD1 and URA5) followed by assignment of allele and sequence types using the Fungal MLST 
Database (http://mlst.mycologylab.org).  
Concatenated MLST sequences were aligned by MUSCLE (Edgar, 2004) and underwent 
maximum likelihood phylogenetic analysis, using the Kimura 2-parameter model (Kimura, 
1980) with gamma distribution, to construct a phylogenetic tree. Four standard strains were 
included for comparison and outgrouping (C. gattii VGI: WM 179; VGIV: WM 779; C. 
neoformans VNI: WM 148; VNII: WM 626). Bootstrap values were calculated using the 
maximum likelihood algorithm and 1,000 replicates. All analyses were performed using the 
MEGA7 program (Kumar et al., 2016). 
 
RESULTS 
Serology 
A serum sample from one asymptomatic ferret was negative for cryptococcal antigen using 
both the LFA and LCAT. The clinical case tested positive on both the LFA and LCAT (reciprocal 
titre of 1,024). The serosanguinous abdominal fluid, collected at postmortem from the clinical 
case, returned positive LFA and LCAT (with a reciprocal titre of 32) results. 
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FIGURES 4.3.1 - 4.3.4 Cryptococcosis in a ferret. FIGURE 4.3.1 Facial asymmetry in a ferret 
later confirmed to be sinonasal cryptococcosis caused by Cryptococcus gattii VGI; note the 
swelling (arrow) in the right naso-ocular subcutaneous tissues. FIGURE 4.3.2 Fine-needle 
aspirate of a cutaneous nodule in a ferret - abundant large yeast cells with rare narrow-necked 
budding (later determined to be C. gattii VGI) are present; note the prominent negatively-
stained capsules with surrounding inflammatory cells (predominantly macrophages). Diff-
Quik. FIGURE 4.3.3 Cryptococcosis in the cerebrum of a ferret; note the numerous heavily 
encapsulated yeasts, some exhibiting narrow-based budding (arrow), consistent with 
Cryptococcus spp. (later identified as C. gattii VGI); also note the minimal inflammatory 
response. Haematoxylin & Eosin. FIGURE 4.3.4 Bird seed agar culture of a swab collected from 
a hollow eucalypt log used for environmental enrichment in a ferret enclosure in western 
Sydney, Australia; note the heavy growth of yeast colonies exhibiting the brown-colour-effect 
(consistent with Cryptococcus spp.) and presence of 2 distinct colony morphologies: paler 
brown and more mucoid (red arrow, later identified as C. gattii VGI), or darker brown and 
drier (black arrow, later identified as C. neoformans VNI). 
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Culture 
All three swabs collected from the hollow log were heavily positive (>100 colonies) for 
Cryptococcus spp. on primary culture (Figure 4.3.4). All soil samples were negative. Of the 
eight asymptomatic ferrets from which nasal swabs were collected, one was heavily culture-
positive for Cryptococcus spp. The nasal exudate swab from the clinical case was also heavily 
culture-positive for Cryptococcus spp. Of the tissue samples collected postmortem, the nasal 
turbinates and brain were moderately (11-100 colonies) culture-positive for Cryptococcus 
spp., while the lung was negative.  
 
Molecular and mating type determination 
A total of 17 isolates proceeded to DNA extraction and molecular typing; environmental 
isolates collected from the positive log (14/17), an asymptomatic ferret nasal swab isolate 
(1/17) and disease isolates from the clinical case (2/17: one from the nasal exudate at the 
time of diagnosis; one from the brain at postmortem). URA5 RFLP analysis determined that 
C. gattii VGI accounted for 11/17 isolates, comprising nine environmental and the two disease 
isolates. The remaining six isolates were C. neoformans VNI, comprising the nasal colonising 
isolate from the asymptomatic ferret and five environmental isolates. 
A total of 15/17 isolates were identified as mating type α. Two isolates (both 
environmental C. gattii VGI from the hollow log) were  mating type a (Supplementary tables 
S4.3.1 and S4.3.2). 
 
Multi-locus sequence typing and phylogenetic analysis 
Amongst the 11 C. gattii VGI isolates, two sequence types (ST) were identified: ST 154 (10 
isolates) and ST 541 (1 environmental isolate). Allele type (AT) variation between these two 
STs was seen only at the IGS1 locus, with two unique ATs identified, differing by just a single 
nucleotide polymorphism (SNP) (Supplementary table S4.31). Of the six C. neoformans VNI 
isolates, 5/6 were ST 13 while the remaining isolate was ST 23. Variation between ST 13 and 
23 occurred at the CAP59, GPD1, LAC1, PLB1 and URA5 loci, with two unique ATs identified 
for each (Supplementary table S4.3.2). 
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The phylogenetic tree (Figure 4.3.5) confirmed the URA5 RFLP results by its separation 
of isolates into clades corresponding with their species and molecular type standards, with 
high bootstrap support.  
FIGURE 4.3.5 (A) Maximum likelihood phylogenetic tree based on concatenated MLST 
sequences (from Cryptococcus gattii VGI and C. neoformans VNI isolates collected from a 
group of ferrets and their environment in western Sydney, Australia, and 4 standard strains 
[WM 148, WM 179, WM 626 and WM 779]), using the MEGA7 program and the Kimura 2-
parameter model with gamma distribution. Green circles and silhouettes indicate 
environmental and ferret isolates, respectively. (B) Higher resolution tree showing the 
relationships of the C. gattii VGI isolates. Bars = number of nucleotide substitutions per site. 
 
DISCUSSION 
This study identified a hollow eucalypt log, used for shelter and environmental enrichment, 
as the likely point source of infection for C. gattii VGI in a ferret with cryptococcosis and the 
likely source of a nasal colonising isolate in another asymptomatic ferret. A mixed mating type 
C. gattii VGI population (both α and a) was identified in this environmental niche, raising the 
possibility of sexual production of basidiospores in the pathogenesis of cryptococcosis in this 
setting. The findings of this study suggest that careful consideration of environmental 
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enrichment items for use by ferrets (and potentially other animal species susceptible to 
cryptococcosis) may be indicated. 
18-month survival in a ferret with widely disseminated cryptococcosis is a good clinical 
outcome, considering the patient had a good quality of life before developing a terminal 
malignancy, with two concurrent age-related co-morbidities (dilated cardiomyopathy and 
chronic renal disease). The prognosis for disseminated cryptococcosis in ferrets is not well-
established, but could reasonably be considered guarded, based on a review of prior case 
reports (Wyre et al., 2013). The decision to use itraconazole was based on the ease with which 
itraconazole capsules can be opened and mixed in with palatable food, and because its 
pharmacokinetics in other carnivores permit once daily dosing (compared to fluconazole, 
which is generally given twice daily). Ideally, antifungal susceptibility testing should have been 
undertaken prior to treatment to determine minimum inhibitory concentrations (MICs) for 
itraconazole and fluconazole, but financial constraints made this impossible. Retrospective 
testing of both disease isolates (nasal exudate isolate collected at the time of diagnosis and 
brain isolate collected postmortem) suggested that they were susceptible to all antifungals 
tested (including itraconazole and fluconazole). This is consistent with the expectation that 
cases of cryptococcosis on the east coast of Australia are usually susceptible to both agents, 
as the C. gattii VGII molecular type [more associated with higher MICs for some antifungals 
(Chong et al., 2010)] is rare in this area (McGill et al., 2009). Antifungal pharmacokinetics are 
not reported for the ferret and it is possible that therapeutic failure was related to 
pharmacokinetic variations. 
With the benefit of hindsight, it seems likely that this ferret had asymptomatic CNS 
disease at the time of initial diagnosis, but that long term itraconazole therapy was enough 
to prevent this developing further, and indeed the substantial clinical improvement suggested 
efficacy of therapy. Infusions of amphotericin B given subcutaneously (Malik et al., 1996a) or 
intravenously (Richardson & Perpiñán, 2017) two to three times weekly in concert with an 
oral triazole antifungal would have represented a more aggressive approach and likely been 
more effective but was also beyond the financial and time constraints of the owner. The dose 
of itraconazole could also have been increased, with successful treatment reported in a case 
of localised disease using a dose of 25 mg/kg once daily orally (Malik et al., 2002). Given that 
the clinical signs largely resolved and the dose of 10 mg/kg was well tolerated, this was not 
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thought worthwhile at the time. Fluconazole is generally considered the drug of choice for 
treating cryptococcal meningitis due to better penetration of the blood brain barrier (Felton 
et al., 2014), but it requires twice daily therapy in most species, and for ferrets this would 
probably have required use of a compounded palatable liquid formulation. Ideally, therapy 
should also have been monitored with ongoing serological testing, and indeed our findings of 
microscopic foci of ongoing infection (despite full resolution of clinical signs) emphasise the 
value of sequential antigen titres. Unfortunately, sequential LCAT titre determination was 
beyond the financial resources of the owner. Therapeutic drug monitoring would have been 
ideal to ensure dosing was producing effective itraconazole levels in blood, given that the 
pharmacokinetics of no antifungal drugs have been determined for ferrets. 
Most of the environmental C. gattii VGI strains collected from the enclosure log were 
ST 154, with one C. gattii VGI ST 541 isolate detected also (these two STs differing by a SNP in 
the IGS1 allele). MLST also showed that both disease isolates, collected approximately 18 
months apart, were C. gattii VGI ST 154. A similar pattern was observed amongst the C. 
neoformans VNI isolates, with a colonising isolate from one asymptomatic ferret identical to 
most environmental C. neoformans VNI isolates (ST 13). One C. neoformans VNI ST 23 strain 
was identified, which differed from ST 13 at five of the seven MLST loci. Phylogenetic analyses 
of the MLST sequences confirmed the molecular typing results, grouping all isolates with their 
appropriate standard strain and further confirming a high degree of similarity between C. 
gattii VGI STs 154 and 541, but a greater difference between C. neoformans VNI STs 13 and 
23 (Figure 4.3.5). 
The MLST results, along with the absence of any positive cultures from other 
environmental samples, provide high support for the notion that this single eucalypt log was 
the point source of disease and nasal colonisation for two in-contact ferrets. The log was 
therefore removed from the enclosure. Aerosolisation of Cryptococcus spp. from a source 
external to the enclosure cannot be excluded, but in the absence of any large trees nearby 
and no significant soil disturbances, this is unlikely. The hollow decaying log, which had been 
present in the enclosure for three years prior to the time of the initial diagnosis, likely 
provided an ideal substrate for the growth of pathogenic Cryptococcus spp. This may have 
been enhanced by ongoing scarification by the ferrets and regular soiling with organic matter 
(urine and faeces). This is very similar to a phenomenon observed in captive koalas, where it 
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is presumed that their use of enclosure furniture helps to greatly amplify the amount of 
Cryptococcus spp. in the environment (Krockenberger et al., 2002b, Malik et al., 2011). The 
log, sourced by the ferret’s owner from the locale of Bogan Gate, New South Wales, Australia, 
is of unknown tree species, but originates from an area within the natural range of Eucalyptus 
camaldulensis (Brooker & Kleinig, 2006) [a tree with well-established associations with C. 
gattii VGI (Ellis & Pfeiffer, 1990)]. Approximately two years after its removal, a follow-up swab 
sample was collected from the log and bird seed agar culture revealed a persistent heavy 
growth of Cryptococcus spp. RFLP analysis confirmed that the mixture of C. gattii VGI and C. 
neoformans VNI isolates remained. 
Our findings are similar to a study where a likely environmental source of infection for 
C. gattii VGI was identified in a large flight aviary (Schmertmann et al., 2018a). In addition, 
our study provides comparable findings to another publication where an environmental 
source of infection for C. gattii VGI in a domestic ferret was identified, although this 
publication used amplified fragment length polymorphism typing, a less discriminatory typing 
technique than MLST, to establish the connection (Morera et al., 2014). Another study 
reported two sibling ferrets residing in the same environment both developing 
cryptococcosis, but separated temporally, due to disease isolates shown to be identical using 
PCR fingerprinting. This technique is again less discriminatory than MLST, however, and the 
exact source of infection was not identified (Malik et al., 2002). Our findings raise a similar 
question to prior studies: why has only one of nine ferrets in contact with this source of 
infection developed cryptococcosis? In this case, the answer remains unclear. Genetic 
susceptibilities could play a role, as suggested by the report of cryptococcosis in two sibling 
ferrets (Malik et al., 2002). In the avian case mentioned previously, a high stress period was 
considered the likely cause of increased susceptibility (Schmertmann et al., 2018a). In one 
ferret case, concurrent lymphoma was reported as a likely cause of immunosuppression, 
leading to cryptococcosis (Erdman et al., 1992). It is also possible that more of the in-contact 
asymptomatic ferrets were colonised but this remained unidentified due to either transient 
colonisation or the relatively superficial swabs able to be collected safely while under manual 
restraint. General anaesthesia could have allowed for the collection of potentially more 
representative samples (either deeper swabs or nasal flushes). It may also have been of 
interest to test the human owners for cryptococcal antigenaemia and nasal colonisation, as 
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colonised humans were identified in association with another case of ferret cryptococcosis 
(Morera et al., 2011), but this was not possible. 
The mixed mating type population (9 type α and 2 type a) amongst the C. gattii VGI 
isolates in this study, despite identical MLST results, indicates that genetic differences outside 
of the seven MLST loci exist between these ST 154 isolates. Mixed mating types amongst C. 
gattii VGI isolates of identical MLST type have also been reported in a prior study (Hagen et 
al., 2012). Whole genome sequencing would provide further insights into this but was beyond 
the scope of this study. Sexual reproduction (both mixed mating type and same-sex mating) 
is the possible source of basidiospores as an infectious propagule in this scenario (Fraser et 
al., 2005). Mating type a is also considered relatively rare in Australia, and a finding of 2/11 
(18%) C. gattii VGI isolates being of this type is unusual, although similar results have been 
reported in E. camaldulensis tree hollows in New South Wales, Australia (Halliday et al., 1999). 
Based on the findings of this study, and our knowledge of the environmental niches of 
pathogenic Cryptococcus spp., we recommend the use of other objects for environmental 
enrichment in ferrets and other species, such as unused porcelain or clay drainage pipes. If 
hollow logs, particularly from eucalypts, are to be used, the risk of cryptococcal infection 
might be minimised by regular manual cleaning followed by the application of an appropriate 
disinfectant. For example, a quaternary ammonium compound (such as F10®SC Veterinary 
Disinfectant, Health and Hygiene Pty Ltd, Roodepoort, South Africa) used at the 
manufacturer’s recommended standard concentration (1 : 500) and contact time (at least 30 
seconds) might provide a reasonable option based on a prior study (Krangvichain et al., 2016), 
but further testing is needed. Accelerated hydrogen peroxide disinfectants remain untested 
against Cryptococcus spp. but have shown great potential against other fungi and infectious 
agents of animals, including as an environmental disinfectant (Moriello & Hondzo, 2014, 
Holtkamp et al., 2017). A topical antifungal agent such as enilconazole (e.g. Imaverol, Elanco 
Pty Ltd, West Ryde, New South Wales, Australia) used as a rinse could also be an effective 
means of controlling environmental Cryptococcus spp., although this remains untested and 
could theoretically promote antifungal resistance. Systematic studies comparing the utility of 
various disinfectants for managing environmental Cryptococcus spp. are lacking, and this 
would be a highly useful area for future research. Such knowledge would allow for more 
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definitive recommendations regarding environmental decontamination, and this would 
benefit a variety of captive and domestic animal species prone to cryptococcosis. 
This study successfully identified an environmental point source of infection for C. 
gattii VGI in captive ferrets, which led to the removal of the enclosure log in question, as it 
posed an ongoing risk of infection to the other ferrets and the owners. This emphasises both 
the importance of environmental investigations into cases of captive animal cryptococcosis 
and the utility of ferrets as sentinels for disease in humans and other animal species. 
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SUPPLEMENTARY TABLE S4.3.1 Accession numbers, multi-locus sequence typing results and 
strain information for Cryptococcus gattii species complex isolates identified from domestic 
ferrets and their environment in western Sydney, Australia. Red colour indicates allele and 
sequence type differences. Two standard strains (grey rows) used in phylogenetic analyses 
are also included. 
 
 Allele and sequence type numbers 
WM 
number 
Mol. 
type 
Date Location Category Specific source MT 
C
A
P
5
9 
G
P
D
1 
IG
S1
 
LA
C
1 
P
LB
1 
SO
D
1 
U
R
A
5 
ST
 
17.116 VGI Apr 2016 Sydney, Australia Vet 
Ferret (nasal 
exudate) 
α 16 5 3 5 5 45 12 154 
17.118 VGI Sep 2017 Sydney, Australia Vet Ferret (brain) α 16 5 3 5 5 45 12 154 
18.117 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 16 5 109 5 5 45 12 541 
18.118 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 16 5 3 5 5 45 12 154 
18.119 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 16 5 3 5 5 45 12 154 
18.121 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 16 5 3 5 5 45 12 154 
18.122 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) a 16 5 3 5 5 45 12 154 
18.123 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) a 16 5 3 5 5 45 12 154 
18.125 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 16 5 3 5 5 45 12 154 
18.127 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 16 5 3 5 5 45 12 154 
18.130 VGI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 16 5 3 5 5 45 12 154 
179 VGI 1993 Sydney, Australia Clin CSF α 16 5 3 5 5 32 12 51 
779 VGIV 1995 Johannesburg, SA Vet Cheetah α 17 10 8 18 3 37 11 70 
 
Apr = April; Clin = clinical; CSF = cerebrospinal fluid; Enviro = environmental; Mol. = molecular; MT = mating 
type; SA = South Africa; Sep = September; ST = sequence type; WM = Westmead Medical Mycology Culture 
Collection; Vet = veterinary. 
 
 
SUPPLEMENTARY TABLE S4.3.2 Culture collection numbers, multi-locus sequence typing 
results and strain information for the Cryptococcus neoformans species complex isolates 
identified from domestic ferrets and their environment in western Sydney, Australia. Red 
colour indicates allele and sequence type differences. Two standard strains (grey rows) used 
in phylogenetic analyses are also included. 
 
 Allele and sequence type numbers 
WM 
number 
Mol. 
type 
Date Location Category Specific source MT 
C
A
P
5
9 
G
P
D
1 
IG
S1
 
LA
C
1 
P
LB
1 
SO
D
1 
U
R
A
5 
ST
 
17.117 VNI Apr 2016 Sydney, Australia Vet 
Ferret (nasal 
swab) 
α 1 5 1 1 4 1 1 13 
18.120 VNI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 1 5 1 1 4 1 1 13 
18.124 VNI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 1 5 1 1 4 1 1 13 
18.126 VNI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 1 5 1 1 4 1 1 13 
18.128 VNI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 1 5 1 1 4 1 1 13 
18.129 VNI Apr 2016 Sydney, Australia Enviro Enclosure (log) α 7 1 1 2 1 1 2 23 
148 VNI 1989 Sydney, Australia Clin CSF α 7 1 1 18 1 1 1 7 
626 VNII 1993 Sydney, Australia Clin CSF α 2 14 14 8 11 11 4 2 
 
 
Apr = April; Clin = clinical; CSF = cerebrospinal fluid; Enviro = environmental; Mol. = molecular; MT = mating 
type; ST = sequence type; WM = Westmead Medical Mycology Culture Collection; Vet = veterinary. 
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4.4  Jet-setting koalas spread Cryptococcus gattii VGII in 
Australia 
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Supplementary table S1: List of Cryptococcus gattii species complex isolates with multi-locus sequence typing data included in this 
study. Strain information, allele types and sequence types are listed. Standard strains are included at the top of the table (grey 
rows). Strains are subsequently ordered by sequence type number, then culture collection number. Isolates in bold were included in 
whole genome analyses. 
 
  Allele and sequence type numbers 
WM 
number 
Species and 
molecular 
type 
Year Country (state) Category Park Specific source MT 
C
A
P
5
9
 
G
P
D
1
 
I
G
S
1
 
L
A
C
1
 
P
L
B
1
 
S
O
D
1
 
U
R
A
5
 
S
T
 
175 C. gattii VGIII - USA Enviro - Eucalypt (standard)  18 18 14 3 6 28 19 60 
178 C. gattii VGII 1991 Australia (NSW) Disease - Human - lung (standard)  1 17 16 16 14 19 7 21 
179 C. gattii VGI 1993 Australia (NSW) Disease - Human - CSF (standard)  16 5 3 5 5 32 12 51 
779 C. gattii VGIV 1995 South Africa Disease - Cheetah (standard)  17 10 8 18 3 37 11 70 
03.27 C. gattii VGII 1999 Australia (NT) Enviro - Eucalypt  2 6 10 4 2 15 2 7 
04.71 C. gattii VGII 1991 Australia (NSW) Disease - Cat - nasal  2 6 10 4 2 15 2 7 
09.153 C. gattii VGII 2009 Australia (WA) Enviro 4 New enclosure  2 6 10 4 2 15 2 7 
09.154 C. gattii VGII 2009 Australia (WA) Enviro 4 New enclosure  2 6 10 4 2 15 2 7 
09.155 C. gattii VGII 2009 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
09.156 C. gattii VGII 2009 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
09.157 C. gattii VGII 2009 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
09.158 C. gattii VGII 2009 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
09.160 C. gattii VGII 2009 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
09.161 C. gattii VGII 2009 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
09.163 C. gattii VGII 2009 Australia (WA) Enviro 4 Old enclosure  2 6 10 4 2 15 2 7 
09.164 C. gattii VGII 2009 Australia (WA) Enviro 4 Old enclosure  2 6 10 4 2 15 2 7 
09.166 C. gattii VGII 2009 Australia (WA) Enviro 4 Visitor area  2 6 10 4 2 15 2 7 
09.167 C. gattii VGII 2009 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
12.198 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
12.200 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
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12.201 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
12.204 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
12.205 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
12.206 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
12.208 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
12.211 C. gattii VGII 2012 Australia (WA) Enviro 4 Main enclosure  2 6 10 4 2 15 2 7 
12.212 C. gattii VGII 2012 Australia (WA) Enviro 4 Main enclosure  2 6 10 4 2 15 2 7 
12.214 C. gattii VGII 2012 Australia (WA) Enviro 4 Nursery enclosure  2 6 10 4 2 15 2 7 
12.215 C. gattii VGII 2012 Australia (WA) Enviro 4 QLD enclosure  2 6 10 4 2 15 2 7 
12.216 C. gattii VGII 2012 Australia (WA) Enviro 4 QLD enclosure  2 6 10 4 2 15 2 7 
12.217 C. gattii VGII 2012 Australia (WA) Enviro 4 VIC enclosure  2 6 10 4 2 15 2 7 
12.219 C. gattii VGII 2012 Australia (WA) Enviro 4 VIC enclosure  2 6 10 4 2 15 2 7 
13.222 C. gattii VGII 2013 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
13.223 C. gattii VGII 2013 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
13.244 C. gattii VGII 2013 Australia (WA) Colonising 4 Koala - nasal  2 6 10 4 2 15 2 7 
13.373 C. gattii VGII 2013 Australia (QLD) Disease 2 Koala - thoracic mass  2 6 10 4 2 15 2 7 
14.206 C. gattii VGII 2014 Australia (QLD) Disease 3 Koala - nasal mass  2 6 10 4 2 15 2 7 
16.20 C. gattii VGII 2005 Australia (QLD) Disease 4 Koala - nasal mass  2 6 10 4 2 15 2 7 
17.119 C. gattii VGII 2016 Australia (QLD) Disease 3 Koala - nasal discharge  2 6 10 4 2 15 2 7 
17.120 C. gattii VGII 2016 Australia (QLD) Disease 3 Koala - lymph node  2 6 10 4 2 15 2 7 
18.14 C. gattii VGII 2016 Australia (QLD) Colonising 2 Koala - nasal  2 6 10 4 2 15 2 7 
18.74 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA4  2 6 10 4 2 15 2 7 
18.76 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA8  2 6 10 4 2 15 2 7 
18.78 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA8  2 6 10 4 2 15 2 7 
18.79 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA5  2 6 10 4 2 15 2 7 
18.80 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA5  2 6 10 4 2 15 2 7 
18.81 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA5  2 6 10 4 2 15 2 7 
18.82 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA5  2 6 10 4 2 15 2 7 
18.83 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA5  2 6 10 4 2 15 2 7 
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18.84 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA6  2 6 10 4 2 15 2 7 
18.92 C. gattii VGII 2017 Australia (QLD) Colonising 3 Koala - nasal  2 6 10 4 2 15 2 7 
18.93 C. gattii VGII 2017 Australia (QLD) Colonising 3 Koala - nasal  2 6 10 4 2 15 2 7 
18.94 C. gattii VGII 2017 Australia (QLD) Colonising 3 Koala - nasal  2 6 10 4 2 15 2 7 
18.95 C. gattii VGII 2017 Australia (QLD) Colonising 1 Koala - nasal  2 6 10 4 2 15 2 7 
18.96 C. gattii VGII 2017 Australia (QLD) Enviro 1 Group enclosure  2 6 10 4 2 15 2 7 
18.97 C. gattii VGII 2017 Australia (QLD) Enviro 1 Group enclosure  2 6 10 4 2 15 2 7 
18.98 C. gattii VGII 2017 Australia (QLD) Enviro 3 Enclosure 1A  2 6 10 4 2 15 2 7 
18.99 C. gattii VGII 2017 Australia (QLD) Enviro 3 Enclosure 1A  2 6 10 4 2 15 2 7 
18.152 C. gattii VGII 2017 Australia (QLD) Enviro 1 GD Enclosure  2 6 10 4 2 15 2 7 
18.158 C. gattii VGII 2017 Australia (QLD) Colonising 3 Koala - nasal  2 6 10 4 2 15 2 7 
18.160 C. gattii VGII 2017 Australia (QLD) Colonising 3 Koala - nasal  2 6 10 4 2 15 2 7 
18.161 C. gattii VGII 2016 Australia (QLD) Colonising 1 Koala - nasal  2 6 10 4 2 15 2 7 
18.162 C. gattii VGII 2016 Australia (QLD) Colonising 1 Koala - nasal  2 6 10 4 2 15 2 7 
18.163 C. gattii VGII 2016 Australia (QLD) Colonising 2 Koala - nasal  2 6 10 4 2 15 2 7 
18.164 C. gattii VGII 2016 Australia (QLD) Enviro 2 Enclosure KOA8  2 6 10 4 2 15 2 7 
18.165 C. gattii VGII 2017 Australia (QLD) Enviro 1 Group enclosure  2 6 10 4 2 15 2 7 
09.165 C. gattii VGII 2009 Australia (WA) Enviro 4 Old enclosure a 14 21 27 28 27 46 2 38 
09.152 C. gattii VGII 2009 Australia (WA) Enviro 4 New enclosure  27 6 4 4 1 43 7 48 
12.197 C. gattii VGII 2012 Australia (WA) Colonising 4 Koala - nasal  27 6 4 4 1 43 7 48 
12.213 C. gattii VGII 2012 Australia (WA) Enviro 4 Nursery enclosure  27 6 4 4 1 43 7 48 
18.12 C. gattii VGII 2016 Australia (QLD) Colonising 2 Koala - nasal  2 6 10 4 2 15 56 539 
18.13 C. gattii VGII 2016 Australia (QLD) Colonising 2 Koala - nasal  2 6 10 4 2 15 56 539 
 
Enviro = environmental; MT = mating type; NSW = New South Wales; NT = Northern Territory, QLD = Queensland; ST=sequence type; VIC = Victoria; WA = 
Western Australia; WM = Westmead Mycology Culture Collection. Locations of Parks 1-4: Park 1 = 16°39'47.1"S 145°33'51.9"E; Park 2 = 16°45'28.9"S 
145°39'46.4"E; Park 3 = 16°49'07.9"S 145°37'58.3"E); Park 4 = 31°50'03.6"S 115°57'01.2" 
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Supplementary Table S2: List of all genomes included in the phylogenetic analysis of Cryptococcus gattii 
VGIIb in Figure 5. 
 
Strain Location Category Specific source Year Reference BioSample number 
B7394 Washington, USA Veterinary Cat 2008 [1] SAMN02851018 
B8554 Oregon, USA Veterinary Dog 2008 [2] SAMN02851020 
B8828 Washington, USA Veterinary Porpoise 2010 [1] SAMN02851021 
B9157 Washington, USA Veterinary Horse 2011 [2] SAMN02851022 
B9552 Washington, USA Veterinary Porpoise 2011 [2] SAMN02851023 
B9563 Washington, USA Veterinary Porpoise 2011 [2] SAMN02851024 
B9758 British Columbia, Canada Environmental Soil 2002 [2] SAMN02851026 
B11567 Nova Scotia, Canada Veterinary Deer - brain lesion 2015 [1] SAMN07738531 
V6 Sydney, NSW, Australia Veterinary Cat - CNS 1992 [3] SAMN02906888 
V9 Coogee, NSW, Australia Veterinary Cat  lesion aspirate 1992 [3] SAMN02906887 
V26 Rosemeadow, NSW, Australia Veterinary Cat  nasal lesion 1996 [3] SAMN02906889 
WM 1008 Blacktown, NSW, Australia Environmental Eucalyptus tereticornis 2000 [4]* Pending 
WM 03.27 Arnhem Land, NT, Australia Environmental Eucalyptus spp. 1992 [2] SAMN02851029 
WM 04.71 Chiswick, NSW, Australia Veterinary Cat  nasal lesion 1991 [2] SAMN02851030 
WM 09.154 Caversham, WA, Australia Environmental Koala enclosure 2009 This study Pending 
WM 09.155 Caversham, WA, Australia Veterinary Koala  nasal swab 2009 Unpublished Pending 
WM 09.156 Caversham, WA, Australia Veterinary Koala  nasal swab 2009 This study Pending 
WM 13.373 Palm Cove, QLD, Australia Veterinary Koala  thoracic mass 2013 This study Pending 
WM 14.206 Kuranda, QLD, Australia Veterinary Koala  nasal mass 2014 This study Pending 
WM 16.20 Currumbin, QLD, Australia Veterinary Koala  nasal mass 2005 This study Pending 
WM 17.119 Kuranda, QLD, Australia Veterinary Koala  nasal discharge 2016 This study Pending 
WM 17.120 Kuranda, QLD, Australia Veterinary Koala  lymph node 2016 This study Pending 
WM 18.12 Palm Cove, QLD, Australia Veterinary Koala  nasal swab 2016 This study Pending 
WM 18.14 Palm Cove, QLD, Australia Veterinary Koala  nasal swab 2016 This study Pending 
WM 18.76 Palm Cove, QLD, Australia Environmental Koala enclosure 2016 This study Pending 
WM 18.79 Palm Cove, QLD, Australia Environmental Koala enclosure 2016 This study Pending 
WM 18.92 Kuranda, QLD, Australia Veterinary Koala  nasal swab 2017 This study Pending 
WM 18.93 Kuranda, QLD, Australia Veterinary Koala  nasal swab 2017 This study Pending 
WM 18.94 Kuranda, QLD, Australia Veterinary Koala  nasal swab 2017 This study Pending 
WM 18.95 Wangetti, QLD, Australia Veterinary Koala  nasal swab 2017 This study Pending 
WM 18.97 Wangetti, QLD, Australia Environmental Koala enclosure 2017 This study Pending 
WM 18.99 Kuranda, QLD, Australia Environmental Koala enclosure 2017 This study Pending 
 
CNS = central nervous system; NSW = New South Wales; NT = Northern Territory; QLD = Queensland; WA = 
Western Australia. 
 
*Genome unpublished. Reference acknowledges the source of initial isolation. 
 
[1] Roe CC, Bowers J, Oltean H, et al. Dating the Cryptococcus gattii dispersal to the North American Pacific 
Northwest. mSphere. 2018; 3 (1): e00499-00417. 
[2] Engelthaler DM, Hicks ND, Gillece JD, et al. Cryptococcus gattii in North American Pacific Northwest: whole-
population genome analysis provides insights into species evolution and dispersal. mBio. 2014; 5 (4): e01464-
01414. 
[3] Billmyre RB, Croll D, Li W, et al. Highly recombinant VGII Cryptococcus gattii population develops clonal 
outbreak clusters through both sexual macroevolution and asexual microevolution. mBio. 2014; 5 (4): e01494-
01414. 
[4] Kidd SE, Sorrell TC, Meyer W. Isolation of two molecular types of Cryptococcus neoformans var. gattii from 
insect frass. Med Mycol. 2003; 41 (2): 171-176. 
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5. General discussion and future directions
Many aspects of the pathogenesis of cryptococcosis caused by the C. gattii species complex 
remain enigmatic, particularly the relationship between environmental exposure, mucosal 
colonisation and the development of disease. We have a reasonable grasp of this in some 
experimental animal models and in koalas kept in captivity (Krockenberger et al., 2002a, 
Krockenberger et al., 2010), but our understanding of the phenomenon in a broader context, 
and in relation to naturally-occurring disease in free-ranging animals, companion animals, 
birds and especially people, is much poorer.  
 This thesis investigated the central hypothesis, that in the context of cryptococcosis 
caused by the C. gattii species complex, ‘disease is a random outcome of heavy environmental 
exposure’, on several levels. These included exploring:  
1. The notion that some environmental associations for these pathogens could affect
their survival and abundance, and thus the likelihood of host exposure;
2. Some clinical aspects of cryptococcosis in koalas, including the tendency for free-
ranging animals to exhibit cryptococcal colonisation or disease, and whether this
is affected by any individual host or environmental factors; and
3. The utility of fine-scale molecular epidemiology to elucidate aspects of the host-
pathogen-environment interactions in cases of animal cryptococcosis.
This section will discuss the major findings of the thesis, in the context of the hypothesis and 
aims, and suggest directions for future research. 
5.1 General discussion 
In section 2.1, the findings of this investigation into the mycobiome of Australian tree hollows 
were consistent with expectations of a decaying woody environment. Yet, no clear 
relationships between Cryptococcus spp. and any other fungi were established, thus 
addressing aim 1. The predominant genera detected were all fungi classically associated with 
ligneous breakdown and decay. The lack of a relationship between the presence of 
Cryptococcus spp. in a tree hollow and any other specific fungal genera was somewhat 
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surprising but consistent with previous findings (Vanhove et al., 2017). The differential heat 
tree analysis did suggest some differences in the relative abundance of other fungi in 
association with Cryptococcus spp., but no striking pattern was observed and thus no 
definitive conclusions could be drawn. This does not exclude the possibility of involvement in 
the rot process or associations with other organisms, such as insects or free-living amoebae. 
Further investigations of different aspects of the tree hollow ‘biosphere’ should be explored 
in order to determine the role of this niche in the ecology of the fungus. 
Differences in the results of culture-dependent and culture-independent methods for 
detecting environmental Cryptococcus spp. suggested that neither was superior, but that 
these methods are complementary. The sensitivity of culture-based identification is 
unknown, however, and thus there is no gold standard to compare results with. Culture-
dependent methods are advantageous in many ways, as they allow for the collection of 
isolates and thus further downstream analyses (including more in-depth genotyping), but NGS 
barcoding may provide a more sensitive methodology. The biological relevance of a positive 
result on NGS must be interpreted with care, however, given the possibility that such results 
could represent only residual DNA in a sample, rather than vegetative organisms or spores 
(Lindahl et al., 2013, Nguyen et al., 2015).  
The major limitation of this study was the small sample size. The experiments were 
effectively a pilot study to determine whether the methodology was suitable for examination 
of the mycobiome, and samples collected as part of other investigations were relied upon. 
Consequently, metadata that could have been of interest was sometimes lacking. These 
factors made statistical inferences difficult to make, and thus no relationships between the 
mycobiome and e.g. tree species, tree age, number of hollows, hollow aspect, etc. could be 
established. With regards to the central hypothesis, since the findings of this study did not 
offer any predictors as to when a heavy environmental presence of members of the C. gattii 
species complex might occur, they can neither be considered to clearly support nor refute the 
hypothesis, and further work is needed (discussed in section 5.2). Indeed, the expansion of 
the known environmental niches of the C. gattii VGI in this study highlights the fact that this 
organism can likely be associated with any decaying wood, not just eucalypts (given its 
isolation from Australian trees of other genera). This suggests that any exposure to 
environments with a heavy burden of Cryptococcus spp. (such as tree hollows) could result in 
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an increased likelihood of disease, rather than a relationship to particular tree species (such 
as E. camaldulensis and E. tereticornis). 
In section 3.1, two cases that acted as sentinels for a cluster of cryptococcosis (further 
characterised in section 4.1) are described, with the successful treatment of subclinical 
disease (to full resolution) in one koala and the presence of concurrent disease in both a 
mother and dependent juvenile also reported for the first time. This also presented a review 
of published cases of the treatment and management of cryptococcosis in koalas, and thus 
addressed aim 2. Important insights into serological testing in koalas were also identified, 
with the LFA remaining positive at least four months beyond the first negative LCAT. This 
suggests that the LFA should be used, particularly once the LCAT is negative, to ensure full 
resolution of antigenaemia. The primary, and strikingly severe, appendicular osteomyelitis 
lesion reported in this case expands the current knowledge of the clinical presentation of 
cryptococcosis in koalas. 
These cases offered the opportunity to consider some aspects of the host-pathogen-
environment interactions of koala cryptococcosis, namely how both koalas (the mother and 
the joey) developed cryptococcosis simultaneously. Host susceptibility could play a role given 
the relatedness between these two individuals, but with the joey recovering well, the mother 
testing negative for KoRV-B and no recrudescence of disease in the joey three years later, this 
seems less likely. The joey did later contract chlamydiosis as an adult, but this is a very 
common infectious disease of koalas (Blanshard & Bodley, 2008) and such a result is not 
necessarily indicative of immunocompromise. The most likely cause is the exposure of both 
the mother and the joey to a common heavily contaminated environment, and thus likely the 
same heavy inoculum of C. gattii VGI, offering some support to the overarching hypothesis. A 
disease isolate from the joey could have helped to confirm this, but unfortunately was not 
available. 
Section 3.2 extends the preliminary data of the previous section by systematically 
confirming the utility of the LFA as a diagnostic tool for cryptococcosis in koalas (along with 
cats and dogs). This validated a crucial tool for addressing aim 3. The LFA achieved excellent 
sensitivity and negative predictive values in all species when compared to the LCAT, but 
specificity and positive predictive values were more variable and generally less impressive, 
particularly in koalas. These findings indicate that the LFA presents an excellent screening test 
for quickly ruling out cryptococcosis in these species, with the potential to be used ‘cage-side’ 
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in veterinary hospitals or in the field, but that positive LFA results need to be followed up with 
further testing (such as the LCAT). 
The large number of LFA-positive yet LCAT-negative results, particularly in koalas, was 
considered likely due to both the superior sensitivity of the LFA (Kozel & Bauman, 2012) 
allowing it to pick up low-level antigenaemia, and the greater tendency for koalas (compared 
to cats and dogs) to develop nasal colonisation and subclinical disease. The LFA may be 
detecting very limited subclinical disease, or even heavy nasal colonisation, in koalas that is 
indicative of early exposure to cryptococcal antigen (which is likely to be cleared quickly by 
the host). Such low levels of circulating antigen are unlikely to be of clinical relevance to the 
host and probably do not warrant treatment in most cases but should still be monitored with 
follow-up testing. On the other hand, the LCAT may only return a positive result when 
subclinical disease is well-established. Therefore, both tests remain relevant to the diagnosis 
of cryptococcosis in animals, with the LFA more useful as a screening test and to detect early 
exposure, but the LCAT (or other diagnostic testing, such as culture) still required to confirm 
positive LFA results. 
A limitation of this study was the use of the LCAT as the gold standard against which 
to compare the LFA. In a veterinary context (particularly in general practice), a diagnosis of 
cryptococcosis is often made based on only LCAT results and consistent clinical signs (largely 
due to financial constraints). Many of the cases in this study were followed up with other 
confirmatory testing, but particularly for koalas, there are relatively few cases in which 
mycological culture results (the classic gold standard) were available to validate the LFA. The 
strength of this study lies in the robust sample size, with over 500 specimens included across 
the three different animal species.  
Section 3.3 offered the first large-scale and systematic insight into cryptococcosis in 
free-ranging koalas, partially by utilising a tool that was validated in the previous section. 
Overall, these findings characterised a finite prevalence of antigenaemia and nasal 
colonisation in free-ranging koalas that was much lower than that found in most captive 
populations (Connolly et al., 1999, Krockenberger et al., 2002a, Krockenberger et al., 2002b). 
This suggests that other factors in captivity inflate the prevalence of colonisation and 
antigenaemia in certain settings. A combination of confinement to a small area, regular soiling 
and scarification of wooden perches (providing a substrate for cryptococcal growth) and 
ongoing seeding of the environment by colonised koalas likely leads to an amplified 
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environmental presence in captivity, as speculated by Krockenberger et al. (2002b) and Malik 
et al. (2011). Given the observation that captive koalas can seed new environments with the 
C. gattii species complex (Krockenberger et al., 2002b) (further supported by the findings of 
section 4.4), evidence of nasal colonisation amongst free-ranging koalas indicates that this 
could present another method of natural dispersal in Australia. More Australian tree species 
with environmental associations to the C. gattii and C. neoformans species complexes were 
also identified, with E. albens a new environmental niche for C. gattii VGI and E. populnea for 
C. neoformans VNI.  
The statistical analyses in this study found no significant relationships between 
antigenaemia or nasal colonisation and any of the individual koala or environmental 
characteristics tested, but there was a noticeable trend (that closely approached statistical 
significance) for antigenaemia-positive koalas to reside in areas with a high relative 
abundance of E. camaldulensis. While this may suggest an important role for E. camaldulensis 
in cryptococcal exposure and infection, this study did not sample enough trees in each area 
to assess the overall environmental prevalence. Thus, other differences between koalas and 
their habitat in the low and high abundance E. camaldulensis areas may have led to this result, 
and indeed the findings suggest that other tree species likely also act as important sources of 
exposure to Cryptococcus spp. in the region studied. Preliminary findings from another study 
(in which all of the authors of section 3.3 have also been involved) have suggested a 
reasonably high prevalence of environmental C. gattii VGI (approximately 50% of trees 
colonised) in this region, and that hollow size may be a significant predictor of the likelihood 
of colonisation (A. Kan, unpublished data). The significant relationship between nasal 
colonisation and antigenaemia provides strong evidence in support of previous studies and 
speculation that colonisation is a requisite precursor to tissue invasion and thus, 
antigenaemia (Krockenberger et al., 2002a, Malik et al., 2011). 
This study, along with components of section 4, has addressed aim 3, and shown that 
this population of koalas has great potential to act as biological samplers for the presence of 
environmental Cryptococcus spp. and sentinels for human disease. With regards to the central 
hypothesis, the study offers some support, given the finding of no statistical significance 
associated with any of the individual koala or environmental factors tested and either 
antigenaemia or nasal colonisation. Further work is needed to confirm this, however, 
particularly since one relationship showed an obvious trend (despite not reaching 
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significance) and the environmental prevalence of Cryptococcus spp. was not determined. 
The weaknesses of this study primarily centre around the limited number of environmental 
samples collected and the lack of more in-depth molecular typing of isolates. Further 
strategies to address this will be discussed in section 5.2. 
Section 4.1 identified and characterised a spatial and temporal case cluster of 
cryptococcosis amongst a group of free-ranging koalas and found that there was no apparent 
emergent outbreak strain responsible, addressing aims 4 and 6. This study was unable to 
identify an underlying cause for the outbreak, although the possibility of habitat destruction 
and other anthropogenic factors causing increased stress, and potentially 
immunosuppression, could not be ruled out. This, in isolation, could provide further support 
for the notion that these koalas randomly developed disease after heavy environmental 
exposure. The tendency for many koalas in this small area to exhibit nasal colonisation could 
suggest that other factors were at play, but only nine koalas were tested. Therefore, despite 
the significant difference reported between the two groups of koalas (with substantially more 
koalas from Soldiers Point and Salamander Bay colonised than from the other areas), it would 
be prudent to test more koalas from this region before drawing firm conclusions from this 
data. 
The MLST data reported in this study indicates that: 1) koala nasal cavities are indeed 
excellent biological samplers, encompassing a broad range (phylogenetically speaking) of 
isolates and thus being representative of the local environmental C. gattii VGI population; and 
2) C. gattii VGI disease and environmental isolates are fundamentally different. This was 
because disease isolates mostly clustered together (yet separate from most environmental 
isolates) in the phylogenetic analysis. Whether this difference is present due to random host 
contact with rare, higher virulence strains in the environment or from micro-evolution in the 
host remains undetermined, and WGS is needed to further elucidate this. Nevertheless, this 
brings the central hypothesis into question, as the involvement of specific, potentially more 
virulent strains could negate the randomness of C. gattii VGI cryptococcosis. 
In section 4.2 the likely source of infection for a case of cryptococcosis in a captive 
parrot was identified, thus successfully addressing aim 5. Although MLST could not 
unequivocally support this notion with an exact match between disease and environmental 
isolates, it was concluded that the tree in question must be the source of infection. This was 
based on a failure to identify any other environmental sources, the heavy and consistent 
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growth of C. gattii VGI from this tree, the tree’s known heavy usage by parrots in this 
enclosure and the finding that disease and environmental isolates were very closely related 
using fine-scale epidemiology (with only one base pair insertion separating the disease strain 
from an environmental strain, according to MLST). This study highlighted the fact that animals 
(particularly those for which the range of domicile is strictly defined) offer an ideal 
opportunity to identify potential environmental sources of infection, when cases of disease 
or colonisation emerge. The enclosure in this case was regularly entered by staff, but also 
functions as a walk-through experience for members of the public. Thus, the identification of 
a tree heavily colonised by C. gattii VGI that had caused disease in one bird was important to 
minimise the risk of exposure for others, including humans and birds, and the tree was then 
carefully removed. This case also highlights the importance of animals as sentinels. 
The underlying cause of disease in this parrot may have been related to stress (from 
its recent transfer to the enclosure and a change in the level of human contact it received). 
However, it may simply be that many birds were exposed to the source of infection but by 
chance, only this one went on to develop disease, which would support the central hypothesis 
of this thesis. 
A similar scenario was reported in section 4.3, where one domestic ferret amongst a 
group residing in an outdoor enclosure developed cryptococcosis caused by C. gattii VGI. A 
hollow log used for enclosure enrichment (that was heavily and consistently colonised by both 
C. gattii VGI and C. neoformans VNI) was identified as the point source of infection, thus also 
addressing aim 5. Another ferret amongst the group was found to have cryptococcal nasal 
colonisation originating from the same log. These findings were supported by both culture 
and fine-scale epidemiology, but this time identical isolates to those found in the diseased 
and colonised ferrets were identified in a sample collected from the log. Again, and with 
parallels with section 4.2, other animals and humans (the remaining ferrets and their owners) 
were at risk of exposure to this source of infection, and these findings enabled this risk to be 
mitigated through the removal of the log. The results did suggest that at least one other ferret 
had already been exposed, thus again raising the question as to why no other in-contact 
animals developed disease. Unlike the previous section, there was no indication of increased 
stress or other potential causes of immunosuppression, and so this may represent the 
random development of disease in a host after incessant heavy exposure.  
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Sections 4.2 and 4.3 are both subject to similar limitations, namely that exposure of 
other in-contact animals to the source of infection could not be thoroughly investigated. 
Appropriate samples for this surveillance were not systematically collected by the attending 
veterinarians due to a combination of logistical difficulties (particularly in the free flight 
aviary), unnecessary risk to the animals, a lack of client consent and/or financial constraints. 
Also, in both cases, the diseased patients were not thoroughly assessed for underlying 
immunosuppression for similar reasons. Furthermore, clinical tools for immunological 
assessment, such as CD4 cell counts and measurement of antibody levels, are not well 
developed for most animal species. 
Nevertheless, these studies remain ground-breaking in their successful identification 
of environmental point sources of infection, a rare achievement in the cryptococcosis  
literature that had not previously been defined beyond culture or basic genotyping (Sorrell et 
al., 1996, Bauwens et al., 2004, Singh et al., 2007, Morera et al., 2014). The successful 
identification of sources of infection using fine-scale molecular epidemiology (particularly in 
section 4.3, where an identical match was found between disease and environmental isolates) 
confirms that such investigations are worthwhile and can provide pertinent information for 
the management and prevention of further cases of disease. 
Although sections 4.2 and 4.3 deal with different animal species, they still offer 
pertinent insights into the host-pathogen-environment interactions of cryptococcosis caused 
by the C. gattii species complex. They emphasise the commonalities between the disease in 
these species and koalas and thus highlight that any host has the potential to provide valuable 
insights into the pathogenesis of naturally-occurring cryptococcosis. 
Section 4.4 examined a case cluster of cryptococcosis amongst a group of captive 
koalas and found that it was likely attributable to the relatively recent introduction of C. gattii 
VGII into this environment. The findings implicated koalas as being capable of translocating 
C. gattii VGII into new environments, including an initial introduction from WA to one of the 
wildlife parks in northern Queensland, and then subsequent spread from this facility to two 
other related wildlife parks. This presumably occurred when colonised koalas transferred 
organisms into a new environment via direct contact, sneezing, vocalisation, etc. Evidence of 
this phenomenon was found using a combination of culture and high-resolution genotyping. 
Overall, these results successfully addressed aims 4, 6 and 7. 
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The MLST results from this study indicated that the vast majority of VGII isolates (from 
the parks in eastern Australia) were the same ST. WGS offered a greater distinction between 
these isolates, but still confirmed that this is a closely related population, suggestive of a 
founder effect and clonal bloom after the initial introduction from WA (also supported by the 
basal relationship between a WA isolate and one clade of eastern Australian isolates). One 
limitation of this study was that only a representative portion of isolates proceeded to WGS, 
but this was still sufficient to provide insights into the molecular epidemiology, and largely 
correlated with MLST results. These results also maintain the previously established 
relationship between C. gattii VGII and western and northern central parts of Australia, with 
no evidence from WGS that this case cluster represented a long-term, established local 
population in eastern Australia. The inclusion of two other unrelated Australian C. gattii VGIIb 
isolates in the phylogenetic analyses (both were collected 15-20 years prior to this study; one 
was an environmental sample from the NT and the other from a cat in eastern Australia) also 
highlighted the overall low genetic diversity amongst Australian C. gattii VGIIb isolates and 
their stability over time. 
The ability of koalas to translocate C. gattii VGII has implications for the management 
of outbreaks in Australia, and the transfer or export of koalas. Koalas are already routinely 
tested for cryptococcal antigenaemia prior to transfer or export, but these findings suggest 
that perhaps this protocol should extend to tests for nasal colonisation. The interpretation 
and outcome of such results, however, could be problematic. For example, a negative result 
on a nasal swab culture does not necessarily prove that a koala is not colonised (the sensitivity 
of this method is unknown, and deeper nasal washings may prove more fruitful than 
superficial samples from the nasal vestibule), and there is no established protocol for 
resolving nasal colonisation, thus a positive result would put all involved in a quandary. Given 
that in some captive populations, all koalas can also be colonised (Krockenberger et al., 
2002b), this problem is likely to occur eventually. Therefore, the solution may be to monitor 
colonised animals and the new environment they are introduced in to closely (with baseline 
environmental samples collected prior to their introduction), institute a regular 
decontamination protocol and regularly monitor all koalas with serological testing and 
culturing of nasal swabs. A more aggressive stance might be to attempt to resolve the 
colonisation, particularly if C. gattii VGII is involved, using a combination of systemic and 
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topical antifungal therapy (potentially including nebulised AMB), but previous published 
attempts at this have yielded inconclusive results (Kido et al., 2012).  
It is of note that the distinct phylogenetic difference between disease and 
environmental isolates, seen clearly in section 4.1, was not seen in sections 4.2 to 4.4. This 
may simply be because section 4.1 reflects a natural, free-ranging environment. The animals 
in the other sections were all either in captivity (4.2 and 4.4) or in a domestic scenario (4.3), 
where the environment is artificial, highly limited and may be regularly disturbed by cleaning, 
etc. These scenarios could also reflect single (or relatively few) introduction events of the C. 
gattii species complex into these environments and resulting clonal blooms of isolates. The 
natural environment likely represents a much more complex scenario. Therefore, section 4.1 
may be more reflective of natural disease, but sections 4.2 to 4.4 still offer fascinating insights 
into the host-pathogen-environment interactions and provide important considerations for 
the management and prevention of this disease in captivity. 
 
5.2 Future directions 
The findings of this thesis have highlighted several areas for further study. 
1) Broader-scale studies of the mycobiome of Australian tree hollows, including: 
a. The collection of more samples and the inclusion of metadata (e.g. size of tree, 
number of hollows, local climate, etc.) in statistical analyses; 
b. Choosing bigger genomic target regions (and thus using long-read 
technologies) to allow for more in-depth inter and intra-species distinctions; 
and 
c. Exploring possible relationships between Cryptococcus spp. and other 
microbes (including bacteria, protozoa, nematodes), and insects. 
2) Further investigations into the treatment of cryptococcosis in koalas to improve case 
outcomes, including: 
a. Retrospective studies into all cases in which treatment has been attempted (as 
many remain unpublished); 
b. Systematic trials of treatment protocols; and 
c. Studies into the pharmacokinetics of AMB and itraconazole in koalas. 
5. General discussion and future directions
189
3) Exploring the relationship between koalas, C. gattii VGI and the environment in 
greater detail, utilising the Liverpool Plains population, through: 
a. Systematic environmental surveys in this area to establish the environmental 
prevalence, and characterise different tree species and their individual 
characteristics; 
b. Continuing to monitor this population to observe if differences between koalas 
in low and high relative abundance E. camaldulensis areas persist as the 
sample size increases; 
c. Utilising tracking and home range data already obtained from some colonised 
koalas (as part of an ecological study) to determine which trees are used most 
heavily, and thus focus environmental sampling efforts on these trees; 
d. Performing more discriminatory genotyping of C. gattii VGI isolates from 
koalas and the environment to further explore the interactions between koalas 
and individual trees; 
e. Testing all koalas for KoRV and assessing if a relationship between KoRV 
(including different variants and insertion sites) and cryptococcal 
antigenaemia or nasal colonisation exists in this population; 
f. Determining the prevalence of cryptococcosis, caused by C. gattii VGI, in 
humans and other species in this region; and 
g. Performing similar systematic surveys in other free-ranging koala populations. 
4) Further characterisation of the two case clusters observed in koalas through: 
a. WGS (with phylogenetic analysis) of isolates from section 4.1; 
b. Assessing the virulence of all isolates through analysis of WGS data (to 
determine if the infective strain does play a role in the development of 
disease), including:  
i. In silico examination of virulence genes;  
ii. In vitro virulence studies and the use of invertebrate or vertebrate 
animal models; 
iii. Comparing the genomes of environmental, disease and colonising 
isolates to highlight any changes to genes that may be involved in 
disease or virulence versus environmental survival; 
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c. Including more C. gattii VGII samples from WA, the NT and other parts of 
Australia in the phylogenetic analysis (section 4.4) to further test the basal 
relationship with eastern Australian isolates and to explore the population 
genomics of C. gattii VGII in Australia; and 
d. Determining the prevalence of cryptococcosis, caused by C. gattii VGI, in 
humans and other species in the Port Stephens region (for the cluster 
described in section 4.1). 
5) Exploring the biological control of environmental members of the C. gattii species 
complex, particularly in relation to captive koalas, through: 
a. Determining the efficacy of disinfectants (including quaternary ammonium 
compounds and accelerated hydrogen peroxide) against C. gattii VGI and VGII 
in a laboratory setting; and 
b. Using these results to develop and systematically test environmental cleaning 
and decontamination protocols in koala enclosures. 
 
5.3 Final comments 
This thesis has presented evidence largely in favour of the hypothesis that, with regards to 
naturally-occurring infections caused by members of the C. gattii species complex in animals 
in Australia, ‘disease is a random outcome of heavy environmental exposure’. Nevertheless, 
the findings in sections 3.3 and 4.1, where free-ranging animals were studied, indicate that 
the exact relationship between environmental exposure and eventual disease in a host is 
inevitably more complex and requires further investigation, with the infective strain 
potentially also playing a role. 
 The evidence that koalas (along with other animals) play a pivotal role in 
cryptococcosis caused by C. gattii VGI and VGII as sentinels, biological samplers, models for 
naturally-occurring infection and an environmental dispersal mechanism in Australia is 
compelling. A ‘One Health’ approach to C. gattii species complex cryptococcosis will inevitably 
lead to even greater insights to improve the prevention, treatment and management of this 
disease in all species.  
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Appendix 1: Supplementary methods 
Culture 
Two mycological media were used for culture in this thesis, Staib’s bird seed extract agar 
(containing penicillin and gentamicin) and SDA. The former was supplied by Veronica Ventura 
at the Sydney School of Veterinary Science, The University of Sydney while the latter was 
supplied by the Institute for Clinical Pathology and Medical Research, Westmead Hospital. 
Primary cultures were performed by inoculating environmental samples on to bird 
seed agar plates. All swabs were gently rolled across the entire surface of the plate, while 
debris samples were inoculated by either: 1) inserting a pre-moistened sterile swab into the 
debris bag, and rolling this swab across the agar plate, or 2) agitating approximately 10 g of 
the debris in 50-100 ml of sterile saline solution, allowing it to stand for 30 minutes and then 
spreading a 1 ml aliquot of the supernatant across the agar plate. The agar plates were then 
sealed with a plastic paraffin film and incubated at 27°C for 10 days and observed daily for 
evidence of cryptococcal growth (yeast colonies exhibiting the brown-colour-effect). If no 
such growth was observed, the plates were discarded after 10 days. 
If suspect cryptococcal growth was observed on a primary culture plate, 1-10 
cryptococal colonies were subcultured to obtain a pure single colony isolate. This involved 
picking up an individual colony using a sterile plastic disposable inoculation loop and streaking 
it onto an SDA plate. These plates were sealed with a plastic paraffin film and incubated at 
37°C. If any evidence of contamination was observed, a cryptococcal colony was subcultured 
onto another SDA plate. This process continued until there was confidence that a pure isolate, 
derived from a single colony, had been obtained. 
Throughout this study, pure cultures of isolates were routinely stored as water 
cultures for easy access and regular use in the shorter term (typically several months). This 
involved collecting approximately one generous 10 µl inoculation loop of a pure, single colony 
culture and placing it into 1 ml of sterile distilled water in a sealed tube. For long term storage, 
isolates were submitted to the Medical Mycology Culture Collection at the Westmead 
Institute for Medical Research in Westmead, NSW, Australia where they were assigned 
accession numbers and stored at -80°C in 10% glycerol. 
224
Serological testing 
Two serological tests for cryptococcal antigen were used throughout this study, the LCAT and 
the LFA. Both were performed mostly according the manufacturer’s instructions, with a few 
small modifications for the LCAT. The LFA was performed exactly according to the 
manufacturer’s instructions. Minor adaptations to the manufacturer’s LCAT protocol were 
used, which will be explained below. The LCAT was always used to determine antigen titres, 
barring a few examples shown in section 3.2. 
LCATs were performed using the Cryptococcal Antigen Latex Agglutination System 
(CALAS®) manufactured by Meridian Bioscience, Inc., (Cincinatti, Ohio, USA). In this test, 200 
µl of the serum sample is added to 200 µl of reconstituted pronase solution in a 1.5 ml sealed 
tube and incubated at 56°C for 15 minutes using a water bath. In the meantime, 50 µl of the 
supplied negative control is incubated at 56°C for 30 minutes and set aside for later use. The 
sample is removed from the water bath and immediately heated to 100°C for 5 minutes to 
inactivate the pronase. It is then allowed to cool to room temperature before being 
centrifuged on a mini benchtop centrifuge at approximately 1,000 g for 5 minutes (the exact 
specifications are not critical). The negative control (25 µl), positive control (one drop) and 
antibody control (one drop) (all provided in the kit) are then placed in their respective wells 
on a detection card while 25 µl of the sample to be tested is also placed in the top and bottom 
well of one column. One drop of detection latex is added to each well in the top row, while 
one drop of control latex is added to each well in the bottom row of the detection card. The 
wells are gently mixed using sterile applicator sticks. The card is then agitated gently for 5 
minutes after which results are read immediately. Samples are considered positive if visible 
clumping is present and the controls have all behaved appropriately. 
 In the event of a positive result, a titration is performed to determine the antigen titre. 
Titration diluent (25 µl) is added to each well in one row of a 96 well plate. The pronase and 
heat-treated sample (25 µl) is added to the first well and mixed thoroughly. Half of contents 
of well 1 (25 µl) are transferred into well 2 and mixed. This continues to well 12. To determine 
the antigen titre, 25 µl of the contents of any well are placed on the top and bottom rows of 
one column of a detection card, and then processed as described in the previous paragraph. 
To determine the antigen titre, the endpoint of positivity must be determined. Typically, this 
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is done by testing wells 3, 6, 9 and 12. Then, for example, if well 3 is positive but wells 6, 9 
and 12 are negative, wells 4 and 5 can be tested. Once the final positive well is confirmed, the 
antigen titre can be calculated. For example, if the positive endpoint is well 4, the titre is 1:32. 
 
Genotyping 
A minor adaptation of a fungal DNA extraction protocol developed by Ferrer et al. (2001) was 
used throughout this thesis. This involved collecting a generous 10 µl inoculating loop of pure, 
single colony culture, homogenising this in 250 µl of sterile water and freezing the mixture 
overnight at -20°C. After thawing, 2-mercaptoethanol (2 µl) and lysis buffer (0.5 g SDS, 1.4 g 
sodium chloride, 0.73 g EDTA, 20ml tris hydrochloride 1M, 80 ml sterile distilled water) (500 
µl) were added. The mixture was vigorously vortexed then heated to 65°C for 1 hour in a heat 
block. During this time, the mixture was briefly and vigorously vortexed at least once 
(preferably more often). Phenol:chloroform:isoamyl alcohol (500 µl) was then added and the 
mixture was vigorously vortexed until it was homogenous (this took approximately 2 
minutes). The mixture was then centrifuged at 14,000 g for 15 minutes and the upper aqueous 
layer was removed and mixed with an equal quantity of isopropanol (typically 500 µl of each). 
This new mixture was again stored overnight at -20°C then centrifuged at 4°C at 14,000 g for 
15 minutes. The supernatant was discarded, and the pellet was washed with 70% ethanol 
(500 µl) then centrifuged at room temperature at 14,000 g for another 15 minutes. The 
supernatant was again discarded, and the pellet was dried in a concentrator at 45°C for 10 
minutes. The pellet was resuspended in 50-100 µl of sterile distilled water. The DNA 
concentration was then determined and the 260:280 ratio checked using a 
spectrophotometer. The stock DNA was then diluted to 10 ng/µl for downstream PCR. 
 For WGS, initially a generous 10 µl inoculating loop of pure, single colony pure culture 
was collected and homogenised in 200 µl of sterile water and frozen overnight at -80°C. After 
thawing, this mixture underwent extraction using the Quick-DNA™ Fungal/Bacterial Miniprep 
Kit (Zymo Research, Irvine, California, USA) according to the manufacturer’s instructions. The 
DNA concentration was then measured using a spectrophotometer. 
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PCR amplifications were performed in 50 µl reaction volumes: 100 ng of DNA (10 µl 
volume), 10x reaction buffer (5 µl), 2 mmol dNTP solution (5 µl), 50 ng of forward primer (5 
µl volume), 50 ng of reverse primer (5 µl volume), 50 mmol (3 µl) magnesium chloride and 
taq polymerase (0.5 µl). All reagents (BIOTAQ™ DNA Polymerase and dNTP Set) were sourced 
from Bioline (London, UK). The rest of the reaction volume consisted of sterile distilled water. 
Mating type PCR was the exception, where only 5 ng of DNA (5 µl volume), 12 ng (1.2 µl) of 
forward primer and 15.8 ng (1.58 µl) of reverse primer were used. PCR amplifications were 
performed using the SensoQuest Thermocycler (SensoQuest GMBH, Göttingen, Germany). A 
negative control was always included. The amplicons (10 µl) were then run on a 1.5% agarose 
gel (containing ethidium bromide) at 80 V for 40 minutes (with a 1 kb extension ladder). The 
gel was visualised under an ultraviolet lamp to determine if amplification had been successful, 
the product was of the appropriate size, and the controls had behaved appropriately. 
RFLP analysis involved a URA5 PCR amplification of each sample, with the inclusion of 
eight standard strains (VGI: WM 179; VGII: WM 178; VGIII: WM 175; VGIV: VM 779; VNI: WM 
148; VNII: WM 626; VNIII: WM 628; VNIV: WM 629) and a negative control. Once amplification 
was confirmed by gel electrophoresis, 25.8 µl of amplicon was added to a mixture of buffer 
(3 µl), bovine serum albumin (0.3 µl) and the enzymes HhaI (0.3 µl) and Sau961 (0.6 µl) (all 
reagents sourced from New England BioLabs® Inc., Ipswich, Massachusetts, USA). The mixture 
was incubated at 37°C for three hours and then run on a 2.5% agarose gel (containing 
ethidium bromide) at 80 V for three hours with a 1 kb extension ladder and standard strains. 
The sample bands were compared to the standard bands to identify molecular type and 
species. This was an adaptation of a prior method develop by Meyer et al. (2003). 
For MLST, PCR amplification of the CAP59, GPD1, IGS1, LAC1, PLB1, SOD1 and URA5 
loci was performed (Meyer et al., 2009). Amplicons were sent to Macrogen, Inc. (Seoul, South 
Korea) for purification and sequencing of forward and reverse reads. Sequences were aligned 
to form contigs and trimmed to the appropriate lengths for the MLST scheme using 
Sequencher© (Gene Codes Corporation, Ann Arbor, Michigan, USA). ATs were assigned using 
a pairwise identification and local BLAST search on the Fungal MLST Database website 
(http://mlst.mycologylab.org/). The combination of AT numbers determined the ST. In the 
event of a novel allele or sequence type, sequences were submitted to the curators of the 
database. 
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Appendix Table 1.1: Kits, equipment and reagents. 
Name Use Manufacturer Location 
BIOTAQ™ DNA Polymerase PCR (standard) Bioline London, UK 
CrAg® LFA LFA IMMY Norman, OK, USA 
CALAS® LCAT Meridian 
Bioscience, Inc. 
Cincinnati, OH, USA 
DNeasy PowerSoil Kit DNA extraction Qiagen GmbH Hilden, Germany 
dNTP Set PCR Bioline London, UK 
DS-11 Series 
Spectrophotometer 
DNA 
concentration 
Denovix® Wilmington, DE, USA 
Q800R2 Sonicator Genomic DNA 
fragmentation 
QSonica Newtown, CT, USA 
Quick-DNA™ Fungal / 
Bacterial Miniprep Kit 
DNA extraction Zymo Research Irvine, CA, USA 
Quick-Load® 1 KB Extend 
DNA Ladder 
Gel 
electrophoresis 
New England 
BioLabs®, Inc. 
Ipswich, MA, USA 
NEBNext® Ultra™ II DNA 
Library Prep Kit 
WGS New England 
BioLabs®, Inc. 
Ipswich, MA, USA 
NEBuffer™ 4, bovine 
serum albumin, HhaI, 
Sau961 
RFLP New England 
BioLabs®, Inc. 
Ipswich, MA, USA 
NextSeq WGS Illumina, Inc. San Diego, CA, USA 
SensoQuest Thermocycler PCR SensoQuest GMBH Göttingen, Germany 
SequalPrep™ 
Normalization Plate Kit 
WGS Thermofisher 
Scientific 
Waltham, MA, USA 
TaKaRa Taq DNA 
Polymerase 
PCR (NGS) Takara Bio USA, Inc. Mountain View, CA, 
USA 
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Appendix Table 1.2: Software, programs, databases and other techniques. 
Name Use Source 
bcl2fastq 2.18.0.12 Mycobiome analysis Illumina, Inc., San Diego, CA, USA 
BWA v 0.7.15 WGS data analysis (Li & Durbin, 2009) 
Fungal MLST 
Database 
MLST – allele and sequence type 
assignment 
http://mlst.mycologylab.org 
(Meyer et al., 2009) 
GATK 3.7 WGS data analysis (McKenna et al., 2010) 
ISHAM-ITS Database Mycobiome analysis http://its.mycologylab.org 
(Irinyi et al., 2015) 
MEGA7 Phylogenetic analysis (Kumar et al., 2016) 
MetacodeR Mycobiome analysis (Foster et al., 2017) 
MUSCLE Sequence alignment (Edgar, 2004) 
NASP Pipeline v 1.1.2 WGS data analysis (Sahl et al., 2016) 
R Mycobiome analysis https://www.r-project.org/ 
Sequencher© Aligning and trimming raw 
Sanger sequences 
Gene Codes Corporation, Ann 
Arbor, Michigan, USA 
SINTAX Classifier Mycobiome analysis (Edgar, 2016a) 
SPAdes v 3.10.1 WGS data analysis (Bankevich et al., 2012) 
SparCC Mycobiome analysis (Friedman et al., 2012) 
Trimmomatic v 0.32 WGS data analysis (Bolger et al., 2014) 
UNITE Mycobiome analysis (Kõljalg et al., 2013) 
UNOISE Mycobiome analysis (Edgar, 2016b) 
USEARCH 10.0 Mycobiome analysis (Edgar, 2010) 
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Appendix Table 1.3: Primers and PCR amplification conditions. 
Target Primer sequences (5’ to 3’) Amplification conditions Source 
CAP59 CAP59-F: CTCTACGTCGAGCAAGTCAAG 
CAP59-R: TCCGCTGCACAAGTGATACCC 
94°C 3 min; 35 cycles: 
94°C 30 s, 56°C 30 s, 
72°C 1 min. 
[1] 
GPD1 GPD1-CG-F: CCACCGAACCCTTCTAGGATA 
GPD1-CG-R: CTTCTTGGCACCTCCCTTGAG 
 
GPD1-CN-F: ATGGTCGTCAAGGTTGGAAT 
GPD1-CN-R: GTATTCGGCACCAGCCTCA 
94°C 3 min; 35 cycles: 
94°C 45 s, 63°C 1 min, 
72°C 2 min. 
[1] 
IGS1 IGS1-F: ATCCTTTGCAGACGACTTGA 
IGS1-R: GTGATCAGTGCATTGCATGA 
94°C 3min; 35 cycles: 94°C 
30 s, 60°C 30 s,72°C 1 min. 
[1] 
ITS1 ITS1-F: CTTGGTCATTTAGAGGAAGTAA 
ITS2: GCTGCGTTCTTCATCGATGC 
95°C 7 min; 35 cycles: 
94°C 30 s, 55°C 45 s, 72°C 
1 min.  
[2] 
LAC1 LAC1-CG-F: AACATGTTCCCTGGGCCTGTG 
LAC1-CG-R: ATGAGAATTGAATCGCCTTGT 
 
LAC1-CG-F: GGCGATACTATTATCGTA 
LAC1-CG-R: TTCTGGAGTGGCTAGAGC 
94°C 3 min; 30 cycles: 
94°C 30 s, 58°C 30 s, 
72°C 1 min. 
[1] 
MATα MFαU: TTCACTGCCATCTTCACCACC 
MFαL: TCTAGGCGATGACACAAAGGG 
94°C 5 min; 30 cycles: 
94°C 1 min, 55°C 1 min, 
72°C 1 min. 
[3] 
MATa MFa2U: ACACCGCCTGTTACAATGGAC 
MFa2L: CAGCGTTTGAAGATGGACTTT 
94°C 5 min; 30 cycles: 
94°C 1 min, 55°C 1 min, 
72°C 1 min. 
[4] 
PLB1 PLB1-F: CTTCAGGCGGAGAGAGGTTT 
PLB1-R: GATTTGGCGTTGGTTTCAGT 
94°C 3 min; 30 cycles: 
94°C 45 s, 61°C 
45 s, 72°C 1 min. 
[1] 
SOD1 SOD1-CG-F: GATCCTCACGCCATTACG 
SOD1-CG-R: GAATGATGCGCTTAGTTGGA 
 
SOD1-CN-F: TCTAATCGAAATGGTCAAGG 
SOD1-CN-R: CGCAGCTGTTCGTCTGGATA 
94°C 3 min; 35 cycles: 
94°C 30 s, 52°C 30 s, 72°C 
1.5 min. 
[1] 
URA5 URA5: ATGTCCTCCCAAGCCCTCGAC 
SJ101: TTAAGACCTCTGAACACCGTACTC 
94°C 3 min; 35 cycles: 
94°C 45 s, 63°C 
1 min, 72°C 2 min. 
[1] 
 
[1] Meyer et al., 2009 
[2] White et al., 1990 
[3] Halliday et al., 1999 
[4] Fraser et al., 2003 
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Appendix 2: Isolates and sequencing data 
Appendix Table 2.1: BioProject numbers 
BioProject number Thesis section Data type 
PRJNA497337 2.1 ITS1 region amplicons from 23 tree hollows 
PRJNA524387 4.4 WGS of 17 C. gattii VGII isolates 
Appendix Table 2.2: GenBank accession numbers – C. neoformans VNI 
Locus Allele type number Accession number Thesis section 
CAP59 
1 MK331940 4.3 
7 MK331941 4.3 
GPD1 
1 MK331942 4.3 
5 MK331943 4.3 
IGS1 1 MK331944 4.3 
LAC1 
1 MK331945 4.3 
2 MK331946 4.3 
PLB1 
1 MK331947 4.3 
4 MK331948 4.3 
SOD1 1 MK331949 4.3 
URA5 
1 MK331950 4.3 
2 MK331951 4.3 
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Appendix Table 2.3: GenBank accession numbers – C. gattii VGI 
Locus Allele type number Accession number Thesis section 
CAP59 16 
MH286888 4.2 
MK092949 4.1 
MK331932 4.3 
GPD1 
5 
MH286889 4.2 
MK092950 4.1 
MK331933 4.3 
14 MH286890 4.2 
IGS1 
3 
MH286891 4.2 
MK092951 4.1 
MK331934 4.3 
12 MK092952 4.1 
20 MK092953 4.1 
97 MK092954 4.1 
109 MK331935 4.3 
LAC1 
5 
MH286892 4.2 
MK092955 4.1 
MK331936 4.3 
57 MK092956 4.1 
PLB1 5 
MH286893 4.2 
MK092957 4.1 
MK331937 4.3 
SOD1 
32 
MH286894 4.2 
MK092958 4.1 
45 
MH286895 4.2 
MK092959 4.1 
MK331938 4.3 
65 
MH286896 4.2 
MK092960 4.1 
111 MK092961 4.1 
URA5 
12 
MH286897 4.2 
MK092962 4.1 
MK331939 4.3 
48 MK092963 4.1 
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Appendix Table 2.4: GenBank accession numbers – C. gattii VGII 
Locus Allele type number Accession number Thesis section 
CAP59 
2 MK133807 4.4 
14 MK133808 4.4 
27 MK133809 4.4 
GPD1 
6 MK133810 4.4 
21 MK133811 4.4 
IGS1 
4 MK133812 4.4 
10 MK133813 4.4 
27 MK133814 4.4 
LAC1 
4 MK133815 4.4 
28 MK133816 4.4 
PLB1 
1 MK133817 4.4 
2 MK133818 4.4 
27 MK133819 4.4 
SOD1 
15 MK133820 4.4 
43 MK133821 4.4 
46 MK133822 4.4 
URA5 
2 MK133823 4.4 
7 MK133824 4.4 
56 MK133825 4.4 
 
 
Appendix Table 2.5: List of isolates with MLST data 
This table begins on the next page. 
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13.223 - 2013 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
13.244 - 2013 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
13.373 13-4029 2013 C. gattii VGIIb α Vet Koala - brain Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
13.375 13-4219 2013 C. gattii VGI α Vet Koala - lymph node Soldiers Point, NSW, Australia 16 5 3 5 5 45 48 364 
14.206 14-3570 2014 C. gattii VGIIb α Vet Koala - nasal mass Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
14.340 14-7190 2014 C. gattii VGI α Vet Koala - nasal swab Salamander Bay, NSW, Australia 16 5 3 5 5 32 12 51 
14.341 14-7197 2014 C. gattii VGI α Vet Koala - lung Tanilba Bay, NSW, Australia 16 5 3 5 5 32 12 51 
15.164 - 2015 C. gattii VGI α Vet Cockatoo - mass Melbourne, VIC, Australia 16 14 3 5 5 45 12 159 
15.169 14-8139N 2015 C. gattii VGI α Vet Koala - nasal swab Williamtown, NSW, Australia 16 5 3 5 5 32 12 51 
15.170 14-8139H 2015 C. gattii VGI α Vet Koala - hock lesion Williamtown, NSW, Australia 16 5 3 5 5 65 12 57 
15.412 15-2658 2015 C. gattii VGI α Vet Koala - brain Kuranda, QLD, Australia 16 5 3 5 5 32 12 51 
15.422 E2652-D 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.423 E2655-A 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.424 E2655-B 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.425 E2655-C 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.426 E2655-D 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.427 E2655-E 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.428 E2656-A 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.429 E2656-B 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.430 E2656-C 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.431 E2656-D 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.432 E2656-E 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.433 E2657-A 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.434 E2657-B 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.435 E2657-C 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.436 E2657-D 2015 C. gattii VGI a Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 45 12 154 
15.437 E2657-E 2015 C. gattii VGI α Enviro E. pilularis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.438 E2659-A 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.439 E2659-B 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.440 E2659-C 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
15.441 E2659-E 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
16.01 E2660-A 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
16.02 E2660-E 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
16.03 E2665-A 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 111 12 365 
16.04 E2665-B 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
16.05 E2665-C 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 12 5 5 32 12 188 
16.06 E2665-D 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
16.07 E2665-E 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 111 12 365 
16.08 E2666-B 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 12 5 5 32 12 188 
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16.09 E2666-C 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
16.10 E2666-D 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
16.11 E2666-E 2015 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
16.12 E2669-B 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
16.13 E2669-C 2015 C. gattii VGI α Enviro E. tereticornis Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
16.14 E2678-A 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 65 12 57 
16.15 E2678-B 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 65 12 57 
16.16 E2678-C 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 45 12 154 
16.17 E2679-A 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 65 12 57 
16.18 E2679-B 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 65 12 57 
16.20 MK1012 2005 C. gattii VGIIb α Vet Koala - nasal mass Currumbin, QLD, Australia 2 6 10 4 2 15 2 7 
16.22 E2689-A 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 65 12 57 
16.23 E2689-B 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 45 12 154 
16.24 E2693-A 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 65 12 57 
16.25 E2693-B 2015 C. gattii VGI α Enviro Large stag hollow Melbourne Zoo, VIC, Australia 16 5 3 5 5 32 12 51 
16.26 E2697-A 2015 C. gattii VGI α Enviro E. robusta Salamander Bay, NSW, Australia 16 5 20 5 5 32 12 366 
16.27 E2699-A 2015 C. gattii VGI α Enviro Melaleuca spp. Salamander Bay, NSW, Australia 16 5 3 5 5 32 12 51 
16.28 E2704-A 2015 C. gattii VGI α Enviro E. tereticornis Salamander Bay, NSW, Australia 16 5 3 5 5 32 12 51 
16.29 E2704-B 2015 C. gattii VGI α Enviro E. tereticornis Salamander Bay, NSW, Australia 16 5 3 5 5 32 12 51 
16.30 E2705-A 2015 C. gattii VGI α Enviro E. tereticornis Salamander Bay, NSW, Australia 16 5 3 5 5 32 12 51 
16.32 LS1-A 2015 C. gattii VGI α Vet Koala - nasal swab Salamander Bay, NSW, Australia 16 5 3 5 5 45 12 154 
16.52 LS78 2015 C. gattii VGI α Vet Koala - nasal swab Bobs Farm, NSW, Australia 16 5 12 5 5 32 12 188 
16.53 LS79 2015 C. gattii VGI α Vet Koala - nasal swab Corlette, NSW, Australia 16 5 3 5 5 32 12 51 
16.54 LS81 2015 C. gattii VGI α Vet Koala - nasal swab Soldiers Point, NSW, Australia 16 5 12 57 5 32 12 395 
16.55 LS82 2015 C. gattii VGI α Vet Koala - nasal swab One Mile, NSW, Australia 16 5 20 5 5 32 12 366 
16.56 LS87 2016 C. gattii VGI α Vet Koala - nasal swab Salamander Bay, NSW, Australia 16 5 97 5 5 32 12 396 
16.57 LS90-A 2016 C. gattii VGI α Vet Koala - nasal swab Salamander Bay, NSW, Australia 16 5 3 5 5 65 12 57 
16.58 16-0158-V 2016 C. gattii VGI α Vet Koala - vertebra Salamander Bay, NSW, Australia 16 5 3 5 5 65 12 57 
16.59 16-0158-NL 2016 C. gattii VGI α Vet Koala - nasal lesion Salamander Bay, NSW, Australia 16 5 3 5 5 65 12 57 
16.60 16-0158-B 2016 C. gattii VGI α Vet Koala - bronchi Salamander Bay, NSW, Australia 16 5 3 5 5 65 12 57 
16.61 16-0158-U 2016 C. gattii VGI α Vet Koala - urine Salamander Bay, NSW, Australia 16 5 3 5 5 65 12 57 
16.62 16-0158-M 2016 C. gattii VGI α Vet Koala - meninges Salamander Bay, NSW, Australia 16 5 3 5 5 65 12 57 
16.63 LS92 2016 C. gattii VGI α Vet Koala - nasal swab Soldiers Point, NSW, Australia 16 5 12 5 5 32 12 188 
17.012 2000419115 2016 C. gattii VGIIb α Vet Koala - lymph node Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
17.112 LS98 2016 C. gattii VGI α Vet Koala - nasal swab Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
17.113 LS176-C 2016 C. gattii VGI α Vet Koala - nasal swab Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
17.114 E2704-C 2016 C. gattii VGI α Enviro E. tereticornis Salamander Bay, NSW, Australia 16 5 3 5 5 32 12 51 
17.116 Ambush 1 2016 C. gattii VGI α Vet Ferret - nasal lesion Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
17.117 Chewy 2016 C. neoformans VNI α Vet Ferret - nasal swab Richmond, NSW, Australia 1 5 1 1 4 1 1 13 
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148 H39.1.1 1989 C. neoformans VNI α Clinical Human - CSF Sydney, NSW, Australia 7 1 1 18 1 1 1 7 
175 91B3214 - C. gattii VGIII α Enviro Eucalyptus spp. San Diego, California, USA 18 18 14 3 6 28 19 60 
178 49435 1991 C. gattii VGII α Clinical Human - lung Sydney, NSW, Australia 1 17 16 16 14 19 7 21 
179 H33.1 1993 C. gattii VGI α Clinical Human - CSF Sydney, NSW, Australia 16 5 3 5 5 32 12 51 
626 CBS 10083 1993 C. neoformans VNII α Clinical Human - CSF Sydney, NSW, Australia 2 14 14 8 11 11 4 2 
779 CBS 10101 1995 C. gattii VGIV α Vet Cheetah Johannesburg, South Africa 17 10 8 18 3 37 11 70 
03.27 RAM 002 1999 C. gattii VGIIb α Enviro Eucalyptus spp. Arnhem Land, NT, Australia 2 6 10 4 2 15 2 7 
04.71 2500/91 1991 C. gattii VGIIb α Vet Cat - nasal lesion Sydney, NSW, Australia 2 6 10 4 2 15 2 7 
09.152 - 2009 C. gattii VGII α Enviro New enclosure Caversham, WA, Australia 27 6 4 4 1 43 7 48 
09.153 - 2009 C. gattii VGIIb α Enviro New enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.154 - 2009 C. gattii VGIIb α Enviro New enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.155 Sarah 2009 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.156 J 2009 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.157 Amie 2009 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.158 Amelie 2009 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.160 - 2009 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.161 - 2009 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.163 - 2009 C. gattii VGIIb α Enviro Old enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.164 - 2009 C. gattii VGIIb α Enviro Old enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.165 - 2009 C. gattii VGII a Enviro Old enclosure Caversham, WA, Australia 14 21 27 28 27 46 2 38 
09.166 - 2009 C. gattii VGIIb α Enviro Visitor area Caversham, WA, Australia 2 6 10 4 2 15 2 7 
09.167 - 2009 C. gattii VGIIb α Enviro Visitor area Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.197 MK1914 2012 C. gattii VGII α Vet Koala - nasal swab Caversham, WA, Australia 27 6 4 4 1 43 7 48 
12.198 MK1915 2012 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.200 MK1917 2012 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.201 MK1919 2012 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.204 MK1923 2012 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.205 MK1925 2012 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.206 MK1926 2012 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.208 MK1928 2012 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.211 E2606 2012 C. gattii VGIIb α Enviro Main enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.212 E2607 2012 C. gattii VGIIb α Enviro Main enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.213 E2609 2012 C. gattii VGII α Enviro Nursery enclosure Caversham, WA, Australia 27 6 4 4 1 43 7 48 
12.214 E2612 2012 C. gattii VGIIb α Enviro Nursery enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.215 E2618 2012 C. gattii VGIIb α Enviro QLD enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.216 E2619 2012 C. gattii VGIIb α Enviro QLD enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.217 E2620 2012 C. gattii VGIIb α Enviro VIC enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
12.219 E2622 2012 C. gattii VGIIb α Enviro VIC enclosure Caversham, WA, Australia 2 6 10 4 2 15 2 7 
13.222 - 2013 C. gattii VGIIb α Vet Koala - nasal swab Caversham, WA, Australia 2 6 10 4 2 15 2 7 
Appendix 2: Isolates and sequencing data
236
W
M
 
n
u
m
b
e
r 
O
th
e
r 
n
u
m
b
e
r 
Year Species 
M
o
le
cu
la
r 
ty
p
e 
M
at
in
g 
ty
p
e 
C
at
e
go
ry
 
Source Location 
C
A
P
5
9 
G
P
D
1 
IG
S1
 
LA
C
1 
P
LB
1 
SO
D
1 
U
R
A
5 
Se
q
u
e
n
ce
 
ty
p
e 
17.118 17-7031 2017 C. gattii VGI α Vet Ferret - brain Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
17.119 16-9116 2016 C. gattii VGIIb α Vet Koala - nasal lesion Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.012 LS55-C 2016 C. gattii VGIIb α Vet Koala - nasal swab Palm Cove, QLD, Australia 2 6 10 4 2 15 56 539 
18.013 LS55-D 2016 C. gattii VGIIb α Vet Koala - nasal swab Palm Cove, QLD, Australia 2 6 10 4 2 15 56 539 
18.014 LS56-B 2016 C. gattii VGIIb α Vet Koala - nasal swab Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.074 E2746-A 2016 C. gattii VGIIb α Enviro Enclosure KOA4 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.076 E2747-A 2016 C. gattii VGIIb α Enviro Enclosure KOA8 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.078 E2748-C 2016 C. gattii VGIIb α Enviro Enclosure KOA8 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.079 E2749-A 2016 C. gattii VGIIb α Enviro Enclosure KOA5 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.080 E2750-A 2016 C. gattii VGIIb α Enviro Enclosure KOA5 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.081 E2750-B 2016 C. gattii VGIIb α Enviro Enclosure KOA5 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.082 E2750-E 2016 C. gattii VGIIb α Enviro Enclosure KOA5 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.083 E2750-F 2016 C. gattii VGIIb α Enviro Enclosure KOA5 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.084 E2752-C 2016 C. gattii VGIIb α Enviro Enclosure KOA6 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.092 LS307-A 2017 C. gattii VGIIb α Vet Koala - nasal swab Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.093 LS310 2017 C. gattii VGIIb α Vet Koala - nasal swab Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.094 LS311-C 2017 C. gattii VGIIb α Vet Koala - nasal swab Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.095 LS298 2017 C. gattii VGIIb α Vet Koala - nasal swab Wangetti, QLD, Australia 2 6 10 4 2 15 2 7 
18.096 E2966-B 2017 C. gattii VGIIb α Enviro Group enclosure Wangetti, QLD, Australia 2 6 10 4 2 15 2 7 
18.097 E2966-C 2017 C. gattii VGIIb α Enviro Group enclosure Wangetti, QLD, Australia 2 6 10 4 2 15 2 7 
18.098 E2994-A 2017 C. gattii VGIIb α Enviro Enclosure 1A Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.099 E2994-B 2017 C. gattii VGIIb α Enviro Enclosure 1A Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.117 E2775-A 2016 C. gattii VGI α Enviro Eucalypt log Richmond, NSW, Australia 16 5 109 5 5 45 12 541 
18.118 E2775-B 2016 C. gattii VGI α Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.119 E2775-C 2016 C. gattii VGI α Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.120 E2775-D 2016 C. neoformans VNI α Enviro Eucalypt log Richmond, NSW, Australia 1 5 1 1 4 1 1 13 
18.121 E2775-E 2016 C. gattii VGI α Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.122 E2775-F 2016 C. gattii VGI a Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.123 E2775-G 2016 C. gattii VGI a Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.124 E2775-H 2016 C. neoformans VNI α Enviro Eucalypt log Richmond, NSW, Australia 1 5 1 1 4 1 1 13 
18.125 E2775-J 2016 C. gattii VGI α Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.126 E2775-K 2016 C. neoformans VNI α Enviro Eucalypt log Richmond, NSW, Australia 1 5 1 1 4 1 1 13 
18.127 E2775-L 2016 C. gattii VGI α Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.128 E2775-M 2016 C. neoformans VNI α Enviro Eucalypt log Richmond, NSW, Australia 1 5 1 1 4 1 1 13 
18.129 E2775-N 2016 C. neoformans VNI α Enviro Eucalypt log Richmond, NSW, Australia 7 1 1 2 1 1 2 23 
18.130 E2775-P 2016 C. gattii VGI α Enviro Eucalypt log Richmond, NSW, Australia 16 5 3 5 5 45 12 154 
18.131 16-1726 2016 C. gattii VGI α Vet Koala - nasal swab Soldiers Point, NSW, Australia 16 5 3 5 5 65 12 57 
18.136 E2666-F 2017 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
18.137 E2666-G 2017 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
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18.138 E2666-H 2017 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
18.139 E2666-J 2017 C. gattii VGI α Enviro A. floribunda Soldiers Point, NSW, Australia 16 5 20 5 5 32 12 366 
18.140 E3036-A 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.141 E3036-B 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.142 E3036-C 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.143 E3036-D 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.144 E3036-E 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.145 E3036-F 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.146 E3039-A 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.147 E3039-B 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.148 E3039-C 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.149 E3039-D 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.150 E3039-E 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.151 E3039-F 2017 C. gattii VGI α Enviro Eucalyptus spp. Soldiers Point, NSW, Australia 16 5 3 5 5 32 12 51 
18.152 E2958 2017 C. gattii VGIIb α Enviro GD enclosure Wangetti, QLD, Australia 2 6 10 4 2 15 2 7 
18.158 LS307-B 2017 C. gattii VGIIb α Vet Koala - nasal swab Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.160 LS311-A 2017 C. gattii VGIIb α Vet Koala - nasal swab Kuranda, QLD, Australia 2 6 10 4 2 15 2 7 
18.161 LS40-C 2016 C. gattii VGIIb α Vet Koala - nasal swab Wangetti, QLD, Australia 2 6 10 4 2 15 2 7 
18.162 LS40-D 2016 C. gattii VGIIb α Vet Koala - nasal swab Wangetti, QLD, Australia 2 6 10 4 2 15 2 7 
18.163 LS56-A 2016 C. gattii VGIIb α Vet Koala - nasal swab Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.164 E2748-A 2016 C. gattii VGIIb α Enviro Enclosure KOA8 Palm Cove, QLD, Australia 2 6 10 4 2 15 2 7 
18.165 E2966-A 2017 C. gattii VGIIb α Enviro Group enclosure Wangetti, QLD, Australia 2 6 10 4 2 15 2 7 
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Appendix 3: Other publications 
I have been involved as a co-author in two other publications during my candidature that 
were either not directly related to, or unable to be included, in my thesis. These are: 
 
Fernandez, C.M., Schmertmann, L.J., Higgins, D., Casteriano, A., Irinyi, L., Mella, V.S.A., 
Crowther, M.S., Meyer, W. & Krockenberger, M.B. 2019. Genetic differences in Chlamydia 
pecorum between neighbouring sub-populations of koalas (Phascolarctos cinereus). 
Veterinary Microbiology, 231, 264-270. 
 
Krockenberger, M., Schmertmann, L.J., Canfield, P. & Malik, R. 2019. Cryptococcosis. In: 
Vogelnest, L. & Portas, T. (eds.) Medicine of Australian mammals: current therapy. 
Collingwood, Victoria: CSIRO Publishing. 
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